{"5edcc6bac35d6b781739d3b9b4c38a586dd79eff": [["In general, the higher is the incidence of infection, the more beneficial is likely to be antimicrobial prophylaxis.", [["infection", "DISEASE", 43, 52], ["infection", "PROBLEM", 43, 52], ["antimicrobial prophylaxis", "TREATMENT", 90, 115], ["infection", "OBSERVATION", 43, 52], ["likely to be", "UNCERTAINTY", 77, 89], ["antimicrobial prophylaxis", "OBSERVATION", 90, 115]]], ["Likewise, the shorter is the period at risk (and therefore the predicted duration of prophylaxis), the higher is the possibility that prophylaxis will work.", [["prophylaxis", "TREATMENT", 85, 96], ["prophylaxis", "TREATMENT", 134, 145], ["shorter", "OBSERVATION_MODIFIER", 14, 21]]], ["However, the prediction of an incidence of infection is not simple, and requires an analysis of various factors including patient's prior exposure to pathogens, underlying disease, previous and current treatment, comorbidities, geographic area, and others.", [["infection", "DISEASE", 43, 52], ["patient", "ORGANISM", 122, 129], ["patient", "SPECIES", 122, 129], ["infection", "PROBLEM", 43, 52], ["an analysis", "TEST", 81, 92], ["various factors", "PROBLEM", 96, 111], ["pathogens", "PROBLEM", 150, 159], ["underlying disease", "PROBLEM", 161, 179], ["current treatment", "TREATMENT", 194, 211], ["comorbidities", "PROBLEM", 213, 226], ["infection", "OBSERVATION", 43, 52], ["disease", "OBSERVATION", 172, 179], ["geographic", "OBSERVATION_MODIFIER", 228, 238], ["area", "OBSERVATION_MODIFIER", 239, 243]]], ["Therefore, three questions are critical in defining the appropriateness of antimicrobial prophylaxis: what is the risk for infection; what are the pathogens that predominate in this setting; and what is the period at risk.", [["infection", "DISEASE", 123, 132], ["antimicrobial prophylaxis", "TREATMENT", 75, 100], ["infection", "PROBLEM", 123, 132], ["the pathogens", "PROBLEM", 143, 156], ["infection", "OBSERVATION", 123, 132]]], ["In this chapter, we describe various strategies directed at the prevention of infections in patients with hematological malignancies, according to this risk-based strategy.", [["hematological malignancies", "ANATOMY", 106, 132], ["infections", "DISEASE", 78, 88], ["hematological malignancies", "DISEASE", 106, 132], ["patients", "ORGANISM", 92, 100], ["hematological malignancies", "CANCER", 106, 132], ["patients", "SPECIES", 92, 100], ["various strategies", "TREATMENT", 29, 47], ["infections", "PROBLEM", 78, 88], ["hematological malignancies", "PROBLEM", 106, 132], ["infections", "OBSERVATION", 78, 88]]], ["Table 49 .1 provides a risk-targeted approach to prophylaxis of infections in patients with hematological malignancies and Table 49 .2 presents the most frequent pathogens responsible for infection according to type of immunodeficiency present.", [["hematological malignancies", "ANATOMY", 92, 118], ["infections", "DISEASE", 64, 74], ["hematological malignancies", "DISEASE", 92, 118], ["infection", "DISEASE", 188, 197], ["immunodeficiency", "DISEASE", 219, 235], ["patients", "ORGANISM", 78, 86], ["hematological malignancies", "CANCER", 92, 118], ["patients", "SPECIES", 78, 86], ["infections", "PROBLEM", 64, 74], ["hematological malignancies", "PROBLEM", 92, 118], ["the most frequent pathogens", "PROBLEM", 144, 171], ["infection", "PROBLEM", 188, 197], ["immunodeficiency", "PROBLEM", 219, 235], ["infections", "OBSERVATION", 64, 74], ["infection", "OBSERVATION", 188, 197], ["immunodeficiency", "OBSERVATION", 219, 235]]], ["Risk assessment in each underlying disease (e.g., age, initial white blood cell count, cytogenetics, immunophenotype, rapidity of cytoreduction in acute lymphoid leukemia; advanced age, de novo vs. secondary leukemia, prior myelodysplasia, cytogenetics, gene mutation profile in acute myeloid leukemia; mutational status of immunoglobulin Vh gene and chromosomal abnormalities in chronic lymphocytic leukemia) b Most common disease-related immunosuppression include: hypogammaglobulinemia (multiple myeloma, low-grade B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukemia), T-cell mediated immunodeficiency (Hodgkin's lymphoma and certain types of non-Hodgkin's lymphoma) and neutrophil dysfunction (acute myeloid leukemia with myelodysplasia) c Infections with higher risk of recurrence include: mycobacteriosis (tuberculosis and others), aspergillosis, pneumocystosis, cytomegalovirus, Herpes simplex and Varicella-zoster virus, toxoplasmosis and strongyloidiasis d Renal failure increases the risk of severe mucositis in patients with multiple myeloma receiving melphalan-based conditioning regimens e Need for additional chemotherapy in lymphoma and acute myeloid leukemia is usually related to relapse of the underlying disease, whereas in multiple myeloma additional chemotherapy is usually part of the treatment strategy f in vitro manipulation of stem cells decreases the content of CD34+ and T-cells, increasing the duration of neutropenia in the early posttransplant period and delaying T-cell immune reconstitution after transplantInfection Control MeasuresPatients and health care workers should be educated about the risk of and methods to prevent acquisition of pathogens.", [["white blood cell", "ANATOMY", 63, 79], ["acute lymphoid leukemia", "ANATOMY", 147, 170], ["leukemia", "ANATOMY", 208, 216], ["acute myeloid leukemia", "ANATOMY", 279, 301], ["chromosomal", "ANATOMY", 351, 362], ["chronic lymphocytic leukemia", "ANATOMY", 380, 408], ["myeloma", "ANATOMY", 499, 506], ["low-grade B-cell non-Hodgkin's lymphoma", "ANATOMY", 508, 547], ["chronic lymphocytic leukemia", "ANATOMY", 549, 577], ["T-cell", "ANATOMY", 580, 586], ["Hodgkin's lymphoma", "ANATOMY", 614, 632], ["non-Hodgkin's lymphoma", "ANATOMY", 654, 676], ["neutrophil", "ANATOMY", 682, 692], ["acute myeloid leukemia", "ANATOMY", 706, 728], ["Renal", "ANATOMY", 974, 979], ["myeloma", "ANATOMY", 1053, 1060], ["lymphoma", "ANATOMY", 1147, 1155], ["acute myeloid leukemia", "ANATOMY", 1160, 1182], ["myeloma", "ANATOMY", 1260, 1267], ["stem cells", "ANATOMY", 1361, 1371], ["CD34+", "ANATOMY", 1397, 1402], ["T-cells", "ANATOMY", 1407, 1414], ["T-cell", "ANATOMY", 1503, 1509], ["acute lymphoid leukemia", "DISEASE", 147, 170], ["secondary leukemia", "DISEASE", 198, 216], ["myelodysplasia", "DISEASE", 224, 238], ["acute myeloid leukemia", "DISEASE", 279, 301], ["chronic lymphocytic leukemia", "DISEASE", 380, 408], ["hypogammaglobulinemia", "DISEASE", 467, 488], ["multiple myeloma", "DISEASE", 490, 506], ["low-grade B-cell non-Hodgkin's lymphoma", "DISEASE", 508, 547], ["chronic lymphocytic leukemia", "DISEASE", 549, 577], ["T-cell mediated immunodeficiency", "DISEASE", 580, 612], ["Hodgkin's lymphoma", "DISEASE", 614, 632], ["non-Hodgkin's lymphoma", "DISEASE", 654, 676], ["neutrophil dysfunction", "DISEASE", 682, 704], ["acute myeloid leukemia", "DISEASE", 706, 728], ["myelodysplasia", "DISEASE", 734, 748], ["mycobacteriosis", "DISEASE", 803, 818], ["tuberculosis", "DISEASE", 820, 832], ["aspergillosis", "DISEASE", 846, 859], ["pneumocystosis", "DISEASE", 861, 875], ["cytomegalovirus", "DISEASE", 877, 892], ["Herpes simplex", "DISEASE", 894, 908], ["Varicella-zoster virus", "DISEASE", 913, 935], ["toxoplasmosis", "DISEASE", 937, 950], ["strongyloidiasis", "DISEASE", 955, 971], ["Renal failure", "DISEASE", 974, 987], ["mucositis", "DISEASE", 1017, 1026], ["multiple myeloma", "DISEASE", 1044, 1060], ["melphalan", "CHEMICAL", 1071, 1080], ["lymphoma", "DISEASE", 1147, 1155], ["acute myeloid leukemia", "DISEASE", 1160, 1182], ["multiple myeloma", "DISEASE", 1251, 1267], ["neutropenia", "DISEASE", 1443, 1454], ["melphalan", "CHEMICAL", 1071, 1080], ["white blood cell", "CELL", 63, 79], ["acute lymphoid leukemia", "CANCER", 147, 170], ["leukemia", "CANCER", 208, 216], ["acute myeloid leukemia", "CANCER", 279, 301], ["immunoglobulin Vh", "GENE_OR_GENE_PRODUCT", 324, 341], ["chromosomal", "CELLULAR_COMPONENT", 351, 362], ["chronic lymphocytic leukemia", "CANCER", 380, 408], ["myeloma", "CANCER", 499, 506], ["low-grade B-cell non-Hodgkin's lymphoma", "CANCER", 508, 547], ["chronic lymphocytic leukemia", "CANCER", 549, 577], ["T-cell", "CANCER", 580, 586], ["Hodgkin's lymphoma", "CANCER", 614, 632], ["non-Hodgkin's lymphoma", "CANCER", 654, 676], ["neutrophil", "CELL", 682, 692], ["acute myeloid leukemia", "CANCER", 706, 728], ["cytomegalovirus", "ORGANISM", 877, 892], ["Herpes simplex", "ORGANISM", 894, 908], ["Varicella-zoster virus", "ORGANISM", 913, 935], ["Renal", "ORGAN", 974, 979], ["patients", "ORGANISM", 1030, 1038], ["myeloma", "CANCER", 1053, 1060], ["melphalan", "SIMPLE_CHEMICAL", 1071, 1080], ["lymphoma", "CANCER", 1147, 1155], ["acute myeloid leukemia", "CANCER", 1160, 1182], ["myeloma", "CANCER", 1260, 1267], ["stem cells", "CELL", 1361, 1371], ["CD34", "GENE_OR_GENE_PRODUCT", 1397, 1401], ["T-cells", "CELL", 1407, 1414], ["T-cell", "CELL", 1503, 1509], ["immunoglobulin Vh gene", "DNA", 324, 346], ["stem cells", "CELL_TYPE", 1361, 1371], ["CD34", "PROTEIN", 1397, 1401], ["T-cells", "CELL_TYPE", 1407, 1414], ["Herpes simplex", "SPECIES", 894, 908], ["Varicella-zoster virus", "SPECIES", 913, 935], ["patients", "SPECIES", 1030, 1038], ["Varicella-zoster virus", "SPECIES", 913, 935], ["Risk assessment", "TEST", 0, 15], ["each underlying disease", "PROBLEM", 19, 42], ["initial white blood cell count", "TEST", 55, 85], ["cytogenetics", "TEST", 87, 99], ["immunophenotype", "TEST", 101, 116], ["cytoreduction", "TREATMENT", 130, 143], ["acute lymphoid leukemia", "PROBLEM", 147, 170], ["secondary leukemia", "PROBLEM", 198, 216], ["prior myelodysplasia", "PROBLEM", 218, 238], ["cytogenetics", "TEST", 240, 252], ["gene mutation profile", "PROBLEM", 254, 275], ["acute myeloid leukemia", "PROBLEM", 279, 301], ["immunoglobulin Vh gene", "PROBLEM", 324, 346], ["chromosomal abnormalities", "PROBLEM", 351, 376], ["chronic lymphocytic leukemia)", "PROBLEM", 380, 409], ["Most common disease", "PROBLEM", 412, 431], ["immunosuppression", "TREATMENT", 440, 457], ["hypogammaglobulinemia", "PROBLEM", 467, 488], ["multiple myeloma", "PROBLEM", 490, 506], ["low-grade B-cell non-Hodgkin's lymphoma", "PROBLEM", 508, 547], ["chronic lymphocytic leukemia", "PROBLEM", 549, 577], ["T-cell mediated immunodeficiency", "PROBLEM", 580, 612], ["Hodgkin's lymphoma", "PROBLEM", 614, 632], ["non-Hodgkin's lymphoma", "PROBLEM", 654, 676], ["neutrophil dysfunction", "PROBLEM", 682, 704], ["acute myeloid leukemia", "PROBLEM", 706, 728], ["myelodysplasia)", "PROBLEM", 734, 749], ["Infections", "PROBLEM", 752, 762], ["recurrence", "PROBLEM", 783, 793], ["mycobacteriosis", "PROBLEM", 803, 818], ["tuberculosis", "PROBLEM", 820, 832], ["aspergillosis", "PROBLEM", 846, 859], ["pneumocystosis", "PROBLEM", 861, 875], ["cytomegalovirus", "PROBLEM", 877, 892], ["Herpes simplex", "PROBLEM", 894, 908], ["Varicella", "PROBLEM", 913, 922], ["zoster virus", "PROBLEM", 923, 935], ["toxoplasmosis", "PROBLEM", 937, 950], ["strongyloidiasis", "PROBLEM", 955, 971], ["Renal failure", "PROBLEM", 974, 987], ["severe mucositis", "PROBLEM", 1010, 1026], ["multiple myeloma", "PROBLEM", 1044, 1060], ["melphalan", "TREATMENT", 1071, 1080], ["based conditioning regimens", "TREATMENT", 1081, 1108], ["additional chemotherapy", "TREATMENT", 1120, 1143], ["lymphoma", "PROBLEM", 1147, 1155], ["acute myeloid leukemia", "PROBLEM", 1160, 1182], ["the underlying disease", "PROBLEM", 1216, 1238], ["multiple myeloma", "PROBLEM", 1251, 1267], ["chemotherapy", "TREATMENT", 1279, 1291], ["the treatment strategy", "TREATMENT", 1311, 1333], ["stem cells", "PROBLEM", 1361, 1371], ["CD34", "TEST", 1397, 1401], ["T-cells", "PROBLEM", 1407, 1414], ["neutropenia", "PROBLEM", 1443, 1454], ["T-cell immune reconstitution", "TREATMENT", 1503, 1531], ["transplant", "TREATMENT", 1538, 1548], ["Infection", "PROBLEM", 1548, 1557], ["methods", "TREATMENT", 1648, 1655], ["pathogens", "PROBLEM", 1682, 1691], ["disease", "OBSERVATION", 35, 42], ["acute lymphoid leukemia", "OBSERVATION", 147, 170], ["leukemia", "OBSERVATION", 208, 216], ["myelodysplasia", "OBSERVATION", 224, 238], ["acute", "OBSERVATION_MODIFIER", 279, 284], ["myeloid leukemia", "OBSERVATION", 285, 301], ["chronic", "OBSERVATION_MODIFIER", 380, 387], ["lymphocytic leukemia", "OBSERVATION", 388, 408], ["immunosuppression", "OBSERVATION", 440, 457], ["hypogammaglobulinemia", "OBSERVATION", 467, 488], ["multiple", "OBSERVATION_MODIFIER", 490, 498], ["myeloma", "OBSERVATION", 499, 506], ["low-grade B-cell non-Hodgkin's lymphoma", "OBSERVATION", 508, 547], ["chronic", "OBSERVATION_MODIFIER", 549, 556], ["lymphocytic leukemia", "OBSERVATION", 557, 577], ["Hodgkin's lymphoma", "OBSERVATION", 614, 632], ["non-Hodgkin's lymphoma", "OBSERVATION", 654, 676], ["neutrophil dysfunction", "OBSERVATION", 682, 704], ["acute", "OBSERVATION_MODIFIER", 706, 711], ["myeloid leukemia", "OBSERVATION", 712, 728], ["myelodysplasia", "OBSERVATION", 734, 748], ["recurrence", "OBSERVATION", 783, 793], ["mycobacteriosis", "OBSERVATION", 803, 818], ["tuberculosis", "OBSERVATION", 820, 832], ["aspergillosis", "OBSERVATION", 846, 859], ["pneumocystosis", "OBSERVATION", 861, 875], ["cytomegalovirus", "OBSERVATION", 877, 892], ["zoster virus", "OBSERVATION", 923, 935], ["strongyloidiasis", "OBSERVATION", 955, 971], ["Renal", "ANATOMY", 974, 979], ["failure", "OBSERVATION", 980, 987], ["severe", "OBSERVATION_MODIFIER", 1010, 1016], ["mucositis", "OBSERVATION", 1017, 1026], ["multiple", "OBSERVATION_MODIFIER", 1044, 1052], ["myeloma", "OBSERVATION", 1053, 1060], ["lymphoma", "OBSERVATION", 1147, 1155], ["acute", "OBSERVATION_MODIFIER", 1160, 1165], ["myeloid leukemia", "OBSERVATION", 1166, 1182], ["disease", "OBSERVATION", 1231, 1238], ["multiple", "OBSERVATION_MODIFIER", 1251, 1259], ["myeloma", "OBSERVATION", 1260, 1267], ["stem cells", "OBSERVATION", 1361, 1371], ["early posttransplant", "OBSERVATION_MODIFIER", 1462, 1482], ["cell immune reconstitution", "OBSERVATION", 1505, 1531]]], ["These methods include:HandwashingHandwashing remains the simplest and most effective measure to prevent the acquisition of organisms by patients [1] .HandwashingPatients and health care workers should wash their hands before eating, smoking, or inserting or removing contact lenses, and after using the restroom, blowing their nose, coughing, sneezing, handling dirty items such as garbage, and after touching an animal.", [["nose", "ANATOMY", 327, 331], ["coughing", "DISEASE", 333, 341], ["sneezing", "DISEASE", 343, 351], ["patients", "ORGANISM", 136, 144], ["Patients", "ORGANISM", 161, 169], ["nose", "ORGANISM_SUBDIVISION", 327, 331], ["patients", "SPECIES", 136, 144], ["Patients", "SPECIES", 161, 169], ["HandwashingHandwashing", "TREATMENT", 22, 44], ["blowing their nose", "PROBLEM", 313, 331], ["coughing", "PROBLEM", 333, 341], ["sneezing", "PROBLEM", 343, 351], ["nose", "ANATOMY", 327, 331]]], ["In addition, health care workers should also wash their hands between patients.", [["hands", "ORGANISM_SUBDIVISION", 56, 61], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78]]], ["All surfaces should be thoroughly cleaned, including wrists, palms, back of hands, fingers, and under the fingernails, preferably with an alcohol-based hand rub [2] .", [["wrists", "ANATOMY", 53, 59], ["palms", "ANATOMY", 61, 66], ["fingers", "ANATOMY", 83, 90], ["fingernails", "ANATOMY", 106, 117], ["hand", "ANATOMY", 152, 156], ["alcohol", "CHEMICAL", 138, 145], ["alcohol", "CHEMICAL", 138, 145], ["wrists", "ORGANISM_SUBDIVISION", 53, 59], ["palms", "ORGANISM_SUBDIVISION", 61, 66], ["hands", "ORGANISM_SUBDIVISION", 76, 81], ["fingers", "ORGANISM_SUBDIVISION", 83, 90], ["fingernails", "ORGANISM_SUBDIVISION", 106, 117], ["alcohol", "SIMPLE_CHEMICAL", 138, 145], ["All surfaces", "TREATMENT", 0, 12], ["surfaces", "OBSERVATION_MODIFIER", 4, 12], ["wrists", "ANATOMY", 53, 59], ["palms", "ANATOMY", 61, 66], ["back", "ANATOMY", 68, 72], ["hands", "ANATOMY", 76, 81], ["fingers", "ANATOMY", 83, 90], ["fingernails", "ANATOMY", 106, 117]]], ["However, if hands are visibly dirty or soiled with blood or body fluids, soap and water are best for cleaning hands [3] .", [["blood", "ANATOMY", 51, 56], ["body", "ANATOMY", 60, 64], ["hands", "ORGANISM_SUBDIVISION", 12, 17], ["blood", "ORGANISM_SUBSTANCE", 51, 56], ["body", "ORGANISM_SUBDIVISION", 60, 64], ["visibly dirty", "PROBLEM", 22, 35], ["soap and water", "TREATMENT", 73, 87]]], ["Additional recommendations include the removal of rings prior to handwashing, keeping nails short and clean, and avoiding the use of artificial nails as they may carry pathogens [4] .Skin and Mucosal CareThe skin flora could potentially be a source of infections.", [["Skin", "ANATOMY", 183, 187], ["Mucosal", "ANATOMY", 192, 199], ["skin flora", "ANATOMY", 208, 218], ["infections", "DISEASE", 252, 262], ["Skin", "ORGAN", 183, 187], ["skin", "ORGAN", 208, 212], ["the removal of rings", "TREATMENT", 35, 55], ["handwashing", "TREATMENT", 65, 76], ["artificial nails", "TREATMENT", 133, 149], ["pathogens", "PROBLEM", 168, 177], ["Mucosal Care", "TREATMENT", 192, 204], ["The skin flora", "PROBLEM", 204, 218], ["infections", "PROBLEM", 252, 262], ["Mucosal", "ANATOMY", 192, 199], ["skin", "ANATOMY", 208, 212], ["flora", "OBSERVATION", 213, 218], ["infections", "OBSERVATION", 252, 262]]], ["Patients should keep their skin clean with daily baths using an antiseptic solution with special attention to potential portals of infection such as the perineum, and catheter sites.", [["skin", "ANATOMY", 27, 31], ["perineum", "ANATOMY", 153, 161], ["catheter sites", "ANATOMY", 167, 181], ["infection", "DISEASE", 131, 140], ["Patients", "ORGANISM", 0, 8], ["skin", "ORGAN", 27, 31], ["perineum", "ORGANISM_SUBDIVISION", 153, 161], ["Patients", "SPECIES", 0, 8], ["daily baths", "TREATMENT", 43, 54], ["an antiseptic solution", "TREATMENT", 61, 83], ["infection", "PROBLEM", 131, 140], ["catheter sites", "TREATMENT", 167, 181], ["skin", "ANATOMY", 27, 31], ["clean", "OBSERVATION", 32, 37], ["infection", "OBSERVATION", 131, 140], ["perineum", "ANATOMY", 153, 161], ["catheter", "OBSERVATION", 167, 175]]], ["The oral flora can lead to infection especially in the setting of severe mucositis, after radiotherapy, or in patients with graft vs. host disease (GVHD).", [["oral flora", "ANATOMY", 4, 14], ["graft", "ANATOMY", 124, 129], ["infection", "DISEASE", 27, 36], ["mucositis", "DISEASE", 73, 82], ["host disease", "DISEASE", 134, 146], ["GVHD", "DISEASE", 148, 152], ["oral", "ORGANISM_SUBDIVISION", 4, 8], ["patients", "ORGANISM", 110, 118], ["graft", "TISSUE", 124, 129], ["patients", "SPECIES", 110, 118], ["The oral flora", "PROBLEM", 0, 14], ["infection", "PROBLEM", 27, 36], ["severe mucositis", "PROBLEM", 66, 82], ["radiotherapy", "TREATMENT", 90, 102], ["host disease", "PROBLEM", 134, 146], ["GVHD", "PROBLEM", 148, 152], ["infection", "OBSERVATION", 27, 36], ["severe", "OBSERVATION_MODIFIER", 66, 72], ["mucositis", "OBSERVATION", 73, 82], ["graft", "OBSERVATION", 124, 129], ["disease", "OBSERVATION", 139, 146], ["GVHD", "OBSERVATION", 148, 152]]], ["Recommendations to maintain a good oral and dental hygiene include: (a) oral rinses 4-6 times a day with sterile water, normal saline, or sodium bicarbonate; (b) tooth brushing at least twice a day with a soft or ultrasoft toothbrush.", [["oral", "ANATOMY", 35, 39], ["oral", "ANATOMY", 72, 76], ["tooth", "ANATOMY", 162, 167], ["sodium bicarbonate", "CHEMICAL", 138, 156], ["sodium bicarbonate", "CHEMICAL", 138, 156], ["oral", "ORGANISM_SUBDIVISION", 35, 39], ["oral", "ORGANISM_SUBDIVISION", 72, 76], ["saline", "SIMPLE_CHEMICAL", 127, 133], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 138, 156], ["tooth", "ORGAN", 162, 167], ["a) oral rinses", "TREATMENT", 69, 83], ["sterile water", "TREATMENT", 105, 118], ["normal saline", "TREATMENT", 120, 133], ["sodium bicarbonate", "TREATMENT", 138, 156], ["b) tooth brushing", "TREATMENT", 159, 176], ["a soft or ultrasoft toothbrush", "TREATMENT", 203, 233]]], ["Swabs are less effective, but should be used if the patient cannot tolerate brushings.Handling PetsPet owners should follow the following recommendations [3, 5] : (a) avoid contact with young animals as pets (higher risk of shedding Salmonella spp. and Campylobacter spp. because of a higher incidence of diarrhea); (b) obtain veterinarian consultation when a new pet is adopted and yearly thereafter; (c) keep pet's vaccinations current; (d) keep pet's feeding areas clean and its litter box away from kitchen and eating areas; (e) feed pets only with high-quality commercial pet foods, cooked egg, poultry and meat products, and pasteurized dairy products, and avoid access to garbage; (f) supervise pets when they are outdoors to prevent contact with other pet's feces; (g) prevent animals from roaming through tick-infested woods; (h) wash hands after handling pets and avoid contact with pet's feces and bird droppings; (i) avoid contact with animals with diarrhea, dogs exposed to shows or kennels, wild birds (especially pigeons), birds with avian tuberculosis, reptiles (high carriage and shedding of Salmonella spp.), and swine (source of B. bronchiseptica); (j) keep pets away from face and wounds; (k) trim pet's nail short; (l) notify physician immediately if patient is bitten or injured by a pet; (m) instruct kids not to share kisses with the classroom pet; and (n) when cleaning cages, wear a particulate mask and avoid shaking cages.Other Personal Hygiene Items Including Food HandlingHigh-risk patients should follow additional precautions to prevent serious infections as summarized in Table 49 .3. -Avoid using tap water for drinking or making juices, other food items -Refrain from skinning animals or cleaning seafood -Use plastic bags in all trash cans for proper disposal -At the supermarket, pick up perishables last and take them home promptly -Defrost meat, turkey, chicken in the refrigerator -Wash the meat before cooking -Cook thoroughly eggs and meat (use thermometers) -Clean your refrigerator regularly discarding food of >3-4 days age, especially salad dressings, sauces, milk and egg products, condiments, processed meats, bacon -Never use canned foods if the can is swollen dented, or rusted -Toss out any cheese or food that's moldy.", [["egg", "ANATOMY", 595, 598], ["meat", "ANATOMY", 612, 616], ["wounds", "ANATOMY", 1201, 1207], ["juices", "ANATOMY", 1664, 1670], ["meat", "ANATOMY", 1879, 1883], ["meat", "ANATOMY", 1931, 1935], ["eggs", "ANATOMY", 1968, 1972], ["meat", "ANATOMY", 1977, 1981], ["milk", "ANATOMY", 2106, 2110], ["egg", "ANATOMY", 2115, 2118], ["meats", "ANATOMY", 2151, 2156], ["Campylobacter spp", "DISEASE", 253, 270], ["diarrhea", "DISEASE", 305, 313], ["diarrhea", "DISEASE", 961, 969], ["avian tuberculosis", "DISEASE", 1049, 1067], ["infections", "DISEASE", 1577, 1587], ["patient", "ORGANISM", 52, 59], ["Campylobacter spp", "ORGANISM", 253, 270], ["egg", "ORGANISM_SUBDIVISION", 595, 598], ["poultry", "ORGANISM_SUBDIVISION", 600, 607], ["meat", "ORGANISM_SUBDIVISION", 612, 616], ["feces", "ORGANISM_SUBDIVISION", 766, 771], ["hands", "ORGANISM_SUBDIVISION", 844, 849], ["feces", "ORGANISM_SUBDIVISION", 899, 904], ["pigeons", "ORGANISM_SUBDIVISION", 1028, 1035], ["Salmonella spp.", "ORGANISM", 1109, 1124], ["B. bronchiseptica", "ORGANISM", 1148, 1165], ["wounds", "PATHOLOGICAL_FORMATION", 1201, 1207], ["patient", "ORGANISM", 1272, 1279], ["patients", "ORGANISM", 1512, 1520], ["juices", "ORGANISM_SUBDIVISION", 1664, 1670], ["meat", "ORGANISM_SUBDIVISION", 1879, 1883], ["turkey", "ORGANISM_SUBDIVISION", 1885, 1891], ["chicken", "ORGANISM", 1893, 1900], ["meat", "ORGANISM_SUBDIVISION", 1931, 1935], ["meat", "ORGANISM_SUBDIVISION", 1977, 1981], ["salad", "ORGANISM_SUBDIVISION", 2081, 2086], ["milk", "ORGANISM_SUBSTANCE", 2106, 2110], ["patient", "SPECIES", 52, 59], ["dogs", "SPECIES", 971, 975], ["avian tuberculosis", "SPECIES", 1049, 1067], ["Salmonella spp.", "SPECIES", 1109, 1124], ["swine", "SPECIES", 1131, 1136], ["B. bronchiseptica", "SPECIES", 1148, 1165], ["patient", "SPECIES", 1272, 1279], ["patients", "SPECIES", 1512, 1520], ["meat", "SPECIES", 1879, 1883], ["turkey", "SPECIES", 1885, 1891], ["chicken", "SPECIES", 1893, 1900], ["milk", "SPECIES", 2106, 2110], ["Salmonella spp.", "SPECIES", 233, 248], ["Salmonella spp.", "SPECIES", 1109, 1124], ["swine", "SPECIES", 1131, 1136], ["B. bronchiseptica", "SPECIES", 1148, 1165], ["turkey", "SPECIES", 1885, 1891], ["chicken", "SPECIES", 1893, 1900], ["Swabs", "TEST", 0, 5], ["brushings", "TREATMENT", 76, 85], ["shedding Salmonella spp.", "PROBLEM", 224, 248], ["Campylobacter spp", "PROBLEM", 253, 270], ["diarrhea", "PROBLEM", 305, 313], ["pet's vaccinations", "TREATMENT", 411, 429], ["pet's feeding areas", "TREATMENT", 448, 467], ["its litter box", "TREATMENT", 478, 492], ["e) feed pets", "TREATMENT", 530, 542], ["meat products", "TREATMENT", 612, 625], ["pasteurized dairy products", "TREATMENT", 631, 657], ["diarrhea", "PROBLEM", 961, 969], ["avian tuberculosis", "PROBLEM", 1049, 1067], ["Salmonella spp.", "PROBLEM", 1109, 1124], ["B. bronchiseptica)", "PROBLEM", 1148, 1166], ["wounds", "PROBLEM", 1201, 1207], ["a particulate mask", "TREATMENT", 1407, 1425], ["shaking cages", "PROBLEM", 1436, 1449], ["additional precautions", "TREATMENT", 1535, 1557], ["serious infections", "PROBLEM", 1569, 1587], ["tap water", "TREATMENT", 1631, 1640], ["skinning animals", "TREATMENT", 1703, 1719], ["plastic bags", "TREATMENT", 1745, 1757], ["salad dressings", "TREATMENT", 2081, 2096], ["milk and egg products", "TREATMENT", 2106, 2127], ["swollen", "PROBLEM", 2202, 2209], ["less effective", "OBSERVATION_MODIFIER", 10, 24], ["Campylobacter spp", "OBSERVATION", 253, 270], ["tuberculosis", "OBSERVATION", 1055, 1067], ["face", "ANATOMY", 1192, 1196], ["wounds", "ANATOMY", 1201, 1207], ["serious", "OBSERVATION_MODIFIER", 1569, 1576], ["infections", "OBSERVATION", 1577, 1587], ["Clean", "OBSERVATION", 2002, 2007]]], ["Cut up fresh cheeses into small portions and store separately in the freezer, taking out only what can be used up quickly -Keep cold foods cold (<40 \u00b0F) and hot foods hot (>140 \u00b0F) -When preparing foods, the hands should be kept away from the hair, mouth and nose.", [["hair", "ANATOMY", 243, 247], ["mouth", "ANATOMY", 249, 254], ["nose", "ANATOMY", 259, 263], ["hands", "ORGANISM_SUBDIVISION", 208, 213], ["hair", "ORGANISM_SUBDIVISION", 243, 247], ["mouth", "ORGANISM_SUBDIVISION", 249, 254], ["nose", "ORGANISM_SUBDIVISION", 259, 263], ["fresh cheeses", "OBSERVATION", 7, 20], ["small", "OBSERVATION_MODIFIER", 26, 31], ["hands", "ANATOMY", 208, 213], ["hair", "ANATOMY", 243, 247], ["mouth", "ANATOMY", 249, 254], ["nose", "ANATOMY", 259, 263]]], ["If possible, rings and jewelry should be removed, because they may harbor germs.", [["germs", "ANATOMY", 74, 79], ["rings and jewelry", "TREATMENT", 13, 30]]], ["Try to limit touching food with the hands at all; use tongs or a fork if possible. -after cutting up raw meats, soak the cutting board and all utensils for 30-40 min in solution of one part bleach and eight or nine parts water -one ounce of bleach to a cup of water.", [["meats", "ANATOMY", 105, 110], ["hands", "ORGANISM_SUBDIVISION", 36, 41]]], ["All foods that are not going to be cooked should be prepared first; only after those are out of the way, can any raw meat and poultry be prepared -Wash all fruits and vegetables well -Keep food preparation surfaces clean, and use a good dishwashing detergent on the work surface often, especially while handling raw meat, chicken, or fish -Never let cats or other animals up on the work surface -Do not prepares food if you have diarrhea or vomiting, or have an open infected sore -Put leftover foods into the fridge right away and divide large leftovers into individual containers (to avoid repeated warming) Food restrictions -Raw eggs (sometimes used in restaurant-prepared Caesar salad dressing or homemade mayonnaise, eggnog) -Dried, uncooked or undercooked meats, seafood and poultry (to include medium or rare steaks, game, pickled fish or oysters), or food from delis such as cold cuts, hot dogs, tofu, sausage, bacon, cold smoked fish, and lox -Unpasteurized commercial fruit and vegetable juices -Unpasteurized milk or cheese products -Soft and aged cheeses such as feta, brie, camembert, blueveined, \u2212Mexican-style cheese, refrigerated cheese-based salad dressings (e.g., blue cheese)Other Personal Hygiene Items Including Food Handling.", [["meat", "ANATOMY", 117, 121], ["fruits", "ANATOMY", 156, 162], ["vegetables", "ANATOMY", 167, 177], ["surface", "ANATOMY", 271, 278], ["meat", "ANATOMY", 316, 320], ["meats", "ANATOMY", 763, 768], ["fruit", "ANATOMY", 979, 984], ["vegetable juices", "ANATOMY", 989, 1005], ["milk", "ANATOMY", 1021, 1025], ["feta", "ANATOMY", 1076, 1080], ["diarrhea", "DISEASE", 429, 437], ["vomiting", "DISEASE", 441, 449], ["sore", "DISEASE", 476, 480], ["tofu, sausage, bacon", "CHEMICAL", 905, 925], ["lox", "CHEMICAL", 949, 952], ["meat", "ORGANISM_SUBDIVISION", 117, 121], ["fruits", "ORGANISM_SUBDIVISION", 156, 162], ["vegetables", "ORGANISM_SUBDIVISION", 167, 177], ["meat", "ORGANISM_SUBDIVISION", 316, 320], ["chicken", "ORGANISM", 322, 329], ["fish", "ORGANISM_SUBDIVISION", 334, 338], ["cats", "ORGANISM", 350, 354], ["meats", "ORGANISM_SUBDIVISION", 763, 768], ["tofu", "ORGANISM_SUBDIVISION", 905, 909], ["sausage", "ORGANISM_SUBDIVISION", 911, 918], ["bacon", "ORGANISM_SUBDIVISION", 920, 925], ["vegetable juices", "ORGANISM_SUBSTANCE", 989, 1005], ["milk", "ORGANISM_SUBSTANCE", 1021, 1025], ["feta", "SIMPLE_CHEMICAL", 1076, 1080], ["camembert", "SIMPLE_CHEMICAL", 1088, 1097], ["chicken", "SPECIES", 322, 329], ["cats", "SPECIES", 350, 354], ["meats", "SPECIES", 763, 768], ["poultry", "SPECIES", 782, 789], ["dogs", "SPECIES", 899, 903], ["tofu", "SPECIES", 905, 909], ["sausage", "SPECIES", 911, 918], ["fruit", "SPECIES", 979, 984], ["vegetable", "SPECIES", 989, 998], ["milk", "SPECIES", 1021, 1025], ["cheese", "SPECIES", 1029, 1035], ["chicken", "SPECIES", 322, 329], ["tofu", "SPECIES", 905, 909], ["cheese", "SPECIES", 1029, 1035], ["blue cheese)", "SPECIES", 1183, 1195], ["diarrhea", "PROBLEM", 429, 437], ["vomiting", "PROBLEM", 441, 449], ["an open infected sore", "PROBLEM", 459, 480], ["repeated warming)", "TREATMENT", 592, 609], ["Caesar salad dressing", "TREATMENT", 677, 698], ["refrigerated cheese", "TREATMENT", 1134, 1153], ["based salad dressings", "TREATMENT", 1154, 1175], ["infected", "OBSERVATION_MODIFIER", 467, 475], ["sore", "OBSERVATION", 476, 480], ["large", "OBSERVATION_MODIFIER", 539, 544], ["Soft", "ANATOMY", 1046, 1050]]], ["Cream cheese, cottage cheese or yogurt (provided they do not contain Lactobacillus spp.) are ok to eat -Unwashed raw vegetables and fruits end those with visible mold -Unpasteurized honey or beer or raw, uncooked brewer's yeast -All miso products (e.g., miso soup); tempe (tempeh); mate'tea -All moldy and outdated food products -Herbal preparations and nutrient supplementsAir PrecautionsAir quality is important to prevent infections in high-risk patients by airborne organisms such as molds (Aspergillus spp. or other filamentous fungi), Legionella spp. and Mycobacterium tuberculosis.", [["vegetables", "ANATOMY", 117, 127], ["fruits", "ANATOMY", 132, 138], ["infections", "DISEASE", 425, 435], ["Legionella spp.", "DISEASE", 541, 556], ["Mycobacterium tuberculosis", "DISEASE", 561, 587], ["yogurt", "ORGANISM_SUBDIVISION", 32, 38], ["Lactobacillus spp.", "ORGANISM", 69, 87], ["vegetables", "ORGANISM_SUBDIVISION", 117, 127], ["fruits", "ORGANISM_SUBDIVISION", 132, 138], ["patients", "ORGANISM", 449, 457], ["Aspergillus spp", "ORGANISM", 495, 510], ["Legionella spp.", "ORGANISM", 541, 556], ["Mycobacterium tuberculosis", "ORGANISM", 561, 587], ["cheese", "SPECIES", 6, 12], ["cheese", "SPECIES", 22, 28], ["yogurt", "SPECIES", 32, 38], ["Lactobacillus spp.", "SPECIES", 69, 87], ["brewer", "SPECIES", 213, 219], ["yeast", "SPECIES", 222, 227], ["patients", "SPECIES", 449, 457], ["Aspergillus spp", "SPECIES", 495, 510], ["Legionella spp.", "SPECIES", 541, 556], ["Mycobacterium tuberculosis", "SPECIES", 561, 587], ["Lactobacillus spp.", "SPECIES", 69, 87], ["yeast", "SPECIES", 222, 227], ["Aspergillus spp", "SPECIES", 495, 510], ["Legionella spp.", "SPECIES", 541, 556], ["Mycobacterium tuberculosis", "SPECIES", 561, 587], ["Cream cheese", "TREATMENT", 0, 12], ["All miso products", "TREATMENT", 229, 246], ["miso soup", "TREATMENT", 254, 263], ["mate'tea", "TREATMENT", 282, 290], ["All moldy", "TREATMENT", 292, 301], ["outdated food products", "TREATMENT", 306, 328], ["Herbal preparations", "TREATMENT", 330, 349], ["nutrient supplements", "TREATMENT", 354, 374], ["Air Precautions", "TREATMENT", 374, 389], ["infections", "PROBLEM", 425, 435], ["airborne organisms", "PROBLEM", 461, 479], ["molds (Aspergillus spp", "PROBLEM", 488, 510], ["other filamentous fungi", "PROBLEM", 515, 538], ["Legionella spp.", "PROBLEM", 541, 556], ["Mycobacterium tuberculosis", "PROBLEM", 561, 587], ["infections", "OBSERVATION", 425, 435], ["high-risk", "OBSERVATION_MODIFIER", 439, 448], ["filamentous fungi", "OBSERVATION", 521, 538], ["Mycobacterium tuberculosis", "OBSERVATION", 561, 587]]], ["Patients at very high risk for invasive aspergillosis (IA) should be placed in sealed rooms with HEPA filters (central or point-in-use) and positive pressure.", [["invasive aspergillosis", "ANATOMY", 31, 53], ["aspergillosis", "DISEASE", 40, 53], ["IA", "DISEASE", 55, 57], ["Patients", "ORGANISM", 0, 8], ["aspergillosis", "CANCER", 40, 53], ["Patients", "SPECIES", 0, 8], ["invasive aspergillosis", "PROBLEM", 31, 53], ["HEPA filters", "TREATMENT", 97, 109], ["invasive", "OBSERVATION_MODIFIER", 31, 39], ["aspergillosis", "OBSERVATION", 40, 53], ["pressure", "OBSERVATION_MODIFIER", 149, 157]]], ["Air flow should be direct (air intake at one side of the room and air exhaust at the opposite side), and the system should be able to make \u226512 air exchanges per hour [6] .", [["Air flow", "TEST", 0, 8], ["flow", "OBSERVATION", 4, 8], ["air exhaust", "OBSERVATION", 66, 77]]], ["This group is represented mostly by patients receiving induction chemotherapy for acute myeloid leukemia (AML) and in the pre-engraftment period of myeloablative allogeneic hematopoietic cell transplantation (HCT).Air PrecautionsThe conidia levels in outdoor air vary widely, from 1-5 cfu/m 3 [7] to 2400 in winter and fall in certain areas [8] .", [["acute myeloid leukemia", "ANATOMY", 82, 104], ["AML", "ANATOMY", 106, 109], ["hematopoietic cell", "ANATOMY", 173, 191], ["HCT", "ANATOMY", 209, 212], ["acute myeloid leukemia", "DISEASE", 82, 104], ["AML", "DISEASE", 106, 109], ["patients", "ORGANISM", 36, 44], ["acute myeloid leukemia", "CANCER", 82, 104], ["AML", "CANCER", 106, 109], ["hematopoietic cell", "CELL", 173, 191], ["HCT", "CANCER", 209, 212], ["patients", "SPECIES", 36, 44], ["induction chemotherapy", "TREATMENT", 55, 77], ["acute myeloid leukemia", "PROBLEM", 82, 104], ["AML", "PROBLEM", 106, 109], ["myeloablative allogeneic hematopoietic cell transplantation", "TREATMENT", 148, 207], ["HCT", "TEST", 209, 212], ["Air Precautions", "TREATMENT", 214, 229], ["The conidia levels", "TEST", 229, 247], ["acute", "OBSERVATION_MODIFIER", 82, 87], ["myeloid leukemia", "OBSERVATION", 88, 104], ["myeloablative allogeneic hematopoietic cell transplantation", "OBSERVATION", 148, 207]]], ["The safe concentration of airborne fungi is not established and probably depends on the patient's immune status.", [["patient", "ORGANISM", 88, 95], ["patient", "SPECIES", 88, 95], ["airborne fungi", "TREATMENT", 26, 40], ["airborne fungi", "OBSERVATION", 26, 40]]], ["The efficacy of HEPA filters in preventing the entry of contaminated outside air into the hospital was confirmed after the demolition of a building.", [["HEPA filters", "TREATMENT", 16, 28], ["a building", "TREATMENT", 137, 147], ["HEPA filters", "OBSERVATION", 16, 28]]], ["Despite the increase in the number of conidia of filamentous fungi, no conidia were found in most HEPA filter-equipped areas [9] .", [["filamentous fungi", "ANATOMY", 49, 66], ["conidia", "ANATOMY", 71, 78], ["filamentous fungi", "PROBLEM", 49, 66], ["conidia", "PROBLEM", 71, 78], ["most HEPA filter", "TREATMENT", 93, 109], ["increase", "OBSERVATION_MODIFIER", 12, 20], ["filamentous fungi", "OBSERVATION", 49, 66], ["HEPA filter", "OBSERVATION", 98, 109]]], ["Because construction and renovation may increase the concentration of airborne fungi, guidelines have been developed when such activities are taking place close to areas were high-risk patients are cared for [10] .Air PrecautionsPortable HEPA filters decrease the concentration of airborne fungal spores [11] and their use has successfully prevented the occurrence of fungal infections during building construction [12] .", [["fungal infections", "DISEASE", 368, 385], ["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 185, 193], ["airborne fungi", "TREATMENT", 70, 84], ["Air Precautions", "TREATMENT", 214, 229], ["HEPA filters", "TREATMENT", 238, 250], ["airborne fungal spores", "PROBLEM", 281, 303], ["fungal infections", "PROBLEM", 368, 385], ["airborne fungi", "OBSERVATION", 70, 84], ["fungal", "OBSERVATION_MODIFIER", 368, 374], ["infections", "OBSERVATION", 375, 385]]], ["However, it is generally agreed that they are less efficient than central or point-in-use HEPA filters [3] .Air PrecautionsAirborne fungi have been shown to secondarily aerosolize from a water source [13] .", [["HEPA filters", "TREATMENT", 90, 102], ["Air Precautions", "TREATMENT", 108, 123], ["Airborne fungi", "TREATMENT", 123, 137]]], ["Therefore, preventive measures to limit exposure to water can decrease the airborne concentration of fungal pathogens (see below).DietAlthough no data exist to support a role for sterile or lowlevel microbial-content (<1000 CFU/mL of nonpathogenic organisms) diets for patients with hematological malignancy, this practice is generally recommended [3] .", [["hematological malignancy", "ANATOMY", 283, 307], ["hematological malignancy", "DISEASE", 283, 307], ["patients", "ORGANISM", 269, 277], ["patients", "SPECIES", 269, 277], ["preventive measures", "TREATMENT", 11, 30], ["fungal pathogens", "PROBLEM", 101, 117], ["sterile or lowlevel microbial", "TREATMENT", 179, 208], ["nonpathogenic organisms) diets", "TREATMENT", 234, 264], ["hematological malignancy", "PROBLEM", 283, 307], ["fungal pathogens", "OBSERVATION", 101, 117], ["malignancy", "OBSERVATION", 297, 307]]], ["A randomized study compared cooked and uncooked diet for patients undergoing induction remission for AML.", [["AML", "ANATOMY", 101, 104], ["AML", "DISEASE", 101, 104], ["patients", "ORGANISM", 57, 65], ["AML", "CANCER", 101, 104], ["patients", "SPECIES", 57, 65], ["A randomized study", "TEST", 0, 18], ["patients undergoing induction remission", "TREATMENT", 57, 96], ["AML", "PROBLEM", 101, 104]]], ["There were no differences in the rates of episodes of major infection and death [14] .", [["infection", "DISEASE", 60, 69], ["death", "DISEASE", 74, 79], ["major infection", "PROBLEM", 54, 69], ["no", "UNCERTAINTY", 11, 13], ["differences", "OBSERVATION_MODIFIER", 14, 25], ["major", "OBSERVATION_MODIFIER", 54, 59], ["infection", "OBSERVATION", 60, 69]]], ["Since pooling of results was not possible, and serious methodologic limitations were found, the authors could not provide solid recommendations for clinical practice [15] .WaterThe hospital water system can be a reservoir for Legionella spp.", [["Legionella spp", "DISEASE", 226, 240], ["Legionella spp", "ORGANISM", 226, 240], ["serious methodologic limitations", "PROBLEM", 47, 79], ["The hospital water system", "TREATMENT", 177, 202], ["a reservoir", "TREATMENT", 210, 221], ["Legionella spp", "PROBLEM", 226, 240], ["not possible", "UNCERTAINTY", 29, 41]]], ["[16] , bacteria [17] [18] [19] , and the opportunistic molds, especially Aspergillus spp.", [["[17] [18] [19]", "CHEMICAL", 16, 30], ["opportunistic molds", "DISEASE", 41, 60], ["Aspergillus spp", "DISEASE", 73, 88], ["[16] , bacteria [17] [18] [19]", "SIMPLE_CHEMICAL", 0, 30], ["Aspergillus spp", "ORGANISM", 73, 88], ["Aspergillus spp", "SPECIES", 73, 88], ["bacteria", "PROBLEM", 7, 15], ["the opportunistic molds", "PROBLEM", 37, 60], ["Aspergillus spp", "PROBLEM", 73, 88], ["opportunistic molds", "OBSERVATION", 41, 60], ["Aspergillus spp", "OBSERVATION", 73, 88]]], ["[13, [20] [21] [22] , Fusarium spp.", [["[13, [20] [21] [22]", "SIMPLE_CHEMICAL", 0, 19], ["Fusarium spp", "SIMPLE_CHEMICAL", 22, 34], ["Fusarium spp", "PROBLEM", 22, 34]]], ["[23, 24] , and Exophiala jeanselmei [25] .", [["Exophiala jeanselmei", "ORGANISM", 15, 35], ["Exophiala jeanselmei", "SPECIES", 15, 35], ["Exophiala jeanselmei", "SPECIES", 15, 35]]], ["Potential modes of acquisition of infection include contamination of intravenous solutions, direct contact with skin breakdowns, and aerosolization of fungal spores.", [["intravenous", "ANATOMY", 69, 80], ["skin", "ANATOMY", 112, 116], ["spores", "ANATOMY", 158, 164], ["infection", "DISEASE", 34, 43], ["skin breakdowns", "DISEASE", 112, 127], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 69, 80], ["skin", "ORGAN", 112, 116], ["infection", "PROBLEM", 34, 43], ["contamination of intravenous solutions", "TREATMENT", 52, 90], ["skin breakdowns", "PROBLEM", 112, 127], ["fungal spores", "PROBLEM", 151, 164], ["infection", "OBSERVATION", 34, 43], ["skin", "ANATOMY", 112, 116], ["breakdowns", "OBSERVATION", 117, 127], ["fungal spores", "OBSERVATION", 151, 164]]], ["Measures to prevent the occurrence of infection depend on the mode of acquisition.", [["infection", "DISEASE", 38, 47], ["Measures", "TREATMENT", 0, 8], ["infection", "PROBLEM", 38, 47], ["infection", "OBSERVATION", 38, 47]]], ["It is generally recommended that patients at risk for such infections should avoid direct exposure to contaminated water.", [["infections", "DISEASE", 59, 69], ["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["such infections", "PROBLEM", 54, 69]]], ["In addition, specific measures have been tested, including the use of point-in-use water filters for Legionella spp.", [["Legionella spp", "ORGANISM", 101, 115], ["water filters", "TREATMENT", 83, 96], ["Legionella spp", "PROBLEM", 101, 115]]], ["[26] and cleaning waterrelated structures to prevent aerosolization of fungi [27] .Health Care Workers (HCW)Infections can be transmitted from the HCW to the patient.", [["Infections", "DISEASE", 108, 118], ["patient", "ORGANISM", 158, 165], ["patient", "SPECIES", 158, 165], ["cleaning waterrelated structures", "TREATMENT", 9, 41], ["aerosolization of fungi", "PROBLEM", 53, 76], ["aerosolization", "OBSERVATION", 53, 67], ["fungi", "OBSERVATION", 71, 76]]], ["The risk of transmission is high for Varicella zoster (VZV), viral conjunctivitis, measles, and tuberculosis, and intermediate for influenza, mumps, Parvovirus B19, pertussis, respiratory syncytial virus (RSV), rotavirus, and rubella.", [["Varicella zoster", "DISEASE", 37, 53], ["VZV", "DISEASE", 55, 58], ["viral conjunctivitis", "DISEASE", 61, 81], ["measles", "DISEASE", 83, 90], ["tuberculosis", "DISEASE", 96, 108], ["influenza", "DISEASE", 131, 140], ["mumps", "DISEASE", 142, 147], ["Parvovirus B19, pertussis", "DISEASE", 149, 174], ["respiratory syncytial virus (RSV), rotavirus, and rubella", "DISEASE", 176, 233], ["Varicella zoster", "ORGANISM", 37, 53], ["VZV", "ORGANISM", 55, 58], ["Parvovirus B19", "ORGANISM", 149, 163], ["pertussis,", "ORGANISM", 165, 175], ["respiratory syncytial virus", "ORGANISM", 176, 203], ["RSV", "ORGANISM", 205, 208], ["Varicella zoster", "SPECIES", 37, 53], ["Parvovirus B19", "SPECIES", 149, 163], [", pertussis", "SPECIES", 163, 174], ["respiratory syncytial virus", "SPECIES", 176, 203], ["RSV", "SPECIES", 205, 208], ["VZV", "SPECIES", 55, 58], ["Parvovirus B19", "SPECIES", 149, 163], ["respiratory syncytial virus", "SPECIES", 176, 203], ["RSV", "SPECIES", 205, 208], ["rotavirus", "SPECIES", 211, 220], ["Varicella zoster", "PROBLEM", 37, 53], ["VZV", "PROBLEM", 55, 58], ["viral conjunctivitis", "PROBLEM", 61, 81], ["measles", "PROBLEM", 83, 90], ["tuberculosis", "PROBLEM", 96, 108], ["influenza", "PROBLEM", 131, 140], ["mumps", "PROBLEM", 142, 147], ["Parvovirus B19", "PROBLEM", 149, 163], ["pertussis", "PROBLEM", 165, 174], ["respiratory syncytial virus", "PROBLEM", 176, 203], ["RSV", "PROBLEM", 205, 208], ["rotavirus", "PROBLEM", 211, 220], ["rubella", "PROBLEM", 226, 233], ["viral conjunctivitis", "OBSERVATION", 61, 81], ["respiratory syncytial", "ANATOMY", 176, 197], ["rubella", "ANATOMY", 226, 233]]], ["Therefore, HCW with any of the abovementioned infections or with HSV lesions in lips or fingers should not be in contact with patients [3] .Health Care Workers (HCW)HCW who care for patients with hematological cancer should be immunized against rubella, measles, mumps, influenza, and chickenpox, in addition to the already recommended tetanus and hepatitis B immunization [3] .Household ExposureThe recommendations for immunization and precautions that apply to the HCW also apply to close contacts of patients with hematological cancer [3] .", [["lesions", "ANATOMY", 69, 76], ["lips", "ANATOMY", 80, 84], ["fingers", "ANATOMY", 88, 95], ["hematological cancer", "ANATOMY", 196, 216], ["hematological cancer", "ANATOMY", 517, 537], ["infections", "DISEASE", 46, 56], ["HSV lesions", "DISEASE", 65, 76], ["hematological cancer", "DISEASE", 196, 216], ["rubella, measles, mumps", "DISEASE", 245, 268], ["influenza", "DISEASE", 270, 279], ["chickenpox", "DISEASE", 285, 295], ["tetanus", "DISEASE", 336, 343], ["hepatitis B", "DISEASE", 348, 359], ["hematological cancer", "DISEASE", 517, 537], ["HSV", "ORGANISM", 65, 68], ["lips", "ORGANISM_SUBDIVISION", 80, 84], ["fingers", "ORGANISM_SUBDIVISION", 88, 95], ["patients", "ORGANISM", 126, 134], ["patients", "ORGANISM", 182, 190], ["hematological cancer", "CANCER", 196, 216], ["rubella", "ORGANISM", 245, 252], ["hepatitis B", "ORGANISM", 348, 359], ["patients", "ORGANISM", 503, 511], ["hematological cancer", "CANCER", 517, 537], ["patients", "SPECIES", 126, 134], ["patients", "SPECIES", 182, 190], ["patients", "SPECIES", 503, 511], ["HSV", "SPECIES", 65, 68], ["the abovementioned infections", "PROBLEM", 27, 56], ["HSV lesions in lips or fingers", "PROBLEM", 65, 95], ["hematological cancer", "PROBLEM", 196, 216], ["rubella", "PROBLEM", 245, 252], ["measles", "PROBLEM", 254, 261], ["mumps", "PROBLEM", 263, 268], ["influenza", "PROBLEM", 270, 279], ["chickenpox", "PROBLEM", 285, 295], ["tetanus", "TREATMENT", 336, 343], ["hepatitis B immunization", "TREATMENT", 348, 372], ["immunization", "TREATMENT", 420, 432], ["precautions", "TREATMENT", 437, 448], ["hematological cancer", "PROBLEM", 517, 537], ["infections", "OBSERVATION", 46, 56], ["lips", "ANATOMY", 80, 84], ["cancer", "OBSERVATION", 210, 216], ["cancer", "OBSERVATION", 531, 537]]], ["Immunization against hepatitis A and B is highly recommended for sexual contacts of patients.", [["hepatitis A and B", "DISEASE", 21, 38], ["hepatitis A", "ORGANISM", 21, 32], ["B", "CANCER", 37, 38], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["hepatitis A", "SPECIES", 21, 32], ["Immunization", "TREATMENT", 0, 12]]], ["In addition, immunization against hepatitis A should be considered for all households of patients with chronic liver disease or living in endemic areas.", [["liver", "ANATOMY", 111, 116], ["hepatitis A", "DISEASE", 34, 45], ["chronic liver disease", "DISEASE", 103, 124], ["hepatitis A", "ORGANISM", 34, 45], ["patients", "ORGANISM", 89, 97], ["liver", "ORGAN", 111, 116], ["patients", "SPECIES", 89, 97], ["hepatitis A", "SPECIES", 34, 45], ["immunization", "TREATMENT", 13, 25], ["hepatitis", "PROBLEM", 34, 43], ["chronic liver disease", "PROBLEM", 103, 124], ["liver", "ANATOMY", 111, 116], ["disease", "OBSERVATION", 117, 124]]], ["Oral polio vaccine is contraindicated for all households of patients with hematological cancer since live polioviruses can be transmitted to and cause disease in immunocompromised patients, especially during the first month after vaccination [28] .", [["Oral", "ANATOMY", 0, 4], ["hematological cancer", "ANATOMY", 74, 94], ["hematological cancer", "DISEASE", 74, 94], ["patients", "ORGANISM", 60, 68], ["hematological cancer", "CANCER", 74, 94], ["patients", "ORGANISM", 180, 188], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 180, 188], ["Oral polio vaccine", "TREATMENT", 0, 18], ["hematological cancer", "PROBLEM", 74, 94], ["live polioviruses", "PROBLEM", 101, 118], ["disease in immunocompromised patients", "PROBLEM", 151, 188], ["cancer", "OBSERVATION", 88, 94], ["immunocompromised", "OBSERVATION", 162, 179]]], ["Patients with hematological cancer should also avoid exposure to individuals with vesicular rash secondary to chickenpox immunization to prevent VZV disease [3] .Household ExposureSexual partners: Sexually active patients should avoid unprotected sex during the periods of significant immunosuppression to reduce the risk of exposure to CMV, HSV, HIV, HPV, HBV, HBC, and other sexually transmitted infections [3] .Invasive ProceduresProcedures that break the integrity of natural barriers such as skin and mucosa should be avoided when possible.", [["hematological cancer", "ANATOMY", 14, 34], ["vesicular", "ANATOMY", 82, 91], ["skin", "ANATOMY", 497, 501], ["mucosa", "ANATOMY", 506, 512], ["hematological cancer", "DISEASE", 14, 34], ["vesicular rash", "DISEASE", 82, 96], ["chickenpox", "DISEASE", 110, 120], ["VZV disease", "DISEASE", 145, 156], ["CMV, HSV, HIV, HPV, HBV, HBC", "DISEASE", 337, 365], ["sexually transmitted infections", "DISEASE", 377, 408], ["Patients", "ORGANISM", 0, 8], ["hematological cancer", "CANCER", 14, 34], ["VZV", "ORGANISM", 145, 148], ["patients", "ORGANISM", 213, 221], ["CMV", "ORGANISM", 337, 340], ["HSV", "ORGANISM", 342, 345], ["HIV", "ORGANISM", 347, 350], ["HPV", "ORGANISM", 352, 355], ["HBV", "ORGANISM", 357, 360], ["HBC", "CANCER", 362, 365], ["skin", "ORGAN", 497, 501], ["mucosa", "MULTI-TISSUE_STRUCTURE", 506, 512], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 213, 221], ["HIV", "SPECIES", 347, 350], ["VZV", "SPECIES", 145, 148], ["CMV", "SPECIES", 337, 340], ["HSV", "SPECIES", 342, 345], ["HIV", "SPECIES", 347, 350], ["HPV", "SPECIES", 352, 355], ["HBV", "SPECIES", 357, 360], ["hematological cancer", "PROBLEM", 14, 34], ["vesicular rash", "PROBLEM", 82, 96], ["chickenpox immunization", "TREATMENT", 110, 133], ["VZV disease", "PROBLEM", 145, 156], ["significant immunosuppression", "TREATMENT", 273, 302], ["CMV", "PROBLEM", 337, 340], ["HSV", "PROBLEM", 342, 345], ["HIV", "PROBLEM", 347, 350], ["HPV", "PROBLEM", 352, 355], ["HBV", "PROBLEM", 357, 360], ["HBC", "PROBLEM", 362, 365], ["other sexually transmitted infections", "PROBLEM", 371, 408], ["Invasive ProceduresProcedures", "TREATMENT", 414, 443], ["natural barriers", "TREATMENT", 472, 488], ["skin and mucosa", "TREATMENT", 497, 512], ["hematological", "ANATOMY", 14, 27], ["cancer", "OBSERVATION", 28, 34], ["skin", "ANATOMY", 497, 501], ["mucosa", "ANATOMY", 506, 512]]], ["Fixed orthodontic appliances and space maintainers should not be worn during any period of neutropenia to avoid oral trauma and infection.", [["oral", "ANATOMY", 112, 116], ["neutropenia", "DISEASE", 91, 102], ["trauma", "DISEASE", 117, 123], ["infection", "DISEASE", 128, 137], ["oral", "ORGANISM_SUBDIVISION", 112, 116], ["Fixed orthodontic appliances", "TREATMENT", 0, 28], ["space maintainers", "TREATMENT", 33, 50], ["neutropenia", "PROBLEM", 91, 102], ["oral trauma", "PROBLEM", 112, 123], ["infection", "PROBLEM", 128, 137], ["orthodontic appliances", "OBSERVATION", 6, 28], ["infection", "OBSERVATION", 128, 137]]], ["Enemas, suppositories, rectal temperature check, or/and rectal examination are contraindicated.", [["rectal", "ANATOMY", 23, 29], ["rectal", "ANATOMY", 56, 62], ["Enemas", "DISEASE", 0, 6], ["rectal", "ORGAN", 56, 62], ["Enemas", "TREATMENT", 0, 6], ["suppositories", "TREATMENT", 8, 21], ["rectal temperature check", "TEST", 23, 47], ["rectal examination", "TEST", 56, 74], ["rectal", "ANATOMY", 23, 29], ["rectal", "ANATOMY", 56, 62]]], ["Necessary dental procedures should be performed prior to chemotherapy to allow proper healing before neutropenia and mucositis develop [29] .", [["neutropenia", "DISEASE", 101, 112], ["mucositis", "DISEASE", 117, 126], ["dental procedures", "TREATMENT", 10, 27], ["chemotherapy", "TREATMENT", 57, 69], ["proper healing", "PROBLEM", 79, 93], ["neutropenia", "PROBLEM", 101, 112], ["mucositis", "PROBLEM", 117, 126]]], ["Bone marrow biopsies should be done aseptically to avoid cellulitis and osteomyelitis.Invasive ProceduresRecommendations for the insertion of indwelling devices include careful cleaning and sterilization of instruments and devices (particularly reusable ones) and guidelines for the prevention of intravascular device-related infections [30] .", [["Bone marrow", "ANATOMY", 0, 11], ["intravascular", "ANATOMY", 297, 310], ["cellulitis", "DISEASE", 57, 67], ["osteomyelitis", "DISEASE", 72, 85], ["infections", "DISEASE", 326, 336], ["Bone marrow biopsies", "MULTI-TISSUE_STRUCTURE", 0, 20], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 297, 310], ["Bone marrow biopsies", "TEST", 0, 20], ["cellulitis", "PROBLEM", 57, 67], ["osteomyelitis", "PROBLEM", 72, 85], ["Invasive ProceduresRecommendations", "TREATMENT", 86, 120], ["the insertion of indwelling devices", "TREATMENT", 125, 160], ["careful cleaning", "TREATMENT", 169, 185], ["sterilization of instruments and devices (particularly reusable ones", "TREATMENT", 190, 258], ["intravascular device", "TREATMENT", 297, 317], ["related infections", "PROBLEM", 318, 336], ["marrow", "ANATOMY", 5, 11], ["cellulitis", "OBSERVATION", 57, 67], ["osteomyelitis", "OBSERVATION", 72, 85], ["indwelling", "OBSERVATION", 142, 152], ["intravascular device", "OBSERVATION", 297, 317], ["infections", "OBSERVATION", 326, 336]]], ["However, solid evidence to support some of the guidelines for the prevention of intravascular device-related infections is lacking.Antimicrobial ProphylaxisAntimicrobial prophylaxis may be primary, when prevention targets an individual that has not been infected in the past, and secondary, when prevention is used to avoid recurrence of infection in an individual who has been previously infected.Antibacterial ProphylaxisBacterial infections occur frequently in two settings: neutropenia and hypogammaglobulinemia.", [["intravascular", "ANATOMY", 80, 93], ["infections", "DISEASE", 109, 119], ["ProphylaxisAntimicrobial", "CHEMICAL", 145, 169], ["infection", "DISEASE", 338, 347], ["ProphylaxisBacterial infections", "DISEASE", 412, 443], ["neutropenia", "DISEASE", 478, 489], ["hypogammaglobulinemia", "DISEASE", 494, 515], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 80, 93], ["the guidelines", "TREATMENT", 43, 57], ["intravascular device", "TREATMENT", 80, 100], ["related infections", "PROBLEM", 101, 119], ["Antimicrobial ProphylaxisAntimicrobial prophylaxis", "TREATMENT", 131, 181], ["infection", "PROBLEM", 338, 347], ["Antibacterial ProphylaxisBacterial infections", "PROBLEM", 398, 443], ["neutropenia", "PROBLEM", 478, 489], ["hypogammaglobulinemia", "PROBLEM", 494, 515], ["intravascular device", "OBSERVATION", 80, 100], ["infections", "OBSERVATION", 109, 119], ["infection", "OBSERVATION", 338, 347], ["infected", "OBSERVATION", 389, 397], ["infections", "OBSERVATION", 433, 443], ["neutropenia", "OBSERVATION", 478, 489], ["hypogammaglobulinemia", "OBSERVATION", 494, 515]]], ["As shown in Table 49 .2, common bacterial infections in patients with neutropenia include staphylococci, enterococci, and viridans streptococci among the Gram-positive bacteria, and enterobacteria and non-fermentative bacteria (especially Pseudomonas aeruginosa, Acinetobacter spp., and Stenotrophomonas spp. among the Gram-negative bacteria).Antibacterial ProphylaxisBecause Gram-negative bacteremia may be associated with high mortality rates, strategies of antibacterial prophylaxis during neutropenia have been focused mostly to prevent the occurrence of Gram-negative bacteremia, and the quinolones have been extensively studied.", [["bacterial infections", "DISEASE", 32, 52], ["neutropenia", "DISEASE", 70, 81], ["staphylococci", "DISEASE", 90, 103], ["bacteremia", "DISEASE", 390, 400], ["neutropenia", "DISEASE", 493, 504], ["bacteremia", "DISEASE", 573, 583], ["quinolones", "CHEMICAL", 593, 603], ["quinolones", "CHEMICAL", 593, 603], ["patients", "ORGANISM", 56, 64], ["Pseudomonas aeruginosa", "ORGANISM", 239, 261], ["Acinetobacter spp.", "ORGANISM", 263, 281], ["Stenotrophomonas spp", "ORGANISM", 287, 307], ["Gram", "GENE_OR_GENE_PRODUCT", 559, 563], ["quinolones", "SIMPLE_CHEMICAL", 593, 603], ["patients", "SPECIES", 56, 64], ["Pseudomonas aeruginosa", "SPECIES", 239, 261], ["Acinetobacter spp.", "SPECIES", 263, 281], ["Pseudomonas aeruginosa", "SPECIES", 239, 261], ["Acinetobacter spp.", "SPECIES", 263, 281], ["Stenotrophomonas spp", "SPECIES", 287, 307], ["common bacterial infections", "PROBLEM", 25, 52], ["neutropenia", "PROBLEM", 70, 81], ["staphylococci", "PROBLEM", 90, 103], ["enterococci", "PROBLEM", 105, 116], ["viridans streptococci", "PROBLEM", 122, 143], ["the Gram-positive bacteria", "PROBLEM", 150, 176], ["enterobacteria", "PROBLEM", 182, 196], ["non-fermentative bacteria", "PROBLEM", 201, 226], ["Pseudomonas aeruginosa", "PROBLEM", 239, 261], ["Acinetobacter spp.", "PROBLEM", 263, 281], ["Stenotrophomonas spp", "PROBLEM", 287, 307], ["Antibacterial", "TREATMENT", 343, 356], ["Gram-negative bacteremia", "PROBLEM", 376, 400], ["high mortality rates", "PROBLEM", 424, 444], ["antibacterial prophylaxis", "TREATMENT", 460, 485], ["neutropenia", "PROBLEM", 493, 504], ["Gram-negative bacteremia", "PROBLEM", 559, 583], ["the quinolones", "TREATMENT", 589, 603], ["bacterial", "OBSERVATION_MODIFIER", 32, 41], ["infections", "OBSERVATION", 42, 52], ["staphylococci", "OBSERVATION", 90, 103], ["enterococci", "OBSERVATION", 105, 116], ["viridans streptococci", "OBSERVATION", 122, 143], ["positive bacteria", "OBSERVATION", 159, 176], ["negative bacteria", "OBSERVATION", 324, 341], ["bacteremia", "OBSERVATION", 390, 400], ["negative", "OBSERVATION_MODIFIER", 564, 572], ["bacteremia", "OBSERVATION", 573, 583]]], ["A meta-analysis pooling data from 95 trials showed that quinolones reduced the incidence of fever, documented infections, and mortality associated with infection [31] .", [["quinolones", "CHEMICAL", 56, 66], ["fever", "DISEASE", 92, 97], ["infections", "DISEASE", 110, 120], ["infection", "DISEASE", 152, 161], ["quinolones", "CHEMICAL", 56, 66], ["quinolones", "SIMPLE_CHEMICAL", 56, 66], ["A meta-analysis pooling data", "TEST", 0, 28], ["quinolones", "TREATMENT", 56, 66], ["fever", "PROBLEM", 92, 97], ["documented infections", "PROBLEM", 99, 120], ["infection", "PROBLEM", 152, 161], ["fever", "OBSERVATION", 92, 97], ["infections", "OBSERVATION", 110, 120]]], ["A major concern is the development of resistance.", [["resistance", "PROBLEM", 38, 48], ["resistance", "OBSERVATION", 38, 48]]], ["Another meta-analysis examined the effect of quinolone prophylaxis on microbial resistance.", [["quinolone", "CHEMICAL", 45, 54], ["quinolone", "CHEMICAL", 45, 54], ["quinolone", "SIMPLE_CHEMICAL", 45, 54], ["Another meta-analysis", "TEST", 0, 21], ["quinolone prophylaxis", "TREATMENT", 45, 66], ["microbial resistance", "TREATMENT", 70, 90], ["microbial resistance", "OBSERVATION", 70, 90]]], ["There was no difference in the incidence of colonization by resistant organisms, or in the rates of infection caused by resistant pathogens [32] .", [["infection", "DISEASE", 100, 109], ["colonization", "PROBLEM", 44, 56], ["resistant organisms", "PROBLEM", 60, 79], ["infection", "PROBLEM", 100, 109], ["resistant pathogens", "PROBLEM", 120, 139], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23], ["colonization", "OBSERVATION", 44, 56], ["infection", "OBSERVATION", 100, 109]]], ["These data, however, must be interpreted with caution, because rates of resistance are very different among different institutions, cities, and countries.", [["These data", "TEST", 0, 10], ["resistance", "PROBLEM", 72, 82]]], ["As a general rule, once the clinician decides to give prophylaxis with a quinolone for neutropenic patients, a careful attention to the development of resistance is advised.Antibacterial ProphylaxisAnother concern when using quinolone prophylaxis is the increase in the incidence of infections caused by Grampositive organism, notably viridans streptococci [33, 34] .", [["quinolone", "CHEMICAL", 73, 82], ["neutropenic", "DISEASE", 87, 98], ["quinolone", "CHEMICAL", 225, 234], ["infections", "DISEASE", 283, 293], ["viridans streptococci", "DISEASE", 335, 356], ["quinolone", "CHEMICAL", 73, 82], ["quinolone", "CHEMICAL", 225, 234], ["quinolone", "SIMPLE_CHEMICAL", 73, 82], ["patients", "ORGANISM", 99, 107], ["quinolone", "SIMPLE_CHEMICAL", 225, 234], ["viridans streptococci", "ORGANISM", 335, 356], ["patients", "SPECIES", 99, 107], ["prophylaxis", "TREATMENT", 54, 65], ["a quinolone", "TREATMENT", 71, 82], ["neutropenic patients", "TREATMENT", 87, 107], ["Antibacterial ProphylaxisAnother", "TREATMENT", 173, 205], ["quinolone prophylaxis", "TREATMENT", 225, 246], ["infections", "PROBLEM", 283, 293], ["Grampositive organism", "PROBLEM", 304, 325], ["viridans streptococci", "PROBLEM", 335, 356], ["increase", "OBSERVATION_MODIFIER", 254, 262], ["infections", "OBSERVATION", 283, 293], ["viridans streptococci", "OBSERVATION", 335, 356]]], ["A great concern related to such infections is that they may occasionally evolve to shock and respiratory failure [35] .Antibacterial ProphylaxisAlthough most of such infections may be prevented by penicillin or macrolides [36] , some strains are resistant to these agents [37] .", [["respiratory", "ANATOMY", 93, 104], ["infections", "DISEASE", 32, 42], ["shock", "DISEASE", 83, 88], ["respiratory failure", "DISEASE", 93, 112], ["infections", "DISEASE", 166, 176], ["penicillin", "CHEMICAL", 197, 207], ["macrolides", "CHEMICAL", 211, 221], ["penicillin", "CHEMICAL", 197, 207], ["macrolides", "CHEMICAL", 211, 221], ["penicillin", "SIMPLE_CHEMICAL", 197, 207], ["macrolides", "SIMPLE_CHEMICAL", 211, 221], ["such infections", "PROBLEM", 27, 42], ["shock", "PROBLEM", 83, 88], ["respiratory failure", "PROBLEM", 93, 112], ["Antibacterial ProphylaxisAlthough", "TREATMENT", 119, 152], ["such infections", "PROBLEM", 161, 176], ["penicillin", "TREATMENT", 197, 207], ["macrolides", "TREATMENT", 211, 221], ["some strains", "PROBLEM", 229, 241], ["infections", "OBSERVATION", 32, 42], ["shock", "OBSERVATION", 83, 88], ["respiratory failure", "OBSERVATION", 93, 112]]], ["The use of glycopeptides is not generally recommended for prophylaxis [3] .", [["glycopeptides", "TREATMENT", 11, 24], ["prophylaxis", "TREATMENT", 58, 69]]], ["Table 49 .4 shows the usual doses of quinolones in the prophylaxis of bacterial infections in neutropenic patients.Antibacterial ProphylaxisHypogammaglobulinemia is frequent in chronic lymphocytic leukemia, multiple myeloma, and in allogeneic HCT recipients who develop GVHD.", [["chronic lymphocytic leukemia", "ANATOMY", 177, 205], ["myeloma", "ANATOMY", 216, 223], ["HCT", "ANATOMY", 243, 246], ["quinolones", "CHEMICAL", 37, 47], ["bacterial infections", "DISEASE", 70, 90], ["neutropenic", "DISEASE", 94, 105], ["Hypogammaglobulinemia", "DISEASE", 140, 161], ["chronic lymphocytic leukemia", "DISEASE", 177, 205], ["multiple myeloma", "DISEASE", 207, 223], ["GVHD", "DISEASE", 270, 274], ["quinolones", "CHEMICAL", 37, 47], ["quinolones", "SIMPLE_CHEMICAL", 37, 47], ["patients", "ORGANISM", 106, 114], ["chronic lymphocytic leukemia", "CANCER", 177, 205], ["myeloma", "CANCER", 216, 223], ["HCT", "CANCER", 243, 246], ["patients", "SPECIES", 106, 114], ["quinolones", "TREATMENT", 37, 47], ["bacterial infections", "PROBLEM", 70, 90], ["neutropenic patients", "TREATMENT", 94, 114], ["Antibacterial Prophylaxis", "TREATMENT", 115, 140], ["Hypogammaglobulinemia", "PROBLEM", 140, 161], ["chronic lymphocytic leukemia", "PROBLEM", 177, 205], ["multiple myeloma", "PROBLEM", 207, 223], ["allogeneic HCT recipients", "TREATMENT", 232, 257], ["GVHD", "PROBLEM", 270, 274], ["bacterial", "OBSERVATION_MODIFIER", 70, 79], ["infections", "OBSERVATION", 80, 90], ["ProphylaxisHypogammaglobulinemia", "OBSERVATION", 129, 161], ["frequent", "OBSERVATION_MODIFIER", 165, 173], ["chronic", "OBSERVATION_MODIFIER", 177, 184], ["lymphocytic leukemia", "OBSERVATION", 185, 205], ["multiple", "OBSERVATION_MODIFIER", 207, 215], ["myeloma", "OBSERVATION", 216, 223], ["GVHD", "OBSERVATION", 270, 274]]], ["These patients are at greater risk of developing bacterial infections, particularly by encapsulated bacteria.", [["bacterial infections", "DISEASE", 49, 69], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["developing bacterial infections", "PROBLEM", 38, 69], ["encapsulated bacteria", "PROBLEM", 87, 108], ["bacterial", "OBSERVATION_MODIFIER", 49, 58], ["infections", "OBSERVATION", 59, 69], ["encapsulated", "OBSERVATION_MODIFIER", 87, 99], ["bacteria", "OBSERVATION", 100, 108]]], ["Intravenous immunoglobulin (400 mg/kg) every 4 weeks may be effective for the prevention of bacterial infections, and this recommendation is supported by randomized controlled studies [38] [39] [40] .", [["bacterial infections", "DISEASE", 92, 112], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 12, 26], ["[38] [39] [40]", "SIMPLE_CHEMICAL", 184, 198], ["immunoglobulin", "PROTEIN", 12, 26], ["Intravenous immunoglobulin", "TREATMENT", 0, 26], ["bacterial infections", "PROBLEM", 92, 112], ["bacterial", "OBSERVATION_MODIFIER", 92, 101], ["infections", "OBSERVATION", 102, 112]]], ["However, since its use is costly, intravenous immunoglobulin should be reserved to a selected population of patients with repeated episodes of severe infections.", [["intravenous", "ANATOMY", 34, 45], ["infections", "DISEASE", 150, 160], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 34, 45], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 46, 60], ["patients", "ORGANISM", 108, 116], ["intravenous immunoglobulin", "PROTEIN", 34, 60], ["patients", "SPECIES", 108, 116], ["intravenous immunoglobulin", "TREATMENT", 34, 60], ["severe infections", "PROBLEM", 143, 160], ["severe", "OBSERVATION_MODIFIER", 143, 149], ["infections", "OBSERVATION", 150, 160]]], ["A meta-analysis of nine studies comparing intravenous immunoglobulin with a control group in patients with chronic lymphocytic leukemia or multiple myeloma did not show any survival benefit of immunoglobulin prophylaxis.", [["intravenous", "ANATOMY", 42, 53], ["chronic lymphocytic leukemia", "ANATOMY", 107, 135], ["myeloma", "ANATOMY", 148, 155], ["chronic lymphocytic leukemia", "DISEASE", 107, 135], ["multiple myeloma", "DISEASE", 139, 155], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 42, 53], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 54, 68], ["patients", "ORGANISM", 93, 101], ["chronic lymphocytic leukemia", "CANCER", 107, 135], ["myeloma", "CANCER", 148, 155], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 193, 207], ["intravenous immunoglobulin", "PROTEIN", 42, 68], ["immunoglobulin", "PROTEIN", 193, 207], ["patients", "SPECIES", 93, 101], ["A meta-analysis", "TEST", 0, 15], ["nine studies", "TEST", 19, 31], ["intravenous immunoglobulin", "TREATMENT", 42, 68], ["chronic lymphocytic leukemia", "PROBLEM", 107, 135], ["multiple myeloma", "PROBLEM", 139, 155], ["immunoglobulin prophylaxis", "TREATMENT", 193, 219], ["chronic", "OBSERVATION_MODIFIER", 107, 114], ["lymphocytic leukemia", "OBSERVATION", 115, 135], ["multiple", "OBSERVATION_MODIFIER", 139, 147], ["myeloma", "OBSERVATION", 148, 155], ["immunoglobulin prophylaxis", "OBSERVATION", 193, 219]]], ["However, a reduction in the incidence of major infections and of clinically documented infections was observed.", [["infections", "DISEASE", 47, 57], ["infections", "DISEASE", 87, 97], ["major infections", "PROBLEM", 41, 57], ["clinically documented infections", "PROBLEM", 65, 97], ["reduction", "OBSERVATION_MODIFIER", 11, 20], ["major", "OBSERVATION_MODIFIER", 41, 46], ["infections", "OBSERVATION", 47, 57], ["infections", "OBSERVATION", 87, 97]]], ["The authors concluded that intravenous immunoglobulin should not be recommended routinely [41] .", [["intravenous", "ANATOMY", 27, 38], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 27, 38], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 39, 53], ["intravenous immunoglobulin", "PROTEIN", 27, 53], ["intravenous immunoglobulin", "TREATMENT", 27, 53]]], ["A cheaper alternative to immunoglobulin is to give quinolone prophylaxis with levofloxacin (500 mg/day), moxifloxacin (400 mg/day), or sulfamethoxazole-trimethoprim (TMP-SMX) (Antifungal ProphylaxisPrimary prophylaxis against invasive candidiasis is not indicated in all neutropenic patients.", [["quinolone", "CHEMICAL", 51, 60], ["levofloxacin", "CHEMICAL", 78, 90], ["moxifloxacin", "CHEMICAL", 105, 117], ["sulfamethoxazole-trimethoprim", "CHEMICAL", 135, 164], ["TMP-SMX", "CHEMICAL", 166, 173], ["ProphylaxisPrimary", "CHEMICAL", 187, 205], ["invasive candidiasis", "DISEASE", 226, 246], ["neutropenic", "DISEASE", 271, 282], ["quinolone", "CHEMICAL", 51, 60], ["levofloxacin", "CHEMICAL", 78, 90], ["moxifloxacin", "CHEMICAL", 105, 117], ["sulfamethoxazole", "CHEMICAL", 135, 151], ["trimethoprim", "CHEMICAL", 152, 164], ["TMP-SMX", "CHEMICAL", 166, 173], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 25, 39], ["quinolone", "SIMPLE_CHEMICAL", 51, 60], ["levofloxacin", "SIMPLE_CHEMICAL", 78, 90], ["moxifloxacin", "SIMPLE_CHEMICAL", 105, 117], ["sulfamethoxazole-trimethoprim", "SIMPLE_CHEMICAL", 135, 164], ["TMP-SMX", "SIMPLE_CHEMICAL", 166, 173], ["patients", "ORGANISM", 283, 291], ["immunoglobulin", "PROTEIN", 25, 39], ["patients", "SPECIES", 283, 291], ["immunoglobulin", "TREATMENT", 25, 39], ["quinolone prophylaxis", "TREATMENT", 51, 72], ["levofloxacin", "TREATMENT", 78, 90], ["moxifloxacin", "TREATMENT", 105, 117], ["sulfamethoxazole", "TREATMENT", 135, 151], ["trimethoprim", "TREATMENT", 152, 164], ["TMP-SMX)", "TREATMENT", 166, 174], ["Antifungal ProphylaxisPrimary prophylaxis", "TREATMENT", 176, 217], ["invasive candidiasis", "PROBLEM", 226, 246]]], ["In allogeneic HCT recipients, two randomized clinical trials (RCTs) showed that fluconazole reduced the frequency of superficial and systemic candidiasis, as well as infection-related mortality [43, 44] .", [["HCT", "ANATOMY", 14, 17], ["superficial", "ANATOMY", 117, 128], ["fluconazole", "CHEMICAL", 80, 91], ["candidiasis", "DISEASE", 142, 153], ["infection", "DISEASE", 166, 175], ["fluconazole", "CHEMICAL", 80, 91], ["HCT", "CANCER", 14, 17], ["fluconazole", "SIMPLE_CHEMICAL", 80, 91], ["candidiasis", "PATHOLOGICAL_FORMATION", 142, 153], ["allogeneic HCT recipients", "TREATMENT", 3, 28], ["RCTs", "TEST", 62, 66], ["fluconazole", "TREATMENT", 80, 91], ["superficial and systemic candidiasis", "PROBLEM", 117, 153], ["infection", "PROBLEM", 166, 175], ["superficial", "OBSERVATION_MODIFIER", 117, 128], ["systemic", "OBSERVATION_MODIFIER", 133, 141], ["candidiasis", "OBSERVATION", 142, 153], ["infection", "OBSERVATION", 166, 175]]], ["In one of these trials, fluconazole was given until day +75 posttransplant, and a post hoc analysis of the trial has shown that fluconazole was associated with prolonged protection against invasive candidiasis, even beyond the period of prophylaxis [45] .", [["invasive candidiasis", "ANATOMY", 189, 209], ["fluconazole", "CHEMICAL", 24, 35], ["fluconazole", "CHEMICAL", 128, 139], ["candidiasis", "DISEASE", 198, 209], ["fluconazole", "CHEMICAL", 24, 35], ["fluconazole", "CHEMICAL", 128, 139], ["fluconazole", "SIMPLE_CHEMICAL", 24, 35], ["fluconazole", "SIMPLE_CHEMICAL", 128, 139], ["candidiasis", "PATHOLOGICAL_FORMATION", 198, 209], ["fluconazole", "TREATMENT", 24, 35], ["a post hoc analysis", "TEST", 80, 99], ["fluconazole", "TREATMENT", 128, 139], ["invasive candidiasis", "PROBLEM", 189, 209], ["prophylaxis", "TREATMENT", 237, 248]]], ["The benefit of prophylaxis against invasive candidiasis was not as apparent in other settings, such as in patients with acute leukemia [46] .", [["acute leukemia", "ANATOMY", 120, 134], ["candidiasis", "DISEASE", 44, 55], ["acute leukemia", "DISEASE", 120, 134], ["patients", "ORGANISM", 106, 114], ["acute leukemia", "CANCER", 120, 134], ["patients", "SPECIES", 106, 114], ["prophylaxis", "TREATMENT", 15, 26], ["invasive candidiasis", "PROBLEM", 35, 55], ["acute leukemia", "PROBLEM", 120, 134], ["acute", "OBSERVATION_MODIFIER", 120, 125], ["leukemia", "OBSERVATION", 126, 134]]], ["However, the ineffectiveness of fluconazole in non-HSCT neutropenic patients is probably related to the heterogeneity of the populations of neutropenic patients studied (with different incidences of invasive candidiasis) rather than an absence of efficacy.", [["fluconazole", "CHEMICAL", 32, 43], ["neutropenic", "DISEASE", 56, 67], ["neutropenic", "DISEASE", 140, 151], ["candidiasis", "DISEASE", 208, 219], ["fluconazole", "CHEMICAL", 32, 43], ["fluconazole", "SIMPLE_CHEMICAL", 32, 43], ["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 152, 160], ["candidiasis", "CANCER", 208, 219], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 152, 160], ["fluconazole", "TREATMENT", 32, 43], ["neutropenic patients", "PROBLEM", 140, 160], ["invasive candidiasis", "PROBLEM", 199, 219], ["probably related to", "UNCERTAINTY", 80, 99], ["populations", "OBSERVATION_MODIFIER", 125, 136], ["neutropenic", "OBSERVATION", 140, 151], ["invasive", "OBSERVATION_MODIFIER", 199, 207], ["candidiasis", "OBSERVATION", 208, 219]]], ["In general, the higher is the risk for the patient to develop severe mucositis during neutropenia, the higher is the risk for invasive candidiasis.Antifungal ProphylaxisFluconazole is the drug of choice, usually at a dose of 400 mg daily.", [["mucositis", "DISEASE", 69, 78], ["neutropenia", "DISEASE", 86, 97], ["candidiasis", "DISEASE", 135, 146], ["ProphylaxisFluconazole", "CHEMICAL", 158, 180], ["ProphylaxisFluconazole", "CHEMICAL", 158, 180], ["patient", "ORGANISM", 43, 50], ["candidiasis", "PATHOLOGICAL_FORMATION", 135, 146], ["ProphylaxisFluconazole", "SIMPLE_CHEMICAL", 158, 180], ["patient", "SPECIES", 43, 50], ["severe mucositis", "PROBLEM", 62, 78], ["neutropenia", "PROBLEM", 86, 97], ["invasive candidiasis", "PROBLEM", 126, 146], ["Antifungal ProphylaxisFluconazole", "TREATMENT", 147, 180], ["severe", "OBSERVATION_MODIFIER", 62, 68], ["mucositis", "OBSERVATION", 69, 78], ["neutropenia", "OBSERVATION", 86, 97], ["invasive", "OBSERVATION_MODIFIER", 126, 134], ["candidiasis", "OBSERVATION", 135, 146]]], ["Fluconazole is not effective in preventing infection caused by all Candida species.", [["Fluconazole", "CHEMICAL", 0, 11], ["infection", "DISEASE", 43, 52], ["Fluconazole", "CHEMICAL", 0, 11], ["Fluconazole", "SIMPLE_CHEMICAL", 0, 11], ["Candida species", "ORGANISM", 67, 82], ["Fluconazole", "TREATMENT", 0, 11], ["infection", "PROBLEM", 43, 52], ["all Candida species", "PROBLEM", 63, 82], ["infection", "OBSERVATION", 43, 52], ["Candida species", "OBSERVATION", 67, 82]]], ["Candida krusei is intrinsically resistant to fluconazole, and Candida glabrata exhibits minimal inhibitory concentrations (MIC) higher than other species.", [["Candida krusei", "DISEASE", 0, 14], ["fluconazole", "CHEMICAL", 45, 56], ["Candida glabrata", "DISEASE", 62, 78], ["fluconazole", "CHEMICAL", 45, 56], ["Candida krusei", "ORGANISM", 0, 14], ["fluconazole", "SIMPLE_CHEMICAL", 45, 56], ["Candida glabrata", "ORGANISM", 62, 78], ["Candida krusei", "SPECIES", 0, 14], ["Candida glabrata", "SPECIES", 62, 78], ["Candida krusei", "SPECIES", 0, 14], ["Candida glabrata", "SPECIES", 62, 78], ["Candida krusei", "PROBLEM", 0, 14], ["fluconazole", "TREATMENT", 45, 56], ["Candida glabrata", "PROBLEM", 62, 78], ["minimal inhibitory concentrations", "PROBLEM", 88, 121], ["krusei", "OBSERVATION", 8, 14], ["resistant", "OBSERVATION_MODIFIER", 32, 41]]], ["As a consequence, fluconazole is not recommended for the prevention of infection due to these two species.Antifungal ProphylaxisOther than fluconazole, itraconazole oral solution (but not capsules) [47] , voriconazole [48] , posaconazole [49] , and micafungin [50] effectively prevent the occurrence of invasive candidiasis during neutropenia.Antifungal ProphylaxisInvasive aspergillosis usually occurs in the context of prolonged (>15 days) and profound (<100/mm 3 ) neutropenia in patients receiving induction therapy for AML or myelodysplasia (MDS), or after myeloablative conditioning regimen for allogeneic HCT [51] .", [["oral", "ANATOMY", 165, 169], ["AML", "ANATOMY", 524, 527], ["fluconazole", "CHEMICAL", 18, 29], ["infection", "DISEASE", 71, 80], ["ProphylaxisOther", "CHEMICAL", 117, 133], ["fluconazole", "CHEMICAL", 139, 150], ["itraconazole", "CHEMICAL", 152, 164], ["voriconazole", "CHEMICAL", 205, 217], ["posaconazole", "CHEMICAL", 225, 237], ["micafungin", "CHEMICAL", 249, 259], ["candidiasis", "DISEASE", 312, 323], ["neutropenia", "DISEASE", 331, 342], ["ProphylaxisInvasive aspergillosis", "DISEASE", 354, 387], ["neutropenia", "DISEASE", 468, 479], ["AML", "DISEASE", 524, 527], ["myelodysplasia", "DISEASE", 531, 545], ["MDS", "DISEASE", 547, 550], ["fluconazole", "CHEMICAL", 18, 29], ["fluconazole", "CHEMICAL", 139, 150], ["itraconazole", "CHEMICAL", 152, 164], ["voriconazole", "CHEMICAL", 205, 217], ["posaconazole", "CHEMICAL", 225, 237], ["micafungin", "CHEMICAL", 249, 259], ["fluconazole", "SIMPLE_CHEMICAL", 18, 29], ["fluconazole", "SIMPLE_CHEMICAL", 139, 150], ["itraconazole", "SIMPLE_CHEMICAL", 152, 164], ["oral", "ORGANISM_SUBDIVISION", 165, 169], ["voriconazole", "SIMPLE_CHEMICAL", 205, 217], ["posaconazole", "SIMPLE_CHEMICAL", 225, 237], ["micafungin", "SIMPLE_CHEMICAL", 249, 259], ["candidiasis", "CANCER", 312, 323], ["patients", "ORGANISM", 483, 491], ["AML", "CANCER", 524, 527], ["patients", "SPECIES", 483, 491], ["fluconazole", "TREATMENT", 18, 29], ["infection", "PROBLEM", 71, 80], ["these two species", "PROBLEM", 88, 105], ["Antifungal ProphylaxisOther", "TREATMENT", 106, 133], ["fluconazole", "TREATMENT", 139, 150], ["itraconazole oral solution", "TREATMENT", 152, 178], ["voriconazole", "TREATMENT", 205, 217], ["posaconazole", "TREATMENT", 225, 237], ["micafungin", "TREATMENT", 249, 259], ["invasive candidiasis", "PROBLEM", 303, 323], ["neutropenia", "PROBLEM", 331, 342], ["Antifungal ProphylaxisInvasive aspergillosis", "TREATMENT", 343, 387], ["profound (<100/mm 3 ) neutropenia", "PROBLEM", 446, 479], ["induction therapy", "TREATMENT", 502, 519], ["AML", "PROBLEM", 524, 527], ["myelodysplasia (MDS)", "PROBLEM", 531, 551], ["myeloablative conditioning regimen", "TREATMENT", 562, 596], ["allogeneic HCT", "TEST", 601, 615], ["infection", "OBSERVATION", 71, 80], ["invasive", "OBSERVATION_MODIFIER", 303, 311], ["candidiasis", "OBSERVATION", 312, 323], ["neutropenia", "OBSERVATION", 331, 342], ["aspergillosis", "OBSERVATION", 374, 387], ["myelodysplasia", "OBSERVATION", 531, 545]]], ["In addition, HCT recipients with GVHD are at high risk for IA.", [["HCT", "ANATOMY", 13, 16], ["GVHD", "DISEASE", 33, 37], ["IA", "DISEASE", 59, 61], ["HCT recipients", "ORGANISM", 13, 27], ["HCT recipients", "TREATMENT", 13, 27], ["GVHD", "PROBLEM", 33, 37], ["IA", "PROBLEM", 59, 61], ["GVHD", "OBSERVATION", 33, 37]]], ["In these patients, severe T-cell mediated immunodeficiency rather than profound and prolonged neutropenia is the main risk factor [52] .", [["T-cell", "ANATOMY", 26, 32], ["T-cell mediated immunodeficiency", "DISEASE", 26, 58], ["neutropenia", "DISEASE", 94, 105], ["patients", "ORGANISM", 9, 17], ["T-cell", "CELL", 26, 32], ["patients", "SPECIES", 9, 17], ["severe T-cell mediated immunodeficiency", "PROBLEM", 19, 58], ["profound and prolonged neutropenia", "PROBLEM", 71, 105], ["severe", "OBSERVATION_MODIFIER", 19, 25], ["immunodeficiency", "OBSERVATION", 42, 58], ["prolonged", "OBSERVATION_MODIFIER", 84, 93], ["neutropenia", "OBSERVATION", 94, 105]]], ["More recently, cases of IA have been diagnosed in patients with other hematological malignancies, including patients with chronic lymphocytic leukemia receiving treatment with alemtuzumab, and patients with multiple myeloma [53] [54] [55] [56] .Antifungal ProphylaxisIn the setting of AML/MDS, posaconazole (200 mg 3\u00d7/day) was superior to fluconazole or itraconazole oral solution in a large randomized controlled trial, and is considered the drug of choice for anti-Aspergillus prophylaxis [49] .", [["hematological malignancies", "ANATOMY", 70, 96], ["chronic lymphocytic leukemia", "ANATOMY", 122, 150], ["myeloma", "ANATOMY", 216, 223], ["AML", "ANATOMY", 285, 288], ["oral", "ANATOMY", 367, 371], ["IA", "DISEASE", 24, 26], ["hematological malignancies", "DISEASE", 70, 96], ["chronic lymphocytic leukemia", "DISEASE", 122, 150], ["alemtuzumab", "CHEMICAL", 176, 187], ["multiple myeloma", "DISEASE", 207, 223], ["ProphylaxisIn", "CHEMICAL", 256, 269], ["AML", "DISEASE", 285, 288], ["MDS", "DISEASE", 289, 292], ["posaconazole", "CHEMICAL", 294, 306], ["fluconazole", "CHEMICAL", 339, 350], ["itraconazole", "CHEMICAL", 354, 366], ["anti-Aspergillus", "CHEMICAL", 462, 478], ["posaconazole", "CHEMICAL", 294, 306], ["fluconazole", "CHEMICAL", 339, 350], ["itraconazole", "CHEMICAL", 354, 366], ["IA", "CANCER", 24, 26], ["patients", "ORGANISM", 50, 58], ["hematological malignancies", "CANCER", 70, 96], ["patients", "ORGANISM", 108, 116], ["chronic lymphocytic leukemia", "CANCER", 122, 150], ["alemtuzumab", "SIMPLE_CHEMICAL", 176, 187], ["patients", "ORGANISM", 193, 201], ["AML", "CANCER", 285, 288], ["posaconazole", "SIMPLE_CHEMICAL", 294, 306], ["fluconazole", "SIMPLE_CHEMICAL", 339, 350], ["itraconazole", "SIMPLE_CHEMICAL", 354, 366], ["oral", "ORGANISM_SUBDIVISION", 367, 371], ["anti-Aspergillus", "SIMPLE_CHEMICAL", 462, 478], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 108, 116], ["patients", "SPECIES", 193, 201], ["other hematological malignancies", "PROBLEM", 64, 96], ["chronic lymphocytic leukemia", "PROBLEM", 122, 150], ["alemtuzumab", "TREATMENT", 176, 187], ["multiple myeloma", "PROBLEM", 207, 223], ["Antifungal ProphylaxisIn", "TREATMENT", 245, 269], ["AML/MDS", "TREATMENT", 285, 292], ["posaconazole", "TREATMENT", 294, 306], ["fluconazole", "TREATMENT", 339, 350], ["itraconazole oral solution", "TREATMENT", 354, 380], ["a large randomized controlled trial", "TREATMENT", 384, 419], ["anti-Aspergillus prophylaxis", "TREATMENT", 462, 490], ["hematological", "ANATOMY", 70, 83], ["malignancies", "OBSERVATION", 84, 96], ["chronic", "OBSERVATION_MODIFIER", 122, 129], ["lymphocytic leukemia", "OBSERVATION", 130, 150], ["myeloma", "OBSERVATION", 216, 223]]], ["By contrast, a reduction in the incidence of IA was not observed in trials comparing itraconazole with fluconazole, and itraconazole was associated with more adverse events [47, 57] .", [["IA", "DISEASE", 45, 47], ["itraconazole", "CHEMICAL", 85, 97], ["fluconazole", "CHEMICAL", 103, 114], ["itraconazole", "CHEMICAL", 120, 132], ["itraconazole", "CHEMICAL", 85, 97], ["fluconazole", "CHEMICAL", 103, 114], ["itraconazole", "CHEMICAL", 120, 132], ["itraconazole", "SIMPLE_CHEMICAL", 85, 97], ["fluconazole", "SIMPLE_CHEMICAL", 103, 114], ["itraconazole", "SIMPLE_CHEMICAL", 120, 132], ["a reduction", "TREATMENT", 13, 24], ["itraconazole", "TREATMENT", 85, 97], ["fluconazole", "TREATMENT", 103, 114], ["itraconazole", "TREATMENT", 120, 132], ["more adverse events", "PROBLEM", 153, 172], ["reduction", "OBSERVATION_MODIFIER", 15, 24]]], ["A recent meta-analysis of itraconazole trials suggest that there is a reduction in Aspergillus infections but only if a certain threshold of bioavailable dosing is used [58] .", [["itraconazole", "CHEMICAL", 26, 38], ["Aspergillus infections", "DISEASE", 83, 105], ["itraconazole", "CHEMICAL", 26, 38], ["itraconazole", "SIMPLE_CHEMICAL", 26, 38], ["itraconazole trials", "TREATMENT", 26, 45], ["Aspergillus infections", "PROBLEM", 83, 105], ["bioavailable dosing", "TREATMENT", 141, 160], ["reduction", "OBSERVATION_MODIFIER", 70, 79], ["Aspergillus infections", "OBSERVATION", 83, 105]]], ["Its ability to prevent invasive fungal diseases (IFD) has been associated with trough itraconazole concentrations >500 ng/mL, best achieved with the IV formulation (followed by the oral solution if the gastrointestinal function is intact).", [["fungal", "ANATOMY", 32, 38], ["oral", "ANATOMY", 181, 185], ["gastrointestinal", "ANATOMY", 202, 218], ["invasive fungal diseases", "DISEASE", 23, 47], ["IFD", "DISEASE", 49, 52], ["itraconazole", "CHEMICAL", 86, 98], ["itraconazole", "CHEMICAL", 86, 98], ["itraconazole", "SIMPLE_CHEMICAL", 86, 98], ["oral", "ORGANISM_SUBDIVISION", 181, 185], ["gastrointestinal", "ORGAN", 202, 218], ["invasive fungal diseases", "PROBLEM", 23, 47], ["trough itraconazole concentrations", "TREATMENT", 79, 113], ["the IV formulation", "TREATMENT", 145, 163], ["the oral solution", "TREATMENT", 177, 194], ["invasive", "OBSERVATION_MODIFIER", 23, 31], ["fungal", "OBSERVATION", 32, 38], ["gastrointestinal", "ANATOMY", 202, 218], ["intact", "OBSERVATION", 231, 237]]], ["The oral capsule formulation suffers from erratic bioavailability and is best avoided.Antifungal ProphylaxisIn allogeneic HCT recipients, itraconazole oral solution resulted in a reduction in the frequency of IA in 2 trials, but about 25% of patients discontinued itraconazole because of gastrointestinal side effects [59, 60] .", [["oral", "ANATOMY", 4, 8], ["HCT", "ANATOMY", 122, 125], ["oral", "ANATOMY", 151, 155], ["gastrointestinal", "ANATOMY", 288, 304], ["ProphylaxisIn", "CHEMICAL", 97, 110], ["itraconazole", "CHEMICAL", 138, 150], ["itraconazole", "CHEMICAL", 264, 276], ["itraconazole", "CHEMICAL", 138, 150], ["itraconazole", "CHEMICAL", 264, 276], ["oral", "ORGANISM_SUBDIVISION", 4, 8], ["HCT", "ORGANISM", 122, 125], ["itraconazole", "SIMPLE_CHEMICAL", 138, 150], ["oral", "ORGANISM_SUBDIVISION", 151, 155], ["patients", "ORGANISM", 242, 250], ["itraconazole", "SIMPLE_CHEMICAL", 264, 276], ["gastrointestinal", "ORGANISM_SUBDIVISION", 288, 304], ["patients", "SPECIES", 242, 250], ["The oral capsule formulation", "TREATMENT", 0, 28], ["erratic bioavailability", "PROBLEM", 42, 65], ["Antifungal ProphylaxisIn", "TREATMENT", 86, 110], ["allogeneic HCT recipients", "TREATMENT", 111, 136], ["itraconazole oral solution", "TREATMENT", 138, 164], ["itraconazole", "TREATMENT", 264, 276], ["gastrointestinal side effects", "PROBLEM", 288, 317], ["reduction", "OBSERVATION_MODIFIER", 179, 188], ["gastrointestinal", "ANATOMY", 288, 304]]], ["In these trials, prophylaxis was used both in the early pre-engraftment and in the post-engraftment period.", [["prophylaxis", "TREATMENT", 17, 28]]], ["Another randomized clinical trial compared posaconazole to fluconazole in allogeneic HCT recipients who developed GVHD.", [["HCT", "ANATOMY", 85, 88], ["posaconazole", "CHEMICAL", 43, 55], ["fluconazole", "CHEMICAL", 59, 70], ["GVHD", "DISEASE", 114, 118], ["posaconazole", "CHEMICAL", 43, 55], ["fluconazole", "CHEMICAL", 59, 70], ["posaconazole", "SIMPLE_CHEMICAL", 43, 55], ["fluconazole", "SIMPLE_CHEMICAL", 59, 70], ["HCT", "CANCER", 85, 88], ["recipients", "ORGANISM", 89, 99], ["posaconazole", "TREATMENT", 43, 55], ["fluconazole", "TREATMENT", 59, 70], ["allogeneic HCT recipients", "TREATMENT", 74, 99], ["GVHD", "PROBLEM", 114, 118], ["GVHD", "OBSERVATION", 114, 118]]], ["Although the primary endpoint (incidence of IFD from randomization to day 112 of prophylaxis) was not achieved, posaconazole significantly reduced the incidence of IA [61] .", [["IFD", "DISEASE", 44, 47], ["posaconazole", "CHEMICAL", 112, 124], ["IA", "DISEASE", 164, 166], ["posaconazole", "CHEMICAL", 112, 124], ["posaconazole", "SIMPLE_CHEMICAL", 112, 124], ["IFD", "PROBLEM", 44, 47], ["randomization", "TREATMENT", 53, 66], ["prophylaxis", "TREATMENT", 81, 92], ["posaconazole", "TREATMENT", 112, 124]]], ["Micafungin given during the pre-engraftment period was associated with a trend suggesting ability to prevent aspergillosis.", [["Micafungin", "CHEMICAL", 0, 10], ["aspergillosis", "DISEASE", 109, 122], ["Micafungin", "CHEMICAL", 0, 10], ["Micafungin", "SIMPLE_CHEMICAL", 0, 10], ["Micafungin", "TREATMENT", 0, 10], ["aspergillosis", "PROBLEM", 109, 122], ["aspergillosis", "OBSERVATION", 109, 122]]], ["In this trial the incidence of IA was 0.2% among 425 patients receiving micafungin and 1.5% among 457 patients receiving fluconazole (p = 0.07) [50] .Antifungal ProphylaxisTwo randomized clinical trials evaluated the efficacy of voriconazole as prophylaxis in allogeneic HCT recipients.", [["HCT", "ANATOMY", 271, 274], ["IA", "DISEASE", 31, 33], ["micafungin", "CHEMICAL", 72, 82], ["fluconazole", "CHEMICAL", 121, 132], ["voriconazole", "CHEMICAL", 229, 241], ["micafungin", "CHEMICAL", 72, 82], ["fluconazole", "CHEMICAL", 121, 132], ["voriconazole", "CHEMICAL", 229, 241], ["patients", "ORGANISM", 53, 61], ["micafungin", "SIMPLE_CHEMICAL", 72, 82], ["patients", "ORGANISM", 102, 110], ["fluconazole", "SIMPLE_CHEMICAL", 121, 132], ["voriconazole", "SIMPLE_CHEMICAL", 229, 241], ["HCT", "CANCER", 271, 274], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 102, 110], ["micafungin", "TREATMENT", 72, 82], ["fluconazole", "TREATMENT", 121, 132], ["Antifungal Prophylaxis", "TREATMENT", 150, 172], ["voriconazole", "TREATMENT", 229, 241], ["prophylaxis", "TREATMENT", 245, 256], ["allogeneic HCT recipients", "TREATMENT", 260, 285]]], ["In the first study, patients received voriconazole or fluconazole from day zero until day +100 (or beyond, in the presence of GVHD) posttransplant.", [["voriconazole", "CHEMICAL", 38, 50], ["fluconazole", "CHEMICAL", 54, 65], ["GVHD", "DISEASE", 126, 130], ["voriconazole", "CHEMICAL", 38, 50], ["fluconazole", "CHEMICAL", 54, 65], ["patients", "ORGANISM", 20, 28], ["voriconazole", "SIMPLE_CHEMICAL", 38, 50], ["fluconazole", "SIMPLE_CHEMICAL", 54, 65], ["patients", "SPECIES", 20, 28], ["the first study", "TEST", 3, 18], ["voriconazole", "TREATMENT", 38, 50], ["fluconazole", "TREATMENT", 54, 65], ["GVHD", "OBSERVATION", 126, 130]]], ["For the primary endpoint (fungalfree survival at 180 days), no differences were observed in the two arms (75% fluconazole vs. 78% voriconazole, p = 0.49).", [["fluconazole", "CHEMICAL", 110, 121], ["voriconazole", "CHEMICAL", 130, 142], ["fluconazole", "CHEMICAL", 110, 121], ["voriconazole", "CHEMICAL", 130, 142], ["fluconazole", "SIMPLE_CHEMICAL", 110, 121], ["voriconazole", "SIMPLE_CHEMICAL", 130, 142], ["fluconazole", "TREATMENT", 110, 121], ["voriconazole", "TREATMENT", 130, 142]]], ["There was a trend for a lower incidence of IA in voriconazole recipients (p = 0.09) [48] .", [["IA", "CHEMICAL", 43, 45], ["voriconazole", "CHEMICAL", 49, 61], ["voriconazole", "CHEMICAL", 49, 61], ["voriconazole", "SIMPLE_CHEMICAL", 49, 61], ["IA in voriconazole recipients", "TREATMENT", 43, 72]]], ["The other study compared voriconazole and itraconazole, given for the same period as the previous study [62] .", [["voriconazole", "CHEMICAL", 25, 37], ["itraconazole", "CHEMICAL", 42, 54], ["voriconazole", "CHEMICAL", 25, 37], ["itraconazole", "CHEMICAL", 42, 54], ["voriconazole", "SIMPLE_CHEMICAL", 25, 37], ["itraconazole", "SIMPLE_CHEMICAL", 42, 54], ["The other study", "TEST", 0, 15], ["voriconazole", "TREATMENT", 25, 37], ["itraconazole", "TREATMENT", 42, 54], ["the previous study", "TEST", 85, 103]]], ["The incidence of IFD (including IA) was similar in the two arms, but tolerability was better with voriconazole.Antifungal ProphylaxisTaken together, it seems that mold-active azoles indeed reduce the incidence of IA.", [["IFD", "DISEASE", 17, 20], ["voriconazole", "CHEMICAL", 98, 110], ["azoles", "CHEMICAL", 175, 181], ["IA", "DISEASE", 213, 215], ["voriconazole", "CHEMICAL", 98, 110], ["azoles", "CHEMICAL", 175, 181], ["voriconazole", "SIMPLE_CHEMICAL", 98, 110], ["azoles", "SIMPLE_CHEMICAL", 175, 181], ["IFD", "PROBLEM", 17, 20], ["voriconazole", "TREATMENT", 98, 110], ["Antifungal ProphylaxisTaken", "TREATMENT", 111, 138], ["mold-active azoles", "TREATMENT", 163, 181], ["IFD", "OBSERVATION", 17, 20], ["active azoles", "OBSERVATION", 168, 181]]], ["These findings, however, should be balanced against our significantly improved ability for the early detection of fungal infections and the potential undesirable consequences including toxicities, drug-drug interactions, costs, and emergence of resistance [63] .", [["fungal infections", "DISEASE", 114, 131], ["toxicities", "DISEASE", 185, 195], ["fungal infections", "PROBLEM", 114, 131], ["toxicities", "PROBLEM", 185, 195], ["fungal", "OBSERVATION_MODIFIER", 114, 120], ["infections", "OBSERVATION", 121, 131]]], ["The application of serial serum galactomannan monitoring has enabled us to make the diagnosis of IA much earlier, with a significant impact in reducing mortality [56] .", [["serum", "ANATOMY", 26, 31], ["serum", "ORGANISM_SUBSTANCE", 26, 31], ["serial serum galactomannan monitoring", "TEST", 19, 56]]], ["Indeed, in the trial comparing voriconazole and fluconazole, screening with twice-weekly serum galactomannan was part of the protocol in the two arms, and appropriate antifungal therapy was started based on positive galactomannan tests.", [["serum", "ANATOMY", 89, 94], ["voriconazole", "CHEMICAL", 31, 43], ["fluconazole", "CHEMICAL", 48, 59], ["voriconazole", "CHEMICAL", 31, 43], ["fluconazole", "CHEMICAL", 48, 59], ["voriconazole", "SIMPLE_CHEMICAL", 31, 43], ["fluconazole", "SIMPLE_CHEMICAL", 48, 59], ["serum", "ORGANISM_SUBSTANCE", 89, 94], ["voriconazole", "TREATMENT", 31, 43], ["fluconazole", "TREATMENT", 48, 59], ["screening", "TEST", 61, 70], ["serum galactomannan", "TEST", 89, 108], ["the protocol", "TEST", 121, 133], ["appropriate antifungal therapy", "TREATMENT", 155, 185], ["positive galactomannan tests", "TEST", 207, 235], ["antifungal therapy", "OBSERVATION", 167, 185]]], ["The absence of a significant difference in the incidence of IA suggests that giving an anti-mold agent as prophylaxis or giving fluconazole plus serial monitoring with serum galactomannan results in similar outcomes.Antifungal ProphylaxisTherefore, several factors should be taken into consideration in determining if prophylaxis is appropriate at a specific treatment center, for a given patient or patient population to target a specific infection or if prophylaxis should be withheld and a diagnostic-based preemptive strategy used instead.", [["serum", "ANATOMY", 168, 173], ["IA", "DISEASE", 60, 62], ["fluconazole", "CHEMICAL", 128, 139], ["infection", "DISEASE", 440, 449], ["fluconazole", "CHEMICAL", 128, 139], ["fluconazole", "SIMPLE_CHEMICAL", 128, 139], ["serum", "ORGANISM_SUBSTANCE", 168, 173], ["patient", "ORGANISM", 389, 396], ["patient", "ORGANISM", 400, 407], ["patient", "SPECIES", 389, 396], ["patient", "SPECIES", 400, 407], ["an anti-mold agent", "TREATMENT", 84, 102], ["prophylaxis", "TREATMENT", 106, 117], ["fluconazole", "TREATMENT", 128, 139], ["serial monitoring", "TEST", 145, 162], ["serum galactomannan", "TEST", 168, 187], ["Antifungal Prophylaxis", "TREATMENT", 216, 238], ["prophylaxis", "TREATMENT", 318, 329], ["a specific infection", "PROBLEM", 429, 449], ["prophylaxis", "TREATMENT", 456, 467], ["preemptive strategy", "TREATMENT", 510, 529], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["difference", "OBSERVATION_MODIFIER", 29, 39], ["infection", "OBSERVATION", 440, 449]]], ["In general, the higher the risk, the more likely anti-mold prophylaxis should be given.", [["anti-mold", "SIMPLE_CHEMICAL", 49, 58], ["anti-mold prophylaxis", "TREATMENT", 49, 70]]], ["Therefore, risk assessment (Table 49 .1) should be performed in order to decide the best strategy.", [["risk assessment", "TEST", 11, 26]]], ["Patients at high risk to develop IFD should receive anti-mold prophylaxis, while low-risk patients can be managed with fluconazole plus active monitoring with serial (3\u00d7/ week) serum galactomannan and CT scans, provided that these tools are available in the hospital [64] .", [["serum", "ANATOMY", 177, 182], ["IFD", "DISEASE", 33, 36], ["fluconazole", "CHEMICAL", 119, 130], ["fluconazole", "CHEMICAL", 119, 130], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 90, 98], ["fluconazole", "SIMPLE_CHEMICAL", 119, 130], ["serum", "ORGANISM_SUBSTANCE", 177, 182], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 90, 98], ["IFD", "PROBLEM", 33, 36], ["anti-mold prophylaxis", "TREATMENT", 52, 73], ["fluconazole", "TREATMENT", 119, 130], ["active monitoring", "TEST", 136, 153], ["serum galactomannan", "TEST", 177, 196], ["CT scans", "TEST", 201, 209], ["these tools", "TEST", 225, 236]]], ["Clinicians should keep in mind that this risk assessment is dynamic.", [["this risk assessment", "TEST", 36, 56]]], ["For example, a patient with AML who was considered at low risk on admission but presents residual blast cells on day 15 of admission should be reclassified to a higher risk and the prophylactic regimen should be changed accordingly [64] .", [["AML", "ANATOMY", 28, 31], ["blast cells", "ANATOMY", 98, 109], ["AML", "DISEASE", 28, 31], ["patient", "ORGANISM", 15, 22], ["AML", "CANCER", 28, 31], ["residual blast cells", "CELL", 89, 109], ["blast cells", "CELL_TYPE", 98, 109], ["patient", "SPECIES", 15, 22], ["AML", "PROBLEM", 28, 31], ["residual blast cells", "PROBLEM", 89, 109], ["the prophylactic regimen", "TREATMENT", 177, 201], ["blast cells", "OBSERVATION", 98, 109]]], ["Secondary prophylaxis is indicated for patients who developed an invasive mold infection and will receive treatment for the underlying malignancy that results in immunosuppression, particularly neutropenia and/or T-cell immunodeficiency [65] .", [["T-cell", "ANATOMY", 213, 219], ["mold infection", "DISEASE", 74, 88], ["malignancy", "DISEASE", 135, 145], ["neutropenia", "DISEASE", 194, 205], ["T-cell immunodeficiency", "DISEASE", 213, 236], ["patients", "ORGANISM", 39, 47], ["malignancy", "CANCER", 135, 145], ["T-cell", "CANCER", 213, 219], ["patients", "SPECIES", 39, 47], ["Secondary prophylaxis", "TREATMENT", 0, 21], ["an invasive mold infection", "PROBLEM", 62, 88], ["treatment", "TREATMENT", 106, 115], ["the underlying malignancy", "PROBLEM", 120, 145], ["immunosuppression", "TREATMENT", 162, 179], ["neutropenia", "PROBLEM", 194, 205], ["T-cell immunodeficiency", "PROBLEM", 213, 236], ["invasive", "OBSERVATION_MODIFIER", 65, 73], ["mold", "OBSERVATION_MODIFIER", 74, 78], ["infection", "OBSERVATION", 79, 88], ["malignancy", "OBSERVATION", 135, 145]]], ["Options for secondary prophylaxis include amphotericin B and its lipid formulations, caspofungin, itraconazole, voriconazole and lipid amphotericin B followed by voriconazole [66] [67] [68] [69] [70] .", [["amphotericin B", "CHEMICAL", 42, 56], ["caspofungin", "CHEMICAL", 85, 96], ["itraconazole", "CHEMICAL", 98, 110], ["voriconazole", "CHEMICAL", 112, 124], ["amphotericin B", "CHEMICAL", 135, 149], ["voriconazole", "CHEMICAL", 162, 174], ["amphotericin B", "CHEMICAL", 42, 56], ["caspofungin", "CHEMICAL", 85, 96], ["itraconazole", "CHEMICAL", 98, 110], ["voriconazole", "CHEMICAL", 112, 124], ["amphotericin B", "CHEMICAL", 135, 149], ["voriconazole", "CHEMICAL", 162, 174], ["amphotericin B", "SIMPLE_CHEMICAL", 42, 56], ["lipid", "SIMPLE_CHEMICAL", 65, 70], ["caspofungin", "SIMPLE_CHEMICAL", 85, 96], ["itraconazole", "SIMPLE_CHEMICAL", 98, 110], ["voriconazole", "SIMPLE_CHEMICAL", 112, 124], ["lipid amphotericin B", "SIMPLE_CHEMICAL", 129, 149], ["voriconazole", "SIMPLE_CHEMICAL", 162, 174], ["[66] [67] [68] [69] [70]", "SIMPLE_CHEMICAL", 175, 199], ["secondary prophylaxis", "TREATMENT", 12, 33], ["amphotericin B", "TREATMENT", 42, 56], ["its lipid formulations", "TREATMENT", 61, 83], ["caspofungin", "TREATMENT", 85, 96], ["itraconazole", "TREATMENT", 98, 110], ["voriconazole", "TREATMENT", 112, 124], ["lipid amphotericin B", "TREATMENT", 129, 149], ["voriconazole", "TREATMENT", 162, 174]]], ["In addition to secondary chemoprophylaxis, strategies to abbreviate the duration of neutropenia, such as the use of reduced-intensity conditioning regimens and peripheral blood stem cells, and the use of granulocyte transfusions may be employed [71, 72] .", [["peripheral blood stem cells", "ANATOMY", 160, 187], ["granulocyte", "ANATOMY", 204, 215], ["neutropenia", "DISEASE", 84, 95], ["peripheral blood stem cells", "CELL", 160, 187], ["granulocyte", "CELL", 204, 215], ["peripheral blood stem cells", "CELL_TYPE", 160, 187], ["secondary chemoprophylaxis", "TREATMENT", 15, 41], ["strategies", "TREATMENT", 43, 53], ["neutropenia", "PROBLEM", 84, 95], ["reduced-intensity conditioning regimens", "TREATMENT", 116, 155], ["peripheral blood stem cells", "TREATMENT", 160, 187], ["granulocyte transfusions", "TREATMENT", 204, 228], ["secondary", "OBSERVATION_MODIFIER", 15, 24], ["chemoprophylaxis", "OBSERVATION", 25, 41], ["neutropenia", "OBSERVATION", 84, 95], ["peripheral", "ANATOMY_MODIFIER", 160, 170], ["blood", "ANATOMY", 171, 176], ["stem cells", "OBSERVATION", 177, 187]]], ["The antifungal agents and doses given as prophylaxis are summarized in Table 49 .4.Antiviral ProphylaxisMost viral infections that complicate the course of chemotherapy in patients with hematological malignancies represent reactivation of latent infections, while a minority are due to exogenous acquisition (such as respiratory viruses).Cytomegalovirus (CMV)Until the early 1990s, CMV seropositive allogeneic HCT recipients had a 70-80% risk of viral reactivation, and onethird of these patients developed CMV disease (mainly pneumonia) [73] with a high fatality rate [74] .", [["hematological malignancies", "ANATOMY", 186, 212], ["HCT", "ANATOMY", 410, 413], ["viral infections", "DISEASE", 109, 125], ["hematological malignancies", "DISEASE", 186, 212], ["infections", "DISEASE", 246, 256], ["respiratory viruses", "DISEASE", 317, 336], ["CMV disease", "DISEASE", 507, 518], ["pneumonia", "DISEASE", 527, 536], ["patients", "ORGANISM", 172, 180], ["hematological malignancies", "CANCER", 186, 212], ["Cytomegalovirus", "ORGANISM", 338, 353], ["CMV", "ORGANISM", 355, 358], ["CMV", "ORGANISM", 382, 385], ["HCT", "CANCER", 410, 413], ["patients", "ORGANISM", 488, 496], ["CMV", "ORGANISM", 507, 510], ["patients", "SPECIES", 172, 180], ["patients", "SPECIES", 488, 496], ["CMV", "SPECIES", 355, 358], ["CMV", "SPECIES", 382, 385], ["CMV", "SPECIES", 507, 510], ["The antifungal agents", "TREATMENT", 0, 21], ["prophylaxis", "TREATMENT", 41, 52], ["Antiviral Prophylaxis", "TREATMENT", 83, 104], ["Most viral infections", "PROBLEM", 104, 125], ["chemotherapy", "TREATMENT", 156, 168], ["hematological malignancies", "PROBLEM", 186, 212], ["latent infections", "PROBLEM", 239, 256], ["exogenous acquisition", "PROBLEM", 286, 307], ["respiratory viruses", "PROBLEM", 317, 336], ["Cytomegalovirus", "PROBLEM", 338, 353], ["CMV", "TEST", 355, 358], ["CMV seropositive allogeneic HCT recipients", "TREATMENT", 382, 424], ["viral reactivation", "PROBLEM", 446, 464], ["CMV disease", "PROBLEM", 507, 518], ["pneumonia", "PROBLEM", 527, 536], ["a high fatality rate", "PROBLEM", 548, 568], ["antifungal", "OBSERVATION_MODIFIER", 4, 14], ["latent", "OBSERVATION_MODIFIER", 239, 245], ["infections", "OBSERVATION", 246, 256], ["respiratory viruses", "OBSERVATION", 317, 336], ["viral reactivation", "OBSERVATION", 446, 464], ["CMV disease", "OBSERVATION", 507, 518], ["pneumonia", "OBSERVATION", 527, 536]]], ["The application of preemptive therapy guided by serial monitoring with CMV antigenemia has markedly reduced the incidence of patients who develop overt manifestations and/or die of CMV pneumonia [75] .", [["CMV antigenemia", "DISEASE", 71, 86], ["pneumonia", "DISEASE", 185, 194], ["CMV", "ORGANISM", 71, 74], ["patients", "ORGANISM", 125, 133], ["CMV", "ORGANISM", 181, 184], ["patients", "SPECIES", 125, 133], ["CMV", "SPECIES", 71, 74], ["CMV", "SPECIES", 181, 184], ["preemptive therapy", "TREATMENT", 19, 37], ["serial monitoring", "TEST", 48, 65], ["CMV antigenemia", "PROBLEM", 71, 86], ["overt manifestations", "PROBLEM", 146, 166], ["CMV pneumonia", "PROBLEM", 181, 194], ["pneumonia", "OBSERVATION", 185, 194]]], ["More recently, quantitative PCR for the detection of CMV DNA and CMV RNA have been introduced as alternatives for the antigenemia [76, 77] .", [["antigenemia", "DISEASE", 118, 129], ["CMV", "ORGANISM", 53, 56], ["DNA", "CELLULAR_COMPONENT", 57, 60], ["CMV", "ORGANISM", 65, 68], ["CMV DNA", "DNA", 53, 60], ["CMV RNA", "RNA", 65, 72], ["CMV", "SPECIES", 53, 56], ["CMV", "SPECIES", 65, 68], ["quantitative PCR", "TEST", 15, 31], ["the detection", "TEST", 36, 49], ["CMV DNA", "PROBLEM", 53, 60], ["CMV RNA", "PROBLEM", 65, 72], ["the antigenemia", "TEST", 114, 129]]], ["Since these techniques are more sensitive than antigenemia, a threshold for starting preemptive therapy should be established for every group of patients; in other words, a specific number of copies of CMV DNA above which triggers the institution of preemptive therapy in allogeneic HCT may not be the same for patients with less severe immunodeficiency.", [["immunodeficiency", "DISEASE", 337, 353], ["patients", "ORGANISM", 145, 153], ["CMV", "ORGANISM", 202, 205], ["DNA", "CELLULAR_COMPONENT", 206, 209], ["HCT", "CANCER", 283, 286], ["patients", "ORGANISM", 311, 319], ["CMV DNA", "DNA", 202, 209], ["patients", "SPECIES", 145, 153], ["patients", "SPECIES", 311, 319], ["CMV", "SPECIES", 202, 205], ["these techniques", "TEST", 6, 22], ["antigenemia", "PROBLEM", 47, 58], ["starting preemptive therapy", "TREATMENT", 76, 103], ["CMV DNA", "PROBLEM", 202, 209], ["preemptive therapy", "TREATMENT", 250, 268], ["allogeneic HCT", "TREATMENT", 272, 286], ["less severe immunodeficiency", "PROBLEM", 325, 353], ["immunodeficiency", "OBSERVATION", 337, 353]]], ["Indeed, the application of these sensitive biomarkers has revealed that hosts not thought to be at risk for CMV reactivation may indeed have positive CMV PCR quite frequently [78] .", [["CMV", "ORGANISM", 108, 111], ["CMV", "ORGANISM", 150, 153], ["CMV", "SPECIES", 108, 111], ["CMV", "SPECIES", 150, 153], ["these sensitive biomarkers", "TEST", 27, 53], ["CMV reactivation", "PROBLEM", 108, 124], ["CMV PCR", "TEST", 150, 157]]], ["Outside the setting of allogeneic HCT, patients at higher risk to develop CMV reactivation include patients with chronic lymphocytic leukemia (CLL) receiving fludarabine or (especially) alemtuzumab [79] , patients with multiple myeloma receiving highly intensive therapies [80] , and autologous HCT recipients treated previously with rituximab [81] .Cytomegalovirus (CMV)Two strategies were reported effective for the prophylaxis of CMV disease in allogeneic HCT recipients: universal prophylaxis and preemptive therapy.", [["chronic lymphocytic leukemia", "ANATOMY", 113, 141], ["CLL", "ANATOMY", 143, 146], ["myeloma", "ANATOMY", 228, 235], ["HCT", "ANATOMY", 295, 298], ["HCT", "ANATOMY", 459, 462], ["chronic lymphocytic leukemia", "DISEASE", 113, 141], ["CLL", "DISEASE", 143, 146], ["fludarabine", "CHEMICAL", 158, 169], ["alemtuzumab", "CHEMICAL", 186, 197], ["multiple myeloma", "DISEASE", 219, 235], ["rituximab", "CHEMICAL", 334, 343], ["CMV disease", "DISEASE", 433, 444], ["fludarabine", "CHEMICAL", 158, 169], ["HCT", "CANCER", 34, 37], ["patients", "ORGANISM", 39, 47], ["CMV", "ORGANISM", 74, 77], ["patients", "ORGANISM", 99, 107], ["chronic lymphocytic leukemia", "CANCER", 113, 141], ["CLL", "CANCER", 143, 146], ["fludarabine", "SIMPLE_CHEMICAL", 158, 169], ["alemtuzumab", "SIMPLE_CHEMICAL", 186, 197], ["patients", "ORGANISM", 205, 213], ["myeloma", "CANCER", 228, 235], ["HCT", "CANCER", 295, 298], ["rituximab", "SIMPLE_CHEMICAL", 334, 343], ["Cytomegalovirus", "ORGANISM", 350, 365], ["CMV", "ORGANISM", 367, 370], ["CMV", "ORGANISM", 433, 436], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 99, 107], ["patients", "SPECIES", 205, 213], ["CMV", "SPECIES", 74, 77], ["CMV", "SPECIES", 367, 370], ["CMV", "SPECIES", 433, 436], ["allogeneic HCT", "TEST", 23, 37], ["CMV reactivation", "PROBLEM", 74, 90], ["chronic lymphocytic leukemia", "PROBLEM", 113, 141], ["CLL", "PROBLEM", 143, 146], ["fludarabine", "TREATMENT", 158, 169], ["alemtuzumab", "TREATMENT", 186, 197], ["multiple myeloma", "PROBLEM", 219, 235], ["highly intensive therapies", "TREATMENT", 246, 272], ["autologous HCT recipients", "TREATMENT", 284, 309], ["rituximab", "TREATMENT", 334, 343], ["Cytomegalovirus", "PROBLEM", 350, 365], ["CMV disease", "PROBLEM", 433, 444], ["allogeneic HCT recipients", "TREATMENT", 448, 473], ["universal prophylaxis", "TREATMENT", 475, 496], ["preemptive therapy", "TREATMENT", 501, 519], ["CMV reactivation", "OBSERVATION", 74, 90], ["chronic", "OBSERVATION_MODIFIER", 113, 120], ["lymphocytic leukemia", "OBSERVATION", 121, 141], ["multiple", "OBSERVATION_MODIFIER", 219, 227], ["myeloma", "OBSERVATION", 228, 235], ["CMV disease", "OBSERVATION", 433, 444]]], ["Universal prophylaxis is not usually given because this strategy may lead to a significant increase in the incidence of bacterial and fungal superinfections associated with ganciclovir-induced neutropenia and immunosuppression [82] , and the occurrence of late CMV disease [74] .", [["bacterial and fungal superinfections", "DISEASE", 120, 156], ["ganciclovir", "CHEMICAL", 173, 184], ["neutropenia", "DISEASE", 193, 204], ["CMV disease", "DISEASE", 261, 272], ["ganciclovir", "CHEMICAL", 173, 184], ["ganciclovir", "SIMPLE_CHEMICAL", 173, 184], ["CMV", "ORGANISM", 261, 264], ["CMV", "SPECIES", 261, 264], ["Universal prophylaxis", "TREATMENT", 0, 21], ["a significant increase", "PROBLEM", 77, 99], ["bacterial and fungal superinfections", "PROBLEM", 120, 156], ["ganciclovir", "TREATMENT", 173, 184], ["induced neutropenia", "PROBLEM", 185, 204], ["immunosuppression", "TREATMENT", 209, 226], ["late CMV disease", "PROBLEM", 256, 272], ["significant", "OBSERVATION_MODIFIER", 79, 90], ["increase", "OBSERVATION_MODIFIER", 91, 99], ["bacterial", "OBSERVATION_MODIFIER", 120, 129], ["fungal superinfections", "OBSERVATION", 134, 156], ["late", "OBSERVATION_MODIFIER", 256, 260], ["CMV disease", "OBSERVATION", 261, 272]]], ["Ganciclovir, administered intravenously, is the drug most often used for preemptive therapy.", [["intravenously", "ANATOMY", 26, 39], ["Ganciclovir", "CHEMICAL", 0, 11], ["Ganciclovir", "CHEMICAL", 0, 11], ["Ganciclovir", "SIMPLE_CHEMICAL", 0, 11], ["Ganciclovir", "TREATMENT", 0, 11], ["the drug", "TREATMENT", 44, 52], ["preemptive therapy", "TREATMENT", 73, 91]]], ["The usual duration of therapy is 2 weeks, provided antigenemia (or PCR) becomes promptly negative.", [["therapy", "TREATMENT", 22, 29], ["antigenemia", "PROBLEM", 51, 62], ["PCR", "TEST", 67, 70]]], ["Otherwise, a prolonged course of ganciclovir or maintenance therapy is indicated.", [["ganciclovir", "CHEMICAL", 33, 44], ["ganciclovir", "CHEMICAL", 33, 44], ["ganciclovir", "SIMPLE_CHEMICAL", 33, 44], ["ganciclovir", "TREATMENT", 33, 44], ["maintenance therapy", "TREATMENT", 48, 67]]], ["Alternatives to ganciclovir include foscarnet and oral valganciclovir [3] .", [["oral", "ANATOMY", 50, 54], ["ganciclovir", "CHEMICAL", 16, 27], ["foscarnet", "CHEMICAL", 36, 45], ["valganciclovir", "CHEMICAL", 55, 69], ["ganciclovir", "CHEMICAL", 16, 27], ["foscarnet", "CHEMICAL", 36, 45], ["valganciclovir", "CHEMICAL", 55, 69], ["ganciclovir", "SIMPLE_CHEMICAL", 16, 27], ["foscarnet", "SIMPLE_CHEMICAL", 36, 45], ["oral", "ORGANISM_SUBDIVISION", 50, 54], ["ganciclovir", "TREATMENT", 16, 27], ["foscarnet", "TREATMENT", 36, 45], ["oral valganciclovir", "TREATMENT", 50, 69]]], ["Investigational agents include brincidofovir [83] , letermovir [84] , and maribavir [85] .Herpes Simplex Virus (HSV)Reactivation of HSV is frequent in patients with hematological malignancies, especially after induction chemotherapy for acute leukemia, and following conditioning regimens for HCT, and manifests as oral lesions indistinguishable from chemotherapy-induced mucositis [86] .", [["hematological malignancies", "ANATOMY", 165, 191], ["acute leukemia", "ANATOMY", 237, 251], ["oral lesions", "ANATOMY", 315, 327], ["brincidofovir", "CHEMICAL", 31, 44], ["letermovir", "CHEMICAL", 52, 62], ["maribavir", "CHEMICAL", 74, 83], ["Herpes Simplex Virus", "DISEASE", 90, 110], ["hematological malignancies", "DISEASE", 165, 191], ["acute leukemia", "DISEASE", 237, 251], ["HCT", "DISEASE", 293, 296], ["mucositis", "DISEASE", 372, 381], ["brincidofovir", "CHEMICAL", 31, 44], ["letermovir", "CHEMICAL", 52, 62], ["maribavir", "CHEMICAL", 74, 83], ["brincidofovir", "SIMPLE_CHEMICAL", 31, 44], ["letermovir [84]", "SIMPLE_CHEMICAL", 52, 67], ["maribavir [85", "SIMPLE_CHEMICAL", 74, 87], ["Herpes Simplex Virus", "ORGANISM", 90, 110], ["HSV", "ORGANISM", 112, 115], ["HSV", "ORGANISM", 132, 135], ["patients", "ORGANISM", 151, 159], ["hematological malignancies", "CANCER", 165, 191], ["acute leukemia", "CANCER", 237, 251], ["HCT", "CANCER", 293, 296], ["oral lesions", "PATHOLOGICAL_FORMATION", 315, 327], ["Herpes Simplex Virus", "SPECIES", 90, 110], ["patients", "SPECIES", 151, 159], ["Herpes Simplex Virus", "SPECIES", 90, 110], ["HSV", "SPECIES", 112, 115], ["HSV", "SPECIES", 132, 135], ["Investigational agents", "TREATMENT", 0, 22], ["brincidofovir", "TREATMENT", 31, 44], ["letermovir", "TREATMENT", 52, 62], ["maribavir", "TREATMENT", 74, 83], ["Herpes Simplex Virus (HSV", "PROBLEM", 90, 115], ["HSV", "PROBLEM", 132, 135], ["hematological malignancies", "PROBLEM", 165, 191], ["induction chemotherapy", "TREATMENT", 210, 232], ["acute leukemia", "PROBLEM", 237, 251], ["conditioning regimens", "TREATMENT", 267, 288], ["HCT", "TEST", 293, 296], ["oral lesions", "PROBLEM", 315, 327], ["chemotherapy", "TREATMENT", 351, 363], ["induced mucositis", "PROBLEM", 364, 381], ["Simplex Virus", "OBSERVATION", 97, 110], ["HSV", "OBSERVATION", 132, 135], ["frequent", "OBSERVATION_MODIFIER", 139, 147], ["malignancies", "OBSERVATION", 179, 191], ["acute", "OBSERVATION_MODIFIER", 237, 242], ["leukemia", "OBSERVATION", 243, 251], ["oral", "ANATOMY", 315, 319], ["lesions", "OBSERVATION", 320, 327]]], ["Less frequent manifestations include genital ulcers, esophagitis, hepatitis, and pneumonia.", [["genital ulcers", "ANATOMY", 37, 51], ["genital ulcers", "DISEASE", 37, 51], ["esophagitis", "DISEASE", 53, 64], ["hepatitis", "DISEASE", 66, 75], ["pneumonia", "DISEASE", 81, 90], ["genital ulcers", "PATHOLOGICAL_FORMATION", 37, 51], ["Less frequent manifestations", "PROBLEM", 0, 28], ["genital ulcers", "PROBLEM", 37, 51], ["esophagitis", "PROBLEM", 53, 64], ["hepatitis", "PROBLEM", 66, 75], ["pneumonia", "PROBLEM", 81, 90], ["genital", "ANATOMY", 37, 44], ["ulcers", "OBSERVATION", 45, 51], ["esophagitis", "OBSERVATION", 53, 64], ["hepatitis", "OBSERVATION", 66, 75], ["pneumonia", "OBSERVATION", 81, 90]]], ["Antiviral prophylaxis against HSV is administered if the patient is seropositive for HSV or conveys a history of recurrent fever blisters, cold sores, or other indications of recurrent HSV infections, particularly if the CD4 counts are low (<50/mm 3 ).", [["blisters", "ANATOMY", 129, 137], ["CD4", "ANATOMY", 221, 224], ["fever", "DISEASE", 123, 128], ["blisters", "DISEASE", 129, 137], ["cold sores", "DISEASE", 139, 149], ["HSV infections", "DISEASE", 185, 199], ["HSV", "ORGANISM", 30, 33], ["patient", "ORGANISM", 57, 64], ["HSV", "ORGANISM", 85, 88], ["HSV", "ORGANISM", 185, 188], ["CD4", "GENE_OR_GENE_PRODUCT", 221, 224], ["CD4", "PROTEIN", 221, 224], ["patient", "SPECIES", 57, 64], ["HSV", "SPECIES", 30, 33], ["HSV", "SPECIES", 85, 88], ["HSV", "SPECIES", 185, 188], ["Antiviral prophylaxis", "TREATMENT", 0, 21], ["HSV", "PROBLEM", 30, 33], ["HSV", "PROBLEM", 85, 88], ["recurrent fever blisters", "PROBLEM", 113, 137], ["cold sores", "PROBLEM", 139, 149], ["recurrent HSV infections", "PROBLEM", 175, 199], ["the CD4 counts", "TEST", 217, 231], ["recurrent", "OBSERVATION_MODIFIER", 113, 122], ["fever", "OBSERVATION", 123, 128], ["infections", "OBSERVATION", 189, 199]]], ["The drug of choice is acyclovir, and should be given prior to or at the time of cytotoxic or myeloablative chemotherapy and continued until bone marrow recovery and/or resolution of mucositis [86] .", [["bone marrow", "ANATOMY", 140, 151], ["acyclovir", "CHEMICAL", 22, 31], ["mucositis", "DISEASE", 182, 191], ["acyclovir", "CHEMICAL", 22, 31], ["acyclovir", "SIMPLE_CHEMICAL", 22, 31], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 140, 151], ["acyclovir", "TREATMENT", 22, 31], ["cytotoxic or myeloablative chemotherapy", "TREATMENT", 80, 119], ["bone marrow recovery", "TEST", 140, 160], ["mucositis", "PROBLEM", 182, 191]]], ["Alternatives to acyclovir are valacyclovir and famciclovir (Table 49 .4).Varicella-Zoster Virus (VZV)Patients at highest risk for VZV reactivation are those with severe lymphopenia and/or CD4 cytopenia such as patients with lymphoma, leukemia (mainly CLL), heavily treated myeloma patients, HCT recipients and patients receiving fludarabine or alemtuzumab.", [["lymphoma", "ANATOMY", 224, 232], ["leukemia", "ANATOMY", 234, 242], ["CLL", "ANATOMY", 251, 254], ["myeloma", "ANATOMY", 273, 280], ["HCT", "ANATOMY", 291, 294], ["acyclovir", "CHEMICAL", 16, 25], ["valacyclovir", "CHEMICAL", 30, 42], ["famciclovir", "CHEMICAL", 47, 58], ["Varicella-Zoster Virus", "DISEASE", 73, 95], ["lymphopenia", "DISEASE", 169, 180], ["cytopenia", "DISEASE", 192, 201], ["lymphoma", "DISEASE", 224, 232], ["leukemia", "DISEASE", 234, 242], ["CLL", "DISEASE", 251, 254], ["myeloma", "DISEASE", 273, 280], ["HCT", "DISEASE", 291, 294], ["fludarabine", "CHEMICAL", 329, 340], ["alemtuzumab", "CHEMICAL", 344, 355], ["acyclovir", "CHEMICAL", 16, 25], ["valacyclovir", "CHEMICAL", 30, 42], ["famciclovir", "CHEMICAL", 47, 58], ["fludarabine", "CHEMICAL", 329, 340], ["acyclovir", "SIMPLE_CHEMICAL", 16, 25], ["valacyclovir", "SIMPLE_CHEMICAL", 30, 42], ["famciclovir", "SIMPLE_CHEMICAL", 47, 58], ["Varicella-Zoster Virus", "ORGANISM", 73, 95], ["VZV", "ORGANISM", 97, 100], ["Patients", "ORGANISM", 101, 109], ["VZV", "ORGANISM", 130, 133], ["CD4", "GENE_OR_GENE_PRODUCT", 188, 191], ["patients", "ORGANISM", 210, 218], ["lymphoma", "CANCER", 224, 232], ["leukemia", "CANCER", 234, 242], ["CLL", "CANCER", 251, 254], ["myeloma", "CANCER", 273, 280], ["patients", "ORGANISM", 281, 289], ["HCT", "CANCER", 291, 294], ["patients", "ORGANISM", 310, 318], ["fludarabine", "SIMPLE_CHEMICAL", 329, 340], ["alemtuzumab", "SIMPLE_CHEMICAL", 344, 355], ["Varicella-Zoster Virus", "SPECIES", 73, 95], ["Patients", "SPECIES", 101, 109], ["patients", "SPECIES", 210, 218], ["patients", "SPECIES", 281, 289], ["patients", "SPECIES", 310, 318], ["Varicella-Zoster Virus", "SPECIES", 73, 95], ["VZV", "SPECIES", 97, 100], ["VZV", "SPECIES", 130, 133], ["acyclovir", "TREATMENT", 16, 25], ["valacyclovir", "TREATMENT", 30, 42], ["famciclovir", "TREATMENT", 47, 58], ["Varicella", "PROBLEM", 73, 82], ["Zoster Virus (VZV)", "PROBLEM", 83, 101], ["VZV reactivation", "PROBLEM", 130, 146], ["severe lymphopenia", "PROBLEM", 162, 180], ["CD4 cytopenia", "PROBLEM", 188, 201], ["lymphoma", "PROBLEM", 224, 232], ["leukemia", "PROBLEM", 234, 242], ["CLL", "PROBLEM", 251, 254], ["heavily treated myeloma", "PROBLEM", 257, 280], ["HCT recipients", "TREATMENT", 291, 305], ["fludarabine", "TREATMENT", 329, 340], ["alemtuzumab", "TREATMENT", 344, 355], ["Zoster Virus", "OBSERVATION", 83, 95], ["VZV reactivation", "OBSERVATION", 130, 146], ["severe", "OBSERVATION_MODIFIER", 162, 168], ["lymphopenia", "OBSERVATION", 169, 180], ["CD4 cytopenia", "OBSERVATION", 188, 201], ["lymphoma", "OBSERVATION", 224, 232], ["leukemia", "OBSERVATION", 234, 242], ["myeloma", "OBSERVATION", 273, 280]]], ["Without acyclovir prophylaxis, reactivation of VZV is common and can be complicated with severe post-herpetic neuralgia.", [["acyclovir", "CHEMICAL", 8, 17], ["VZV", "DISEASE", 47, 50], ["post-herpetic neuralgia", "DISEASE", 96, 119], ["acyclovir", "CHEMICAL", 8, 17], ["acyclovir", "SIMPLE_CHEMICAL", 8, 17], ["VZV", "ORGANISM", 47, 50], ["VZV", "SPECIES", 47, 50], ["acyclovir prophylaxis", "TREATMENT", 8, 29], ["VZV", "PROBLEM", 47, 50], ["severe post-herpetic neuralgia", "PROBLEM", 89, 119], ["acyclovir prophylaxis", "OBSERVATION", 8, 29], ["VZV", "OBSERVATION", 47, 50], ["severe", "OBSERVATION_MODIFIER", 89, 95], ["post-herpetic", "OBSERVATION_MODIFIER", 96, 109], ["neuralgia", "OBSERVATION", 110, 119]]], ["Visceral dissemination (pneumonitis, meningoencephalitis, and hepatitis) may rarely occur in severely immunocompromised patients [87] .Varicella-Zoster Virus (VZV)Patients at high risk should avoid contact with persons with VZV disease, as well as vaccine recipients who develop a rash after vaccination.", [["Visceral", "ANATOMY", 0, 8], ["pneumonitis", "DISEASE", 24, 35], ["meningoencephalitis", "DISEASE", 37, 56], ["hepatitis", "DISEASE", 62, 71], ["Varicella-Zoster Virus", "DISEASE", 135, 157], ["VZV disease", "DISEASE", 224, 235], ["rash", "DISEASE", 281, 285], ["patients", "ORGANISM", 120, 128], ["Varicella-Zoster Virus", "ORGANISM", 135, 157], ["VZV", "ORGANISM", 159, 162], ["Patients", "ORGANISM", 163, 171], ["persons", "ORGANISM", 211, 218], ["VZV", "ORGANISM", 224, 227], ["recipients", "ORGANISM", 256, 266], ["patients", "SPECIES", 120, 128], ["Varicella-Zoster Virus", "SPECIES", 135, 157], ["Patients", "SPECIES", 163, 171], ["persons", "SPECIES", 211, 218], ["Varicella-Zoster Virus", "SPECIES", 135, 157], ["VZV", "SPECIES", 159, 162], ["VZV", "SPECIES", 224, 227], ["Visceral dissemination (pneumonitis", "PROBLEM", 0, 35], ["meningoencephalitis", "PROBLEM", 37, 56], ["hepatitis", "PROBLEM", 62, 71], ["Varicella", "PROBLEM", 135, 144], ["Zoster Virus (VZV)", "PROBLEM", 145, 163], ["VZV disease", "PROBLEM", 224, 235], ["vaccine recipients", "TREATMENT", 248, 266], ["a rash", "PROBLEM", 279, 285], ["vaccination", "TREATMENT", 292, 303], ["dissemination", "OBSERVATION", 9, 22], ["pneumonitis", "OBSERVATION", 24, 35], ["meningoencephalitis", "OBSERVATION", 37, 56], ["hepatitis", "OBSERVATION", 62, 71], ["severely", "OBSERVATION_MODIFIER", 93, 101], ["immunocompromised", "OBSERVATION", 102, 119], ["Zoster Virus", "OBSERVATION", 145, 157]]], ["In addition, contact and airborne precautions are recommended if an immunocompromised patient develops VZV disease, in order to decrease the risk of transmission to other patients and to HCW [3] .Varicella-Zoster Virus (VZV)High-risk patients with a history of recent contact with any person with VZV disease should receive varicella-zoster immunoglobulin (VZIG) or, as an alternative, acyclovir or valacyclovir [88] .", [["VZV disease", "DISEASE", 103, 114], ["Varicella-Zoster Virus", "DISEASE", 196, 218], ["VZV disease", "DISEASE", 297, 308], ["varicella-zoster", "DISEASE", 324, 340], ["VZIG", "CHEMICAL", 357, 361], ["acyclovir", "CHEMICAL", 386, 395], ["valacyclovir", "CHEMICAL", 399, 411], ["acyclovir", "CHEMICAL", 386, 395], ["valacyclovir", "CHEMICAL", 399, 411], ["patient", "ORGANISM", 86, 93], ["VZV", "ORGANISM", 103, 106], ["patients", "ORGANISM", 171, 179], ["Varicella-Zoster Virus", "ORGANISM", 196, 218], ["VZV", "ORGANISM", 220, 223], ["patients", "ORGANISM", 234, 242], ["VZV", "ORGANISM", 297, 300], ["zoster", "ORGANISM", 334, 340], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 341, 355], ["VZIG", "SIMPLE_CHEMICAL", 357, 361], ["acyclovir", "SIMPLE_CHEMICAL", 386, 395], ["valacyclovir", "SIMPLE_CHEMICAL", 399, 411], ["patient", "SPECIES", 86, 93], ["patients", "SPECIES", 171, 179], ["Varicella-Zoster Virus", "SPECIES", 196, 218], ["patients", "SPECIES", 234, 242], ["person", "SPECIES", 285, 291], ["varicella-zoster", "SPECIES", 324, 340], ["VZV", "SPECIES", 103, 106], ["Varicella-Zoster Virus", "SPECIES", 196, 218], ["VZV", "SPECIES", 220, 223], ["VZV", "SPECIES", 297, 300], ["airborne precautions", "TREATMENT", 25, 45], ["an immunocompromised", "PROBLEM", 65, 85], ["VZV disease", "PROBLEM", 103, 114], ["Varicella", "PROBLEM", 196, 205], ["Zoster Virus (VZV", "PROBLEM", 206, 223], ["VZV disease", "PROBLEM", 297, 308], ["varicella", "PROBLEM", 324, 333], ["zoster immunoglobulin (VZIG)", "TREATMENT", 334, 362], ["acyclovir", "TREATMENT", 386, 395], ["valacyclovir", "TREATMENT", 399, 411], ["Zoster Virus", "OBSERVATION", 206, 218]]], ["Acyclovir is indicated as prophylaxis against VZV reactivation in allogeneic HCT recipients, usually given for 1 year [89] .", [["HCT", "ANATOMY", 77, 80], ["Acyclovir", "CHEMICAL", 0, 9], ["Acyclovir", "CHEMICAL", 0, 9], ["Acyclovir", "SIMPLE_CHEMICAL", 0, 9], ["VZV", "ORGANISM", 46, 49], ["HCT", "CANCER", 77, 80], ["VZV", "SPECIES", 46, 49], ["Acyclovir", "TREATMENT", 0, 9], ["prophylaxis", "TREATMENT", 26, 37], ["VZV reactivation", "PROBLEM", 46, 62], ["allogeneic HCT recipients", "TREATMENT", 66, 91]]], ["In addition, patients with multiple myeloma receiving regimens containing bortezomib should receive prophylaxis because of the high risk of VZV reactivation [80] .", [["myeloma", "ANATOMY", 36, 43], ["multiple myeloma", "DISEASE", 27, 43], ["bortezomib", "CHEMICAL", 74, 84], ["bortezomib", "CHEMICAL", 74, 84], ["patients", "ORGANISM", 13, 21], ["myeloma", "CANCER", 36, 43], ["bortezomib", "SIMPLE_CHEMICAL", 74, 84], ["VZV", "ORGANISM", 140, 143], ["patients", "SPECIES", 13, 21], ["VZV", "SPECIES", 140, 143], ["multiple myeloma", "PROBLEM", 27, 43], ["regimens", "TREATMENT", 54, 62], ["bortezomib", "TREATMENT", 74, 84], ["prophylaxis", "TREATMENT", 100, 111], ["VZV reactivation", "PROBLEM", 140, 156], ["multiple", "OBSERVATION_MODIFIER", 27, 35], ["myeloma", "OBSERVATION", 36, 43], ["VZV reactivation", "OBSERVATION", 140, 156]]], ["The use of VZV prophylaxis in other settings is more debatable and should be reserved for severely immunosuppressed patients, especially if they develop herpes zoster.Epstein Barr Virus (EBV)Patients with EBV disease may present with fever and mononucleosis syndrome.", [["herpes zoster", "DISEASE", 153, 166], ["Epstein Barr Virus", "DISEASE", 167, 185], ["EBV disease", "DISEASE", 205, 216], ["fever", "DISEASE", 234, 239], ["mononucleosis syndrome", "DISEASE", 244, 266], ["VZV", "ORGANISM", 11, 14], ["patients", "ORGANISM", 116, 124], ["herpes zoster", "ORGANISM", 153, 166], ["Epstein Barr Virus", "ORGANISM", 167, 185], ["EBV", "ORGANISM", 187, 190], ["Patients", "ORGANISM", 191, 199], ["EBV", "ORGANISM", 205, 208], ["patients", "SPECIES", 116, 124], ["herpes zoster", "SPECIES", 153, 166], ["Patients", "SPECIES", 191, 199], ["VZV", "SPECIES", 11, 14], ["Epstein Barr Virus", "SPECIES", 167, 185], ["EBV", "SPECIES", 187, 190], ["EBV", "SPECIES", 205, 208], ["VZV prophylaxis", "TREATMENT", 11, 26], ["severely immunosuppressed patients", "PROBLEM", 90, 124], ["herpes zoster", "PROBLEM", 153, 166], ["Epstein Barr Virus", "PROBLEM", 167, 185], ["EBV disease", "PROBLEM", 205, 216], ["fever", "PROBLEM", 234, 239], ["mononucleosis syndrome", "PROBLEM", 244, 266], ["VZV prophylaxis", "OBSERVATION", 11, 26], ["Barr Virus", "OBSERVATION", 175, 185], ["EBV disease", "OBSERVATION", 205, 216], ["mononucleosis syndrome", "OBSERVATION", 244, 266]]], ["In addition, HCT recipients may present with posttransplant lymphoproliferative disease (PTLD).", [["HCT", "ANATOMY", 13, 16], ["posttransplant lymphoproliferative disease", "DISEASE", 45, 87], ["PTLD", "DISEASE", 89, 93], ["HCT recipients", "ORGANISM", 13, 27], ["HCT recipients", "TREATMENT", 13, 27], ["posttransplant lymphoproliferative disease", "PROBLEM", 45, 87], ["PTLD", "PROBLEM", 89, 93], ["lymphoproliferative disease", "OBSERVATION", 60, 87]]], ["Patients at high risk for PTLD include recipients of matched unrelated, mismatched, or T-cell depleted transplants, recipients of high dose antithymocyte globulin or anti-T-cell monoclonal antibodies, patients with acute and chronic GVHD, and those receiving radiation as part of the conditioning regimen [90] .Epstein Barr Virus (EBV)High-risk patients who are EBV seronegative should be advised to avoid close contact with EBV seropositive individuals.", [["T-cell", "ANATOMY", 87, 93], ["PTLD", "DISEASE", 26, 30], ["antithymocyte globulin", "CHEMICAL", 140, 162], ["GVHD", "DISEASE", 233, 237], ["Patients", "ORGANISM", 0, 8], ["T-cell", "CELL", 87, 93], ["recipients", "ORGANISM", 116, 126], ["antithymocyte globulin", "SIMPLE_CHEMICAL", 140, 162], ["patients", "ORGANISM", 201, 209], ["Epstein Barr Virus", "ORGANISM", 311, 329], ["EBV", "ORGANISM", 331, 334], ["patients", "ORGANISM", 345, 353], ["EBV", "ORGANISM", 362, 365], ["EBV", "ORGANISM", 425, 428], ["high dose antithymocyte globulin", "PROTEIN", 130, 162], ["anti-T-cell monoclonal antibodies", "PROTEIN", 166, 199], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 201, 209], ["patients", "SPECIES", 345, 353], ["Epstein Barr Virus", "SPECIES", 311, 329], ["EBV", "SPECIES", 331, 334], ["EBV", "SPECIES", 362, 365], ["PTLD", "PROBLEM", 26, 30], ["T-cell depleted transplants", "TREATMENT", 87, 114], ["high dose antithymocyte globulin", "TREATMENT", 130, 162], ["anti-T-cell monoclonal antibodies", "TREATMENT", 166, 199], ["acute and chronic GVHD", "PROBLEM", 215, 237], ["radiation", "TREATMENT", 259, 268], ["the conditioning regimen", "TREATMENT", 280, 304], ["Epstein Barr Virus", "PROBLEM", 311, 329], ["EBV seronegative", "PROBLEM", 362, 378], ["depleted transplants", "OBSERVATION", 94, 114], ["acute", "OBSERVATION_MODIFIER", 215, 220], ["chronic", "OBSERVATION_MODIFIER", 225, 232], ["GVHD", "OBSERVATION", 233, 237], ["Barr Virus", "OBSERVATION", 319, 329]]], ["Increases in EBV viral load following PPSCT/BMT are common, and are highest in patients at risk for PTLD.", [["PTLD", "DISEASE", 100, 104], ["EBV", "ORGANISM", 13, 16], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["EBV", "SPECIES", 13, 16], ["Increases in EBV viral load", "PROBLEM", 0, 27], ["PPSCT/BMT", "TREATMENT", 38, 47], ["PTLD", "PROBLEM", 100, 104], ["EBV", "OBSERVATION", 13, 16], ["viral load", "OBSERVATION", 17, 27], ["PTLD", "OBSERVATION", 100, 104]]], ["The best strategy to prevent PLTD is to serial monitor high-risk patients with serum quantitative PCR technique and giving rituximab preemptively for patients who present EBV replication [91] .Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV)Patients with hematological malignancies undergoing cytotoxic chemotherapy while infected with HBV have a higher risk for severe liver dysfunction [92] .", [["serum", "ANATOMY", 79, 84], ["hematological malignancies", "ANATOMY", 258, 284], ["liver", "ANATOMY", 373, 378], ["PLTD", "DISEASE", 29, 33], ["rituximab", "CHEMICAL", 123, 132], ["Hepatitis B", "DISEASE", 193, 204], ["Hepatitis C Virus", "DISEASE", 221, 238], ["hematological malignancies", "DISEASE", 258, 284], ["liver dysfunction", "DISEASE", 373, 390], ["patients", "ORGANISM", 65, 73], ["serum", "ORGANISM_SUBSTANCE", 79, 84], ["rituximab", "SIMPLE_CHEMICAL", 123, 132], ["patients", "ORGANISM", 150, 158], ["EBV", "ORGANISM", 171, 174], ["Hepatitis B Virus", "ORGANISM", 193, 210], ["HBV", "ORGANISM", 212, 215], ["Hepatitis C Virus", "ORGANISM", 221, 238], ["HCV", "ORGANISM", 240, 243], ["Patients", "ORGANISM", 244, 252], ["hematological malignancies", "CANCER", 258, 284], ["HBV", "ORGANISM", 339, 342], ["liver", "ORGAN", 373, 378], ["patients", "SPECIES", 65, 73], ["patients", "SPECIES", 150, 158], ["Hepatitis B Virus", "SPECIES", 193, 210], ["Hepatitis C Virus", "SPECIES", 221, 238], ["Patients", "SPECIES", 244, 252], ["Hepatitis B Virus", "SPECIES", 193, 210], ["HBV", "SPECIES", 212, 215], ["Hepatitis C Virus", "SPECIES", 221, 238], ["HCV", "SPECIES", 240, 243], ["HBV", "SPECIES", 339, 342], ["serum quantitative PCR technique", "TEST", 79, 111], ["rituximab", "TREATMENT", 123, 132], ["Hepatitis B Virus (HBV)", "PROBLEM", 193, 216], ["Hepatitis C Virus (HCV)", "PROBLEM", 221, 244], ["hematological malignancies", "PROBLEM", 258, 284], ["cytotoxic chemotherapy", "TREATMENT", 296, 318], ["HBV", "PROBLEM", 339, 342], ["severe liver dysfunction", "PROBLEM", 366, 390], ["severe", "OBSERVATION_MODIFIER", 366, 372], ["liver", "ANATOMY", 373, 378], ["dysfunction", "OBSERVATION", 379, 390]]], ["During therapy-induced aplasia, the possibility of viral replication increases dramatically resulting in acute HBV infection that may be mild, asymptomatic, or chronically progressive leading to fulminant hepatitis.", [["aplasia", "DISEASE", 23, 30], ["HBV infection", "DISEASE", 111, 124], ["hepatitis", "DISEASE", 205, 214], ["HBV", "ORGANISM", 111, 114], ["HBV", "SPECIES", 111, 114], ["therapy", "TREATMENT", 7, 14], ["induced aplasia", "PROBLEM", 15, 30], ["viral replication", "PROBLEM", 51, 68], ["acute HBV infection", "PROBLEM", 105, 124], ["asymptomatic", "PROBLEM", 143, 155], ["fulminant hepatitis", "PROBLEM", 195, 214], ["aplasia", "OBSERVATION", 23, 30], ["possibility of", "UNCERTAINTY", 36, 50], ["viral replication", "OBSERVATION", 51, 68], ["acute", "OBSERVATION_MODIFIER", 105, 110], ["HBV", "OBSERVATION_MODIFIER", 111, 114], ["infection", "OBSERVATION", 115, 124], ["may be", "UNCERTAINTY", 130, 136], ["mild", "OBSERVATION_MODIFIER", 137, 141], ["asymptomatic", "OBSERVATION_MODIFIER", 143, 155], ["chronically", "OBSERVATION_MODIFIER", 160, 171], ["progressive", "OBSERVATION_MODIFIER", 172, 183], ["fulminant", "OBSERVATION_MODIFIER", 195, 204], ["hepatitis", "OBSERVATION", 205, 214]]], ["Fulminant hepatitis usually coincides with discontinuation of immunosuppression [93] .", [["Fulminant hepatitis", "DISEASE", 0, 19], ["Fulminant hepatitis", "PROBLEM", 0, 19], ["immunosuppression", "TREATMENT", 62, 79], ["hepatitis", "OBSERVATION", 10, 19]]], ["Risk factors for reactivation include male gender, younger age, a diagnosis of lymphoma, and positive HBV e antigen [94] .", [["lymphoma", "ANATOMY", 79, 87], ["lymphoma", "DISEASE", 79, 87], ["lymphoma", "CANCER", 79, 87], ["HBV", "SPECIES", 102, 105], ["Risk factors", "PROBLEM", 0, 12], ["reactivation", "PROBLEM", 17, 29], ["lymphoma", "PROBLEM", 79, 87], ["positive HBV e antigen", "PROBLEM", 93, 115], ["lymphoma", "OBSERVATION", 79, 87]]], ["In HCT recipients, the risk of reactivation is as high as 50% [95] .", [["HCT", "ANATOMY", 3, 6], ["HCT", "CANCER", 3, 6], ["HCT recipients", "TREATMENT", 3, 17], ["reactivation", "PROBLEM", 31, 43], ["HCT recipients", "OBSERVATION", 3, 17], ["reactivation", "OBSERVATION", 31, 43]]], ["Although any chemotherapy regimen may result in HBV reactivation, the risk is particularly higher after exposure to corticosteroids, rituximab, and alemtuzumab [96, 97] .Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV)Patients with circulating HBV DNA should receive preemptive therapy with lamivudine (100 mg/day).", [["corticosteroids", "CHEMICAL", 116, 131], ["rituximab", "CHEMICAL", 133, 142], ["alemtuzumab", "CHEMICAL", 148, 159], ["Hepatitis B", "DISEASE", 170, 181], ["Hepatitis C Virus", "DISEASE", 198, 215], ["lamivudine", "CHEMICAL", 294, 304], ["corticosteroids", "CHEMICAL", 116, 131], ["lamivudine", "CHEMICAL", 294, 304], ["HBV", "ORGANISM", 48, 51], ["corticosteroids", "SIMPLE_CHEMICAL", 116, 131], ["rituximab", "SIMPLE_CHEMICAL", 133, 142], ["alemtuzumab", "SIMPLE_CHEMICAL", 148, 159], ["Hepatitis B Virus", "ORGANISM", 170, 187], ["HBV", "ORGANISM", 189, 192], ["Hepatitis C Virus", "ORGANISM", 198, 215], ["HCV", "ORGANISM", 217, 220], ["Patients", "ORGANISM", 221, 229], ["HBV", "ORGANISM", 247, 250], ["DNA", "CELLULAR_COMPONENT", 251, 254], ["lamivudine", "SIMPLE_CHEMICAL", 294, 304], ["Hepatitis B Virus", "SPECIES", 170, 187], ["Hepatitis C Virus", "SPECIES", 198, 215], ["Patients", "SPECIES", 221, 229], ["HBV", "SPECIES", 48, 51], ["Hepatitis B Virus", "SPECIES", 170, 187], ["HBV", "SPECIES", 189, 192], ["Hepatitis C Virus", "SPECIES", 198, 215], ["HCV", "SPECIES", 217, 220], ["HBV", "SPECIES", 247, 250], ["any chemotherapy regimen", "TREATMENT", 9, 33], ["HBV reactivation", "PROBLEM", 48, 64], ["corticosteroids", "TREATMENT", 116, 131], ["rituximab", "TREATMENT", 133, 142], ["alemtuzumab", "TREATMENT", 148, 159], ["Hepatitis B Virus (HBV)", "PROBLEM", 170, 193], ["Hepatitis C Virus (HCV)", "PROBLEM", 198, 221], ["circulating HBV DNA", "TREATMENT", 235, 254], ["preemptive therapy", "TREATMENT", 270, 288], ["lamivudine", "TREATMENT", 294, 304], ["HBV", "OBSERVATION", 48, 51]]], ["This regimen is effective and relatively nontoxic.", [["This regimen", "TREATMENT", 0, 12], ["nontoxic", "OBSERVATION_MODIFIER", 41, 49]]], ["However, prolonged exposure to lamivudine may result in the development of resistance.", [["lamivudine", "CHEMICAL", 31, 41], ["lamivudine", "CHEMICAL", 31, 41], ["lamivudine", "SIMPLE_CHEMICAL", 31, 41], ["lamivudine", "TREATMENT", 31, 41], ["resistance", "PROBLEM", 75, 85], ["resistance", "OBSERVATION", 75, 85]]], ["The optimal duration of preemptive therapy is not established, but is usually recommended to be at least 6 months after discontinuation of chemotherapy, to avoid viral reactivation and the development of hepatitis [95, 98] .Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV)Patients infected with HCV may receive chemotherapy or HCT without major complications except for a higher risk for sinusoidal obstruction syndrome; the risk for such patients is the development of late cirrhosis, several years after HCT [99] .", [["sinusoidal", "ANATOMY", 391, 401], ["hepatitis", "DISEASE", 204, 213], ["Hepatitis B", "DISEASE", 224, 235], ["Hepatitis C Virus (HCV)", "DISEASE", 252, 275], ["HCV", "DISEASE", 298, 301], ["sinusoidal obstruction syndrome", "DISEASE", 391, 422], ["cirrhosis", "DISEASE", 478, 487], ["Hepatitis B Virus", "ORGANISM", 224, 241], ["HBV", "ORGANISM", 243, 246], ["Hepatitis C Virus", "ORGANISM", 252, 269], ["HCV", "ORGANISM", 271, 274], ["Patients", "ORGANISM", 275, 283], ["HCV", "ORGANISM", 298, 301], ["patients", "ORGANISM", 442, 450], ["Hepatitis B Virus", "SPECIES", 224, 241], ["Hepatitis C Virus", "SPECIES", 252, 269], ["Patients", "SPECIES", 275, 283], ["patients", "SPECIES", 442, 450], ["Hepatitis B Virus", "SPECIES", 224, 241], ["HBV", "SPECIES", 243, 246], ["Hepatitis C Virus", "SPECIES", 252, 269], ["HCV", "SPECIES", 271, 274], ["HCV", "SPECIES", 298, 301], ["preemptive therapy", "TREATMENT", 24, 42], ["chemotherapy", "TREATMENT", 139, 151], ["viral reactivation", "PROBLEM", 162, 180], ["hepatitis", "PROBLEM", 204, 213], ["Hepatitis B Virus (HBV)", "PROBLEM", 224, 247], ["Hepatitis C Virus (HCV)", "PROBLEM", 252, 275], ["HCV", "PROBLEM", 298, 301], ["chemotherapy", "TREATMENT", 314, 326], ["HCT", "TREATMENT", 330, 333], ["major complications", "PROBLEM", 342, 361], ["sinusoidal obstruction syndrome", "PROBLEM", 391, 422], ["late cirrhosis", "PROBLEM", 473, 487], ["HCT", "TEST", 509, 512], ["hepatitis", "OBSERVATION", 204, 213], ["sinusoidal", "ANATOMY", 391, 401], ["obstruction", "OBSERVATION", 402, 413], ["late", "OBSERVATION_MODIFIER", 473, 477], ["cirrhosis", "OBSERVATION", 478, 487]]], ["Patients with HCV should be assessed for the evidence of chronic liver disease.", [["liver", "ANATOMY", 65, 70], ["chronic liver disease", "DISEASE", 57, 78], ["Patients", "ORGANISM", 0, 8], ["HCV", "ORGANISM", 14, 17], ["liver", "ORGAN", 65, 70], ["Patients", "SPECIES", 0, 8], ["HCV", "SPECIES", 14, 17], ["HCV", "PROBLEM", 14, 17], ["chronic liver disease", "PROBLEM", 57, 78], ["HCV", "OBSERVATION", 14, 17], ["chronic", "OBSERVATION_MODIFIER", 57, 64], ["liver", "ANATOMY", 65, 70], ["disease", "OBSERVATION", 71, 78]]], ["Patients with cirrhosis who are selected for receipt of HCT should not receive conventional conditioning regimens.", [["cirrhosis", "DISEASE", 14, 23], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["cirrhosis", "PROBLEM", 14, 23], ["HCT", "TEST", 56, 59], ["conventional conditioning regimens", "TREATMENT", 79, 113], ["cirrhosis", "OBSERVATION", 14, 23]]], ["Although oral ribavirin may clear HCV viremia, its routine use as prophylaxis is not recommended.Respiratory VirusesThe respiratory viruses Adenovirus, Influenzae, Parainfluenza, Respiratory Syncytial Virus (RSV), Rhinovirus, Coronavirus, and Metapneumovirus may cause infections in patients with hematological malignancies.", [["oral", "ANATOMY", 9, 13], ["hematological malignancies", "ANATOMY", 297, 323], ["ribavirin", "CHEMICAL", 14, 23], ["viremia", "DISEASE", 38, 45], ["Respiratory Viruses", "DISEASE", 97, 116], ["respiratory viruses", "DISEASE", 120, 139], ["Respiratory Syncytial Virus (RSV)", "DISEASE", 179, 212], ["infections", "DISEASE", 269, 279], ["hematological malignancies", "DISEASE", 297, 323], ["ribavirin", "CHEMICAL", 14, 23], ["oral", "ORGANISM_SUBDIVISION", 9, 13], ["ribavirin", "SIMPLE_CHEMICAL", 14, 23], ["HCV", "ORGANISM", 34, 37], ["Respiratory Viruses", "ORGANISM", 97, 116], ["respiratory viruses Adenovirus", "ORGANISM", 120, 150], ["Influenzae", "ORGANISM", 152, 162], ["Parainfluenza, Respiratory Syncytial Virus", "ORGANISM", 164, 206], ["RSV", "ORGANISM", 208, 211], ["Rhinovirus", "GENE_OR_GENE_PRODUCT", 214, 224], ["Coronavirus", "GENE_OR_GENE_PRODUCT", 226, 237], ["Metapneumovirus", "GENE_OR_GENE_PRODUCT", 243, 258], ["patients", "ORGANISM", 283, 291], ["hematological malignancies", "CANCER", 297, 323], ["Respiratory Syncytial Virus", "SPECIES", 179, 206], ["patients", "SPECIES", 283, 291], ["HCV", "SPECIES", 34, 37], ["Respiratory Syncytial Virus", "SPECIES", 179, 206], ["RSV", "SPECIES", 208, 211], ["oral ribavirin", "TREATMENT", 9, 23], ["HCV viremia", "PROBLEM", 34, 45], ["prophylaxis", "TREATMENT", 66, 77], ["Respiratory Viruses", "PROBLEM", 97, 116], ["The respiratory viruses Adenovirus", "PROBLEM", 116, 150], ["Influenzae", "PROBLEM", 152, 162], ["Parainfluenza", "PROBLEM", 164, 177], ["Respiratory Syncytial Virus (RSV)", "PROBLEM", 179, 212], ["Rhinovirus", "PROBLEM", 214, 224], ["Coronavirus", "PROBLEM", 226, 237], ["Metapneumovirus", "PROBLEM", 243, 258], ["infections", "PROBLEM", 269, 279], ["hematological malignancies", "PROBLEM", 297, 323], ["ribavirin", "OBSERVATION", 14, 23], ["HCV viremia", "OBSERVATION", 34, 45], ["Viruses", "OBSERVATION", 109, 116], ["respiratory viruses", "OBSERVATION", 120, 139], ["Respiratory Syncytial Virus", "OBSERVATION", 179, 206], ["Metapneumovirus", "OBSERVATION", 243, 258]]], ["Most of these infections appear to be self-limited, although progression to severe lower respiratory infection may occur [100] [101] [102] [103] .", [["respiratory", "ANATOMY", 89, 100], ["infections", "DISEASE", 14, 24], ["lower respiratory infection", "DISEASE", 83, 110], ["these infections", "PROBLEM", 8, 24], ["severe lower respiratory infection", "PROBLEM", 76, 110], ["infections", "OBSERVATION", 14, 24], ["severe", "OBSERVATION_MODIFIER", 76, 82], ["lower", "ANATOMY_MODIFIER", 83, 88], ["respiratory", "ANATOMY", 89, 100], ["infection", "OBSERVATION", 101, 110]]], ["The main strategy for prophylaxis of infections by respiratory viruses is to prevent exposure of patients with hematological malignancies to individuals with symptoms of respiratory infections.Respiratory VirusesVaccination of household contacts and HCWs for Influenza is recommended during each Influenza season [3] .", [["hematological malignancies", "ANATOMY", 111, 137], ["respiratory", "ANATOMY", 170, 181], ["infections", "DISEASE", 37, 47], ["respiratory viruses", "DISEASE", 51, 70], ["hematological malignancies", "DISEASE", 111, 137], ["respiratory infections", "DISEASE", 170, 192], ["Influenza", "DISEASE", 259, 268], ["patients", "ORGANISM", 97, 105], ["hematological malignancies", "CANCER", 111, 137], ["patients", "SPECIES", 97, 105], ["The main strategy", "TREATMENT", 0, 17], ["infections", "PROBLEM", 37, 47], ["respiratory viruses", "PROBLEM", 51, 70], ["hematological malignancies", "PROBLEM", 111, 137], ["symptoms", "PROBLEM", 158, 166], ["respiratory infections", "PROBLEM", 170, 192], ["Influenza", "PROBLEM", 259, 268], ["main", "OBSERVATION_MODIFIER", 4, 8], ["infections", "OBSERVATION", 37, 47], ["respiratory viruses", "OBSERVATION", 51, 70], ["respiratory", "ANATOMY", 170, 181], ["infections", "OBSERVATION", 182, 192]]], ["In addition, patients receiving chemotherapy should also receive the vaccine, considering that they may be able to respond vaccination and the intervention is safe [104] .", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["chemotherapy", "TREATMENT", 32, 44], ["the vaccine", "TREATMENT", 65, 76]]], ["However, considering that the response to vaccination may be suboptimal, chemoprophylaxis with neuraminidase inhibitors during a community outbreak has been recommended [3] .Respiratory VirusesRegarding RSV, parainfluenza virus, and adenovirus, while highly immunosuppressive patients may be at risk for severe pneumonia, no formal prophylaxis is available and approved.", [["Respiratory VirusesRegarding RSV, parainfluenza virus", "DISEASE", 174, 227], ["pneumonia", "DISEASE", 311, 320], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 95, 108], ["Respiratory VirusesRegarding RSV", "ORGANISM", 174, 206], ["parainfluenza virus", "ORGANISM", 208, 227], ["adenovirus", "ORGANISM", 233, 243], ["patients", "ORGANISM", 276, 284], ["RSV", "SPECIES", 203, 206], ["parainfluenza virus", "SPECIES", 208, 227], ["patients", "SPECIES", 276, 284], ["RSV", "SPECIES", 203, 206], ["parainfluenza virus", "SPECIES", 208, 227], ["adenovirus", "SPECIES", 233, 243], ["vaccination", "TREATMENT", 42, 53], ["chemoprophylaxis", "TREATMENT", 73, 89], ["neuraminidase inhibitors", "TREATMENT", 95, 119], ["Respiratory VirusesRegarding RSV", "PROBLEM", 174, 206], ["parainfluenza virus", "PROBLEM", 208, 227], ["adenovirus", "PROBLEM", 233, 243], ["severe pneumonia", "PROBLEM", 304, 320], ["formal prophylaxis", "TREATMENT", 325, 343], ["RSV", "OBSERVATION", 203, 206], ["parainfluenza virus", "OBSERVATION", 208, 227], ["severe", "OBSERVATION_MODIFIER", 304, 310], ["pneumonia", "OBSERVATION", 311, 320]]], ["Therefore prevention of severe disease is best approached by early diagnosis and therapy.MycobacteriaThe incidence of tuberculosis in patients with hematological malignancies is low, even in highly endemic regions.", [["hematological malignancies", "ANATOMY", 148, 174], ["Mycobacteria", "DISEASE", 89, 101], ["tuberculosis", "DISEASE", 118, 130], ["hematological malignancies", "DISEASE", 148, 174], ["patients", "ORGANISM", 134, 142], ["hematological malignancies", "CANCER", 148, 174], ["patients", "SPECIES", 134, 142], ["severe disease", "PROBLEM", 24, 38], ["therapy", "TREATMENT", 81, 88], ["Mycobacteria", "PROBLEM", 89, 101], ["tuberculosis", "PROBLEM", 118, 130], ["hematological malignancies", "PROBLEM", 148, 174], ["severe", "OBSERVATION_MODIFIER", 24, 30], ["disease", "OBSERVATION", 31, 38], ["tuberculosis", "OBSERVATION", 118, 130], ["hematological", "ANATOMY", 148, 161], ["malignancies", "OBSERVATION", 162, 174], ["low", "OBSERVATION_MODIFIER", 178, 181], ["highly", "OBSERVATION_MODIFIER", 191, 197], ["endemic", "OBSERVATION", 198, 205]]], ["In a study from Spain, the incidence of tuberculosis was significantly higher than the general population among allogeneic but not autologous HCT recipients [105] .", [["HCT", "ANATOMY", 142, 145], ["tuberculosis", "DISEASE", 40, 52], ["HCT", "CELL", 142, 145], ["a study", "TEST", 3, 10], ["tuberculosis", "PROBLEM", 40, 52], ["autologous HCT recipients", "TREATMENT", 131, 156], ["tuberculosis", "OBSERVATION", 40, 52], ["significantly", "OBSERVATION_MODIFIER", 57, 70], ["higher", "OBSERVATION_MODIFIER", 71, 77]]], ["In another study, 917 patients with hematological malignancies from Brazil were retrospectively reviewed for a diagnosis of tuberculosis.", [["hematological malignancies", "ANATOMY", 36, 62], ["hematological malignancies", "DISEASE", 36, 62], ["tuberculosis", "DISEASE", 124, 136], ["patients", "ORGANISM", 22, 30], ["hematological malignancies", "CANCER", 36, 62], ["patients", "SPECIES", 22, 30], ["hematological malignancies", "PROBLEM", 36, 62], ["tuberculosis", "PROBLEM", 124, 136], ["tuberculosis", "OBSERVATION", 124, 136]]], ["The prevalence was 2.6% only; risk factors were an underlying disease associated with significant impairment in CMI (e.g., receipt of fludarabine and corticosteroids) and malnutrition [106] .", [["CMI", "DISEASE", 112, 115], ["fludarabine", "CHEMICAL", 134, 145], ["corticosteroids", "CHEMICAL", 150, 165], ["malnutrition", "DISEASE", 171, 183], ["fludarabine", "CHEMICAL", 134, 145], ["corticosteroids", "CHEMICAL", 150, 165], ["fludarabine", "SIMPLE_CHEMICAL", 134, 145], ["corticosteroids", "SIMPLE_CHEMICAL", 150, 165], ["risk factors", "PROBLEM", 30, 42], ["an underlying disease", "PROBLEM", 48, 69], ["significant impairment in CMI", "PROBLEM", 86, 115], ["fludarabine", "TREATMENT", 134, 145], ["corticosteroids", "TREATMENT", 150, 165], ["malnutrition", "PROBLEM", 171, 183], ["significant", "OBSERVATION_MODIFIER", 86, 97], ["impairment", "OBSERVATION", 98, 108]]], ["The problem is that most patients who develop tuberculosis have not had clearly identified risk factors.MycobacteriaPatients should avoid contact with persons with active tuberculosis, as well as environments that may potentially have patients with tuberculosis, such as health care facilities and shelters for the homeless.", [["tuberculosis", "DISEASE", 46, 58], ["MycobacteriaPatients", "CHEMICAL", 104, 124], ["tuberculosis", "DISEASE", 171, 183], ["tuberculosis", "DISEASE", 249, 261], ["patients", "ORGANISM", 25, 33], ["patients", "ORGANISM", 235, 243], ["patients", "SPECIES", 25, 33], ["persons", "SPECIES", 151, 158], ["patients", "SPECIES", 235, 243], ["tuberculosis", "PROBLEM", 46, 58], ["MycobacteriaPatients", "TREATMENT", 104, 124], ["active tuberculosis", "PROBLEM", 164, 183], ["tuberculosis", "PROBLEM", 249, 261], ["tuberculosis", "OBSERVATION", 46, 58], ["tuberculosis", "OBSERVATION", 171, 183], ["tuberculosis", "OBSERVATION", 249, 261]]], ["There are no studies testing antimicrobial prophylaxis in high-risk patients.", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["studies", "TEST", 13, 20], ["antimicrobial prophylaxis", "TREATMENT", 29, 54], ["no", "UNCERTAINTY", 10, 12]]], ["Recently published guidelines for infection prophylaxis in HCT recipients recommend the use of isoniazid (5-10 mg/kg, maximum, 300 mg/day) with pyridoxine 25 mg daily for >9 months and until immunosuppression dosages are substantially reduced in patients with past history of tuberculosis or exposure to someone with active tuberculosis, patients with positive tuberculin test or interferon-gamma release assays without a history of BCG vaccination [3] .Pneumocystis jiroveciiReactivation of latent infection is the most common mechanism of pneumonia by Pneumocystis jirovecii among immunocompromised patients.", [["infection", "DISEASE", 34, 43], ["isoniazid", "CHEMICAL", 95, 104], ["pyridoxine", "CHEMICAL", 144, 154], ["tuberculosis", "DISEASE", 276, 288], ["tuberculosis", "DISEASE", 324, 336], ["Pneumocystis jiroveciiReactivation", "DISEASE", 454, 488], ["latent infection", "DISEASE", 492, 508], ["pneumonia", "DISEASE", 541, 550], ["Pneumocystis jirovecii", "DISEASE", 554, 576], ["isoniazid", "CHEMICAL", 95, 104], ["pyridoxine", "CHEMICAL", 144, 154], ["isoniazid", "SIMPLE_CHEMICAL", 95, 104], ["pyridoxine", "SIMPLE_CHEMICAL", 144, 154], ["patients", "ORGANISM", 246, 254], ["patients", "ORGANISM", 338, 346], ["interferon-gamma", "GENE_OR_GENE_PRODUCT", 380, 396], ["Pneumocystis jirovecii", "ORGANISM", 554, 576], ["patients", "ORGANISM", 601, 609], ["interferon", "PROTEIN", 380, 390], ["patients", "SPECIES", 246, 254], ["patients", "SPECIES", 338, 346], ["Pneumocystis jirovecii", "SPECIES", 554, 576], ["patients", "SPECIES", 601, 609], ["Pneumocystis jirovecii", "SPECIES", 554, 576], ["infection prophylaxis", "TREATMENT", 34, 55], ["HCT recipients", "TREATMENT", 59, 73], ["isoniazid", "TREATMENT", 95, 104], ["pyridoxine", "TREATMENT", 144, 154], ["immunosuppression dosages", "TREATMENT", 191, 216], ["tuberculosis", "PROBLEM", 276, 288], ["active tuberculosis", "PROBLEM", 317, 336], ["positive tuberculin test", "PROBLEM", 352, 376], ["interferon", "TREATMENT", 380, 390], ["gamma release assays", "TEST", 391, 411], ["BCG vaccination", "TREATMENT", 433, 448], ["Pneumocystis jiroveciiReactivation", "PROBLEM", 454, 488], ["latent infection", "PROBLEM", 492, 508], ["pneumonia", "PROBLEM", 541, 550], ["Pneumocystis jirovecii", "PROBLEM", 554, 576], ["infection", "OBSERVATION", 34, 43], ["tuberculosis", "OBSERVATION", 276, 288], ["tuberculosis", "OBSERVATION", 324, 336], ["latent", "OBSERVATION_MODIFIER", 492, 498], ["infection", "OBSERVATION", 499, 508], ["most common", "OBSERVATION_MODIFIER", 516, 527], ["pneumonia", "OBSERVATION", 541, 550], ["Pneumocystis jirovecii", "OBSERVATION", 554, 576]]], ["Patients at high risk for Pneumocystis jirovecii pneumonia (PJP) are those with chronic T-cell immunodeficiency, particularly: children with acute lymphoid leukemia (ALL), HCT recipients, and patients receiving purine analogues, monoclonal antibodies, or corticosteroids for long periods [107, 108] .Pneumocystis jiroveciiThe most effective drug for prophylaxis is TMP-SMX.", [["T-cell", "ANATOMY", 88, 94], ["acute lymphoid leukemia", "ANATOMY", 141, 164], ["ALL", "ANATOMY", 166, 169], ["HCT", "ANATOMY", 172, 175], ["Pneumocystis jirovecii pneumonia", "DISEASE", 26, 58], ["PJP", "DISEASE", 60, 63], ["chronic T-cell immunodeficiency", "DISEASE", 80, 111], ["acute lymphoid leukemia", "DISEASE", 141, 164], ["ALL", "DISEASE", 166, 169], ["HCT", "DISEASE", 172, 175], ["purine", "CHEMICAL", 211, 217], ["Pneumocystis jirovecii", "DISEASE", 300, 322], ["TMP-SMX", "CHEMICAL", 365, 372], ["purine", "CHEMICAL", 211, 217], ["TMP-SMX", "CHEMICAL", 365, 372], ["Patients", "ORGANISM", 0, 8], ["Pneumocystis jirovecii", "ORGANISM", 26, 48], ["T-cell", "CANCER", 88, 94], ["children", "ORGANISM", 127, 135], ["acute lymphoid leukemia", "CANCER", 141, 164], ["ALL", "CANCER", 166, 169], ["HCT", "CANCER", 172, 175], ["patients", "ORGANISM", 192, 200], ["purine analogues", "SIMPLE_CHEMICAL", 211, 227], ["Pneumocystis jirovecii", "ORGANISM", 300, 322], ["TMP-SMX", "SIMPLE_CHEMICAL", 365, 372], ["monoclonal antibodies", "PROTEIN", 229, 250], ["Patients", "SPECIES", 0, 8], ["Pneumocystis jirovecii", "SPECIES", 26, 48], ["children", "SPECIES", 127, 135], ["patients", "SPECIES", 192, 200], ["Pneumocystis jirovecii", "SPECIES", 300, 322], ["Pneumocystis jirovecii", "SPECIES", 26, 48], ["Pneumocystis jirovecii", "SPECIES", 300, 322], ["Pneumocystis jirovecii pneumonia (PJP", "PROBLEM", 26, 63], ["chronic T-cell immunodeficiency", "PROBLEM", 80, 111], ["acute lymphoid leukemia", "PROBLEM", 141, 164], ["HCT recipients", "TREATMENT", 172, 186], ["purine analogues", "TREATMENT", 211, 227], ["monoclonal antibodies", "TREATMENT", 229, 250], ["corticosteroids", "TREATMENT", 255, 270], ["Pneumocystis jirovecii", "PROBLEM", 300, 322], ["prophylaxis", "TREATMENT", 350, 361], ["high risk", "OBSERVATION_MODIFIER", 12, 21], ["for", "UNCERTAINTY", 22, 25], ["Pneumocystis jirovecii", "OBSERVATION", 26, 48], ["chronic", "OBSERVATION_MODIFIER", 80, 87], ["cell immunodeficiency", "OBSERVATION", 90, 111], ["acute", "OBSERVATION_MODIFIER", 141, 146], ["lymphoid leukemia", "OBSERVATION", 147, 164], ["jirovecii", "OBSERVATION", 313, 322], ["most effective", "OBSERVATION_MODIFIER", 326, 340]]], ["Accepted dosages include one double-strength tablet (trimethoprim 160 mg + sulfamethoxazole 800 mg) bid 2 days a week, one double-strength tablet (daily or 3 times a week), and 1 single-strength tablet (trimethoprim 80 mg + sulfamethoxazole 400 mg) daily.", [["trimethoprim", "CHEMICAL", 53, 65], ["sulfamethoxazole", "CHEMICAL", 75, 91], ["trimethoprim 80 mg + sulfamethoxazole", "CHEMICAL", 203, 240], ["trimethoprim", "CHEMICAL", 53, 65], ["sulfamethoxazole", "CHEMICAL", 75, 91], ["trimethoprim", "CHEMICAL", 203, 215], ["sulfamethoxazole", "CHEMICAL", 224, 240], ["trimethoprim", "SIMPLE_CHEMICAL", 53, 65], ["sulfamethoxazole", "SIMPLE_CHEMICAL", 75, 91], ["trimethoprim", "SIMPLE_CHEMICAL", 203, 215], ["sulfamethoxazole", "SIMPLE_CHEMICAL", 224, 240], ["dosages", "TREATMENT", 9, 16], ["one double-strength tablet (trimethoprim", "TREATMENT", 25, 65], ["sulfamethoxazole", "TREATMENT", 75, 91], ["trimethoprim", "TREATMENT", 203, 215], ["sulfamethoxazole", "TREATMENT", 224, 240]]], ["The time of initiation and the duration of prophylaxis should be individualized according to the underlying disease and type of treatment.", [["prophylaxis", "TREATMENT", 43, 54], ["the underlying disease", "PROBLEM", 93, 115], ["treatment", "TREATMENT", 128, 137]]], ["For example, in ALL patients, prophylaxis is usually started at the end of the induction period and discontinued 3 months after completion of maintenance therapy; in HCT recipients it should be started after engraftment and continued as long as immunosuppressive therapy is ongoing, extensive GVHD is present and CD4 count is <200 cells/mm 3 .", [["ALL", "ANATOMY", 16, 19], ["cells", "ANATOMY", 331, 336], ["ALL", "DISEASE", 16, 19], ["GVHD", "DISEASE", 293, 297], ["ALL", "CANCER", 16, 19], ["patients", "ORGANISM", 20, 28], ["HCT recipients", "ORGANISM", 166, 180], ["CD4", "GENE_OR_GENE_PRODUCT", 313, 316], ["CD4", "PROTEIN", 313, 316], ["patients", "SPECIES", 20, 28], ["prophylaxis", "TREATMENT", 30, 41], ["maintenance therapy", "TREATMENT", 142, 161], ["HCT recipients", "TREATMENT", 166, 180], ["engraftment", "TREATMENT", 208, 219], ["immunosuppressive therapy", "TREATMENT", 245, 270], ["extensive GVHD", "PROBLEM", 283, 297], ["CD4 count", "TEST", 313, 322], ["extensive", "OBSERVATION_MODIFIER", 283, 292], ["GVHD", "OBSERVATION", 293, 297]]], ["Alternative agents include: aerosolized pentamidine (given with Respirgard II nebulizer 300 mg every month after an initial loading dose given every other week), atovaquone suspension (1500 mg/day), and dapsone (50 mg bid or 100 mg/day) [3, 109] .ToxoplasmosisSeropositive patients are at risk of reactivation of toxoplasmosis following HCT.", [["pentamidine", "CHEMICAL", 40, 51], ["Respirgard II", "CHEMICAL", 64, 77], ["atovaquone", "CHEMICAL", 162, 172], ["dapsone", "CHEMICAL", 203, 210], ["ToxoplasmosisSeropositive", "DISEASE", 247, 272], ["toxoplasmosis", "DISEASE", 313, 326], ["HCT", "DISEASE", 337, 340], ["pentamidine", "CHEMICAL", 40, 51], ["atovaquone", "CHEMICAL", 162, 172], ["dapsone", "CHEMICAL", 203, 210], ["pentamidine", "SIMPLE_CHEMICAL", 40, 51], ["atovaquone", "SIMPLE_CHEMICAL", 162, 172], ["dapsone", "SIMPLE_CHEMICAL", 203, 210], ["patients", "ORGANISM", 273, 281], ["HCT", "CANCER", 337, 340], ["patients", "SPECIES", 273, 281], ["Alternative agents", "TREATMENT", 0, 18], ["aerosolized pentamidine", "TREATMENT", 28, 51], ["Respirgard II nebulizer", "TREATMENT", 64, 87], ["an initial loading dose", "TREATMENT", 113, 136], ["atovaquone suspension", "TREATMENT", 162, 183], ["dapsone", "TREATMENT", 203, 210], ["ToxoplasmosisSeropositive patients", "PROBLEM", 247, 281], ["toxoplasmosis", "PROBLEM", 313, 326], ["HCT", "TEST", 337, 340], ["toxoplasmosis", "OBSERVATION", 313, 326]]], ["When the recipient and donor are seronegative, special precautions should be taken to avoid primary infection.", [["primary infection", "DISEASE", 92, 109], ["the recipient and donor", "TREATMENT", 5, 28], ["seronegative", "PROBLEM", 33, 45], ["special precautions", "TREATMENT", 47, 66], ["primary infection", "PROBLEM", 92, 109], ["infection", "OBSERVATION", 100, 109]]], ["Those precautions include eating only well-cooked meats (>66\u00b0C), well-washed vegetables, cooked eggs, pasteurized milk, sterile water, handwashing after outdoor activities or after handling raw meat or vegetables, using gloves for contact with soil or gardening, avoiding contact with cat litter, and having someone change litter box daily and soak it in boiling water for 5 min.ToxoplasmosisReactivation of toxoplasmosis is highest among recipients of T-cell depleted allogeneic PSCT/BMT (5-15%) and is otherwise rare among other allogeneic recipients (<1%).", [["meats", "ANATOMY", 50, 55], ["vegetables", "ANATOMY", 77, 87], ["eggs", "ANATOMY", 96, 100], ["milk", "ANATOMY", 114, 118], ["meat", "ANATOMY", 194, 198], ["vegetables", "ANATOMY", 202, 212], ["T-cell", "ANATOMY", 453, 459], ["PSCT", "ANATOMY", 480, 484], ["toxoplasmosis", "DISEASE", 408, 421], ["vegetables", "ORGANISM_SUBDIVISION", 77, 87], ["milk", "ORGANISM_SUBDIVISION", 114, 118], ["vegetables", "ORGANISM_SUBDIVISION", 202, 212], ["cat", "ORGANISM", 285, 288], ["litter", "ORGANISM_SUBDIVISION", 289, 295], ["T-cell", "CELL", 453, 459], ["PSCT", "CELL", 480, 484], ["BMT", "CANCER", 485, 488], ["recipients", "ORGANISM", 542, 552], ["milk", "SPECIES", 114, 118], ["Those precautions", "TREATMENT", 0, 17], ["sterile water", "TREATMENT", 120, 133], ["ToxoplasmosisReactivation of toxoplasmosis", "PROBLEM", 379, 421], ["T-cell depleted allogeneic PSCT/BMT", "TREATMENT", 453, 488], ["other allogeneic recipients", "TREATMENT", 525, 552], ["toxoplasmosis", "OBSERVATION", 408, 421], ["highest", "OBSERVATION_MODIFIER", 425, 432], ["-cell", "OBSERVATION_MODIFIER", 454, 459], ["depleted", "OBSERVATION_MODIFIER", 460, 468], ["allogeneic PSCT", "OBSERVATION", 469, 484]]], ["The potential toxicities of effective agents preclude routine prophylaxis against toxoplasmosis.", [["toxicities", "DISEASE", 14, 24], ["toxoplasmosis", "DISEASE", 82, 95], ["The potential toxicities", "PROBLEM", 0, 24], ["effective agents", "TREATMENT", 28, 44], ["routine prophylaxis", "TREATMENT", 54, 73], ["toxoplasmosis", "PROBLEM", 82, 95]]], ["However, preemptive therapy of high-risk patients (positive serology prior to transplantation, T-cell depleted allogeneic transplants) with PCR-based tests is recommended.", [["T-cell", "ANATOMY", 95, 101], ["patients", "ORGANISM", 41, 49], ["T-cell", "CELL", 95, 101], ["patients", "SPECIES", 41, 49], ["preemptive therapy", "TREATMENT", 9, 27], ["transplantation", "TREATMENT", 78, 93], ["T-cell depleted allogeneic transplants", "TREATMENT", 95, 133], ["PCR-based tests", "TEST", 140, 155]]], ["Primary prophylaxis may be considered in patients with history of ocular toxoplasmosis.", [["ocular", "ANATOMY", 66, 72], ["ocular toxoplasmosis", "DISEASE", 66, 86], ["patients", "ORGANISM", 41, 49], ["ocular", "ORGAN", 66, 72], ["patients", "SPECIES", 41, 49], ["Primary prophylaxis", "TREATMENT", 0, 19], ["ocular toxoplasmosis", "PROBLEM", 66, 86], ["ocular", "ANATOMY", 66, 72], ["toxoplasmosis", "OBSERVATION", 73, 86]]], ["Effective prophylaxis includes TMP-SMX, one doublestrength tablet daily or 3 times a week, or 1 single-strength tablet daily, Clindamycin 300-450 mg thrice daily plus pyrimethamine 25-75 mg/day plus leucovorin 10-25 mg, pyrimethamine-sulfadoxine (Fansidar) 1 tablet (25 mg pyrimethamine/500 mg sulfadoxine)/20 kg weight on day 1 with folinic acid, 50 mg/20 kg on day 2, then daily following engraftment, atovaquone (750-1500 mg/day), and dapsone 50 mg/day plus pyrimethamine 50 mg/week plus folinic acid 25 mg/week.", [["TMP-SMX", "CHEMICAL", 31, 38], ["Clindamycin", "CHEMICAL", 126, 137], ["pyrimethamine", "CHEMICAL", 167, 180], ["leucovorin", "CHEMICAL", 199, 209], ["pyrimethamine", "CHEMICAL", 220, 233], ["sulfadoxine", "CHEMICAL", 234, 245], ["Fansidar", "CHEMICAL", 247, 255], ["pyrimethamine", "CHEMICAL", 273, 286], ["sulfadoxine", "CHEMICAL", 294, 305], ["folinic acid", "CHEMICAL", 334, 346], ["atovaquone", "CHEMICAL", 404, 414], ["dapsone", "CHEMICAL", 438, 445], ["pyrimethamine", "CHEMICAL", 461, 474], ["folinic acid", "CHEMICAL", 491, 503], ["TMP-SMX", "CHEMICAL", 31, 38], ["Clindamycin", "CHEMICAL", 126, 137], ["pyrimethamine", "CHEMICAL", 167, 180], ["leucovorin", "CHEMICAL", 199, 209], ["pyrimethamine", "CHEMICAL", 220, 233], ["sulfadoxine", "CHEMICAL", 234, 245], ["Fansidar", "CHEMICAL", 247, 255], ["pyrimethamine", "CHEMICAL", 273, 286], ["sulfadoxine", "CHEMICAL", 294, 305], ["folinic acid", "CHEMICAL", 334, 346], ["atovaquone", "CHEMICAL", 404, 414], ["dapsone", "CHEMICAL", 438, 445], ["pyrimethamine", "CHEMICAL", 461, 474], ["folinic acid", "CHEMICAL", 491, 503], ["TMP-SMX", "SIMPLE_CHEMICAL", 31, 38], ["Clindamycin", "SIMPLE_CHEMICAL", 126, 137], ["pyrimethamine", "SIMPLE_CHEMICAL", 167, 180], ["leucovorin", "SIMPLE_CHEMICAL", 199, 209], ["pyrimethamine-sulfadoxine", "SIMPLE_CHEMICAL", 220, 245], ["Fansidar", "SIMPLE_CHEMICAL", 247, 255], ["pyrimethamine", "SIMPLE_CHEMICAL", 273, 286], ["sulfadoxine", "SIMPLE_CHEMICAL", 294, 305], ["folinic acid", "SIMPLE_CHEMICAL", 334, 346], ["atovaquone", "SIMPLE_CHEMICAL", 404, 414], ["dapsone", "SIMPLE_CHEMICAL", 438, 445], ["pyrimethamine", "SIMPLE_CHEMICAL", 461, 474], ["folinic acid", "SIMPLE_CHEMICAL", 491, 503], ["Effective prophylaxis", "TREATMENT", 0, 21], ["TMP-SMX", "TREATMENT", 31, 38], ["Clindamycin", "TREATMENT", 126, 137], ["pyrimethamine", "TREATMENT", 167, 180], ["leucovorin", "TREATMENT", 199, 209], ["pyrimethamine-sulfadoxine (Fansidar)", "TREATMENT", 220, 256], ["pyrimethamine", "TREATMENT", 273, 286], ["sulfadoxine", "TREATMENT", 294, 305], ["folinic acid", "TREATMENT", 334, 346], ["engraftment", "TREATMENT", 391, 402], ["atovaquone", "TREATMENT", 404, 414], ["dapsone", "TREATMENT", 438, 445], ["pyrimethamine", "TREATMENT", 461, 474], ["folinic acid", "TREATMENT", 491, 503]]], ["Fansidar is associated with significant toxicities [110] .Other ParasitesStrongyloides stercoralis may cause a fatal disseminated syndrome with intestinal larval invasion and bacterial superinfection.", [["intestinal", "ANATOMY", 144, 154], ["Fansidar", "CHEMICAL", 0, 8], ["toxicities", "DISEASE", 40, 50], ["Strongyloides stercoralis", "DISEASE", 73, 98], ["intestinal larval invasion", "DISEASE", 144, 170], ["bacterial superinfection", "DISEASE", 175, 199], ["Fansidar", "SIMPLE_CHEMICAL", 0, 8], ["ParasitesStrongyloides stercoralis", "ORGANISM", 64, 98], ["intestinal", "ORGAN", 144, 154], ["Strongyloides stercoralis", "SPECIES", 73, 98], ["Strongyloides stercoralis", "SPECIES", 73, 98], ["significant toxicities", "PROBLEM", 28, 50], ["Other ParasitesStrongyloides stercoralis", "PROBLEM", 58, 98], ["a fatal disseminated syndrome", "PROBLEM", 109, 138], ["intestinal larval invasion", "PROBLEM", 144, 170], ["bacterial superinfection", "PROBLEM", 175, 199], ["associated with", "UNCERTAINTY", 12, 27], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["toxicities", "OBSERVATION", 40, 50], ["Strongyloides stercoralis", "OBSERVATION", 73, 98], ["may cause", "UNCERTAINTY", 99, 108], ["fatal", "OBSERVATION_MODIFIER", 111, 116], ["disseminated syndrome", "OBSERVATION", 117, 138], ["intestinal", "ANATOMY", 144, 154], ["larval invasion", "OBSERVATION", 155, 170], ["bacterial", "OBSERVATION_MODIFIER", 175, 184], ["superinfection", "OBSERVATION", 185, 199]]], ["Patients at high risk are those with T-cell immunodeficiency [111] .", [["T-cell", "ANATOMY", 37, 43], ["T-cell immunodeficiency", "DISEASE", 37, 60], ["Patients", "ORGANISM", 0, 8], ["T-cell", "CANCER", 37, 43], ["Patients", "SPECIES", 0, 8], ["T-cell immunodeficiency", "PROBLEM", 37, 60]]], ["Patients at risk should avoid contact with outhouses and cutaneous exposure to soil or other surfaces that might be contaminated with human feces.", [["cutaneous", "ANATOMY", 57, 66], ["feces", "ANATOMY", 140, 145], ["Patients", "ORGANISM", 0, 8], ["human", "ORGANISM", 134, 139], ["feces", "ORGANISM_SUBDIVISION", 140, 145], ["Patients", "SPECIES", 0, 8], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 134, 139]]], ["In addition, patients with unexplained eosinophilia, or those who live in, have resided, or traveled to endemic areas should be screened with either stool examinations (\u22653 stool examinations), or an enzyme-linked immunosorbent assay (ELISA) [112] .", [["stool", "ANATOMY", 149, 154], ["eosinophilia", "DISEASE", 39, 51], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["unexplained eosinophilia", "PROBLEM", 27, 51], ["stool examinations", "TEST", 149, 167], ["stool examinations", "TEST", 172, 190], ["an enzyme", "TEST", 196, 205], ["immunosorbent assay", "TEST", 213, 232], ["eosinophilia", "OBSERVATION", 39, 51]]], ["Patients whose screening is positive should receive empiric treatment with ivermectin (200 \u03bcg/kg/day for 2 days, repeat after 2 weeks) [113] .Immune ReconstitutionPassive Immunization (IV Immunoglobulin, IVIG)Immune ReconstitutionIntravenous immunoglobulins may benefit patients with CLL, non-Hodgkin lymphoma and myeloma who have severe hypogammaglobulinemia (serum IgG levels <500 mg/dL) and recurrent and/or severe infections despite appropriate antimicrobial prophylaxis and immunizations [38] [39] [40] .", [["CLL", "ANATOMY", 284, 287], ["non-Hodgkin lymphoma", "ANATOMY", 289, 309], ["myeloma", "ANATOMY", 314, 321], ["serum", "ANATOMY", 361, 366], ["ivermectin", "CHEMICAL", 75, 85], ["CLL", "DISEASE", 284, 287], ["non-Hodgkin lymphoma", "DISEASE", 289, 309], ["myeloma", "DISEASE", 314, 321], ["hypogammaglobulinemia", "DISEASE", 338, 359], ["infections", "DISEASE", 418, 428], ["ivermectin", "CHEMICAL", 75, 85], ["Patients", "ORGANISM", 0, 8], ["ivermectin", "SIMPLE_CHEMICAL", 75, 85], ["Immunoglobulin", "GENE_OR_GENE_PRODUCT", 188, 202], ["IVIG", "SIMPLE_CHEMICAL", 204, 208], ["patients", "ORGANISM", 270, 278], ["CLL", "CANCER", 284, 287], ["non-Hodgkin lymphoma", "CANCER", 289, 309], ["myeloma", "CANCER", 314, 321], ["serum", "ORGANISM_SUBSTANCE", 361, 366], ["IgG", "ORGANISM_SUBSTANCE", 367, 370], ["serum IgG", "PROTEIN", 361, 370], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 270, 278], ["Patients whose screening", "TEST", 0, 24], ["empiric treatment", "TREATMENT", 52, 69], ["ivermectin", "TREATMENT", 75, 85], ["Immune ReconstitutionPassive Immunization (IV Immunoglobulin, IVIG)", "TREATMENT", 142, 209], ["Immune ReconstitutionIntravenous immunoglobulins", "TREATMENT", 209, 257], ["CLL", "PROBLEM", 284, 287], ["non-Hodgkin lymphoma", "PROBLEM", 289, 309], ["myeloma", "PROBLEM", 314, 321], ["severe hypogammaglobulinemia", "PROBLEM", 331, 359], ["serum IgG levels", "TEST", 361, 377], ["recurrent and/or severe infections", "PROBLEM", 394, 428], ["appropriate antimicrobial prophylaxis", "TREATMENT", 437, 474], ["immunizations", "TREATMENT", 479, 492], ["CLL", "OBSERVATION", 284, 287], ["non-Hodgkin lymphoma", "OBSERVATION", 289, 309], ["myeloma", "OBSERVATION", 314, 321], ["severe", "OBSERVATION_MODIFIER", 331, 337], ["hypogammaglobulinemia", "OBSERVATION", 338, 359], ["severe", "OBSERVATION_MODIFIER", 411, 417], ["infections", "OBSERVATION", 418, 428]]], ["Doses of IVIG of 250 mg/kg every 4 weeks were shown to be as effective as 500 mg/kg every 4 weeks.", [["IVIG", "SIMPLE_CHEMICAL", 9, 13], ["IVIG", "TREATMENT", 9, 13]]], ["However, the role of IVIG in the prevention of infections among patients with hematological malignancies is not clear and is unlikely to be superior to that of antibiotic prophylaxis (see Antibacterial Prophylaxis above).", [["hematological malignancies", "ANATOMY", 78, 104], ["IVIG", "CHEMICAL", 21, 25], ["infections", "DISEASE", 47, 57], ["hematological malignancies", "DISEASE", 78, 104], ["IVIG", "SIMPLE_CHEMICAL", 21, 25], ["patients", "ORGANISM", 64, 72], ["hematological malignancies", "CANCER", 78, 104], ["patients", "SPECIES", 64, 72], ["IVIG", "TREATMENT", 21, 25], ["infections", "PROBLEM", 47, 57], ["hematological malignancies", "PROBLEM", 78, 104], ["antibiotic prophylaxis", "TREATMENT", 160, 182], ["Antibacterial Prophylaxis", "TREATMENT", 188, 213], ["infections", "OBSERVATION", 47, 57]]], ["Therefore, IVIG should probably be given to patients with hypogammaglobulinemia and recurrent bacterial infections despite prophylactic antibiotics [114] .Immune ReconstitutionAmong HCT recipients, the major benefit of IVIG is the reduction of acute GVHD in allogeneic HCT.", [["HCT", "ANATOMY", 269, 272], ["hypogammaglobulinemia", "DISEASE", 58, 79], ["bacterial infections", "DISEASE", 94, 114], ["GVHD", "DISEASE", 250, 254], ["IVIG", "SIMPLE_CHEMICAL", 11, 15], ["patients", "ORGANISM", 44, 52], ["HCT", "CANCER", 182, 185], ["IVIG", "SIMPLE_CHEMICAL", 219, 223], ["HCT", "CANCER", 269, 272], ["patients", "SPECIES", 44, 52], ["IVIG", "TREATMENT", 11, 15], ["hypogammaglobulinemia", "PROBLEM", 58, 79], ["recurrent bacterial infections", "PROBLEM", 84, 114], ["prophylactic antibiotics", "TREATMENT", 123, 147], ["Immune Reconstitution", "TREATMENT", 155, 176], ["HCT recipients", "TREATMENT", 182, 196], ["IVIG", "TREATMENT", 219, 223], ["acute GVHD", "PROBLEM", 244, 254], ["allogeneic HCT", "TEST", 258, 272], ["bacterial", "OBSERVATION_MODIFIER", 94, 103], ["infections", "OBSERVATION", 104, 114], ["acute", "OBSERVATION_MODIFIER", 244, 249], ["GVHD", "OBSERVATION", 250, 254]]], ["The administration of IVIG for the prevention of infections among these patients with severe hypogammaglobulinemia (serum Ig G < 400 mg/dL) is commonly practiced but is of unproven value.Active ImmunizationThe immunization of patients with hematological malignancies undergoing cytotoxic chemotherapy has three goals: (a) maintaining the appropriate adult immunization schedule; (b) restoring the immunity that could have been lost after the immunosuppressive treatment; and (c) protecting the patient from the receipt of live vaccines.", [["serum", "ANATOMY", 116, 121], ["hematological malignancies", "ANATOMY", 240, 266], ["IVIG", "CHEMICAL", 22, 26], ["infections", "DISEASE", 49, 59], ["hypogammaglobulinemia", "DISEASE", 93, 114], ["hematological malignancies", "DISEASE", 240, 266], ["IVIG", "SIMPLE_CHEMICAL", 22, 26], ["patients", "ORGANISM", 72, 80], ["serum", "ORGANISM_SUBSTANCE", 116, 121], ["Ig G", "GENE_OR_GENE_PRODUCT", 122, 126], ["patients", "ORGANISM", 226, 234], ["hematological malignancies", "CANCER", 240, 266], ["patient", "ORGANISM", 494, 501], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 226, 234], ["patient", "SPECIES", 494, 501], ["IVIG", "TREATMENT", 22, 26], ["infections", "PROBLEM", 49, 59], ["severe hypogammaglobulinemia", "PROBLEM", 86, 114], ["serum Ig G", "TEST", 116, 126], ["Active Immunization", "TREATMENT", 187, 206], ["hematological malignancies", "PROBLEM", 240, 266], ["cytotoxic chemotherapy", "TREATMENT", 278, 300], ["the appropriate adult immunization schedule", "TREATMENT", 334, 377], ["the immunosuppressive treatment", "TREATMENT", 438, 469], ["live vaccines", "TREATMENT", 522, 535], ["infections", "OBSERVATION", 49, 59], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["hypogammaglobulinemia", "OBSERVATION", 93, 114]]], ["A suggested schedule for immunization in HCT is shown in Table 49 .5.Colony-Stimulating Factors (CSF)Granulocyte colony-stimulating factor (G-CSF) has been shown to reduce the incidence of fever, and duration of antibiotic therapy and hospitalization in some studies.", [["fever", "DISEASE", 189, 194], ["HCT", "CANCER", 41, 44], ["Colony-Stimulating Factors", "GENE_OR_GENE_PRODUCT", 69, 95], ["CSF)", "GENE_OR_GENE_PRODUCT", 97, 101], ["Granulocyte colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 101, 138], ["G-CSF", "GENE_OR_GENE_PRODUCT", 140, 145], ["Colony-Stimulating Factors (CSF)Granulocyte colony-stimulating factor", "PROTEIN", 69, 138], ["CSF", "PROTEIN", 142, 145], ["immunization", "TREATMENT", 25, 37], ["HCT", "TEST", 41, 44], ["Colony", "TEST", 69, 75], ["Stimulating Factors", "TEST", 76, 95], ["CSF)", "TEST", 97, 101], ["Granulocyte colony", "TEST", 101, 119], ["stimulating factor", "TEST", 120, 138], ["G-CSF", "TEST", 140, 145], ["fever", "PROBLEM", 189, 194], ["antibiotic therapy", "TREATMENT", 212, 230], ["hospitalization", "TREATMENT", 235, 250], ["some studies", "TEST", 254, 266], ["fever", "OBSERVATION", 189, 194]]], ["However, a significant reduction of culture-proven infections or mortality HCT hematopoietic cell transplantation AVOID live vaccines until patient in complete remission, and not receiving immunosuppressive therapy for 6 months and has a CD 4 + count >400/\u03bcL and does not have chronic graft versus host disease Live vaccines: -Adenovirus, BCG, Measles-Mumps-Rubella, Oral typhoid, Oral polio, Yellow fever, Varicella zoster -AVOID oral polio in household contacts (the polio virus may spread and cause uncontrolled infection) AVOID vaccines until CD 4+ counts > 200/\u03bcL (unlikely to be effective) Consider measuring antibody titers after vaccination to ensure efficacy and repeat doses until optimal titers achieved has not been shown.", [["HCT hematopoietic cell", "ANATOMY", 75, 97], ["graft", "ANATOMY", 285, 290], ["infections", "DISEASE", 51, 61], ["chronic graft versus host disease", "DISEASE", 277, 310], ["Measles-Mumps-Rubella", "DISEASE", 344, 365], ["Oral typhoid", "DISEASE", 367, 379], ["Oral polio", "DISEASE", 381, 391], ["Yellow fever", "DISEASE", 393, 405], ["Varicella zoster", "DISEASE", 407, 423], ["infection", "DISEASE", 515, 524], ["HCT hematopoietic cell", "CELL", 75, 97], ["patient", "ORGANISM", 140, 147], ["graft", "TISSUE", 285, 290], ["Adenovirus", "ORGANISM", 327, 337], ["Measles-Mumps-Rubella", "ORGANISM", 344, 365], ["Oral typhoid", "ORGANISM", 367, 379], ["Oral polio", "ORGANISM", 381, 391], ["Yellow fever", "ORGANISM", 393, 405], ["Varicella zoster -AVOID oral polio", "ORGANISM", 407, 441], ["polio virus", "ORGANISM", 469, 480], ["patient", "SPECIES", 140, 147], ["Varicella zoster", "SPECIES", 407, 423], ["Adenovirus", "SPECIES", 327, 337], ["polio virus", "SPECIES", 469, 480], ["culture", "TEST", 36, 43], ["infections", "PROBLEM", 51, 61], ["mortality HCT hematopoietic cell transplantation", "TREATMENT", 65, 113], ["live vaccines", "TREATMENT", 120, 133], ["immunosuppressive therapy", "TREATMENT", 189, 214], ["a CD", "TEST", 236, 240], ["count", "TEST", 245, 250], ["chronic graft versus host disease", "PROBLEM", 277, 310], ["Live vaccines", "TREATMENT", 311, 324], ["Adenovirus", "PROBLEM", 327, 337], ["BCG", "TEST", 339, 342], ["Measles", "TEST", 344, 351], ["Mumps", "TEST", 352, 357], ["Rubella", "PROBLEM", 358, 365], ["Oral typhoid", "PROBLEM", 367, 379], ["Oral polio", "PROBLEM", 381, 391], ["Yellow fever", "PROBLEM", 393, 405], ["Varicella zoster", "PROBLEM", 407, 423], ["oral polio", "PROBLEM", 431, 441], ["the polio virus", "PROBLEM", 465, 480], ["uncontrolled infection", "PROBLEM", 502, 524], ["AVOID vaccines", "TREATMENT", 526, 540], ["CD", "TEST", 547, 549], ["counts", "TEST", 553, 559], ["measuring antibody titers", "TEST", 605, 630], ["vaccination", "TREATMENT", 637, 648], ["repeat doses", "TREATMENT", 672, 684], ["optimal titers", "TEST", 691, 705], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["reduction", "OBSERVATION_MODIFIER", 23, 32], ["hematopoietic cell transplantation", "OBSERVATION", 79, 113], ["chronic", "OBSERVATION_MODIFIER", 277, 284], ["graft versus host disease", "OBSERVATION", 285, 310], ["Varicella zoster", "OBSERVATION", 407, 423], ["infection", "OBSERVATION", 515, 524]]], ["The best cost-effective prophylactic use of G-CSF is in settings when the risk of febrile neutropenia is >20% [115] [116] [117] .Granulocyte TransfusionsProphylactic GM-CSF or G-CSF elicited granulocyte transfusions remains investigational and may be considered in patients with a history of a neutropenia-related invasive mold infection (such as aspergillosis or fusariosis) who are expected to be neutropenic for \u226514 days [118] .SummaryInfection is a frequent complication and a leading cause of morbidity and mortality in patients with hematological malignancies.", [["granulocyte", "ANATOMY", 191, 202], ["hematological malignancies", "ANATOMY", 539, 565], ["neutropenia", "DISEASE", 90, 101], ["GM", "CHEMICAL", 166, 168], ["neutropenia", "DISEASE", 294, 305], ["mold infection", "DISEASE", 323, 337], ["aspergillosis", "DISEASE", 347, 360], ["fusariosis", "DISEASE", 364, 374], ["neutropenic", "DISEASE", 399, 410], ["SummaryInfection", "DISEASE", 431, 447], ["hematological malignancies", "DISEASE", 539, 565], ["G-CSF", "GENE_OR_GENE_PRODUCT", 44, 49], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 166, 172], ["G-CSF", "GENE_OR_GENE_PRODUCT", 176, 181], ["granulocyte", "CELL", 191, 202], ["patients", "ORGANISM", 265, 273], ["patients", "ORGANISM", 525, 533], ["hematological malignancies", "CANCER", 539, 565], ["CSF", "PROTEIN", 169, 172], ["CSF", "PROTEIN", 178, 181], ["patients", "SPECIES", 265, 273], ["patients", "SPECIES", 525, 533], ["G-CSF", "TREATMENT", 44, 49], ["febrile neutropenia", "PROBLEM", 82, 101], ["Granulocyte Transfusions", "TREATMENT", 129, 153], ["CSF", "TEST", 169, 172], ["G-CSF elicited granulocyte transfusions", "TREATMENT", 176, 215], ["a neutropenia", "PROBLEM", 292, 305], ["invasive mold infection", "PROBLEM", 314, 337], ["aspergillosis", "PROBLEM", 347, 360], ["fusariosis", "PROBLEM", 364, 374], ["neutropenic", "PROBLEM", 399, 410], ["a frequent complication", "PROBLEM", 451, 474], ["morbidity", "PROBLEM", 498, 507], ["hematological malignancies", "PROBLEM", 539, 565], ["neutropenia", "OBSERVATION", 294, 305], ["invasive", "OBSERVATION_MODIFIER", 314, 322], ["mold infection", "OBSERVATION", 323, 337], ["aspergillosis", "OBSERVATION", 347, 360], ["morbidity", "OBSERVATION", 498, 507], ["malignancies", "OBSERVATION", 553, 565]]], ["In general, the higher is the risk for a certain infection, the more beneficial is likely to be prophylaxis.", [["infection", "DISEASE", 49, 58], ["a certain infection", "PROBLEM", 39, 58], ["infection", "OBSERVATION", 49, 58]]], ["Likewise, the shorter is the period at risk (and therefore the predicted duration of prophylaxis), the higher is the possibility that prophylaxis will work.", [["prophylaxis", "TREATMENT", 85, 96], ["prophylaxis", "TREATMENT", 134, 145], ["shorter", "OBSERVATION_MODIFIER", 14, 21]]], ["The decision of giving prophylaxis should take into account its potential benefits, but also side effects, costs, induction of resistance, and the potential for drug interactions with antineoplastic h48 drugs.", [["antineoplastic h48 drugs", "SIMPLE_CHEMICAL", 184, 208], ["prophylaxis", "TREATMENT", 23, 34], ["antineoplastic h48 drugs", "TREATMENT", 184, 208]]], ["Risk assessment is a key element in defining prophylactic strategies.", [["Risk assessment", "TEST", 0, 15], ["prophylactic strategies", "TREATMENT", 45, 68]]]], "3f28faf7fc6a5fad5405c308c14bee8d605ba3be": [["IntroductionUp to March 31, 2020 more than 800,000 cases of COVID-19 have been reported in the world and France has declared 50,000 patients and 3500 deaths.", [["deaths", "DISEASE", 150, 156], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["COVID", "TEST", 60, 65]]], ["The COVID-19 epidemic is unique because of its scale, the speed of its spread, the lack of pre-existing scientific data and the importance of media coverage.", [["The COVID", "TEST", 0, 9], ["media coverage", "TREATMENT", 142, 156]]], ["2 However, the resilience of health systems in response to COVID-19 is under question, including in high-income countries.", [["COVID", "TEST", 59, 64]]], ["3, 4 Health system resilience can be defined as the capacity of health actors, institutions, and populations to prepare for and effectively respond to crises; maintain core functions when a crisis hits; and, informed by lessons learned during the crisis, reorganise if conditions require it.", [["crises", "PROBLEM", 151, 157]]], ["5 Bichat-Claude Bernard hospital is a 1000-bed University hospital in Paris belonging to the Assistance Publique -H\u00f4pitaux de Paris (AP-HP), the largest hospital system in Europe employing more than 90,000 people in 39 hospitals.", [["people", "ORGANISM", 206, 212], ["people", "SPECIES", 206, 212], ["largest", "OBSERVATION_MODIFIER", 145, 152]]], ["The hospital is one of the reference centres in France for patients with suspected or confirmed emerging infectious diseases, such as patients with Ebola or Middle East Respiratory Syndrome Coronavirus (MERS-CoV).", [["infectious diseases", "DISEASE", 105, 124], ["Ebola or Middle East Respiratory Syndrome Coronavirus", "DISEASE", 148, 201], ["patients", "ORGANISM", 59, 67], ["patients", "ORGANISM", 134, 142], ["Middle East Respiratory Syndrome Coronavirus", "ORGANISM", 157, 201], ["MERS-CoV", "ORGANISM", 203, 211], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 134, 142], ["Middle East Respiratory Syndrome Coronavirus (MERS-CoV", "SPECIES", 157, 211], ["emerging infectious diseases", "PROBLEM", 96, 124], ["Ebola", "PROBLEM", 148, 153], ["Middle East Respiratory Syndrome Coronavirus", "PROBLEM", 157, 201], ["infectious", "OBSERVATION", 105, 115], ["Middle", "ANATOMY_MODIFIER", 157, 163], ["Respiratory Syndrome", "OBSERVATION", 169, 189]]], ["Bichat hospital managed the first three COVID-19 cases in Europe diagnosed on January 24 , 2020 6 and has managed more than 400 COVID-19 patients since.", [["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145]]], ["On March 31, 2020 more than 280 patients with COVID-19 are hospitalized in the hospital including 65 in Intensive Care Units (ICU).", [["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40]]], ["In order to provide data on health systems resilience during COVID-19, we describe, at the hospital level, the key elements of the response to COVID-19 including the challenges and issues to anticipate following the experience of our centre (Table 1) .Establishing the clinical management of the suspected or confirmed patients with COVID-19During epidemics, a coordinated and multidisciplinary management between infectious diseases (ID), ICU and Infection Prevention and Control (IPC) specialists, and also the hospital management, is of paramount importance to provide optimal care (Figure 1 ).", [["infectious diseases", "DISEASE", 414, 433], ["ID", "DISEASE", 435, 437], ["Infection", "DISEASE", 448, 457], ["patients", "ORGANISM", 319, 327], ["patients", "SPECIES", 319, 327], ["COVID", "TEST", 61, 66], ["COVID", "TEST", 143, 148], ["COVID", "TREATMENT", 333, 338], ["epidemics", "PROBLEM", 348, 357], ["multidisciplinary management", "TREATMENT", 377, 405], ["Infection Prevention", "TREATMENT", 448, 468], ["the hospital management", "TREATMENT", 509, 532], ["Infection", "OBSERVATION", 448, 457]]], ["The management of the first infected patients was based on scientific data published since the start of the outbreak, as well as our experience from previous outbreaks (SARS and MERS-CoV).", [["SARS", "DISEASE", 169, 173], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["MERS-CoV", "SPECIES", 178, 186], ["previous outbreaks (SARS", "PROBLEM", 149, 173]]], ["When the first patients arrived in January, we used the procedures for MERS-CoV 7 and also applied the principle of \"supervision\", developed for Ebola, with 4 to 6 head nurses from the most involved units (ID, IPC, ICU) who are trained to manage all the aspects of caring for suspected of confirmed cases together with logistical matters.", [["Ebola", "DISEASE", 145, 150], ["patients", "ORGANISM", 15, 23], ["Ebola", "ORGANISM", 145, 150], ["patients", "SPECIES", 15, 23], ["the procedures", "TREATMENT", 52, 66], ["Ebola", "PROBLEM", 145, 150]]], ["In a context of dayto-day evolution of scientific information, it was necessary to adapt in real-time to new data and new guidelines were produced at a rapid pace.", [["a rapid pace", "TREATMENT", 150, 162]]], ["Education, training and exercises have been regularly organised since the beginning of the outbreak for frontline healthcare workers (HCW) to ensure that all HCWs caring for patients receive adequate information and training on PPE and clinical management of the patients.Anticipating the next steps of the epidemicThe ID department had a unit with 7 bedrooms with negative air pressure and anteroom.", [["patients", "ORGANISM", 174, 182], ["patients", "ORGANISM", 263, 271], ["patients", "SPECIES", 174, 182], ["patients", "SPECIES", 263, 271], ["PPE", "TREATMENT", 228, 231], ["clinical management", "TREATMENT", 236, 255], ["air pressure", "OBSERVATION", 374, 386]]], ["This unit was used first but as more beds were needed, we dedicated more and more units with a scale-up approach to the management of COVID-19 patients.", [["COVID", "DISEASE", 134, 139], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151], ["a scale-up approach", "TREATMENT", 93, 112], ["COVID", "TEST", 134, 139]]], ["On March 13, 2020 the 59 beds of Bichat hospital and the 13 beds of day hospital were exclusively dedicated to COVID-19 and the STI screening centre was used for COVID-19 screening and the follow-up of discharged COVID-19 patients.", [["patients", "ORGANISM", 222, 230], ["patients", "SPECIES", 222, 230], ["the STI screening", "TEST", 124, 141], ["COVID", "TEST", 162, 167]]], ["On March 16, we added the 60 beds of the rehabilitation unit of Bichat for the management of hospitalized COVID-19 patients.", [["COVID", "DISEASE", 106, 111], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["Bichat", "TREATMENT", 64, 70]]], ["The ICU capacity increased up to 65 beds in the same time by mobilizing the three ICUs of our centre, as well as surgery theatres.", [["The ICU capacity", "PROBLEM", 0, 16], ["surgery theatres", "TREATMENT", 113, 129], ["capacity", "OBSERVATION_MODIFIER", 8, 16], ["increased", "OBSERVATION_MODIFIER", 17, 26]]], ["We thus had to discharge all the patients who were not infected with SARS-CoV-2 or to transfer them to other hospitals.", [["SARS", "DISEASE", 69, 73], ["patients", "ORGANISM", 33, 41], ["SARS-CoV-2", "ORGANISM", 69, 79], ["patients", "SPECIES", 33, 41], ["SARS-CoV", "SPECIES", 69, 77]]], ["As previously reported by some Italian and Chinese colleague, many activities that are not related to COVID-19 had to be stopped in the midst of the epidemic.", [["COVID", "TEST", 102, 107]]], ["8, 9 Despite this, medical staff in the ID department had to be doubled and then tripled night and day to cope with the increase of work and three teams were created: one to manage external calls, one to organise the testing of cases and one to take care of the infected patients.", [["patients", "ORGANISM", 271, 279], ["patients", "SPECIES", 271, 279], ["infected", "OBSERVATION", 262, 270]]], ["They first managed all the COVID-19 patients of the hospital but then had to let the other departments take care of their infected patients under the supervision of the IPC team.", [["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 131, 139]]], ["At first, doctors from the emergency department managed at night the hospitalized patients with COVID-19 outside of the ICU but a specific night duty service was soon needed, first with one ID resident and now with 6 residents and two senior consultants.Anticipating the next steps of the epidemicVentilatory support is critical and efforts have been made to provide the highest number of ventilators available.", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["COVID", "TREATMENT", 96, 101], ["the epidemicVentilatory support", "TREATMENT", 285, 316], ["ventilators", "TREATMENT", 389, 400]]], ["To this aim, the decision was taken in France to delay all surgical interventions that are not urgent.", [["all surgical interventions", "TREATMENT", 55, 81]]], ["Microbiology services had to develop and increase the capacities for SARS-CoV-2 detection and monitoring.", [["the capacities", "PROBLEM", 50, 64], ["SARS", "PROBLEM", 69, 73], ["monitoring", "TEST", 94, 104]]], ["All the biology departments had to organise the analysis of samples biosafety level 2.", [["the analysis", "TEST", 44, 56]]], ["Point-of-care testing was already available in the ICU in order to decrease the workload of biological departments, and was rapidly installed in the ID unit.Involving and caring for the HCWsHCWs are at the forefront of the epidemic response and they must be supported.", [["HCWsHCWs", "CANCER", 186, 194]]], ["The hospital had to call in temporary nurses to deal with COVID-19 but the epidemic arrived in a national context where public hospitals are at the centre of a protest movement due to, among other difficulties, the difficulty in recruiting HCWs and bed shortage.", [["COVID", "TEST", 58, 63]]], ["The existence of a large health system such as AP-HP was helpful to recruit nurses and other HCWs from outside the hospital and to organise support between different hospitals when absenteeism was a problem.", [["absenteeism", "PROBLEM", 181, 192], ["large", "OBSERVATION_MODIFIER", 19, 24]]], ["Vacations were put on hold and many HCWs did extra hours that the hospital and AP-HP management committed to pay.", [["Vacations", "TREATMENT", 0, 9], ["AP-HP management", "TREATMENT", 79, 95]]], ["HCWs who developed COVID-19 were managed in the hospital if needed or as outpatients and were put on sick leave for at least 7 days and 2 days free of symptoms.", [["HCWs", "ORGANISM", 0, 4], ["COVID", "TEST", 19, 24], ["symptoms", "PROBLEM", 151, 159]]], ["From March 18 onward, all the HWCs were asked to always put surgical masks in the hospital.", [["HWCs", "CANCER", 30, 34], ["surgical masks", "TREATMENT", 60, 74]]], ["Psychological support was offered to HCWs who take care of patients but also to those who may feel threatened or anxious.", [["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["Psychological support", "TREATMENT", 0, 21], ["anxious", "PROBLEM", 113, 120]]], ["Media pressure about the COVID-19 epidemic has been felt at all levels: 10 rumours and global anxiety led to difficulties for the recruitment of temporary staff who sometimes refused to come to the hospital.", [["anxiety", "DISEASE", 94, 101], ["Media pressure", "TEST", 0, 14], ["the COVID", "TEST", 21, 30], ["epidemic", "PROBLEM", 34, 42], ["global anxiety", "PROBLEM", 87, 101], ["pressure", "OBSERVATION_MODIFIER", 6, 14]]], ["Internal communication was addressed with conferences open to all the HCWs of the hospital and information was shared on the intranet on a daily basis.Logistical mattersAn unexpected difficulty was the management of hazardous waste: the service provider initially refused to come following the announcement of confirmed SARS-CoV-2 cases in the hospital.", [["SARS", "DISEASE", 320, 324]]], ["This problem was resolved through the involvement of the IPC team and the head of the administrative staff of the hospital.", [["head", "ANATOMY", 74, 78], ["head", "ORGANISM_SUBDIVISION", 74, 78]]], ["The severity of the disease among patients made it necessary to perform CT scans in dedicated CT-scanners.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["the disease", "PROBLEM", 16, 27], ["CT scans", "TEST", 72, 80], ["dedicated CT", "TEST", 84, 96], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["disease", "OBSERVATION", 20, 27]]], ["The transport of the patients to other departments was found to be a critical point to anticipate.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29]]], ["Patient movement circuits to avoid nosocomial spread had to be organised by the IPC team and forwarded to involved HCWs.", [["Patient", "SPECIES", 0, 7], ["Patient movement circuits", "TREATMENT", 0, 25], ["nosocomial spread", "PROBLEM", 35, 52]]], ["The logistics services for medical equipment management had to adapt to a rapidly growing demand and provide the personnel with the necessary equipment for treatment.", [["medical equipment management", "TREATMENT", 27, 55], ["the necessary equipment", "TREATMENT", 128, 151], ["treatment", "TREATMENT", 156, 165]]], ["The security service was called upon to manage the arrival of journalists and the media, in particular to protect the entry of the ID and ICU departments.", [["the media", "TREATMENT", 78, 87]]], ["They were also mobilized to secure the patient transport circuits.", [["patient", "ORGANISM", 39, 46], ["patient", "SPECIES", 39, 46], ["the patient transport circuits", "TREATMENT", 35, 65]]], ["The hospital switchboard was a key department to handle external calls about COVID-19.Ensuring the commitment of hospital management staff and health authoritiesThe elaboration of the hospital response was of course integrated at the level of the AP-HP as well as at the regional, national and international level.", [["COVID-19", "CHEMICAL", 77, 85], ["COVID-19", "DNA", 77, 85], ["COVID", "TEST", 77, 82], ["HP", "OBSERVATION", 250, 252], ["regional", "ANATOMY_MODIFIER", 271, 279]]], ["This support was, for example, necessary to accelerate the transfer of patients from the hospital to rehabilitation units, including patients with highly-resistant bacteria, such as carbapenemaseproducing Enterobacterales.", [["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 133, 141], ["rehabilitation units", "TREATMENT", 101, 121], ["highly-resistant bacteria", "PROBLEM", 147, 172], ["carbapenemaseproducing Enterobacterales", "TREATMENT", 182, 221], ["bacteria", "OBSERVATION", 164, 172]]], ["The hospital's communication unit was crucial in informing the media about the management of the epidemic.", [["the management", "TREATMENT", 75, 89], ["the epidemic", "PROBLEM", 93, 105]]], ["11Concluding remarksMany health structures will face an increasing number of patients with COVID-19 and have to anticipate the consequences including the need for more beds, trained HCWs, and ventilators.", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["COVID", "TEST", 91, 96], ["ventilators", "TREATMENT", 192, 203], ["increasing", "OBSERVATION_MODIFIER", 56, 66], ["number", "OBSERVATION_MODIFIER", 67, 73]]], ["In order to face the outbreak, hospitals have to anticipate the consequences of COVID-19 on all the departments including indirect impact on non-infected patients, to ensure the commitment of hospital management staff and health authorities, to encourage effective leadership, to involve and care for all the HCWs, and to organise communication with the wider public.", [["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162]]]], "1b689b8dc7c666acd5cdd6675ed54cc6612a5607": [["IntroductionThe respiratory tract (RT) is a dynamic organ whose role in gas exchange is vital for life.", [["respiratory tract", "ANATOMY", 16, 33], ["organ", "ANATOMY", 52, 57], ["respiratory tract", "DISEASE", 16, 33], ["respiratory tract", "ORGANISM_SUBDIVISION", 16, 33], ["organ", "ORGAN", 52, 57], ["The respiratory tract (RT)", "TREATMENT", 12, 38], ["respiratory tract", "ANATOMY", 16, 33], ["gas exchange", "OBSERVATION", 72, 84]]], ["Because a large volume of air is exchanged by the lungs (i.e. up to ten liters/min.), the lungs are continuously exposed to microbial and chemical insults [1] .", [["lungs", "ANATOMY", 50, 55], ["lungs", "ANATOMY", 90, 95], ["lungs", "ORGAN", 50, 55], ["lungs", "ORGAN", 90, 95], ["a large volume of air", "PROBLEM", 8, 29], ["large", "OBSERVATION_MODIFIER", 10, 15], ["volume", "OBSERVATION_MODIFIER", 16, 22], ["air", "OBSERVATION", 26, 29], ["lungs", "ANATOMY", 50, 55], ["lungs", "ANATOMY", 90, 95]]], ["The importance of respiratory viruses (RV) as a major threat to mankind is evidenced by the outbreak of infection by the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), the sporadic human infections with high pathogenic avian H5N1 influenza, and the recent pandemic caused by swine origin influenza H1N1 infection.", [["respiratory viruses", "DISEASE", 18, 37], ["infection", "DISEASE", 104, 113], ["Acute Respiratory Syndrome coronavirus", "DISEASE", 128, 166], ["SARS-CoV)", "DISEASE", 168, 177], ["infections", "DISEASE", 198, 208], ["avian H5N1 influenza", "DISEASE", 230, 250], ["influenza H1N1 infection", "DISEASE", 299, 323], ["respiratory viruses", "ORGANISM", 18, 37], ["Severe Acute Respiratory Syndrome coronavirus", "ORGANISM", 121, 166], ["SARS-CoV", "ORGANISM", 168, 176], ["human", "ORGANISM", 192, 197], ["avian H5N1 influenza", "ORGANISM", 230, 250], ["swine origin influenza H1N1", "ORGANISM", 286, 313], ["human", "SPECIES", 192, 197], ["avian H5N1 influenza", "SPECIES", 230, 250], ["swine", "SPECIES", 286, 291], ["influenza H1N1", "SPECIES", 299, 313], ["RV", "SPECIES", 39, 41], ["Severe Acute Respiratory Syndrome coronavirus", "SPECIES", 121, 166], ["SARS-CoV", "SPECIES", 168, 176], ["human", "SPECIES", 192, 197], ["swine origin influenza H1N1", "SPECIES", 286, 313], ["respiratory viruses", "PROBLEM", 18, 37], ["infection", "PROBLEM", 104, 113], ["the Severe Acute Respiratory Syndrome coronavirus", "PROBLEM", 117, 166], ["the sporadic human infections", "PROBLEM", 179, 208], ["high pathogenic avian H5N1 influenza", "PROBLEM", 214, 250], ["influenza H1N1 infection", "PROBLEM", 299, 323], ["respiratory viruses", "OBSERVATION", 18, 37], ["infection", "OBSERVATION", 104, 113], ["Severe", "OBSERVATION_MODIFIER", 121, 127], ["Acute", "OBSERVATION_MODIFIER", 128, 133], ["Respiratory Syndrome coronavirus", "OBSERVATION", 134, 166]]], ["As more and more evidence has emerged, it is becoming increasingly clear that the pathogenicity associated with RV infection reflects not only the efficiency of virus replication and the tropism of a given virus/strain for particular cell types within the RT but also the magnitude and characteristics of the host anti-viral immune response.", [["cell", "ANATOMY", 234, 238], ["RV infection", "DISEASE", 112, 124], ["cell", "CELL", 234, 238], ["RV", "SPECIES", 112, 114], ["the pathogenicity", "PROBLEM", 78, 95], ["RV infection", "PROBLEM", 112, 124], ["virus replication", "PROBLEM", 161, 178], ["virus", "PROBLEM", 206, 211], ["strain", "PROBLEM", 212, 218], ["particular cell types", "PROBLEM", 223, 244], ["increasingly", "OBSERVATION_MODIFIER", 54, 66], ["clear", "OBSERVATION", 67, 72], ["RV", "ANATOMY", 112, 114], ["infection", "OBSERVATION", 115, 124], ["virus", "OBSERVATION", 161, 166], ["host anti-viral immune response", "OBSERVATION", 309, 340]]], ["Recovery from RV infection requires the elimination of virus/ virus-infected cells, the resolution of injury-associated inflammation, and importantly, cellular and molecular repair mechanisms necessary for restoration of normal lung structure and function.", [["RV", "ANATOMY", 14, 16], ["cells", "ANATOMY", 77, 82], ["cellular", "ANATOMY", 151, 159], ["lung", "ANATOMY", 228, 232], ["RV infection", "DISEASE", 14, 26], ["injury", "DISEASE", 102, 108], ["inflammation", "DISEASE", 120, 132], ["RV", "MULTI-TISSUE_STRUCTURE", 14, 16], ["virus/ virus", "ORGANISM", 55, 67], ["cells", "CELL", 77, 82], ["cellular", "CELL", 151, 159], ["lung", "ORGAN", 228, 232], ["infected cells", "CELL_TYPE", 68, 82], ["RV infection", "PROBLEM", 14, 26], ["virus", "PROBLEM", 55, 60], ["virus", "PROBLEM", 62, 67], ["infected cells", "PROBLEM", 68, 82], ["injury", "PROBLEM", 102, 108], ["associated inflammation", "PROBLEM", 109, 132], ["cellular and molecular repair mechanisms", "TREATMENT", 151, 191], ["RV", "ANATOMY", 14, 16], ["infection", "OBSERVATION", 17, 26], ["infected cells", "OBSERVATION", 68, 82], ["resolution", "OBSERVATION_MODIFIER", 88, 98], ["injury", "OBSERVATION", 102, 108], ["inflammation", "OBSERVATION", 120, 132], ["molecular repair", "OBSERVATION", 164, 180], ["normal", "OBSERVATION", 221, 227], ["lung", "ANATOMY", 228, 232], ["structure", "OBSERVATION_MODIFIER", 233, 242]]], ["This review will first briefly summarize virus and host immune mediated damage to the RT and then focus on recent findings implicating specific cell types in repair and recovery from pulmonary injury following RV infection.Virus Induced Respiratory Tract Inflammation and InjuryA variety of RT cell types can potentially serve as targets of infection by RV.", [["cell", "ANATOMY", 144, 148], ["pulmonary", "ANATOMY", 183, 192], ["RV", "ANATOMY", 210, 212], ["cell", "ANATOMY", 294, 298], ["pulmonary injury", "DISEASE", 183, 199], ["RV infection", "DISEASE", 210, 222], ["Respiratory Tract Inflammation", "DISEASE", 237, 267], ["infection", "DISEASE", 341, 350], ["cell", "CELL", 144, 148], ["pulmonary", "ORGAN", 183, 192], ["Virus", "ORGANISM", 223, 228], ["RT cell", "CELL", 291, 298], ["virus", "PROBLEM", 41, 46], ["host immune mediated damage", "PROBLEM", 51, 78], ["the RT", "TREATMENT", 82, 88], ["specific cell types", "TREATMENT", 135, 154], ["repair", "TREATMENT", 158, 164], ["pulmonary injury", "PROBLEM", 183, 199], ["RV infection", "PROBLEM", 210, 222], ["Virus Induced Respiratory Tract Inflammation", "PROBLEM", 223, 267], ["InjuryA", "PROBLEM", 272, 279], ["RT cell types", "TREATMENT", 291, 304], ["infection", "PROBLEM", 341, 350], ["specific cell types", "OBSERVATION", 135, 154], ["repair", "OBSERVATION", 158, 164], ["pulmonary", "ANATOMY", 183, 192], ["injury", "OBSERVATION", 193, 199], ["RV", "ANATOMY", 210, 212], ["infection", "OBSERVATION", 213, 222], ["Respiratory Tract", "ANATOMY", 237, 254], ["RT cell types", "OBSERVATION", 291, 304], ["infection", "OBSERVATION", 341, 350], ["RV", "ANATOMY", 354, 356]]], ["These include lung resident cells, most notably: (1) airway and alveolar respiratory epithelial cells (REC) whose destruction (or dysregulation) can, if severe, compromise respiratory function and (2) hematopoietic origin (bone marrow-derived CD45 + ) inflammatory and immune cells which can, like virus, induce tissue damage and compromise lung function potentially triggered following infection of RT resident or recruited CD45 + cells by certain RV (Table 1) .", [["lung resident cells", "ANATOMY", 14, 33], ["airway", "ANATOMY", 53, 59], ["alveolar respiratory epithelial cells", "ANATOMY", 64, 101], ["REC", "ANATOMY", 103, 106], ["respiratory", "ANATOMY", 172, 183], ["hematopoietic", "ANATOMY", 201, 214], ["bone marrow", "ANATOMY", 223, 234], ["immune cells", "ANATOMY", 269, 281], ["tissue", "ANATOMY", 312, 318], ["lung", "ANATOMY", 341, 345], ["CD45 + cells", "ANATOMY", 425, 437], ["tissue damage", "DISEASE", 312, 325], ["infection", "DISEASE", 387, 396], ["lung resident cells", "CELL", 14, 33], ["airway", "CELL", 53, 59], ["alveolar respiratory epithelial cells", "CELL", 64, 101], ["REC", "CELL", 103, 106], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 223, 234], ["CD45", "GENE_OR_GENE_PRODUCT", 243, 247], ["immune cells", "CELL", 269, 281], ["tissue", "TISSUE", 312, 318], ["lung", "ORGAN", 341, 345], ["CD45", "GENE_OR_GENE_PRODUCT", 425, 429], ["lung resident cells", "CELL_TYPE", 14, 33], ["alveolar respiratory epithelial cells", "CELL_TYPE", 64, 101], ["REC", "CELL_TYPE", 103, 106], ["hematopoietic origin", "CELL_TYPE", 201, 221], ["CD45", "PROTEIN", 243, 247], ["inflammatory and immune cells", "CELL_TYPE", 252, 281], ["CD45", "PROTEIN", 425, 429], ["airway and alveolar respiratory epithelial cells", "PROBLEM", 53, 101], ["whose destruction", "PROBLEM", 108, 125], ["severe, compromise respiratory function", "PROBLEM", 153, 192], ["hematopoietic origin", "PROBLEM", 201, 221], ["bone marrow", "TEST", 223, 234], ["inflammatory and immune cells", "PROBLEM", 252, 281], ["virus", "PROBLEM", 298, 303], ["tissue damage", "PROBLEM", 312, 325], ["compromise lung function", "PROBLEM", 330, 354], ["lung", "ANATOMY", 14, 18], ["airway", "ANATOMY", 53, 59], ["alveolar", "ANATOMY_MODIFIER", 64, 72], ["respiratory", "ANATOMY", 73, 84], ["epithelial cells", "OBSERVATION", 85, 101], ["hematopoietic", "ANATOMY", 201, 214], ["origin", "ANATOMY_MODIFIER", 215, 221], ["bone", "ANATOMY", 223, 227], ["inflammatory", "OBSERVATION_MODIFIER", 252, 264], ["immune cells", "OBSERVATION", 269, 281]]], ["For example, SARS-CoV and Type A Influenza virus (IAV) can productively infect certain REC types triggering extensive necrosis and apoptosis of infected cells which in turn results in the accumulation of cellular debris leading to edema and mucous production within the airways [2, 3] .", [["cells", "ANATOMY", 153, 158], ["cellular debris", "ANATOMY", 204, 219], ["edema", "ANATOMY", 231, 236], ["mucous", "ANATOMY", 241, 247], ["airways", "ANATOMY", 270, 277], ["SARS", "DISEASE", 13, 17], ["necrosis", "DISEASE", 118, 126], ["edema", "DISEASE", 231, 236], ["SARS-CoV", "ORGANISM", 13, 21], ["Type A Influenza virus", "ORGANISM", 26, 48], ["IAV", "ORGANISM", 50, 53], ["cells", "CELL", 153, 158], ["cellular", "CELL", 204, 212], ["edema", "PATHOLOGICAL_FORMATION", 231, 236], ["mucous", "ORGAN", 241, 247], ["airways", "MULTI-TISSUE_STRUCTURE", 270, 277], ["infected cells", "CELL_TYPE", 144, 158], ["A Influenza virus", "SPECIES", 31, 48], ["SARS-CoV", "SPECIES", 13, 21], ["Type A Influenza virus", "SPECIES", 26, 48], ["IAV", "SPECIES", 50, 53], ["SARS", "PROBLEM", 13, 17], ["CoV", "PROBLEM", 18, 21], ["Type A Influenza virus (IAV)", "PROBLEM", 26, 54], ["extensive necrosis", "PROBLEM", 108, 126], ["apoptosis of infected cells", "PROBLEM", 131, 158], ["cellular debris", "PROBLEM", 204, 219], ["edema", "PROBLEM", 231, 236], ["mucous production within the airways", "PROBLEM", 241, 277], ["Influenza virus", "OBSERVATION", 33, 48], ["extensive", "OBSERVATION_MODIFIER", 108, 117], ["necrosis", "OBSERVATION", 118, 126], ["infected cells", "OBSERVATION", 144, 158], ["accumulation", "OBSERVATION_MODIFIER", 188, 200], ["cellular debris", "OBSERVATION", 204, 219], ["edema", "OBSERVATION", 231, 236], ["mucous production", "OBSERVATION", 241, 258], ["airways", "ANATOMY", 270, 277]]], ["SARS-CoV has been reported to have a cellular tropism either for alveolar REC or more recently, respiratory epithelial stem cells involved in REC regeneration (see below) [4] [5] [6] .", [["cellular", "ANATOMY", 37, 45], ["alveolar REC", "ANATOMY", 65, 77], ["respiratory epithelial stem cells", "ANATOMY", 96, 129], ["SARS", "DISEASE", 0, 4], ["SARS-CoV", "ORGANISM", 0, 8], ["cellular", "CELL", 37, 45], ["alveolar REC", "CELL", 65, 77], ["respiratory epithelial stem cells", "CELL", 96, 129], ["REC", "TISSUE", 142, 145], ["alveolar REC", "CELL_TYPE", 65, 77], ["respiratory epithelial stem cells", "CELL_TYPE", 96, 129], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["a cellular tropism", "PROBLEM", 35, 53], ["alveolar REC", "PROBLEM", 65, 77], ["respiratory epithelial stem cells", "PROBLEM", 96, 129], ["epithelial stem cells", "OBSERVATION", 108, 129]]], ["SARS-CoV exploits the angiotensin-converting enzyme 2 (ACE2), a negative regulator of the rennin-angiotensin system for blood pressure homeostasis as a receptor for entry into epithelial cells [7, 8] .", [["blood", "ANATOMY", 120, 125], ["epithelial cells", "ANATOMY", 176, 192], ["SARS", "DISEASE", 0, 4], ["angiotensin", "CHEMICAL", 22, 33], ["angiotensin", "CHEMICAL", 97, 108], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 22, 53], ["ACE2", "GENE_OR_GENE_PRODUCT", 55, 59], ["rennin-angiotensin", "GENE_OR_GENE_PRODUCT", 90, 108], ["blood", "ORGANISM_SUBSTANCE", 120, 125], ["epithelial cells", "CELL", 176, 192], ["angiotensin-converting enzyme 2", "PROTEIN", 22, 53], ["ACE2", "PROTEIN", 55, 59], ["epithelial cells", "CELL_TYPE", 176, 192], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["the angiotensin", "TEST", 18, 33], ["blood pressure homeostasis", "TREATMENT", 120, 146], ["epithelial cells", "OBSERVATION", 176, 192]]], ["Subsequent down-regulation of ACE2 expression following SARS-CoV infection of REC has been linked to increased lung edema and severe acute lung injury [7, 9, 10] .Virus Induced Respiratory Tract Inflammation and InjuryIn most instances, productive infection of REC by RV is necessary for virus propagation and as a consequence, contributes to RT inflammation/injury.", [["lung", "ANATOMY", 111, 115], ["lung", "ANATOMY", 139, 143], ["infection", "DISEASE", 65, 74], ["REC", "CHEMICAL", 78, 81], ["lung edema", "DISEASE", 111, 121], ["acute lung injury", "DISEASE", 133, 150], ["Respiratory Tract Inflammation", "DISEASE", 177, 207], ["infection", "DISEASE", 248, 257], ["inflammation", "DISEASE", 346, 358], ["ACE2", "GENE_OR_GENE_PRODUCT", 30, 34], ["SARS-CoV", "ORGANISM", 56, 64], ["REC", "CELL", 78, 81], ["lung", "ORGAN", 111, 115], ["lung", "ORGAN", 139, 143], ["Virus", "ORGANISM", 163, 168], ["RV", "MULTI-TISSUE_STRUCTURE", 268, 270], ["ACE2", "PROTEIN", 30, 34], ["SARS-CoV", "SPECIES", 56, 64], ["ACE2 expression", "TREATMENT", 30, 45], ["SARS", "PROBLEM", 56, 60], ["CoV infection", "PROBLEM", 61, 74], ["increased lung edema", "PROBLEM", 101, 121], ["severe acute lung injury", "PROBLEM", 126, 150], ["Virus Induced Respiratory Tract Inflammation", "PROBLEM", 163, 207], ["InjuryIn most instances", "PROBLEM", 212, 235], ["productive infection", "PROBLEM", 237, 257], ["virus propagation", "PROBLEM", 288, 305], ["RT inflammation", "PROBLEM", 343, 358], ["injury", "PROBLEM", 359, 365], ["increased", "OBSERVATION_MODIFIER", 101, 110], ["lung", "ANATOMY", 111, 115], ["edema", "OBSERVATION", 116, 121], ["severe", "OBSERVATION_MODIFIER", 126, 132], ["acute", "OBSERVATION_MODIFIER", 133, 138], ["lung", "ANATOMY", 139, 143], ["injury", "OBSERVATION", 144, 150], ["Respiratory Tract", "ANATOMY", 177, 194], ["productive", "OBSERVATION_MODIFIER", 237, 247], ["infection", "OBSERVATION", 248, 257], ["RV", "ANATOMY", 268, 270], ["RT", "ANATOMY", 343, 345], ["inflammation", "OBSERVATION", 346, 358], ["injury", "OBSERVATION", 359, 365]]], ["However, infection of bone marrow-derived CD45 + RT resident cells (e.g. respiratory dendritic cells (RDC)) and recruited inflammatory myeloid lineage cells (e.g. inflammatory mononuclear cells and possibly neutrophils) may profoundly influence the course and ultimate outcome of RV infection [11, 12] .", [["bone marrow-derived CD45 + RT resident cells", "ANATOMY", 22, 66], ["respiratory dendritic cells", "ANATOMY", 73, 100], ["RDC", "ANATOMY", 102, 105], ["inflammatory myeloid lineage cells", "ANATOMY", 122, 156], ["inflammatory mononuclear cells", "ANATOMY", 163, 193], ["neutrophils", "ANATOMY", 207, 218], ["RV", "ANATOMY", 280, 282], ["infection", "DISEASE", 9, 18], ["RV infection", "DISEASE", 280, 292], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 22, 33], ["CD45", "GENE_OR_GENE_PRODUCT", 42, 46], ["respiratory dendritic cells", "CELL", 73, 100], ["RDC", "CELL", 102, 105], ["myeloid lineage cells", "CELL", 135, 156], ["inflammatory mononuclear cells", "CELL", 163, 193], ["neutrophils", "CELL", 207, 218], ["RV", "ORGAN", 280, 282], ["CD45", "PROTEIN", 42, 46], ["RT resident cells", "CELL_TYPE", 49, 66], ["respiratory dendritic cells", "CELL_TYPE", 73, 100], ["RDC", "CELL_TYPE", 102, 105], ["inflammatory myeloid lineage cells", "CELL_TYPE", 122, 156], ["inflammatory mononuclear cells", "CELL_TYPE", 163, 193], ["neutrophils", "CELL_TYPE", 207, 218], ["RV", "SPECIES", 280, 282], ["infection of bone marrow", "PROBLEM", 9, 33], ["CD45", "TEST", 42, 46], ["RT resident cells", "TEST", 49, 66], ["respiratory dendritic cells", "PROBLEM", 73, 100], ["recruited inflammatory myeloid lineage cells", "PROBLEM", 112, 156], ["inflammatory mononuclear cells", "PROBLEM", 163, 193], ["neutrophils", "PROBLEM", 207, 218], ["RV infection", "PROBLEM", 280, 292], ["infection", "OBSERVATION", 9, 18], ["bone marrow", "ANATOMY", 22, 33], ["respiratory", "ANATOMY", 73, 84], ["dendritic cells", "OBSERVATION", 85, 100], ["inflammatory myeloid lineage cells", "OBSERVATION", 122, 156], ["inflammatory mononuclear cells", "OBSERVATION", 163, 193], ["possibly", "UNCERTAINTY", 198, 206], ["RV", "ANATOMY", 280, 282], ["infection", "OBSERVATION", 283, 292]]], ["Both SARS-CoV and highly pathogenic avian H5N1 IAV can productively infect cells of hematopoietic origin, which may account for the propensity of these agents to leave the RT and disseminate systemically [13] [14] [15] .", [["cells", "ANATOMY", 75, 80], ["hematopoietic", "ANATOMY", 84, 97], ["SARS", "DISEASE", 5, 9], ["SARS-CoV", "ORGANISM", 5, 13], ["avian H5N1 IAV", "ORGANISM", 36, 50], ["cells", "CELL", 75, 80], ["avian H5N1 IAV", "SPECIES", 36, 50], ["SARS-CoV", "SPECIES", 5, 13], ["H5N1 IAV", "SPECIES", 42, 50], ["Both SARS-CoV", "PROBLEM", 0, 13], ["highly pathogenic avian H5N1 IAV", "PROBLEM", 18, 50], ["SARS", "OBSERVATION", 5, 9], ["hematopoietic origin", "OBSERVATION", 84, 104]]], ["RV infection of resident RDC and alveolar macrophages results in the engagement of intracellular pathogen associated molecular pattern (PAMP) receptors (e.g. TLR and/or RLR) and initiates robust cytokine production [11, 16] .", [["RDC", "ANATOMY", 25, 28], ["alveolar macrophages", "ANATOMY", 33, 53], ["intracellular", "ANATOMY", 83, 96], ["infection", "DISEASE", 3, 12], ["RDC", "CELL", 25, 28], ["alveolar macrophages", "CELL", 33, 53], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 83, 96], ["pathogen associated molecular pattern (PAMP) receptors", "GENE_OR_GENE_PRODUCT", 97, 151], ["TLR", "GENE_OR_GENE_PRODUCT", 158, 161], ["RLR", "GENE_OR_GENE_PRODUCT", 169, 172], ["RDC", "CELL_TYPE", 25, 28], ["alveolar macrophages", "CELL_TYPE", 33, 53], ["intracellular pathogen associated molecular pattern (PAMP) receptors", "PROTEIN", 83, 151], ["TLR", "PROTEIN", 158, 161], ["RLR", "PROTEIN", 169, 172], ["cytokine", "PROTEIN", 195, 203], ["RV infection of resident RDC and alveolar macrophages", "PROBLEM", 0, 53], ["intracellular pathogen associated molecular pattern (PAMP) receptors", "PROBLEM", 83, 151], ["TLR", "TEST", 158, 161], ["infection", "OBSERVATION", 3, 12], ["alveolar macrophages", "OBSERVATION", 33, 53]]], ["Of note, the infection of RDC by IAV may also be a pivotal step for the activation of the CD8 + T lymphocyte response [17] .", [["CD8 + T lymphocyte", "ANATOMY", 90, 108], ["infection", "DISEASE", 13, 22], ["RDC", "CELL", 26, 29], ["IAV", "ORGANISM", 33, 36], ["CD8", "GENE_OR_GENE_PRODUCT", 90, 93], ["RDC", "CELL_TYPE", 26, 29], ["CD8", "PROTEIN", 90, 93], ["IAV", "SPECIES", 33, 36], ["the infection of RDC", "PROBLEM", 9, 29], ["IAV", "PROBLEM", 33, 36], ["infection", "OBSERVATION", 13, 22]]], ["However, one or more subsets of RT resident RDC, notably RDC expressing CD103 may be specialized to take up viral antigen without infection and efficiently initiate an adaptive immune response [18] .", [["infection", "DISEASE", 130, 139], ["RDC", "CELL", 44, 47], ["RDC", "CELL", 57, 60], ["CD103", "GENE_OR_GENE_PRODUCT", 72, 77], ["RDC", "CELL_TYPE", 44, 47], ["RDC", "CELL_TYPE", 57, 60], ["CD103", "PROTEIN", 72, 77], ["viral antigen", "PROTEIN", 108, 121], ["viral antigen", "PROBLEM", 108, 121], ["infection", "PROBLEM", 130, 139]]], ["Interestingly, alveolar macrophages, through a mechanism dependent on TLR3 engagement, inhibit RDC activation during SARS-CoV infections, which in turn results in lymphopenia and prolongation of virus-induced inflammation [19] .", [["alveolar macrophages", "ANATOMY", 15, 35], ["SARS-CoV infections", "DISEASE", 117, 136], ["lymphopenia", "DISEASE", 163, 174], ["inflammation", "DISEASE", 209, 221], ["alveolar macrophages", "CELL", 15, 35], ["TLR3", "GENE_OR_GENE_PRODUCT", 70, 74], ["SARS-CoV", "ORGANISM", 117, 125], ["alveolar macrophages", "CELL_TYPE", 15, 35], ["TLR3", "PROTEIN", 70, 74], ["SARS-CoV", "SPECIES", 117, 125], ["alveolar macrophages", "PROBLEM", 15, 35], ["TLR3 engagement", "TREATMENT", 70, 85], ["RDC activation", "PROBLEM", 95, 109], ["SARS", "PROBLEM", 117, 121], ["CoV infections", "PROBLEM", 122, 136], ["lymphopenia", "PROBLEM", 163, 174], ["prolongation of virus", "PROBLEM", 179, 200], ["induced inflammation", "PROBLEM", 201, 221], ["alveolar macrophages", "OBSERVATION", 15, 35], ["lymphopenia", "OBSERVATION", 163, 174]]], ["During the evolution of virus infection, infection of or at least viral antigen uptake by CD45 + inflammatory cells in the infected RT may also serve as a potent stimulus for the development of an excessive host immune response through interaction of these RV antigen expressing inflammatory cells with adaptive immune effector T lymphocytes [20,21].Host Immune Mediated Respiratory Tract Inflammation and InjuryEngagement of epithelial and hematopoietic cell PAMP receptors by viral proteins and nucleic acids during infection up-regulates a number of chemoattractant mediators (e.g. MCP-1 and KC), which recruit various innate immune cell types.", [["CD45 + inflammatory cells", "ANATOMY", 90, 115], ["inflammatory cells", "ANATOMY", 279, 297], ["immune effector T lymphocytes", "ANATOMY", 312, 341], ["epithelial", "ANATOMY", 426, 436], ["hematopoietic cell", "ANATOMY", 441, 459], ["immune cell", "ANATOMY", 629, 640], ["infection", "DISEASE", 30, 39], ["infection", "DISEASE", 41, 50], ["nucleic acids", "CHEMICAL", 497, 510], ["infection", "DISEASE", 518, 527], ["CD45", "GENE_OR_GENE_PRODUCT", 90, 94], ["RV antigen", "GENE_OR_GENE_PRODUCT", 257, 267], ["inflammatory cells", "CELL", 279, 297], ["immune effector T lymphocytes", "CELL", 312, 341], ["epithelial", "CELL", 426, 436], ["hematopoietic cell PAMP receptors", "GENE_OR_GENE_PRODUCT", 441, 474], ["MCP-1", "GENE_OR_GENE_PRODUCT", 585, 590], ["KC", "GENE_OR_GENE_PRODUCT", 595, 597], ["immune cell", "CELL", 629, 640], ["CD45", "PROTEIN", 90, 94], ["inflammatory cells", "CELL_TYPE", 97, 115], ["RV antigen expressing inflammatory cells", "CELL_TYPE", 257, 297], ["adaptive immune effector T lymphocytes", "CELL_TYPE", 303, 341], ["epithelial and hematopoietic cell PAMP receptors", "PROTEIN", 426, 474], ["viral proteins", "PROTEIN", 478, 492], ["chemoattractant mediators", "PROTEIN", 553, 578], ["MCP", "PROTEIN", 585, 588], ["KC", "PROTEIN", 595, 597], ["innate immune cell types", "CELL_TYPE", 622, 646], ["virus infection", "PROBLEM", 24, 39], ["infection", "PROBLEM", 41, 50], ["viral antigen uptake", "TEST", 66, 86], ["CD45", "TEST", 90, 94], ["inflammatory cells", "PROBLEM", 97, 115], ["the infected RT", "PROBLEM", 119, 134], ["a potent stimulus", "TREATMENT", 153, 170], ["an excessive host immune response", "PROBLEM", 194, 227], ["these RV antigen", "TEST", 251, 267], ["inflammatory cells", "PROBLEM", 279, 297], ["Host Immune Mediated Respiratory Tract Inflammation", "PROBLEM", 350, 401], ["epithelial and hematopoietic cell PAMP receptors", "PROBLEM", 426, 474], ["viral proteins", "PROBLEM", 478, 492], ["nucleic acids during infection", "PROBLEM", 497, 527], ["chemoattractant mediators", "TEST", 553, 578], ["MCP", "TEST", 585, 588], ["virus", "OBSERVATION_MODIFIER", 24, 29], ["infection", "OBSERVATION", 30, 39], ["inflammatory cells", "OBSERVATION", 97, 115], ["excessive", "OBSERVATION_MODIFIER", 197, 206], ["host immune response", "OBSERVATION", 207, 227], ["RV", "ANATOMY", 257, 259], ["inflammatory cells", "OBSERVATION", 279, 297], ["Respiratory Tract", "ANATOMY", 371, 388], ["Inflammation", "OBSERVATION", 389, 401], ["epithelial", "ANATOMY_MODIFIER", 426, 436], ["hematopoietic cell", "OBSERVATION", 441, 459], ["viral proteins", "OBSERVATION", 478, 492], ["nucleic acids", "OBSERVATION", 497, 510], ["innate immune cell types", "OBSERVATION", 622, 646]]], ["While contributing to viral clearance, these innate immune cells are also notable for their role in promoting pulmonary tissue damage [11, 16, 22, 23] .", [["immune cells", "ANATOMY", 52, 64], ["pulmonary tissue", "ANATOMY", 110, 126], ["pulmonary tissue damage", "DISEASE", 110, 133], ["innate immune cells", "CELL", 45, 64], ["pulmonary tissue", "TISSUE", 110, 126], ["innate immune cells", "CELL_TYPE", 45, 64], ["viral clearance", "PROBLEM", 22, 37], ["promoting pulmonary tissue damage", "PROBLEM", 100, 133], ["viral clearance", "OBSERVATION", 22, 37], ["pulmonary tissue", "ANATOMY", 110, 126]]], ["Excessive accumulation of neutrophils and inflammatory mononuclear cells (a heterogeneous cell type encompassing monocytes and TNF/inducible nitric oxide synthase producing DCs (tipDCs)) is strongly correlated with severe lung pathology in cases of human SARS-CoV, avian influenza, and respiratory syncytial virus (RSV) infections [24] [25] [26] .", [["neutrophils", "ANATOMY", 26, 37], ["inflammatory mononuclear cells", "ANATOMY", 42, 72], ["cell", "ANATOMY", 90, 94], ["monocytes", "ANATOMY", 113, 122], ["DCs", "ANATOMY", 173, 176], ["lung", "ANATOMY", 222, 226], ["nitric oxide", "CHEMICAL", 141, 153], ["SARS-CoV", "DISEASE", 255, 263], ["avian influenza", "DISEASE", 265, 280], ["respiratory syncytial virus (RSV) infections", "DISEASE", 286, 330], ["nitric oxide", "CHEMICAL", 141, 153], ["neutrophils", "CELL", 26, 37], ["inflammatory mononuclear cells", "CELL", 42, 72], ["cell type", "CELL", 90, 99], ["monocytes", "CELL", 113, 122], ["TNF/inducible nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 127, 162], ["DCs", "CELL", 173, 176], ["tipDCs", "GENE_OR_GENE_PRODUCT", 178, 184], ["lung", "ORGAN", 222, 226], ["human", "ORGANISM", 249, 254], ["SARS-CoV", "ORGANISM", 255, 263], ["avian influenza", "ORGANISM", 265, 280], ["respiratory syncytial virus", "ORGANISM", 286, 313], ["RSV", "ORGANISM", 315, 318], ["neutrophils", "CELL_TYPE", 26, 37], ["inflammatory mononuclear cells", "CELL_TYPE", 42, 72], ["monocytes", "CELL_TYPE", 113, 122], ["TNF", "PROTEIN", 127, 130], ["nitric oxide synthase", "PROTEIN", 141, 162], ["DCs", "CELL_TYPE", 173, 176], ["tipDCs", "CELL_TYPE", 178, 184], ["human", "SPECIES", 249, 254], ["avian influenza", "SPECIES", 265, 280], ["respiratory syncytial virus", "SPECIES", 286, 313], ["human SARS-CoV", "SPECIES", 249, 263], ["respiratory syncytial virus", "SPECIES", 286, 313], ["RSV", "SPECIES", 315, 318], ["Excessive accumulation of neutrophils", "PROBLEM", 0, 37], ["inflammatory mononuclear cells", "PROBLEM", 42, 72], ["a heterogeneous cell type encompassing monocytes", "PROBLEM", 74, 122], ["TNF", "TREATMENT", 127, 130], ["inducible nitric oxide synthase", "TREATMENT", 131, 162], ["DCs (tipDCs)", "TREATMENT", 173, 185], ["severe lung pathology", "PROBLEM", 215, 236], ["human SARS", "PROBLEM", 249, 259], ["CoV", "PROBLEM", 260, 263], ["avian influenza", "PROBLEM", 265, 280], ["respiratory syncytial virus (RSV) infections", "PROBLEM", 286, 330], ["accumulation of neutrophils", "OBSERVATION", 10, 37], ["inflammatory mononuclear cells", "OBSERVATION", 42, 72], ["heterogeneous", "OBSERVATION_MODIFIER", 76, 89], ["cell type", "OBSERVATION", 90, 99], ["encompassing monocytes", "OBSERVATION", 100, 122], ["severe", "OBSERVATION_MODIFIER", 215, 221], ["lung", "ANATOMY", 222, 226], ["pathology", "OBSERVATION", 227, 236], ["respiratory syncytial", "ANATOMY", 286, 307]]], ["In murine models of RV infection, however, it is clear that the extent of inflammatory cell infiltration into the RT alone is not the sole factor accounting for host-mediated pulmonary injury [27, 28] .", [["RV", "ANATOMY", 20, 22], ["cell", "ANATOMY", 87, 91], ["pulmonary", "ANATOMY", 175, 184], ["RV infection", "DISEASE", 20, 32], ["pulmonary injury", "DISEASE", 175, 191], ["murine", "ORGANISM", 3, 9], ["RV", "ORGAN", 20, 22], ["inflammatory cell", "CELL", 74, 91], ["pulmonary", "ORGAN", 175, 184], ["murine", "SPECIES", 3, 9], ["RV", "SPECIES", 20, 22], ["RV infection", "PROBLEM", 20, 32], ["inflammatory cell infiltration", "PROBLEM", 74, 104], ["host-mediated pulmonary injury", "PROBLEM", 161, 191], ["RV", "ANATOMY", 20, 22], ["infection", "OBSERVATION", 23, 32], ["inflammatory cell infiltration", "OBSERVATION", 74, 104], ["pulmonary", "ANATOMY", 175, 184], ["injury", "OBSERVATION", 185, 191]]], ["Rather, RT damage is linked to the characteristics of the soluble and cell-associated inflammatory mediators produced or expressed by innate immune cells ( Table 2 ).", [["cell", "ANATOMY", 70, 74], ["immune cells", "ANATOMY", 141, 153], ["cell", "CELL", 70, 74], ["innate immune cells", "CELL", 134, 153], ["inflammatory mediators", "PROTEIN", 86, 108], ["innate immune cells", "CELL_TYPE", 134, 153], ["RT damage", "PROBLEM", 8, 17], ["the soluble and cell-associated inflammatory mediators", "PROBLEM", 54, 108], ["damage", "OBSERVATION", 11, 17], ["inflammatory", "OBSERVATION_MODIFIER", 86, 98]]], ["Release of soluble factors by phagocytic cells (e.g. proinflammatory cytokines and free radicals) can damage bystander un-infected cells in addition to infected cell targets resulting in excessive pulmonary tissue damage [29, 30] .", [["phagocytic cells", "ANATOMY", 30, 46], ["cells", "ANATOMY", 131, 136], ["cell", "ANATOMY", 161, 165], ["pulmonary tissue", "ANATOMY", 197, 213], ["pulmonary tissue damage", "DISEASE", 197, 220], ["phagocytic cells", "CELL", 30, 46], ["cells", "CELL", 131, 136], ["cell", "CELL", 161, 165], ["pulmonary tissue", "TISSUE", 197, 213], ["soluble factors", "PROTEIN", 11, 26], ["phagocytic cells", "CELL_TYPE", 30, 46], ["proinflammatory cytokines", "PROTEIN", 53, 78], ["Release of soluble factors", "TREATMENT", 0, 26], ["phagocytic cells", "TREATMENT", 30, 46], ["proinflammatory cytokines and free radicals)", "TREATMENT", 53, 97], ["bystander un-infected cells", "TREATMENT", 109, 136], ["infected cell targets", "TREATMENT", 152, 173], ["excessive pulmonary tissue damage", "PROBLEM", 187, 220], ["phagocytic cells", "OBSERVATION", 30, 46], ["infected cells", "OBSERVATION", 122, 136], ["infected cell targets", "OBSERVATION", 152, 173], ["excessive", "OBSERVATION_MODIFIER", 187, 196], ["pulmonary tissue", "ANATOMY", 197, 213]]], ["Also, inflammatory mononuclear cells express the surface molecule TNF-related apoptosisinducing ligand (TRAIL) which can induce apoptosis in cells expressing the corresponding ligand(s) as can occur in IAV infection [31] .", [["inflammatory mononuclear cells", "ANATOMY", 6, 36], ["cells", "ANATOMY", 141, 146], ["IAV infection", "DISEASE", 202, 215], ["inflammatory mononuclear cells", "CELL", 6, 36], ["TNF-related apoptosisinducing ligand", "GENE_OR_GENE_PRODUCT", 66, 102], ["TRAIL", "GENE_OR_GENE_PRODUCT", 104, 109], ["cells", "CELL", 141, 146], ["IAV", "ORGANISM", 202, 205], ["inflammatory mononuclear cells", "CELL_TYPE", 6, 36], ["surface molecule TNF-related apoptosisinducing ligand", "PROTEIN", 49, 102], ["TRAIL", "PROTEIN", 104, 109], ["IAV", "SPECIES", 202, 205], ["inflammatory mononuclear cells", "PROBLEM", 6, 36], ["the surface molecule TNF", "TEST", 45, 69], ["apoptosis in cells", "PROBLEM", 128, 146], ["IAV infection", "PROBLEM", 202, 215], ["inflammatory", "OBSERVATION_MODIFIER", 6, 18], ["mononuclear cells", "OBSERVATION", 19, 36], ["surface", "OBSERVATION_MODIFIER", 49, 56], ["IAV", "OBSERVATION_MODIFIER", 202, 205], ["infection", "OBSERVATION", 206, 215]]], ["Because un-infected REC express TRAIL ligands, albeit at lower levels than IAV-infected alveolar REC, inflammatory mononuclear cells have the potential to indiscriminately eliminate REC, contributing to increased airway permeability and alveolitis.", [["alveolar REC", "ANATOMY", 88, 100], ["inflammatory mononuclear cells", "ANATOMY", 102, 132], ["airway", "ANATOMY", 213, 219], ["alveolitis", "DISEASE", 237, 247], ["REC", "CELL", 20, 23], ["TRAIL", "GENE_OR_GENE_PRODUCT", 32, 37], ["alveolar REC", "CELL", 88, 100], ["inflammatory mononuclear cells", "CELL", 102, 132], ["REC", "CELL", 182, 185], ["airway", "MULTI-TISSUE_STRUCTURE", 213, 219], ["REC", "CELL_TYPE", 20, 23], ["TRAIL", "PROTEIN", 32, 37], ["inflammatory mononuclear cells", "CELL_TYPE", 102, 132], ["un-infected REC express TRAIL ligands", "PROBLEM", 8, 45], ["IAV", "TEST", 75, 78], ["inflammatory mononuclear cells", "PROBLEM", 102, 132], ["increased airway permeability", "PROBLEM", 203, 232], ["alveolitis", "PROBLEM", 237, 247], ["infected", "OBSERVATION", 79, 87], ["alveolar", "ANATOMY", 88, 96], ["inflammatory mononuclear cells", "OBSERVATION", 102, 132], ["increased", "OBSERVATION_MODIFIER", 203, 212], ["airway permeability", "OBSERVATION", 213, 232], ["alveolitis", "OBSERVATION", 237, 247]]], ["While exuberant neutrophil and inflammatory mononuclear cell accumulation and activation does enhance pulmonary inflammation and excess mortality in murine models of IAV infection, the depletion or absence of these innate immune effector cells can paradoxically result in augmented tissue damage, possibly reflecting the contribution of these innate immune cells directly to IAV clearance or feedback control of the host immune response [32-36].", [["neutrophil", "ANATOMY", 16, 26], ["inflammatory mononuclear cell", "ANATOMY", 31, 60], ["pulmonary", "ANATOMY", 102, 111], ["immune effector cells", "ANATOMY", 222, 243], ["tissue", "ANATOMY", 282, 288], ["immune cells", "ANATOMY", 350, 362], ["pulmonary inflammation", "DISEASE", 102, 124], ["IAV infection", "DISEASE", 166, 179], ["neutrophil", "CELL", 16, 26], ["inflammatory mononuclear cell", "CELL", 31, 60], ["pulmonary", "ORGAN", 102, 111], ["murine", "ORGANISM", 149, 155], ["IAV", "ORGANISM", 166, 169], ["immune effector cells", "CELL", 222, 243], ["tissue", "TISSUE", 282, 288], ["innate immune cells", "CELL", 343, 362], ["IAV", "ORGANISM", 375, 378], ["innate immune effector cells", "CELL_TYPE", 215, 243], ["innate immune cells", "CELL_TYPE", 343, 362], ["murine", "SPECIES", 149, 155], ["IAV", "SPECIES", 166, 169], ["exuberant neutrophil", "PROBLEM", 6, 26], ["inflammatory mononuclear cell accumulation", "PROBLEM", 31, 73], ["pulmonary inflammation", "PROBLEM", 102, 124], ["excess mortality", "PROBLEM", 129, 145], ["IAV infection", "PROBLEM", 166, 179], ["the depletion", "PROBLEM", 181, 194], ["these innate immune effector cells", "PROBLEM", 209, 243], ["augmented tissue damage", "PROBLEM", 272, 295], ["these innate immune cells", "TREATMENT", 337, 362], ["IAV clearance", "TREATMENT", 375, 388], ["feedback control", "TREATMENT", 392, 408], ["exuberant", "OBSERVATION_MODIFIER", 6, 15], ["neutrophil", "OBSERVATION_MODIFIER", 16, 26], ["inflammatory mononuclear cell accumulation", "OBSERVATION", 31, 73], ["pulmonary", "ANATOMY", 102, 111], ["inflammation", "OBSERVATION", 112, 124], ["excess", "OBSERVATION_MODIFIER", 129, 135], ["mortality", "OBSERVATION_MODIFIER", 136, 145], ["murine models", "OBSERVATION_MODIFIER", 149, 162], ["IAV", "OBSERVATION_MODIFIER", 166, 169], ["infection", "OBSERVATION", 170, 179], ["augmented tissue damage", "OBSERVATION", 272, 295]]], ["Thus, not surprisingly, the role of innate immune cells in virus clearance and/or tissue damage in the RT undoubtedly represents a complex interplay between the host and the particular infecting RV.", [["immune cells", "ANATOMY", 43, 55], ["tissue", "ANATOMY", 82, 88], ["innate immune cells", "CELL", 36, 55], ["tissue", "TISSUE", 82, 88], ["RV", "ORGAN", 195, 197], ["innate immune cells", "CELL_TYPE", 36, 55], ["innate immune cells", "TREATMENT", 36, 55], ["virus clearance", "TEST", 59, 74], ["tissue damage", "PROBLEM", 82, 95], ["RV", "ANATOMY", 195, 197]]], ["Thus, there is a delicate balance between the extent of accumulation of innate immune cells in the infected RT and the activation state of the cells, which is in part controlled by the properties of the infecting RV.Host Immune Mediated Respiratory Tract Inflammation and InjuryThe adaptive immune response to primary RV infection consists of infiltrating antigenspecific T lymphocytes and humoral immunity.", [["immune cells", "ANATOMY", 79, 91], ["cells", "ANATOMY", 143, 148], ["RV", "ANATOMY", 318, 320], ["antigenspecific T lymphocytes", "ANATOMY", 356, 385], ["Respiratory Tract Inflammation", "DISEASE", 237, 267], ["RV infection", "DISEASE", 318, 330], ["innate immune cells", "CELL", 72, 91], ["cells", "CELL", 143, 148], ["RV", "ORGAN", 318, 320], ["antigenspecific T lymphocytes", "CELL", 356, 385], ["innate immune cells", "CELL_TYPE", 72, 91], ["infiltrating antigenspecific T lymphocytes", "CELL_TYPE", 343, 385], ["RV", "SPECIES", 318, 320], ["innate immune cells", "TREATMENT", 72, 91], ["the infected RT", "TREATMENT", 95, 110], ["Host Immune Mediated Respiratory Tract Inflammation", "PROBLEM", 216, 267], ["Injury", "PROBLEM", 272, 278], ["primary RV infection", "PROBLEM", 310, 330], ["infiltrating antigenspecific T lymphocytes", "PROBLEM", 343, 385], ["humoral immunity", "TREATMENT", 390, 406], ["innate immune cells", "OBSERVATION", 72, 91], ["infected", "OBSERVATION", 99, 107], ["cells", "ANATOMY", 143, 148], ["infecting RV", "OBSERVATION", 203, 215], ["Respiratory Tract", "ANATOMY", 237, 254], ["Inflammation", "OBSERVATION", 255, 267], ["Injury", "OBSERVATION", 272, 278], ["RV", "ANATOMY", 318, 320], ["infection", "OBSERVATION", 321, 330], ["infiltrating", "OBSERVATION_MODIFIER", 343, 355], ["antigenspecific T lymphocytes", "OBSERVATION", 356, 385], ["humoral immunity", "OBSERVATION", 390, 406]]], ["These adaptive immune components gain access to the RT several days post infection and typically are associated with RV clearance.", [["RV", "ANATOMY", 117, 119], ["infection", "DISEASE", 73, 82], ["RV", "ORGAN", 117, 119], ["These adaptive immune components", "TREATMENT", 0, 32], ["the RT", "TREATMENT", 48, 54], ["infection", "PROBLEM", 73, 82], ["RV clearance", "PROBLEM", 117, 129], ["infection", "OBSERVATION", 73, 82]]], ["As with innate immune cell types, T lymphocytes employ a variety of soluble and cellassociated mediators that contribute to RV elimination and inflammation (see Table 2 ).", [["immune cell", "ANATOMY", 15, 26], ["T lymphocytes", "ANATOMY", 34, 47], ["RV", "ANATOMY", 124, 126], ["inflammation", "DISEASE", 143, 155], ["innate immune cell", "CELL", 8, 26], ["T lymphocytes", "CELL", 34, 47], ["RV", "MULTI-TISSUE_STRUCTURE", 124, 126], ["T lymphocytes", "CELL_TYPE", 34, 47], ["innate immune cell types", "TREATMENT", 8, 32], ["T lymphocytes", "PROBLEM", 34, 47], ["soluble and cellassociated mediators", "TREATMENT", 68, 104], ["RV elimination", "PROBLEM", 124, 138], ["inflammation", "PROBLEM", 143, 155], ["immune cell types", "OBSERVATION", 15, 32], ["RV", "ANATOMY", 124, 126], ["inflammation", "OBSERVATION", 143, 155]]], ["CD8 + T lymphocytes, and to a lesser extent CD4 + T lymphocytes, employ cell-associated mediators (e.g. perforin/granzyme, FasL) to trigger apoptosis in target cells [21, 37] .", [["CD8 + T lymphocytes", "ANATOMY", 0, 19], ["CD4 + T lymphocytes", "ANATOMY", 44, 63], ["cell", "ANATOMY", 72, 76], ["cells", "ANATOMY", 160, 165], ["CD8", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD4", "GENE_OR_GENE_PRODUCT", 44, 47], ["cell", "CELL", 72, 76], ["perforin", "GENE_OR_GENE_PRODUCT", 104, 112], ["granzyme", "GENE_OR_GENE_PRODUCT", 113, 121], ["FasL", "GENE_OR_GENE_PRODUCT", 123, 127], ["cells", "CELL", 160, 165], ["CD8", "PROTEIN", 0, 3], ["T lymphocytes", "CELL_TYPE", 6, 19], ["CD4", "PROTEIN", 44, 47], ["T lymphocytes", "CELL_TYPE", 50, 63], ["cell-associated mediators", "PROTEIN", 72, 97], ["perforin", "PROTEIN", 104, 112], ["granzyme", "PROTEIN", 113, 121], ["FasL", "PROTEIN", 123, 127], ["target cells", "CELL_TYPE", 153, 165], ["CD8", "TEST", 0, 3], ["lymphocytes", "TEST", 8, 19], ["cell", "TEST", 72, 76], ["perforin/granzyme", "TREATMENT", 104, 121], ["apoptosis in target cells", "PROBLEM", 140, 165], ["T lymphocytes", "OBSERVATION", 6, 19], ["lesser", "OBSERVATION_MODIFIER", 30, 36], ["extent", "OBSERVATION_MODIFIER", 37, 43], ["CD4 + T lymphocytes", "OBSERVATION", 44, 63]]], ["Since cytolysis induction requires engagement of the T lymphocyte antigen receptor by the viral peptide/MHC molecule complexes, T cell-mediated apoptosis is largely limited to the RVinfected cells.", [["T lymphocyte", "ANATOMY", 53, 65], ["T cell", "ANATOMY", 128, 134], ["cells", "ANATOMY", 191, 196], ["T lymphocyte antigen receptor", "GENE_OR_GENE_PRODUCT", 53, 82], ["T cell", "CELL", 128, 134], ["RVinfected cells", "CELL", 180, 196], ["T lymphocyte antigen receptor", "PROTEIN", 53, 82], ["MHC molecule complexes", "PROTEIN", 104, 126], ["RVinfected cells", "CELL_LINE", 180, 196], ["cytolysis induction", "TREATMENT", 6, 25], ["the T lymphocyte antigen receptor", "TEST", 49, 82], ["the viral peptide/MHC molecule complexes", "TEST", 86, 126], ["T cell-mediated apoptosis", "PROBLEM", 128, 153]]], ["With one notable exception [38] , T lymphocyte mediated cytolysis is considered to play a minor role in the development of tissue injury produced by adaptive immune cells during RV infection [39, 40] .", [["T lymphocyte", "ANATOMY", 34, 46], ["tissue", "ANATOMY", 123, 129], ["immune cells", "ANATOMY", 158, 170], ["RV", "ANATOMY", 178, 180], ["tissue injury", "DISEASE", 123, 136], ["RV infection", "DISEASE", 178, 190], ["T lymphocyte", "CELL", 34, 46], ["tissue", "TISSUE", 123, 129], ["immune cells", "CELL", 158, 170], ["RV", "ORGAN", 178, 180], ["T lymphocyte", "CELL_TYPE", 34, 46], ["adaptive immune cells", "CELL_TYPE", 149, 170], ["RV", "SPECIES", 178, 180], ["T lymphocyte mediated cytolysis", "PROBLEM", 34, 65], ["tissue injury", "PROBLEM", 123, 136], ["adaptive immune cells", "TREATMENT", 149, 170], ["RV infection", "PROBLEM", 178, 190], ["notable", "OBSERVATION_MODIFIER", 9, 16], ["tissue", "ANATOMY", 123, 129], ["injury", "OBSERVATION", 130, 136], ["infection", "OBSERVATION", 181, 190]]], ["In contrast, T cell derived soluble inflammatory mediators (e.g. TNF, MIP-1a, IFNy) can damage un-infected cells within the respiratory tract and augment the infiltration of injury-promoting innate immune cells.", [["T cell", "ANATOMY", 13, 19], ["cells", "ANATOMY", 107, 112], ["respiratory tract", "ANATOMY", 124, 141], ["immune cells", "ANATOMY", 198, 210], ["T cell", "CELL", 13, 19], ["TNF", "GENE_OR_GENE_PRODUCT", 65, 68], ["MIP-1a", "GENE_OR_GENE_PRODUCT", 70, 76], ["IFNy", "GENE_OR_GENE_PRODUCT", 78, 82], ["cells", "CELL", 107, 112], ["respiratory tract", "ORGANISM_SUBDIVISION", 124, 141], ["innate immune cells", "CELL", 191, 210], ["T cell", "CELL_TYPE", 13, 19], ["inflammatory mediators", "PROTEIN", 36, 58], ["TNF", "PROTEIN", 65, 68], ["MIP", "PROTEIN", 70, 73], ["IFNy", "PROTEIN", 78, 82], ["innate immune cells", "CELL_TYPE", 191, 210], ["T cell derived soluble inflammatory mediators", "PROBLEM", 13, 58], ["TNF", "TEST", 65, 68], ["MIP", "TEST", 70, 73], ["damage un-infected cells within the respiratory tract", "PROBLEM", 88, 141], ["the infiltration of injury", "PROBLEM", 154, 180], ["inflammatory", "OBSERVATION_MODIFIER", 36, 48], ["infected cells", "OBSERVATION", 98, 112], ["respiratory tract", "ANATOMY", 124, 141], ["infiltration", "OBSERVATION", 158, 170], ["injury", "OBSERVATION", 174, 180], ["innate immune cells", "OBSERVATION", 191, 210]]], ["The extent of this pro-inflammatory cytokine production may ultimately be determined by viral tropism of infiltrating CD45 + inflammatory cells.", [["infiltrating CD45 + inflammatory cells", "ANATOMY", 105, 143], ["CD45", "GENE_OR_GENE_PRODUCT", 118, 122], ["pro-inflammatory cytokine", "PROTEIN", 19, 44], ["CD45", "PROTEIN", 118, 122], ["inflammatory cells", "CELL_TYPE", 125, 143], ["this pro-inflammatory cytokine production", "PROBLEM", 14, 55], ["inflammatory cells", "PROBLEM", 125, 143], ["extent", "OBSERVATION_MODIFIER", 4, 10], ["pro-inflammatory cytokine", "OBSERVATION", 19, 44], ["infiltrating CD45", "OBSERVATION", 105, 122], ["inflammatory cells", "OBSERVATION", 125, 143]]], ["Our laboratory and others have recently noted that co-stimulation, along with antigen, is required to drive effector T cell pro-inflammatory cytokine responses and proliferation within the respiratory tract during IAV infections [20, 21, 41] .", [["T cell", "ANATOMY", 117, 123], ["respiratory tract", "ANATOMY", 189, 206], ["IAV infections", "DISEASE", 214, 228], ["T cell", "CELL", 117, 123], ["respiratory tract", "ORGANISM_SUBDIVISION", 189, 206], ["cytokine", "PROTEIN", 141, 149], ["IAV", "SPECIES", 214, 217], ["co-stimulation", "PROBLEM", 51, 65], ["effector T cell pro-inflammatory cytokine responses", "TREATMENT", 108, 159], ["proliferation within the respiratory tract", "PROBLEM", 164, 206], ["IAV infections", "PROBLEM", 214, 228], ["respiratory tract", "ANATOMY", 189, 206]]], ["Because co-stimulatory molecule expression is principally limited to hematopoietic cells, the ability of a particular RV to infect these recruited CD45 + inflammatory cells may be an important factor in determining the extent of adaptive immune mediated tissue damage during RV infection.Factors Regulating Pulmonary InflammationThe factors controlling the extent of pulmonary inflammation during RV infection have been recently reviewed [42, 43] .", [["hematopoietic cells", "ANATOMY", 69, 88], ["CD45 + inflammatory cells", "ANATOMY", 147, 172], ["tissue", "ANATOMY", 254, 260], ["RV", "ANATOMY", 275, 277], ["Pulmonary", "ANATOMY", 307, 316], ["pulmonary", "ANATOMY", 367, 376], ["RV infection", "DISEASE", 275, 287], ["Pulmonary Inflammation", "DISEASE", 307, 329], ["pulmonary inflammation", "DISEASE", 367, 389], ["RV infection", "DISEASE", 397, 409], ["hematopoietic cells", "CELL", 69, 88], ["CD45", "GENE_OR_GENE_PRODUCT", 147, 151], ["tissue", "TISSUE", 254, 260], ["RV", "ORGAN", 275, 277], ["Pulmonary", "ORGAN", 307, 316], ["pulmonary", "ORGAN", 367, 376], ["hematopoietic cells", "CELL_TYPE", 69, 88], ["CD45", "PROTEIN", 147, 151], ["inflammatory cells", "CELL_TYPE", 154, 172], ["RV", "SPECIES", 275, 277], ["co-stimulatory molecule expression", "PROBLEM", 8, 42], ["hematopoietic cells", "PROBLEM", 69, 88], ["inflammatory cells", "PROBLEM", 154, 172], ["adaptive immune mediated tissue damage", "PROBLEM", 229, 267], ["RV infection", "PROBLEM", 275, 287], ["Pulmonary Inflammation", "PROBLEM", 307, 329], ["pulmonary inflammation", "PROBLEM", 367, 389], ["RV infection", "PROBLEM", 397, 409], ["hematopoietic cells", "OBSERVATION", 69, 88], ["inflammatory cells", "OBSERVATION", 154, 172], ["RV", "ANATOMY", 275, 277], ["infection", "OBSERVATION", 278, 287], ["Pulmonary", "ANATOMY", 307, 316], ["Inflammation", "OBSERVATION", 317, 329], ["pulmonary", "ANATOMY", 367, 376], ["inflammation", "OBSERVATION", 377, 389], ["RV", "ANATOMY", 397, 399], ["infection", "OBSERVATION", 400, 409]]], ["For adaptive immune cells, it is the encounter of the antigen receptor with its target viral antigen that ultimately controls the number and function of these cells.", [["immune cells", "ANATOMY", 13, 25], ["cells", "ANATOMY", 159, 164], ["immune cells", "CELL", 13, 25], ["cells", "CELL", 159, 164], ["adaptive immune cells", "CELL_TYPE", 4, 25], ["antigen receptor", "PROTEIN", 54, 70], ["viral antigen", "PROTEIN", 87, 100], ["adaptive immune cells", "TREATMENT", 4, 25], ["the antigen receptor", "TREATMENT", 50, 70], ["its target viral antigen", "PROBLEM", 76, 100], ["immune cells", "OBSERVATION", 13, 25]]], ["Likewise for innate immune cells, it is the presence of mediators produced by responding adaptive cells and/or engagement of intracellular sensors within innate immune cells in the infected RT by viral PAMPs that regulates the response of these effector cells.", [["immune cells", "ANATOMY", 20, 32], ["cells", "ANATOMY", 98, 103], ["intracellular", "ANATOMY", 125, 138], ["immune cells", "ANATOMY", 161, 173], ["cells", "ANATOMY", 254, 259], ["innate immune cells", "CELL", 13, 32], ["cells", "CELL", 98, 103], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 125, 138], ["innate immune cells", "CELL", 154, 173], ["cells", "CELL", 254, 259], ["innate immune cells", "CELL_TYPE", 13, 32], ["adaptive cells", "CELL_TYPE", 89, 103], ["innate immune cells", "CELL_TYPE", 154, 173], ["viral PAMPs", "PROTEIN", 196, 207], ["effector cells", "CELL_TYPE", 245, 259], ["innate immune cells", "TREATMENT", 13, 32], ["responding adaptive cells", "PROBLEM", 78, 103], ["intracellular sensors", "PROBLEM", 125, 146], ["innate immune cells", "TREATMENT", 154, 173], ["viral PAMPs", "PROBLEM", 196, 207], ["immune cells", "OBSERVATION", 20, 32], ["adaptive cells", "OBSERVATION", 89, 103], ["viral PAMPs", "OBSERVATION", 196, 207], ["effector cells", "OBSERVATION", 245, 259]]], ["Therefore, it is the cessation of virus replication and the elimination of viral antigen that is the primary factor controlling both host and virus induced injury and inflammation.", [["inflammation", "DISEASE", 167, 179], ["viral antigen", "PROTEIN", 75, 88], ["virus replication", "TREATMENT", 34, 51], ["viral antigen", "PROBLEM", 75, 88], ["virus induced injury", "PROBLEM", 142, 162], ["inflammation", "PROBLEM", 167, 179], ["inflammation", "OBSERVATION", 167, 179]]], ["Furthermore, the down-regulation of co-stimulatory receptors/ligands on immune cells and the up-regulation of inhibitory receptors (e.g. NKG2A, CD200R) and their ligands on CD45 + immune cells (and in some cases CD45 \u2212 REC) may be important factors in controlling excess inflammation during respiratory viral infections [44] [45] [46] .Factors Regulating Pulmonary InflammationThere is also important regulatory elements within the immune response that dampen ongoing inflammation during RV infection.", [["immune cells", "ANATOMY", 72, 84], ["CD45 + immune cells", "ANATOMY", 173, 192], ["Pulmonary", "ANATOMY", 355, 364], ["RV", "ANATOMY", 488, 490], ["inflammation", "DISEASE", 271, 283], ["respiratory viral infections", "DISEASE", 291, 319], ["Pulmonary Inflammation", "DISEASE", 355, 377], ["inflammation", "DISEASE", 468, 480], ["RV infection", "DISEASE", 488, 500], ["immune cells", "CELL", 72, 84], ["NKG2A", "GENE_OR_GENE_PRODUCT", 137, 142], ["CD200R", "GENE_OR_GENE_PRODUCT", 144, 150], ["CD45", "GENE_OR_GENE_PRODUCT", 173, 177], ["CD45", "GENE_OR_GENE_PRODUCT", 212, 216], ["Pulmonary", "ORGAN", 355, 364], ["RV", "ORGAN", 488, 490], ["co-stimulatory receptors", "PROTEIN", 36, 60], ["immune cells", "CELL_TYPE", 72, 84], ["inhibitory receptors", "PROTEIN", 110, 130], ["NKG2A", "PROTEIN", 137, 142], ["CD200R", "PROTEIN", 144, 150], ["CD45", "PROTEIN", 173, 177], ["immune cells", "CELL_TYPE", 180, 192], ["CD45", "PROTEIN", 212, 216], ["regulatory elements", "DNA", 401, 420], ["RV", "SPECIES", 488, 490], ["co-stimulatory receptors/ligands", "TREATMENT", 36, 68], ["immune cells", "TREATMENT", 72, 84], ["inhibitory receptors", "TEST", 110, 130], ["NKG2A", "TEST", 137, 142], ["CD200R", "TEST", 144, 150], ["CD45", "TEST", 173, 177], ["immune cells", "PROBLEM", 180, 192], ["excess inflammation", "PROBLEM", 264, 283], ["respiratory viral infections", "PROBLEM", 291, 319], ["Pulmonary Inflammation", "PROBLEM", 355, 377], ["dampen ongoing inflammation", "PROBLEM", 453, 480], ["RV infection", "PROBLEM", 488, 500], ["immune cells", "OBSERVATION", 180, 192], ["Pulmonary", "ANATOMY", 355, 364], ["Inflammation", "OBSERVATION", 365, 377], ["regulatory elements", "OBSERVATION", 401, 420], ["immune response", "OBSERVATION", 432, 447], ["dampen", "OBSERVATION_MODIFIER", 453, 459], ["ongoing", "OBSERVATION_MODIFIER", 460, 467], ["inflammation", "OBSERVATION", 468, 480], ["RV", "ANATOMY", 488, 490], ["infection", "OBSERVATION", 491, 500]]], ["First, a number of regulatory cytokines are produced to attenuate an inflammatory response.", [["regulatory cytokines", "PROTEIN", 19, 39], ["an inflammatory response", "PROBLEM", 66, 90], ["cytokines", "OBSERVATION", 30, 39], ["inflammatory", "OBSERVATION", 69, 81]]], ["Effector T lymphocytes, in conjunction with their production of pro-inflammatory cytokines, have been noted to produce high levels of the regulatory cytokine IL-10 during IAV and RSV infections [47] [48] [49] .", [["T lymphocytes", "ANATOMY", 9, 22], ["RSV infections", "DISEASE", 179, 193], ["Effector T lymphocytes", "CELL", 0, 22], ["IL-10", "GENE_OR_GENE_PRODUCT", 158, 163], ["IAV", "ORGANISM", 171, 174], ["RSV", "ORGANISM", 179, 182], ["Effector T lymphocytes", "CELL_TYPE", 0, 22], ["pro-inflammatory cytokines", "PROTEIN", 64, 90], ["regulatory cytokine IL-10", "PROTEIN", 138, 163], ["IAV", "SPECIES", 171, 174], ["RSV", "SPECIES", 179, 182], ["Effector T lymphocytes", "PROBLEM", 0, 22], ["pro-inflammatory cytokines", "PROBLEM", 64, 90], ["the regulatory cytokine IL", "TREATMENT", 134, 160], ["RSV infections", "PROBLEM", 179, 193], ["pro-inflammatory cytokines", "OBSERVATION", 64, 90]]], ["Blockade of IL-10 signaling during the effector T cell phase of influenza infection increases pro-inflammatory cytokine production and mortality [48] .", [["T cell", "ANATOMY", 48, 54], ["influenza infection", "DISEASE", 64, 83], ["IL-10", "GENE_OR_GENE_PRODUCT", 12, 17], ["T cell", "CELL", 48, 54], ["influenza", "ORGANISM", 64, 73], ["IL-10", "PROTEIN", 12, 17], ["pro-inflammatory cytokine", "PROTEIN", 94, 119], ["Blockade of IL", "TREATMENT", 0, 14], ["influenza infection", "PROBLEM", 64, 83], ["pro-inflammatory cytokine production", "PROBLEM", 94, 130], ["influenza", "OBSERVATION_MODIFIER", 64, 73], ["infection", "OBSERVATION", 74, 83]]], ["In addition, release of active TGF-\u03b2 can reduce inflammation and increase survival during RV infection [50, 51] .", [["RV", "ANATOMY", 90, 92], ["inflammation", "DISEASE", 48, 60], ["RV infection", "DISEASE", 90, 102], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 31, 36], ["RV", "ORGAN", 90, 92], ["TGF-\u03b2", "PROTEIN", 31, 36], ["RV", "SPECIES", 90, 92], ["active TGF", "TREATMENT", 24, 34], ["inflammation", "PROBLEM", 48, 60], ["increase survival during RV infection", "PROBLEM", 65, 102], ["active", "OBSERVATION_MODIFIER", 24, 30], ["TGF", "OBSERVATION", 31, 34], ["increase", "OBSERVATION_MODIFIER", 65, 73], ["survival", "OBSERVATION_MODIFIER", 74, 82], ["RV", "ANATOMY", 90, 92], ["infection", "OBSERVATION", 93, 102]]], ["As an another facet for inflammation resolution, Foxp3 + regulatory T (Treg) cells can dampen anti-viral responses, notably in RSV and IAV infections, by regulating the extent of adaptive immune responses within the RT [52] [53] [54] [55] [56] .", [["Foxp3 + regulatory T (Treg) cells", "ANATOMY", 49, 82], ["inflammation", "DISEASE", 24, 36], ["infections", "DISEASE", 139, 149], ["RT [52] [53] [54] [55]", "CHEMICAL", 216, 238], ["Foxp3", "GENE_OR_GENE_PRODUCT", 49, 54], ["RSV", "ORGANISM", 127, 130], ["IAV", "ORGANISM", 135, 138], ["Foxp3", "PROTEIN", 49, 54], ["regulatory T (Treg) cells", "CELL_TYPE", 57, 82], ["RSV", "SPECIES", 127, 130], ["IAV", "SPECIES", 135, 138], ["inflammation resolution", "PROBLEM", 24, 47], ["Foxp3 + regulatory T (Treg) cells", "TREATMENT", 49, 82], ["anti-viral responses", "TEST", 94, 114], ["RSV", "PROBLEM", 127, 130], ["IAV infections", "PROBLEM", 135, 149], ["inflammation", "OBSERVATION", 24, 36], ["RSV", "OBSERVATION", 127, 130], ["IAV infections", "OBSERVATION", 135, 149]]], ["Thus, regulatory elements within the anti-viral immune response and eventual viral clearance ultimately curtail the extent of pulmonary inflammation.", [["pulmonary", "ANATOMY", 126, 135], ["pulmonary inflammation", "DISEASE", 126, 148], ["pulmonary", "ORGAN", 126, 135], ["regulatory elements", "DNA", 6, 25], ["the anti-viral immune response", "TREATMENT", 33, 63], ["eventual viral clearance", "TEST", 68, 92], ["pulmonary inflammation", "PROBLEM", 126, 148], ["extent", "OBSERVATION_MODIFIER", 116, 122], ["pulmonary", "ANATOMY", 126, 135], ["inflammation", "OBSERVATION", 136, 148]]], ["The subsequent steps of repairing and re-modeling the RT following RV infections, however, are not as fully understood and appreciated.Re-establishing the Epithelial Barrier and Maintaining Barrier IntegrityA hallmark of RV infection is replication of virus in and the subsequent destruction of the airway epithelium.", [["Epithelial", "ANATOMY", 155, 165], ["airway epithelium", "ANATOMY", 299, 316], ["RV infections", "DISEASE", 67, 80], ["RV infection", "DISEASE", 221, 233], ["Epithelial Barrier", "TISSUE", 155, 173], ["RV", "ORGAN", 221, 223], ["airway epithelium", "TISSUE", 299, 316], ["repairing", "TREATMENT", 24, 33], ["RV infections", "PROBLEM", 67, 80], ["the Epithelial Barrier", "TREATMENT", 151, 173], ["Barrier IntegrityA", "TREATMENT", 190, 208], ["RV infection", "PROBLEM", 221, 233], ["virus", "PROBLEM", 252, 257], ["the subsequent destruction of the airway epithelium", "PROBLEM", 265, 316], ["RV", "ANATOMY", 67, 69], ["infections", "OBSERVATION", 70, 80], ["Epithelial Barrier", "OBSERVATION", 155, 173], ["Barrier IntegrityA", "OBSERVATION_MODIFIER", 190, 208], ["RV", "ANATOMY", 221, 223], ["infection", "OBSERVATION", 224, 233], ["virus", "OBSERVATION", 252, 257], ["destruction", "OBSERVATION", 280, 291], ["airway", "ANATOMY", 299, 305], ["epithelium", "ANATOMY_MODIFIER", 306, 316]]], ["Therefore, by necessity, the repair of the epithelium is essential for recovery.", [["epithelium", "ANATOMY", 43, 53], ["epithelium", "TISSUE", 43, 53], ["the repair of the epithelium", "TREATMENT", 25, 53], ["repair", "OBSERVATION", 29, 35], ["epithelium", "ANATOMY_MODIFIER", 43, 53]]], ["The stages of airway repair have been studied in great detail for a variety of chemically-induced injury models [57, 58] ; however, the unique set of conditions imposed by RV infection (e.g. viral load and the tropism of a given RV for a particular RT cell type) can potentially modify the repair process in ways that are not well understood.", [["airway", "ANATOMY", 14, 20], ["cell", "ANATOMY", 252, 256], ["RV infection", "DISEASE", 172, 184], ["airway", "MULTI-TISSUE_STRUCTURE", 14, 20], ["RV", "ORGANISM", 172, 174], ["cell type", "CELL", 252, 261], ["airway repair", "TREATMENT", 14, 27], ["chemically-induced injury models", "PROBLEM", 79, 111], ["RV infection", "PROBLEM", 172, 184], ["viral load", "PROBLEM", 191, 201], ["a particular RT cell type", "TREATMENT", 236, 261], ["the repair process", "TREATMENT", 286, 304], ["airway", "ANATOMY", 14, 20], ["repair", "OBSERVATION", 21, 27], ["RV", "ANATOMY", 172, 174], ["infection", "OBSERVATION", 175, 184], ["repair", "OBSERVATION", 290, 296]]], ["New research has highlighted the importance of initiating and maintaining a proper repair response during and following respiratory virus infection and has demonstrated a renewed interested in an active repair process, rather than simply a passive dampening of inflammation.Re-establishing the Epithelial Barrier and Maintaining Barrier IntegrityRV infection, including IAV and SARS-CoV, results in large numbers of apoptotic and necrotic epithelial cells, leaving denuded basement membranes of the upper and/or lower airways.", [["Epithelial", "ANATOMY", 294, 304], ["necrotic epithelial cells", "ANATOMY", 430, 455], ["basement membranes", "ANATOMY", 473, 491], ["upper", "ANATOMY", 499, 504], ["lower airways", "ANATOMY", 512, 525], ["respiratory virus infection", "DISEASE", 120, 147], ["inflammation", "DISEASE", 261, 273], ["infection", "DISEASE", 349, 358], ["necrotic", "DISEASE", 430, 438], ["respiratory virus", "ORGANISM", 120, 137], ["Epithelial Barrier", "TISSUE", 294, 312], ["IAV", "ORGANISM", 370, 373], ["SARS-CoV", "ORGANISM", 378, 386], ["necrotic epithelial cells", "CELL", 430, 455], ["basement membranes", "CELLULAR_COMPONENT", 473, 491], ["upper", "ORGANISM_SUBDIVISION", 499, 504], ["lower airways", "MULTI-TISSUE_STRUCTURE", 512, 525], ["apoptotic and necrotic epithelial cells", "CELL_TYPE", 416, 455], ["IAV", "SPECIES", 370, 373], ["SARS-CoV", "SPECIES", 378, 386], ["a proper repair response", "TREATMENT", 74, 98], ["respiratory virus infection", "PROBLEM", 120, 147], ["an active repair process", "TREATMENT", 193, 217], ["a passive dampening of inflammation", "PROBLEM", 238, 273], ["the Epithelial Barrier", "TREATMENT", 290, 312], ["Barrier IntegrityRV infection", "TREATMENT", 329, 358], ["IAV", "PROBLEM", 370, 373], ["apoptotic and necrotic epithelial cells", "PROBLEM", 416, 455], ["active", "OBSERVATION_MODIFIER", 196, 202], ["repair", "OBSERVATION", 203, 209], ["passive", "OBSERVATION_MODIFIER", 240, 247], ["dampening", "OBSERVATION_MODIFIER", 248, 257], ["inflammation", "OBSERVATION", 261, 273], ["Epithelial Barrier", "OBSERVATION", 294, 312], ["Barrier IntegrityRV", "OBSERVATION_MODIFIER", 329, 348], ["infection", "OBSERVATION", 349, 358], ["large", "OBSERVATION_MODIFIER", 399, 404], ["numbers", "OBSERVATION_MODIFIER", 405, 412], ["apoptotic", "OBSERVATION_MODIFIER", 416, 425], ["necrotic epithelial cells", "OBSERVATION", 430, 455], ["denuded", "OBSERVATION_MODIFIER", 465, 472], ["basement membranes", "OBSERVATION", 473, 491], ["upper", "ANATOMY_MODIFIER", 499, 504], ["lower", "ANATOMY_MODIFIER", 512, 517], ["airways", "ANATOMY", 518, 525]]], ["In addition to virus-induced cell death, infiltrating leukocytes secrete large quantities of matrix metalloproteinases (MMP) that damage and degrade the basement membranes of the endothelium and epithelium, which results in the loss of the microarchitecture of the conducting airways and alveoli.", [["cell", "ANATOMY", 29, 33], ["infiltrating leukocytes", "ANATOMY", 41, 64], ["basement membranes", "ANATOMY", 153, 171], ["endothelium", "ANATOMY", 179, 190], ["epithelium", "ANATOMY", 195, 205], ["airways", "ANATOMY", 276, 283], ["alveoli", "ANATOMY", 288, 295], ["death", "DISEASE", 34, 39], ["cell", "CELL", 29, 33], ["leukocytes", "CELL", 54, 64], ["matrix metalloproteinases", "GENE_OR_GENE_PRODUCT", 93, 118], ["MMP", "GENE_OR_GENE_PRODUCT", 120, 123], ["basement membranes", "CELLULAR_COMPONENT", 153, 171], ["endothelium", "TISSUE", 179, 190], ["epithelium", "TISSUE", 195, 205], ["airways", "MULTI-TISSUE_STRUCTURE", 276, 283], ["alveoli", "MULTI-TISSUE_STRUCTURE", 288, 295], ["infiltrating leukocytes", "CELL_TYPE", 41, 64], ["matrix metalloproteinases", "PROTEIN", 93, 118], ["MMP", "PROTEIN", 120, 123], ["virus", "PROBLEM", 15, 20], ["cell death", "PROBLEM", 29, 39], ["infiltrating leukocytes", "PROBLEM", 41, 64], ["matrix metalloproteinases", "PROBLEM", 93, 118], ["damage", "PROBLEM", 130, 136], ["the loss of the microarchitecture", "PROBLEM", 224, 257], ["virus", "OBSERVATION", 15, 20], ["cell death", "OBSERVATION", 29, 39], ["infiltrating", "OBSERVATION_MODIFIER", 41, 53], ["large", "OBSERVATION_MODIFIER", 73, 78], ["quantities", "OBSERVATION_MODIFIER", 79, 89], ["matrix metalloproteinases", "OBSERVATION", 93, 118], ["basement membranes", "OBSERVATION_MODIFIER", 153, 171], ["endothelium", "ANATOMY", 179, 190], ["epithelium", "ANATOMY_MODIFIER", 195, 205], ["loss", "OBSERVATION_MODIFIER", 228, 232], ["microarchitecture", "OBSERVATION", 240, 257], ["airways", "ANATOMY", 276, 283], ["alveoli", "ANATOMY_MODIFIER", 288, 295]]], ["Therefore, the lung must initiate a robust repair response to reconstitute the extracellular matrix, return to homeostasis, and rebuild barrier function.", [["lung", "ANATOMY", 15, 19], ["extracellular matrix", "ANATOMY", 79, 99], ["barrier", "ANATOMY", 136, 143], ["lung", "ORGAN", 15, 19], ["extracellular matrix", "CELLULAR_COMPONENT", 79, 99], ["barrier", "TISSUE", 136, 143], ["a robust repair", "TREATMENT", 34, 49], ["lung", "ANATOMY", 15, 19]]], ["Furthermore, impaired repair processes in the RV-infected lung may also enhance susceptibility to secondary microbial infection.Re-establishing the Epithelial Barrier and Maintaining Barrier IntegrityThe restoration of the respiratory epithelium following injury can be divided into three sequential stages: provisional matrix deposition, epithelial proliferation, and epithelial differentiation.", [["RV", "ANATOMY", 46, 48], ["lung", "ANATOMY", 58, 62], ["Epithelial", "ANATOMY", 148, 158], ["respiratory epithelium", "ANATOMY", 223, 245], ["matrix", "ANATOMY", 320, 326], ["epithelial", "ANATOMY", 339, 349], ["epithelial", "ANATOMY", 369, 379], ["microbial infection", "DISEASE", 108, 127], ["RV", "ORGAN", 46, 48], ["lung", "ORGAN", 58, 62], ["Epithelial Barrier", "TISSUE", 148, 166], ["respiratory epithelium", "TISSUE", 223, 245], ["matrix", "CELLULAR_COMPONENT", 320, 326], ["epithelial", "TISSUE", 339, 349], ["epithelial", "TISSUE", 369, 379], ["impaired repair processes", "PROBLEM", 13, 38], ["infected lung", "PROBLEM", 49, 62], ["secondary microbial infection", "PROBLEM", 98, 127], ["the Epithelial Barrier", "TREATMENT", 144, 166], ["Barrier Integrity", "TREATMENT", 183, 200], ["the respiratory epithelium", "PROBLEM", 219, 245], ["injury", "PROBLEM", 256, 262], ["provisional matrix deposition", "PROBLEM", 308, 337], ["epithelial proliferation", "PROBLEM", 339, 363], ["epithelial differentiation", "PROBLEM", 369, 395], ["impaired", "OBSERVATION_MODIFIER", 13, 21], ["repair", "OBSERVATION", 22, 28], ["RV", "ANATOMY", 46, 48], ["infected", "OBSERVATION", 49, 57], ["lung", "ANATOMY", 58, 62], ["secondary", "OBSERVATION_MODIFIER", 98, 107], ["microbial", "OBSERVATION_MODIFIER", 108, 117], ["infection", "OBSERVATION", 118, 127], ["Epithelial Barrier", "OBSERVATION", 148, 166], ["Barrier Integrity", "OBSERVATION_MODIFIER", 183, 200], ["restoration", "OBSERVATION_MODIFIER", 204, 215], ["respiratory epithelium", "OBSERVATION", 223, 245], ["matrix deposition", "OBSERVATION", 320, 337], ["epithelial proliferation", "OBSERVATION", 339, 363], ["epithelial differentiation", "OBSERVATION", 369, 395]]], ["In order for new epithelial cells to regenerate, fibroblasts and epithelial cells surrounding the infected foci secrete a provisional matrix made predominantly of the structural protein fibronectin [59] .", [["epithelial cells", "ANATOMY", 17, 33], ["fibroblasts", "ANATOMY", 49, 60], ["epithelial cells", "ANATOMY", 65, 81], ["foci", "ANATOMY", 107, 111], ["matrix", "ANATOMY", 134, 140], ["epithelial cells", "CELL", 17, 33], ["fibroblasts", "CELL", 49, 60], ["epithelial cells", "CELL", 65, 81], ["foci", "CELL", 107, 111], ["matrix", "CELLULAR_COMPONENT", 134, 140], ["fibronectin", "GENE_OR_GENE_PRODUCT", 186, 197], ["epithelial cells", "CELL_TYPE", 17, 33], ["fibroblasts", "CELL_TYPE", 49, 60], ["epithelial cells", "CELL_TYPE", 65, 81], ["structural protein", "PROTEIN", 167, 185], ["fibronectin", "PROTEIN", 186, 197], ["new epithelial cells", "PROBLEM", 13, 33], ["fibroblasts", "PROBLEM", 49, 60], ["epithelial cells", "PROBLEM", 65, 81], ["the infected foci", "PROBLEM", 94, 111], ["the structural protein fibronectin", "TEST", 163, 197], ["epithelial cells", "OBSERVATION", 17, 33], ["epithelial cells", "OBSERVATION", 65, 81], ["infected", "OBSERVATION_MODIFIER", 98, 106], ["foci", "OBSERVATION", 107, 111], ["provisional matrix", "OBSERVATION_MODIFIER", 122, 140]]], ["TGF\u03b2, another potent stimulator of the fibro-proliferative response, is released by virally infected epithelial cells [60] , which can subsequently stimulate secretion of provisional matrix proteins from fibroblasts and other nonhematopoietic cell types.", [["epithelial cells", "ANATOMY", 101, 117], ["matrix", "ANATOMY", 183, 189], ["fibroblasts", "ANATOMY", 204, 215], ["nonhematopoietic cell", "ANATOMY", 226, 247], ["TGF\u03b2", "GENE_OR_GENE_PRODUCT", 0, 4], ["epithelial cells", "CELL", 101, 117], ["matrix", "CELLULAR_COMPONENT", 183, 189], ["fibroblasts", "CELL", 204, 215], ["nonhematopoietic cell", "CELL", 226, 247], ["TGF\u03b2", "PROTEIN", 0, 4], ["virally infected epithelial cells", "CELL_TYPE", 84, 117], ["provisional matrix proteins", "PROTEIN", 171, 198], ["fibroblasts", "CELL_TYPE", 204, 215], ["nonhematopoietic cell types", "CELL_TYPE", 226, 253], ["TGF", "TEST", 0, 3], ["virally infected epithelial cells", "PROBLEM", 84, 117], ["provisional matrix proteins", "PROBLEM", 171, 198], ["fibroblasts", "PROBLEM", 204, 215], ["other nonhematopoietic cell types", "PROBLEM", 220, 253], ["proliferative response", "OBSERVATION", 45, 67], ["epithelial cells", "OBSERVATION", 101, 117], ["nonhematopoietic cell types", "OBSERVATION", 226, 253]]], ["Upon completion, the newly formed extracellular matrix can provide a platform for epithelial progenitor cells to proliferate and give rise to new epithelial cells that can regenerate those lost to infection.", [["extracellular matrix", "ANATOMY", 34, 54], ["epithelial progenitor cells", "ANATOMY", 82, 109], ["epithelial cells", "ANATOMY", 146, 162], ["infection", "DISEASE", 197, 206], ["extracellular matrix", "CELLULAR_COMPONENT", 34, 54], ["epithelial progenitor cells", "CELL", 82, 109], ["epithelial cells", "CELL", 146, 162], ["epithelial progenitor cells", "CELL_TYPE", 82, 109], ["epithelial cells", "CELL_TYPE", 146, 162], ["the newly formed extracellular matrix", "PROBLEM", 17, 54], ["epithelial progenitor cells", "TREATMENT", 82, 109], ["new epithelial cells", "PROBLEM", 142, 162], ["infection", "PROBLEM", 197, 206], ["extracellular matrix", "OBSERVATION", 34, 54], ["epithelial cells", "OBSERVATION", 146, 162], ["infection", "OBSERVATION", 197, 206]]], ["A myriad of factors regulate pulmonary epithelial proliferation, most notably TGF\u03b2 [58] .", [["pulmonary epithelial", "ANATOMY", 29, 49], ["pulmonary epithelial", "CELL", 29, 49], ["TGF\u03b2 [58]", "GENE_OR_GENE_PRODUCT", 78, 87], ["TGF\u03b2", "PROTEIN", 78, 82], ["pulmonary epithelial proliferation", "PROBLEM", 29, 63], ["pulmonary", "ANATOMY", 29, 38], ["epithelial proliferation", "OBSERVATION", 39, 63]]], ["It was recently found that the transcription factor Elf3 is an upstream inducer of TGF\u03b2II receptor expression and important for bronchiolar airway cell proliferation [61] .", [["bronchiolar airway cell", "ANATOMY", 128, 151], ["Elf3", "GENE_OR_GENE_PRODUCT", 52, 56], ["TGF\u03b2II receptor", "GENE_OR_GENE_PRODUCT", 83, 98], ["bronchiolar airway cell", "CELL", 128, 151], ["transcription factor", "PROTEIN", 31, 51], ["Elf3", "PROTEIN", 52, 56], ["TGF\u03b2II receptor", "PROTEIN", 83, 98], ["bronchiolar airway cell proliferation", "PROBLEM", 128, 165], ["important for", "UNCERTAINTY", 114, 127], ["bronchiolar airway cell proliferation", "OBSERVATION", 128, 165]]], ["Finally, once the cells have proliferated to cover the denuded areas, they then receive signals (e.g. Notch-and Smad-dependent signaling) to differentiate into the specific cell types found within the airways [62] [63] [64] .", [["cells", "ANATOMY", 18, 23], ["cell", "ANATOMY", 173, 177], ["airways", "ANATOMY", 201, 208], ["cells", "CELL", 18, 23], ["Notch", "GENE_OR_GENE_PRODUCT", 102, 107], ["Smad", "GENE_OR_GENE_PRODUCT", 112, 116], ["cell", "CELL", 173, 177], ["Smad", "PROTEIN", 112, 116], ["the denuded areas", "PROBLEM", 51, 68], ["Notch", "TEST", 102, 107], ["specific cell types", "OBSERVATION", 164, 183], ["airways", "ANATOMY", 201, 208]]], ["Thus, there are many pathways that converge to mount a proper repair response in the infected RT; however, emerging studies have highlighted the role of the innate immune system and distinct stem cell populations in this process.The Role of the Innate Immune System: The Second ActAlthough the innate immune system plays a clear role in the induction of inflammation and injury associated with RV infection during the acute phase, a number of studies have demonstrated the importance of innate immune cells, particularly of the newly described family of innate lymphoid cells, to the maintenance and regeneration of mucosal epithelia.The Role of the Innate Immune System: The Second ActLymphoid tissue inducer (LTi) cells, first described as CD3 \u2212 CD4 + lineage negative cells, are important for the development of lymphoid tissues via the production of lymphotoxins [65] [66] [67] .", [["immune system", "ANATOMY", 164, 177], ["stem cell", "ANATOMY", 191, 200], ["RV", "ANATOMY", 394, 396], ["immune cells", "ANATOMY", 494, 506], ["lymphoid cells", "ANATOMY", 561, 575], ["mucosal epithelia", "ANATOMY", 616, 633], ["ActLymphoid tissue inducer (LTi) cells", "ANATOMY", 683, 721], ["CD3 \u2212 CD4 + lineage negative cells", "ANATOMY", 742, 776], ["lymphoid tissues", "ANATOMY", 815, 831], ["inflammation", "DISEASE", 354, 366], ["RV infection", "DISEASE", 394, 406], ["stem cell populations", "CELL", 191, 212], ["innate immune cells", "CELL", 487, 506], ["innate lymphoid cells", "CELL", 554, 575], ["mucosal epithelia", "TISSUE", 616, 633], ["ActLymphoid tissue inducer (LTi) cells", "CELL", 683, 721], ["CD3", "GENE_OR_GENE_PRODUCT", 742, 745], ["CD4", "GENE_OR_GENE_PRODUCT", 748, 751], ["lymphoid tissues", "TISSUE", 815, 831], ["lymphotoxins", "GENE_OR_GENE_PRODUCT", 854, 866], ["stem cell populations", "CELL_TYPE", 191, 212], ["innate immune cells", "CELL_TYPE", 487, 506], ["innate lymphoid cells", "CELL_TYPE", 554, 575], ["Second ActLymphoid tissue inducer (LTi) cells", "CELL_LINE", 676, 721], ["CD3 \u2212 CD4 + lineage negative cells", "CELL_TYPE", 742, 776], ["RV", "SPECIES", 394, 396], ["the infected RT", "PROBLEM", 81, 96], ["emerging studies", "TEST", 107, 123], ["distinct stem cell populations", "PROBLEM", 182, 212], ["inflammation", "PROBLEM", 354, 366], ["injury", "PROBLEM", 371, 377], ["RV infection", "PROBLEM", 394, 406], ["innate immune cells", "TREATMENT", 487, 506], ["innate lymphoid cells", "TREATMENT", 554, 575], ["mucosal epithelia", "PROBLEM", 616, 633], ["CD3", "TEST", 742, 745], ["CD4", "TEST", 748, 751], ["lineage negative cells", "PROBLEM", 754, 776], ["lymphoid tissues", "PROBLEM", 815, 831], ["infected", "OBSERVATION", 85, 93], ["distinct", "OBSERVATION_MODIFIER", 182, 190], ["stem cell populations", "OBSERVATION", 191, 212], ["inflammation", "OBSERVATION", 354, 366], ["RV", "ANATOMY", 394, 396], ["infection", "OBSERVATION", 397, 406], ["innate lymphoid cells", "OBSERVATION", 554, 575], ["mucosal epithelia", "ANATOMY", 616, 633], ["lineage negative cells", "OBSERVATION", 754, 776], ["lymphoid tissues", "OBSERVATION", 815, 831]]], ["Recently, they have been shown to secrete large quantities of the \"tissueprotective\" cytokine IL-22 in adult mice [68] .", [["IL-22", "GENE_OR_GENE_PRODUCT", 94, 99], ["mice", "ORGANISM", 109, 113], ["cytokine", "PROTEIN", 85, 93], ["IL-22", "PROTEIN", 94, 99], ["mice", "SPECIES", 109, 113], ["mice", "SPECIES", 109, 113], ["the \"tissueprotective\" cytokine IL", "TREATMENT", 62, 96]]], ["IL-22 levels are reduced in the IAV-infected lung; however, levels return to baseline immediately following virus clearance from the lung [69] .", [["lung", "ANATOMY", 45, 49], ["lung", "ANATOMY", 133, 137], ["IL-22", "GENE_OR_GENE_PRODUCT", 0, 5], ["IAV", "ORGANISM", 32, 35], ["lung", "ORGAN", 45, 49], ["lung", "ORGAN", 133, 137], ["IL", "PROTEIN", 0, 2], ["IL", "TEST", 0, 2], ["virus clearance", "TEST", 108, 123], ["reduced", "OBSERVATION_MODIFIER", 17, 24], ["IAV", "OBSERVATION", 32, 35], ["infected", "OBSERVATION", 36, 44], ["lung", "ANATOMY", 45, 49], ["lung", "ANATOMY", 133, 137]]], ["Although IL-22 does not seem to have any direct anti-viral properties in the lung, it does stimulate pulmonary epithelial cells to up-regulate antibacterial genes, such as lipocalin-2, and may be essential for resistance against many Gram negative bacterial pneumonia [70] .", [["lung", "ANATOMY", 77, 81], ["pulmonary epithelial cells", "ANATOMY", 101, 127], ["pneumonia", "DISEASE", 258, 267], ["IL-22", "GENE_OR_GENE_PRODUCT", 9, 14], ["lung", "ORGAN", 77, 81], ["pulmonary epithelial cells", "CELL", 101, 127], ["lipocalin-2", "GENE_OR_GENE_PRODUCT", 172, 183], ["IL", "PROTEIN", 9, 11], ["pulmonary epithelial cells", "CELL_TYPE", 101, 127], ["antibacterial genes", "DNA", 143, 162], ["lipocalin", "PROTEIN", 172, 181], ["any direct anti-viral properties in the lung", "PROBLEM", 37, 81], ["pulmonary epithelial cells", "PROBLEM", 101, 127], ["antibacterial genes", "PROBLEM", 143, 162], ["lipocalin", "TEST", 172, 181], ["resistance", "PROBLEM", 210, 220], ["many Gram negative bacterial pneumonia", "PROBLEM", 229, 267], ["anti-viral", "OBSERVATION", 48, 58], ["lung", "ANATOMY", 77, 81], ["pulmonary", "ANATOMY", 101, 110], ["epithelial cells", "OBSERVATION", 111, 127], ["antibacterial genes", "OBSERVATION", 143, 162], ["bacterial", "OBSERVATION_MODIFIER", 248, 257], ["pneumonia", "OBSERVATION", 258, 267]]], ["IL-22 can also protect airway epithelial cells from apoptosis, which is correlated with increased levels of the anti-apoptotic genes Bcl2 and Bcl2l1 [71] .", [["airway epithelial cells", "ANATOMY", 23, 46], ["IL-22", "GENE_OR_GENE_PRODUCT", 0, 5], ["airway epithelial cells", "CELL", 23, 46], ["Bcl2", "GENE_OR_GENE_PRODUCT", 133, 137], ["Bcl2l1", "GENE_OR_GENE_PRODUCT", 142, 148], ["IL-22", "PROTEIN", 0, 5], ["airway epithelial cells", "CELL_TYPE", 23, 46], ["anti-apoptotic genes", "DNA", 112, 132], ["Bcl2", "DNA", 133, 137], ["Bcl2l1", "DNA", 142, 148], ["IL", "TREATMENT", 0, 2], ["airway epithelial cells", "PROBLEM", 23, 46], ["apoptosis", "PROBLEM", 52, 61], ["increased levels of the anti-apoptotic genes Bcl2", "PROBLEM", 88, 137], ["Bcl2l1", "TEST", 142, 148], ["airway", "ANATOMY", 23, 29], ["epithelial cells", "OBSERVATION", 30, 46], ["apoptosis", "OBSERVATION_MODIFIER", 52, 61]]], ["Thus, IL-22 may be an important factor in maintaining the epithelial barrier.", [["epithelial barrier", "ANATOMY", 58, 76], ["IL-22", "GENE_OR_GENE_PRODUCT", 6, 11], ["epithelial barrier", "TISSUE", 58, 76], ["IL-22", "PROTEIN", 6, 11], ["IL", "TREATMENT", 6, 8], ["the epithelial barrier", "TREATMENT", 54, 76], ["epithelial", "ANATOMY", 58, 68]]], ["LTi-like cells, which are phenotypically similar to LTi cells but also express the NK cell receptor NKp46 in adults (often referred to as NKR + LTi, ILC22, or NK22), are also potent producers of IL-22.", [["LTi-like cells", "ANATOMY", 0, 14], ["LTi cells", "ANATOMY", 52, 61], ["NK cell", "ANATOMY", 83, 90], ["NK", "ANATOMY", 100, 102], ["NKR + LTi", "ANATOMY", 138, 147], ["LTi-like cells", "CELL", 0, 14], ["LTi cells", "CELL", 52, 61], ["NK cell", "CELL", 83, 90], ["NKp46", "GENE_OR_GENE_PRODUCT", 100, 105], ["NKR", "GENE_OR_GENE_PRODUCT", 138, 141], ["LTi", "GENE_OR_GENE_PRODUCT", 144, 147], ["ILC22", "GENE_OR_GENE_PRODUCT", 149, 154], ["NK22", "GENE_OR_GENE_PRODUCT", 159, 163], ["IL-22", "GENE_OR_GENE_PRODUCT", 195, 200], ["LTi-like cells", "CELL_LINE", 0, 14], ["LTi cells", "CELL_LINE", 52, 61], ["NK cell receptor NKp46", "PROTEIN", 83, 105], ["NKR", "PROTEIN", 138, 141], ["LTi", "PROTEIN", 144, 147], ["ILC22", "CELL_LINE", 149, 154], ["NK22", "CELL_LINE", 159, 163], ["IL-22", "PROTEIN", 195, 200], ["LTi-like cells", "PROBLEM", 0, 14], ["NKR", "TEST", 138, 141], ["IL", "TEST", 195, 197], ["like cells", "OBSERVATION", 4, 14]]], ["To date, NK22 cells have been best described in the intestinal lamina propria but can be found in the liver and mesenteric lymph nodes [72] .", [["NK22 cells", "ANATOMY", 9, 19], ["intestinal lamina propria", "ANATOMY", 52, 77], ["liver", "ANATOMY", 102, 107], ["mesenteric lymph nodes", "ANATOMY", 112, 134], ["NK22 cells", "CELL", 9, 19], ["intestinal lamina propria", "TISSUE", 52, 77], ["liver", "ORGAN", 102, 107], ["mesenteric lymph nodes", "MULTI-TISSUE_STRUCTURE", 112, 134], ["NK22 cells", "CELL_LINE", 9, 19], ["intestinal lamina propria", "ANATOMY", 52, 77], ["liver", "ANATOMY", 102, 107], ["mesenteric", "ANATOMY", 112, 122], ["lymph nodes", "OBSERVATION", 123, 134]]], ["However, as more is learned about inducible bronchi associated lymphoid tissue (iBALT) [73, 74] , NK22 cells may very well be found within these structures in the lungs and contribute to repair.", [["bronchi", "ANATOMY", 44, 51], ["lymphoid tissue", "ANATOMY", 63, 78], ["iBALT", "ANATOMY", 80, 85], ["NK22 cells", "ANATOMY", 98, 108], ["structures", "ANATOMY", 145, 155], ["lungs", "ANATOMY", 163, 168], ["bronchi", "MULTI-TISSUE_STRUCTURE", 44, 51], ["lymphoid tissue", "TISSUE", 63, 78], ["iBALT", "CELL", 80, 85], ["NK22 cells", "CELL", 98, 108], ["lungs", "ORGAN", 163, 168], ["NK22 cells", "CELL_LINE", 98, 108], ["inducible bronchi associated lymphoid tissue", "PROBLEM", 34, 78], ["NK22 cells", "PROBLEM", 98, 108], ["repair", "TREATMENT", 187, 193], ["bronchi", "ANATOMY", 44, 51], ["lymphoid tissue", "OBSERVATION", 63, 78], ["lungs", "ANATOMY", 163, 168], ["repair", "OBSERVATION", 187, 193]]], ["NK cell receptor (CD161)expressing innate lymphoid cells have also been identified in humans; however, these cells functionally more resemble the innate lymphoid cell type 2 [75] , described below.The Role of the Innate Immune System: The Second ActAs another member of the innate lymphoid family, natural helper cells or innate lymphoid cell type 2 (ILC2), were variously described by several groups [76] [77] [78] [79] .", [["NK cell", "ANATOMY", 0, 7], ["lymphoid cells", "ANATOMY", 42, 56], ["cells", "ANATOMY", 109, 114], ["lymphoid cell", "ANATOMY", 153, 166], ["natural helper cells", "ANATOMY", 298, 318], ["NK cell receptor", "GENE_OR_GENE_PRODUCT", 0, 16], ["CD161", "GENE_OR_GENE_PRODUCT", 18, 23], ["innate lymphoid cells", "CELL", 35, 56], ["humans", "ORGANISM", 86, 92], ["cells", "CELL", 109, 114], ["lymphoid cell type 2", "CELL", 153, 173], ["natural helper cells", "CELL", 298, 318], ["innate lymphoid cell type 2", "GENE_OR_GENE_PRODUCT", 322, 349], ["ILC2", "GENE_OR_GENE_PRODUCT", 351, 355], ["NK cell receptor (CD161)expressing innate lymphoid cells", "CELL_TYPE", 0, 56], ["natural helper cells", "CELL_TYPE", 298, 318], ["ILC2", "PROTEIN", 351, 355], ["humans", "SPECIES", 86, 92], ["humans", "SPECIES", 86, 92], ["innate lymphoid cells", "PROBLEM", 35, 56], ["natural helper cells", "TREATMENT", 298, 318], ["innate lymphoid cell type", "TREATMENT", 322, 347], ["innate lymphoid cells", "OBSERVATION", 35, 56], ["innate lymphoid cell", "OBSERVATION", 146, 166], ["lymphoid cell", "OBSERVATION", 329, 342]]], ["These ILC2 are potent producers of type 2 cytokines, namely IL-5 and IL-13.", [["ILC2", "GENE_OR_GENE_PRODUCT", 6, 10], ["IL-5", "GENE_OR_GENE_PRODUCT", 60, 64], ["IL-13", "GENE_OR_GENE_PRODUCT", 69, 74], ["ILC2", "PROTEIN", 6, 10], ["type 2 cytokines", "PROTEIN", 35, 51], ["IL-5 and IL-13", "PROTEIN", 60, 74], ["type 2 cytokines", "TREATMENT", 35, 51], ["IL", "TEST", 60, 62], ["IL", "TEST", 69, 71], ["ILC2", "OBSERVATION", 6, 10], ["potent", "OBSERVATION_MODIFIER", 15, 21]]], ["Although originally described in fat associated lymphoid clusters [76] , these ILC2 have been identified in many organs including the spleen, bone marrow, and various regional lymph nodes.", [["fat", "ANATOMY", 33, 36], ["lymphoid", "ANATOMY", 48, 56], ["organs", "ANATOMY", 113, 119], ["spleen", "ANATOMY", 134, 140], ["bone marrow", "ANATOMY", 142, 153], ["lymph nodes", "ANATOMY", 176, 187], ["fat", "TISSUE", 33, 36], ["lymphoid clusters", "CANCER", 48, 65], ["ILC2", "GENE_OR_GENE_PRODUCT", 79, 83], ["organs", "ORGAN", 113, 119], ["spleen", "ORGAN", 134, 140], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 142, 153], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 176, 187], ["ILC2", "PROTEIN", 79, 83], ["various regional lymph nodes", "PROBLEM", 159, 187], ["lymphoid clusters", "OBSERVATION", 48, 65], ["ILC2", "OBSERVATION", 79, 83], ["spleen", "ANATOMY", 134, 140], ["bone marrow", "ANATOMY", 142, 153], ["various", "OBSERVATION_MODIFIER", 159, 166], ["regional", "OBSERVATION_MODIFIER", 167, 175], ["lymph nodes", "OBSERVATION", 176, 187]]], ["Of interest, a relatively large number are also found within the RT [78, 80] .", [["relatively", "OBSERVATION_MODIFIER", 15, 25], ["large", "OBSERVATION_MODIFIER", 26, 31]]], ["The ability of these cells to secrete large quantities of IL-5 and IL-13 (on the order of 30 ng per 5,000 cells) has made them a target for limiting virus induced asthma exacerbations [81] .", [["cells", "ANATOMY", 21, 26], ["cells", "ANATOMY", 106, 111], ["asthma", "DISEASE", 163, 169], ["cells", "CELL", 21, 26], ["IL-5", "GENE_OR_GENE_PRODUCT", 58, 62], ["IL-13", "GENE_OR_GENE_PRODUCT", 67, 72], ["cells", "CELL", 106, 111], ["IL", "PROTEIN", 58, 60], ["IL-13", "PROTEIN", 67, 72], ["IL", "TEST", 58, 60], ["IL", "TEST", 67, 69], ["limiting virus induced asthma exacerbations", "PROBLEM", 140, 183]]], ["However, ILC2 are also essential for epithelial integrity, lung function, and proper airway remodeling during IAV infection via their secretion of the epidermal growth factor ligand, amphiregulin [82] .", [["epithelial", "ANATOMY", 37, 47], ["lung", "ANATOMY", 59, 63], ["airway", "ANATOMY", 85, 91], ["infection", "DISEASE", 114, 123], ["ILC2", "GENE_OR_GENE_PRODUCT", 9, 13], ["epithelial", "TISSUE", 37, 47], ["lung", "ORGAN", 59, 63], ["airway", "MULTI-TISSUE_STRUCTURE", 85, 91], ["epidermal growth factor ligand", "GENE_OR_GENE_PRODUCT", 151, 181], ["amphiregulin", "GENE_OR_GENE_PRODUCT", 183, 195], ["ILC2", "PROTEIN", 9, 13], ["epidermal growth factor ligand", "PROTEIN", 151, 181], ["amphiregulin", "PROTEIN", 183, 195], ["IAV", "SPECIES", 110, 113], ["ILC2", "TREATMENT", 9, 13], ["epithelial integrity", "PROBLEM", 37, 57], ["lung function", "TEST", 59, 72], ["proper airway remodeling", "PROBLEM", 78, 102], ["IAV infection", "PROBLEM", 110, 123], ["ILC2", "OBSERVATION", 9, 13], ["essential for", "UNCERTAINTY", 23, 36], ["epithelial integrity", "OBSERVATION", 37, 57], ["lung", "ANATOMY", 59, 63], ["airway", "ANATOMY", 85, 91], ["remodeling", "OBSERVATION", 92, 102], ["IAV", "OBSERVATION_MODIFIER", 110, 113], ["infection", "OBSERVATION", 114, 123]]], ["Amphiregulin can limit lung inflammation during bleomycin-induced injury [83] ; however, this new demonstration of its role in actively participating in and/or regulating airway repair following RV infection merits further research.", [["lung", "ANATOMY", 23, 27], ["airway", "ANATOMY", 171, 177], ["RV", "ANATOMY", 195, 197], ["Amphiregulin", "CHEMICAL", 0, 12], ["inflammation", "DISEASE", 28, 40], ["bleomycin", "CHEMICAL", 48, 57], ["RV infection", "DISEASE", 195, 207], ["Amphiregulin", "CHEMICAL", 0, 12], ["bleomycin", "CHEMICAL", 48, 57], ["Amphiregulin", "SIMPLE_CHEMICAL", 0, 12], ["lung", "ORGAN", 23, 27], ["bleomycin", "SIMPLE_CHEMICAL", 48, 57], ["airway", "MULTI-TISSUE_STRUCTURE", 171, 177], ["RV", "MULTI-TISSUE_STRUCTURE", 195, 197], ["Amphiregulin", "TREATMENT", 0, 12], ["lung inflammation", "PROBLEM", 23, 40], ["induced injury", "PROBLEM", 58, 72], ["regulating airway repair", "TREATMENT", 160, 184], ["RV infection", "PROBLEM", 195, 207], ["lung", "ANATOMY", 23, 27], ["inflammation", "OBSERVATION", 28, 40], ["airway", "ANATOMY", 171, 177], ["repair", "OBSERVATION", 178, 184], ["RV", "ANATOMY", 195, 197], ["infection", "OBSERVATION", 198, 207]]], ["In addition to amphiregulin, it is also formally possible that ILC2 are secreting other factors that directly or indirectly modulate the repair response.", [["amphiregulin", "GENE_OR_GENE_PRODUCT", 15, 27], ["ILC2", "GENE_OR_GENE_PRODUCT", 63, 67], ["amphiregulin", "PROTEIN", 15, 27], ["ILC2", "PROTEIN", 63, 67], ["amphiregulin", "TREATMENT", 15, 27], ["ILC2", "PROBLEM", 63, 67], ["secreting other factors", "PROBLEM", 72, 95], ["ILC2", "OBSERVATION", 63, 67], ["repair response", "OBSERVATION", 137, 152]]], ["ILC2 are early producers of the type 2 cytokine IL-9 [84] , which although a culprit in asthma and allergy, can protect epithelial cells from apoptosis by upregulating Bcl2 [85] .", [["epithelial cells", "ANATOMY", 120, 136], ["asthma", "DISEASE", 88, 94], ["allergy", "DISEASE", 99, 106], ["ILC2", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL-9", "GENE_OR_GENE_PRODUCT", 48, 52], ["epithelial cells", "CELL", 120, 136], ["Bcl2", "GENE_OR_GENE_PRODUCT", 168, 172], ["ILC2", "PROTEIN", 0, 4], ["epithelial cells", "CELL_TYPE", 120, 136], ["Bcl2", "PROTEIN", 168, 172], ["ILC2", "PROBLEM", 0, 4], ["the type 2 cytokine IL", "TEST", 28, 50], ["asthma", "PROBLEM", 88, 94], ["allergy", "PROBLEM", 99, 106], ["epithelial cells", "PROBLEM", 120, 136], ["apoptosis", "PROBLEM", 142, 151], ["asthma", "OBSERVATION", 88, 94], ["epithelial cells", "OBSERVATION", 120, 136]]], ["ILC2 are located near the bronchi and bronchioles [80] and thus are well situated to mediate the repair response following a RV infection.", [["bronchi", "ANATOMY", 26, 33], ["bronchioles", "ANATOMY", 38, 49], ["RV", "ANATOMY", 125, 127], ["RV infection", "DISEASE", 125, 137], ["ILC2", "GENE_OR_GENE_PRODUCT", 0, 4], ["bronchi", "MULTI-TISSUE_STRUCTURE", 26, 33], ["ILC2", "PROTEIN", 0, 4], ["ILC2", "PROBLEM", 0, 4], ["a RV infection", "PROBLEM", 123, 137], ["bronchi", "ANATOMY", 26, 33], ["bronchioles", "ANATOMY", 38, 49], ["repair", "OBSERVATION", 97, 103], ["RV", "ANATOMY", 125, 127], ["infection", "OBSERVATION", 128, 137]]], ["ILC2 produce large amounts of IL-5 and IL-13 when stimulated by IL-33 or IL25.", [["ILC2", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL-5", "GENE_OR_GENE_PRODUCT", 30, 34], ["IL-13", "GENE_OR_GENE_PRODUCT", 39, 44], ["IL-33", "GENE_OR_GENE_PRODUCT", 64, 69], ["IL25", "GENE_OR_GENE_PRODUCT", 73, 77], ["ILC2", "PROTEIN", 0, 4], ["IL", "PROTEIN", 30, 32], ["IL-13", "PROTEIN", 39, 44], ["IL", "PROTEIN", 64, 66], ["IL25", "PROTEIN", 73, 77], ["ILC2 produce large amounts of IL", "TREATMENT", 0, 32], ["large", "OBSERVATION_MODIFIER", 13, 18], ["amounts", "OBSERVATION_MODIFIER", 19, 26]]], ["IL-33 is present in the IAVinfected lung, with the predominant sources being necrotic epithelial cells [86] , alveolar macrophages [81] , and NKT cells (unpublished observation).", [["IAVinfected lung", "ANATOMY", 24, 40], ["necrotic epithelial cells", "ANATOMY", 77, 102], ["alveolar macrophages", "ANATOMY", 110, 130], ["NKT cells", "ANATOMY", 142, 151], ["necrotic", "DISEASE", 77, 85], ["IL-33", "GENE_OR_GENE_PRODUCT", 0, 5], ["lung", "ORGAN", 36, 40], ["necrotic epithelial cells", "CELL", 77, 102], ["alveolar macrophages", "CELL", 110, 130], ["NKT cells", "CELL", 142, 151], ["IL-33", "PROTEIN", 0, 5], ["necrotic epithelial cells", "CELL_TYPE", 77, 102], ["alveolar macrophages", "CELL_TYPE", 110, 130], ["NKT cells", "CELL_TYPE", 142, 151], ["IL", "TEST", 0, 2], ["necrotic epithelial cells", "PROBLEM", 77, 102], ["alveolar macrophages", "TEST", 110, 130], ["NKT cells", "PROBLEM", 142, 151], ["lung", "ANATOMY", 36, 40], ["necrotic", "OBSERVATION_MODIFIER", 77, 85], ["epithelial cells", "OBSERVATION", 86, 102], ["alveolar", "ANATOMY_MODIFIER", 110, 118], ["macrophages", "ANATOMY", 119, 130], ["NKT cells", "OBSERVATION", 142, 151]]], ["Thus, IL-33 may be the signal to initiate ILC2 into the repair phase.", [["IL-33", "GENE_OR_GENE_PRODUCT", 6, 11], ["ILC2", "GENE_OR_GENE_PRODUCT", 42, 46], ["IL-33", "PROTEIN", 6, 11], ["ILC2", "PROTEIN", 42, 46], ["the repair phase", "TREATMENT", 52, 68], ["repair phase", "OBSERVATION", 56, 68]]], ["Whether IL-25 has a direct role in RV infection, outside of virus induced asthma exacerbation [87] , is not yet clear.The Role of the Innate Immune System: The Second ActThe propensity of innate immune cells to produce predominantly type 2 cytokines in order to orchestrate a pulmonary repair response rather than simply exacerbate asthma is not outside the realm of possibilities.", [["RV", "ANATOMY", 35, 37], ["immune cells", "ANATOMY", 195, 207], ["pulmonary", "ANATOMY", 276, 285], ["RV infection", "DISEASE", 35, 47], ["asthma", "DISEASE", 74, 80], ["asthma", "DISEASE", 332, 338], ["IL-25", "GENE_OR_GENE_PRODUCT", 8, 13], ["RV", "ORGAN", 35, 37], ["innate immune cells", "CELL", 188, 207], ["pulmonary", "ORGAN", 276, 285], ["IL-25", "PROTEIN", 8, 13], ["innate immune cells", "CELL_TYPE", 188, 207], ["cytokines", "PROTEIN", 240, 249], ["RV", "SPECIES", 35, 37], ["IL", "TEST", 8, 10], ["RV infection", "PROBLEM", 35, 47], ["asthma exacerbation", "PROBLEM", 74, 93], ["innate immune cells", "TREATMENT", 188, 207], ["type 2 cytokines", "PROBLEM", 233, 249], ["a pulmonary repair", "TREATMENT", 274, 292], ["asthma", "PROBLEM", 332, 338], ["RV", "ANATOMY", 35, 37], ["infection", "OBSERVATION", 38, 47], ["clear", "OBSERVATION", 112, 117], ["pulmonary", "ANATOMY", 276, 285], ["repair", "OBSERVATION", 286, 292], ["asthma", "OBSERVATION", 332, 338]]], ["Type 2 immune responses can also be thought of as a reparative response [88] .", [["Type 2 immune responses", "PROBLEM", 0, 23]]], ["Type 2 immune responses largely depend on signaling through the IL-4R alpha chain.", [["IL-4R alpha", "GENE_OR_GENE_PRODUCT", 64, 75], ["IL-4R alpha chain", "PROTEIN", 64, 81], ["Type 2 immune responses", "PROBLEM", 0, 23], ["the IL", "TEST", 60, 66], ["chain", "ANATOMY_MODIFIER", 76, 81]]], ["Both IL-4 and IL-13 signal through IL-4Ra, and mice deficient in IL-4Ra have delayed wound repair responses [89, 90] .", [["wound", "ANATOMY", 85, 90], ["IL-4", "GENE_OR_GENE_PRODUCT", 5, 9], ["IL-13", "GENE_OR_GENE_PRODUCT", 14, 19], ["IL-4Ra", "GENE_OR_GENE_PRODUCT", 35, 41], ["mice", "ORGANISM", 47, 51], ["IL-4Ra", "GENE_OR_GENE_PRODUCT", 65, 71], ["wound", "PATHOLOGICAL_FORMATION", 85, 90], ["IL", "PROTEIN", 5, 7], ["IL-4Ra", "PROTEIN", 35, 41], ["IL-4Ra", "PROTEIN", 65, 71], ["mice", "SPECIES", 47, 51], ["mice", "SPECIES", 47, 51], ["IL", "TREATMENT", 14, 16], ["IL", "TEST", 35, 37], ["mice deficient in IL", "TREATMENT", 47, 67], ["delayed wound repair", "TREATMENT", 77, 97], ["IL", "OBSERVATION_MODIFIER", 5, 7], ["wound repair", "OBSERVATION", 85, 97]]], ["In addition, IL-13 is highly pro-fibrotic, which when present in small amounts and under tight regulation, may be able to promote a repair response, particularly in generating a provisional matrix.", [["matrix", "ANATOMY", 190, 196], ["IL-13", "GENE_OR_GENE_PRODUCT", 13, 18], ["matrix", "CELLULAR_COMPONENT", 190, 196], ["IL-13", "PROTEIN", 13, 18], ["IL", "TEST", 13, 15], ["a repair response", "TREATMENT", 130, 147], ["highly", "OBSERVATION_MODIFIER", 22, 28], ["pro-fibrotic", "OBSERVATION", 29, 41], ["small amounts", "OBSERVATION_MODIFIER", 65, 78]]], ["Signaling through the IL-4Ra via IL-4 and/or IL-13 is also important for the generation of alternatively activated macrophages (so called \"M2\" macrophages) [91] .", [["macrophages", "ANATOMY", 115, 126], ["macrophages", "ANATOMY", 143, 154], ["IL-4Ra", "GENE_OR_GENE_PRODUCT", 22, 28], ["IL-4", "GENE_OR_GENE_PRODUCT", 33, 37], ["IL-13", "GENE_OR_GENE_PRODUCT", 45, 50], ["macrophages", "CELL", 115, 126], ["macrophages", "CELL", 143, 154], ["IL-4Ra", "PROTEIN", 22, 28], ["IL-13", "PROTEIN", 45, 50], ["alternatively activated macrophages", "CELL_TYPE", 91, 126], ["macrophages", "CELL_TYPE", 143, 154], ["the IL", "TEST", 18, 24], ["activated macrophages", "PROBLEM", 105, 126]]], ["M2 are known to be anti-inflammatory and involved in tissue repair in a variety of injury models [92] .", [["tissue", "ANATOMY", 53, 59], ["M2", "GENE_OR_GENE_PRODUCT", 0, 2], ["tissue", "TISSUE", 53, 59], ["M2", "PROTEIN", 0, 2], ["tissue repair", "TREATMENT", 53, 66], ["injury models", "PROBLEM", 83, 96], ["known to be", "UNCERTAINTY", 7, 18], ["anti-inflammatory", "OBSERVATION_MODIFIER", 19, 36], ["tissue repair", "OBSERVATION", 53, 66], ["variety", "OBSERVATION_MODIFIER", 72, 79]]], ["M2 express a set of signature molecules including arginase, Ym1/Chi3I3, Fizz1, and MRC1.", [["M2", "GENE_OR_GENE_PRODUCT", 0, 2], ["arginase", "GENE_OR_GENE_PRODUCT", 50, 58], ["Ym1", "GENE_OR_GENE_PRODUCT", 60, 63], ["Chi3I3", "GENE_OR_GENE_PRODUCT", 64, 70], ["Fizz1", "GENE_OR_GENE_PRODUCT", 72, 77], ["MRC1", "GENE_OR_GENE_PRODUCT", 83, 87], ["M2", "PROTEIN", 0, 2], ["signature molecules", "PROTEIN", 20, 39], ["arginase", "PROTEIN", 50, 58], ["Ym1", "PROTEIN", 60, 63], ["Chi3I3", "PROTEIN", 64, 70], ["Fizz1", "PROTEIN", 72, 77], ["MRC1", "PROTEIN", 83, 87], ["arginase", "TEST", 50, 58], ["MRC1", "TREATMENT", 83, 87]]], ["Arginase in particular is known to be involved in the synthesis of collagen [93] and thus may again be important in provisional matrix deposition.", [["matrix", "ANATOMY", 128, 134], ["Arginase", "GENE_OR_GENE_PRODUCT", 0, 8], ["collagen", "GENE_OR_GENE_PRODUCT", 67, 75], ["matrix", "CELLULAR_COMPONENT", 128, 134], ["Arginase", "PROTEIN", 0, 8], ["collagen", "PROTEIN", 67, 75], ["Arginase", "PROBLEM", 0, 8], ["known to be", "UNCERTAINTY", 26, 37], ["may again be", "UNCERTAINTY", 90, 102], ["matrix deposition", "OBSERVATION", 128, 145]]], ["M2 expressing Arginase and Ym1 are significant contributors to lung fibrosis, but this effect is dependent on the pro-inflammatory Ly6C hi monocytic subset [94] .", [["lung", "ANATOMY", 63, 67], ["fibrosis", "DISEASE", 68, 76], ["M2", "GENE_OR_GENE_PRODUCT", 0, 2], ["Arginase", "GENE_OR_GENE_PRODUCT", 14, 22], ["Ym1", "GENE_OR_GENE_PRODUCT", 27, 30], ["lung", "ORGAN", 63, 67], ["M2", "PROTEIN", 0, 2], ["Arginase", "PROTEIN", 14, 22], ["Ym1", "PROTEIN", 27, 30], ["Ly6C", "PROTEIN", 131, 135], ["lung fibrosis", "PROBLEM", 63, 76], ["Arginase", "OBSERVATION", 14, 22], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["lung", "ANATOMY", 63, 67], ["fibrosis", "OBSERVATION", 68, 76], ["pro-inflammatory Ly6C", "OBSERVATION", 114, 135]]], ["Therefore, in the right context (i.e. in the absence of strong inflammation as occurs following virus clearance in the lung), M2 may have a role to play in promoting a reparative response.", [["lung", "ANATOMY", 119, 123], ["inflammation", "DISEASE", 63, 75], ["lung", "ORGAN", 119, 123], ["M2", "GENE_OR_GENE_PRODUCT", 126, 128], ["strong inflammation", "PROBLEM", 56, 75], ["virus clearance", "TREATMENT", 96, 111], ["right", "ANATOMY_MODIFIER", 18, 23], ["strong", "OBSERVATION_MODIFIER", 56, 62], ["inflammation", "OBSERVATION", 63, 75], ["lung", "ANATOMY", 119, 123]]], ["In support of this hypothesis, M2 generation during RSV infection was found to limit inflammation, and in their absence, there was sustained epithelial cell damage in the infected lung [95] .", [["epithelial cell", "ANATOMY", 141, 156], ["lung", "ANATOMY", 180, 184], ["RSV infection", "DISEASE", 52, 65], ["inflammation", "DISEASE", 85, 97], ["M2", "GENE_OR_GENE_PRODUCT", 31, 33], ["RSV", "ORGANISM", 52, 55], ["epithelial cell", "CELL", 141, 156], ["lung", "ORGAN", 180, 184], ["M2", "PROTEIN", 31, 33], ["RSV", "SPECIES", 52, 55], ["this hypothesis", "PROBLEM", 14, 29], ["M2 generation during RSV infection", "PROBLEM", 31, 65], ["inflammation", "PROBLEM", 85, 97], ["sustained epithelial cell damage in the infected lung", "PROBLEM", 131, 184], ["infection", "OBSERVATION", 56, 65], ["inflammation", "OBSERVATION", 85, 97], ["sustained", "OBSERVATION_MODIFIER", 131, 140], ["epithelial cell damage", "OBSERVATION", 141, 163], ["infected", "OBSERVATION_MODIFIER", 171, 179], ["lung", "ANATOMY", 180, 184]]], ["The generation of M2 during RSV infection was found to be IFNp dependent, which was essential for regulating IL-4, IL-13, and IL-4Ra expression, thereby providing a link between RV infection and the induction of M2.", [["RV", "ANATOMY", 178, 180], ["RSV infection", "DISEASE", 28, 41], ["RV infection", "DISEASE", 178, 190], ["M2", "GENE_OR_GENE_PRODUCT", 18, 20], ["RSV", "ORGANISM", 28, 31], ["IFNp", "GENE_OR_GENE_PRODUCT", 58, 62], ["IL-4", "GENE_OR_GENE_PRODUCT", 109, 113], ["IL-13", "GENE_OR_GENE_PRODUCT", 115, 120], ["IL-4Ra", "GENE_OR_GENE_PRODUCT", 126, 132], ["RV", "MULTI-TISSUE_STRUCTURE", 178, 180], ["M2", "GENE_OR_GENE_PRODUCT", 212, 214], ["M2", "PROTEIN", 18, 20], ["IFNp", "PROTEIN", 58, 62], ["4Ra", "PROTEIN", 129, 132], ["M2", "PROTEIN", 212, 214], ["RSV", "SPECIES", 28, 31], ["RSV infection", "PROBLEM", 28, 41], ["IFNp dependent", "PROBLEM", 58, 72], ["IL", "TEST", 109, 111], ["IL", "TEST", 115, 117], ["IL", "TREATMENT", 126, 128], ["RV infection", "PROBLEM", 178, 190], ["the induction of M2", "TREATMENT", 195, 214], ["M2", "OBSERVATION_MODIFIER", 18, 20], ["RSV infection", "OBSERVATION", 28, 41], ["RV", "ANATOMY", 178, 180], ["infection", "OBSERVATION", 181, 190]]], ["Thus, viruses that inhibit the interferon response, such as IAV and RSV, could potentially interfere with the proper repair response via inhibition of M2 generation [96] .Activating Stem CellsThe epithelial proliferation and differentiation phase of repair requires the presence of a pulmonary progenitor cell that is either resident in the lung or recruited following RV infection.", [["Stem Cells", "ANATOMY", 182, 192], ["epithelial", "ANATOMY", 196, 206], ["pulmonary progenitor cell", "ANATOMY", 284, 309], ["lung", "ANATOMY", 341, 345], ["RV", "ANATOMY", 369, 371], ["RV infection", "DISEASE", 369, 381], ["interferon", "GENE_OR_GENE_PRODUCT", 31, 41], ["IAV", "ORGANISM", 60, 63], ["RSV", "ORGANISM", 68, 71], ["M2", "GENE_OR_GENE_PRODUCT", 151, 153], ["Stem Cells", "CELL", 182, 192], ["epithelial", "CELL", 196, 206], ["pulmonary progenitor cell", "CELL", 284, 309], ["lung", "ORGAN", 341, 345], ["RV", "ORGAN", 369, 371], ["interferon", "PROTEIN", 31, 41], ["pulmonary progenitor cell", "CELL_TYPE", 284, 309], ["IAV", "SPECIES", 60, 63], ["RSV", "SPECIES", 68, 71], ["viruses", "PROBLEM", 6, 13], ["the interferon response", "TREATMENT", 27, 50], ["IAV", "PROBLEM", 60, 63], ["RSV", "PROBLEM", 68, 71], ["Activating Stem Cells", "PROBLEM", 171, 192], ["The epithelial proliferation", "PROBLEM", 192, 220], ["repair", "TREATMENT", 250, 256], ["a pulmonary progenitor cell", "PROBLEM", 282, 309], ["RV infection", "PROBLEM", 369, 381], ["viruses", "OBSERVATION", 6, 13], ["Stem Cells", "OBSERVATION", 182, 192], ["epithelial proliferation", "OBSERVATION", 196, 220], ["differentiation", "OBSERVATION_MODIFIER", 225, 240], ["phase", "OBSERVATION_MODIFIER", 241, 246], ["repair", "OBSERVATION", 250, 256], ["pulmonary", "ANATOMY", 284, 293], ["progenitor cell", "OBSERVATION", 294, 309], ["lung", "ANATOMY", 341, 345], ["RV", "ANATOMY", 369, 371], ["infection", "OBSERVATION", 372, 381]]], ["These progenitor cells give rise to the specialized epithelial cells that will regenerate on the denuded areas of the lung.", [["progenitor cells", "ANATOMY", 6, 22], ["epithelial cells", "ANATOMY", 52, 68], ["lung", "ANATOMY", 118, 122], ["progenitor cells", "CELL", 6, 22], ["epithelial cells", "CELL", 52, 68], ["lung", "ORGAN", 118, 122], ["progenitor cells", "CELL_TYPE", 6, 22], ["epithelial cells", "CELL_TYPE", 52, 68], ["These progenitor cells", "PROBLEM", 0, 22], ["the specialized epithelial cells", "PROBLEM", 36, 68], ["progenitor cells", "OBSERVATION", 6, 22], ["epithelial cells", "OBSERVATION", 52, 68], ["denuded", "OBSERVATION_MODIFIER", 97, 104], ["areas", "OBSERVATION", 105, 110], ["lung", "ANATOMY", 118, 122]]], ["Interest in the role of stem cell activation following RV infection has increased recently with the better characterization of regionspecific stem cell populations that can regenerate different cell types of the lung.", [["stem cell", "ANATOMY", 24, 33], ["RV", "ANATOMY", 55, 57], ["stem cell", "ANATOMY", 142, 151], ["cell", "ANATOMY", 194, 198], ["lung", "ANATOMY", 212, 216], ["RV infection", "DISEASE", 55, 67], ["stem cell", "CELL", 24, 33], ["RV", "MULTI-TISSUE_STRUCTURE", 55, 57], ["stem cell populations", "CELL", 142, 163], ["cell", "CELL", 194, 198], ["lung", "ORGAN", 212, 216], ["regionspecific stem cell populations", "CELL_LINE", 127, 163], ["stem cell activation", "TREATMENT", 24, 44], ["RV infection", "PROBLEM", 55, 67], ["regionspecific stem cell populations", "PROBLEM", 127, 163], ["stem cell", "OBSERVATION", 24, 33], ["infection", "OBSERVATION", 58, 67], ["stem cell populations", "OBSERVATION", 142, 163], ["different cell types", "OBSERVATION", 184, 204], ["lung", "ANATOMY", 212, 216]]], ["The factors that regulate pulmonary stem cells, both their activation and/or recruitment, are not well understood, and the study of this population is further complicated by the lack of defined surface markers.Activating Stem CellsMulti-potent progenitor cell populations, such as 'bronchioalveolar stem cells (BASC)' have been identified in the lung [97] .", [["pulmonary stem cells", "ANATOMY", 26, 46], ["surface", "ANATOMY", 194, 201], ["Stem CellsMulti-potent progenitor cell populations", "ANATOMY", 221, 271], ["bronchioalveolar stem cells", "ANATOMY", 282, 309], ["BASC", "ANATOMY", 311, 315], ["lung", "ANATOMY", 346, 350], ["pulmonary stem cells", "CELL", 26, 46], ["Stem CellsMulti-potent progenitor cell populations", "CELL", 221, 271], ["bronchioalveolar stem cells", "CELL", 282, 309], ["BASC", "CELL", 311, 315], ["lung", "ORGAN", 346, 350], ["pulmonary stem cells", "CELL_TYPE", 26, 46], ["surface markers", "PROTEIN", 194, 209], ["Stem CellsMulti-potent progenitor cell populations", "CELL_LINE", 221, 271], ["bronchioalveolar stem cells", "CELL_TYPE", 282, 309], ["BASC", "CELL_TYPE", 311, 315], ["pulmonary stem cells", "PROBLEM", 26, 46], ["the study", "TEST", 119, 128], ["Activating Stem CellsMulti-potent progenitor cell populations", "TREATMENT", 210, 271], ["'bronchioalveolar stem cells", "TREATMENT", 281, 309], ["pulmonary", "ANATOMY", 26, 35], ["stem cells", "OBSERVATION", 36, 46], ["Stem CellsMulti-potent", "OBSERVATION", 221, 243], ["progenitor cell populations", "OBSERVATION", 244, 271], ["bronchioalveolar stem cells", "OBSERVATION", 282, 309], ["lung", "ANATOMY", 346, 350]]], ["These cells have been described as CD45 \u2212 CD31 \u2212 CD34 + Sca-1 + , although many groups maintain that this set of markers represent a heterogeneous population of stem cells that differentially give rise to various lung cell types [98, 99] .", [["cells", "ANATOMY", 6, 11], ["CD45 \u2212 CD31 \u2212 CD34 + Sca-1 +", "ANATOMY", 35, 63], ["stem cells", "ANATOMY", 161, 171], ["lung cell", "ANATOMY", 213, 222], ["cells", "CELL", 6, 11], ["CD45", "GENE_OR_GENE_PRODUCT", 35, 39], ["CD31", "GENE_OR_GENE_PRODUCT", 42, 46], ["CD34", "GENE_OR_GENE_PRODUCT", 49, 53], ["Sca-1", "GENE_OR_GENE_PRODUCT", 56, 61], ["stem cells", "CELL", 161, 171], ["lung cell", "CELL", 213, 222], ["CD45", "PROTEIN", 35, 39], ["CD31", "PROTEIN", 42, 46], ["CD34", "PROTEIN", 49, 53], ["Sca", "PROTEIN", 56, 59], ["stem cells", "CELL_TYPE", 161, 171], ["lung cell types", "CELL_TYPE", 213, 228], ["CD45", "TEST", 35, 39], ["CD31", "TEST", 42, 46], ["CD34", "TEST", 49, 53], ["Sca", "TEST", 56, 59], ["a heterogeneous population of stem cells", "PROBLEM", 131, 171], ["various lung cell types", "TEST", 205, 228], ["heterogeneous", "OBSERVATION_MODIFIER", 133, 146], ["stem cells", "OBSERVATION", 161, 171], ["lung", "ANATOMY", 213, 217], ["cell types", "OBSERVATION", 218, 228]]], ["BASC have been characterized as being able to repopulate both bronchiolar and alveolar epithelia [97, 100] ; however, recent studies show that distinct progenitor cells can exist for both of these regions as well as the trachea [2, 101, 102] .", [["bronchiolar", "ANATOMY", 62, 73], ["alveolar epithelia", "ANATOMY", 78, 96], ["progenitor cells", "ANATOMY", 152, 168], ["trachea", "ANATOMY", 220, 227], ["BASC", "GENE_OR_GENE_PRODUCT", 0, 4], ["bronchiolar", "TISSUE", 62, 73], ["alveolar epithelia", "TISSUE", 78, 96], ["progenitor cells", "CELL", 152, 168], ["trachea", "ORGAN", 220, 227], ["BASC", "PROTEIN", 0, 4], ["progenitor cells", "CELL_TYPE", 152, 168], ["recent studies", "TEST", 118, 132], ["distinct progenitor cells", "PROBLEM", 143, 168], ["bronchiolar", "ANATOMY", 62, 73], ["alveolar epithelia", "ANATOMY", 78, 96], ["distinct", "OBSERVATION_MODIFIER", 143, 151], ["progenitor cells", "OBSERVATION", 152, 168], ["trachea", "ANATOMY", 220, 227]]], ["Of relevance, SARS-CoV has been shown to infect BASC and therefore, could potentially contribute to virus-induced pathology via a mechanism that inhibits pulmonary repair [103] .", [["BASC", "ANATOMY", 48, 52], ["pulmonary", "ANATOMY", 154, 163], ["SARS", "DISEASE", 14, 18], ["SARS-CoV", "ORGANISM", 14, 22], ["BASC", "CELL", 48, 52], ["pulmonary", "ORGAN", 154, 163], ["SARS-CoV", "SPECIES", 14, 22], ["SARS", "PROBLEM", 14, 18], ["CoV", "PROBLEM", 19, 22], ["virus", "PROBLEM", 100, 105], ["pulmonary repair", "TREATMENT", 154, 170], ["pulmonary", "ANATOMY", 154, 163], ["repair", "OBSERVATION", 164, 170]]], ["Since many RV have the ability to infect the lower airways, in the case of severe disease, understanding the mechanisms of how BASC and/or other regional stem cell populations are regulated is paramount to expediting the repair response.Activating Stem CellsIn support of the regional specific stem cell populations, Kumar et al. found that following H1N1 influenza infection of mice, p63 + progenitor cells, which are thought to mark basal cells in the trachea [104, 105] , begin forming clusters around damaged foci into distinct keratin 5 + (Krt5 + ) pods [2] .", [["lower airways", "ANATOMY", 45, 58], ["BASC", "ANATOMY", 127, 131], ["stem cell", "ANATOMY", 154, 163], ["stem cell", "ANATOMY", 294, 303], ["p63 + progenitor cells", "ANATOMY", 385, 407], ["basal cells", "ANATOMY", 435, 446], ["trachea", "ANATOMY", 454, 461], ["foci", "ANATOMY", 513, 517], ["keratin 5 + (Krt5 + ) pods", "ANATOMY", 532, 558], ["influenza infection", "DISEASE", 356, 375], ["RV", "MULTI-TISSUE_STRUCTURE", 11, 13], ["lower airways", "MULTI-TISSUE_STRUCTURE", 45, 58], ["BASC", "GENE_OR_GENE_PRODUCT", 127, 131], ["stem cell populations", "CELL", 154, 175], ["stem cell populations", "CELL", 294, 315], ["H1N1 influenza", "ORGANISM", 351, 365], ["mice", "ORGANISM", 379, 383], ["p63", "GENE_OR_GENE_PRODUCT", 385, 388], ["basal cells", "CELL", 435, 446], ["trachea", "ORGAN", 454, 461], ["keratin", "GENE_OR_GENE_PRODUCT", 532, 539], ["regional stem cell populations", "CELL_TYPE", 145, 175], ["regional specific stem cell populations", "CELL_TYPE", 276, 315], ["p63", "PROTEIN", 385, 388], ["progenitor cells", "CELL_TYPE", 391, 407], ["basal cells", "CELL_TYPE", 435, 446], ["Krt5", "PROTEIN", 545, 549], ["H1N1 influenza", "SPECIES", 351, 365], ["mice", "SPECIES", 379, 383], ["mice", "SPECIES", 379, 383], ["severe disease", "PROBLEM", 75, 89], ["other regional stem cell populations", "PROBLEM", 139, 175], ["Activating Stem CellsIn support", "TREATMENT", 237, 268], ["H1N1 influenza infection of mice", "PROBLEM", 351, 383], ["progenitor cells", "PROBLEM", 391, 407], ["damaged foci", "PROBLEM", 505, 517], ["distinct keratin", "TEST", 523, 539], ["RV", "OBSERVATION", 11, 13], ["lower", "ANATOMY_MODIFIER", 45, 50], ["airways", "ANATOMY", 51, 58], ["severe", "OBSERVATION_MODIFIER", 75, 81], ["disease", "OBSERVATION", 82, 89], ["stem cell populations", "OBSERVATION", 154, 175], ["Stem CellsIn", "OBSERVATION", 248, 260], ["stem cell populations", "OBSERVATION", 294, 315], ["progenitor cells", "OBSERVATION", 391, 407], ["basal cells", "OBSERVATION", 435, 446], ["trachea", "ANATOMY", 454, 461], ["foci", "OBSERVATION", 513, 517]]], ["Within these pods, distal airway stem cells (DASCs), distinct from the upper airway stem cell populations, are capable of differentiating into cells that appear to be of alveolar lineage.", [["pods", "ANATOMY", 13, 17], ["distal airway stem cells", "ANATOMY", 19, 43], ["DASCs", "ANATOMY", 45, 50], ["upper airway stem cell populations", "ANATOMY", 71, 105], ["cells", "ANATOMY", 143, 148], ["alveolar lineage", "ANATOMY", 170, 186], ["distal airway stem cells", "CELL", 19, 43], ["DASCs", "CELL", 45, 50], ["upper airway stem cell populations", "CELL", 71, 105], ["cells", "CELL", 143, 148], ["alveolar lineage", "CELL", 170, 186], ["distal airway stem cells", "CELL_TYPE", 19, 43], ["DASCs", "CELL_TYPE", 45, 50], ["upper airway stem cell populations", "CELL_TYPE", 71, 105], ["alveolar lineage", "CELL_TYPE", 170, 186], ["distal airway stem cells (DASCs)", "PROBLEM", 19, 51], ["the upper airway stem cell populations", "PROBLEM", 67, 105], ["alveolar lineage", "PROBLEM", 170, 186], ["pods", "ANATOMY_MODIFIER", 13, 17], ["distal", "ANATOMY_MODIFIER", 19, 25], ["airway", "ANATOMY", 26, 32], ["stem cells", "OBSERVATION", 33, 43], ["distinct", "OBSERVATION_MODIFIER", 53, 61], ["upper", "ANATOMY_MODIFIER", 71, 76], ["airway", "ANATOMY", 77, 83], ["stem cell populations", "OBSERVATION", 84, 105], ["appear to be of", "UNCERTAINTY", 154, 169], ["alveolar lineage", "OBSERVATION", 170, 186]]], ["What factors and mediators control the DASC differentiation event are not known.", [["the DASC differentiation event", "PROBLEM", 35, 65]]], ["This becomes of further importance during secondary bacterial infection, particularly following the 2009 H1N1 influenza pandemic, where loss of epithelial repair mechanisms was shown to be a major contributor to pathogenesis, as opposed to a heightened inflammatory response [106] .SummaryA part of RV pathogenesis is damage to lung epithelium, either directly or via immuneinduced damage, and in the process, viruses can impede epithelial repair mechanisms.", [["epithelial", "ANATOMY", 144, 154], ["RV", "ANATOMY", 299, 301], ["lung epithelium", "ANATOMY", 328, 343], ["epithelial", "ANATOMY", 429, 439], ["bacterial infection", "DISEASE", 52, 71], ["influenza pandemic", "DISEASE", 110, 128], ["epithelial", "TISSUE", 144, 154], ["RV", "MULTI-TISSUE_STRUCTURE", 299, 301], ["lung epithelium", "TISSUE", 328, 343], ["epithelial", "TISSUE", 429, 439], ["H1N1 influenza pandemic", "SPECIES", 105, 128], ["secondary bacterial infection", "PROBLEM", 42, 71], ["the 2009 H1N1 influenza pandemic", "PROBLEM", 96, 128], ["epithelial repair", "TREATMENT", 144, 161], ["pathogenesis", "PROBLEM", 212, 224], ["a heightened inflammatory response", "PROBLEM", 240, 274], ["damage to lung epithelium", "PROBLEM", 318, 343], ["immuneinduced damage", "PROBLEM", 368, 388], ["viruses", "PROBLEM", 410, 417], ["epithelial repair mechanisms", "TREATMENT", 429, 457], ["bacterial", "OBSERVATION_MODIFIER", 52, 61], ["infection", "OBSERVATION", 62, 71], ["epithelial repair", "OBSERVATION", 144, 161], ["damage", "OBSERVATION", 318, 324], ["lung", "ANATOMY", 328, 332], ["epithelium", "ANATOMY_MODIFIER", 333, 343], ["damage", "OBSERVATION", 382, 388], ["epithelial repair", "OBSERVATION", 429, 446]]], ["The absence of a proper repair response can lengthen morbidity and can certainly contribute to an increase in mortality.", [["a proper repair", "TREATMENT", 15, 30], ["an increase in mortality", "PROBLEM", 95, 119], ["increase", "OBSERVATION_MODIFIER", 98, 106]]], ["Understating the mechanisms that contribute to an appropriate reparative response following RV infection will undoubtedly provide insight about the inappropriate (i.e. over-exuberant, disregulated, or prolonged) repair response that leads to pulmonary fibrosis or asthma exacerbations.", [["RV", "ANATOMY", 92, 94], ["pulmonary", "ANATOMY", 242, 251], ["RV infection", "DISEASE", 92, 104], ["fibrosis", "DISEASE", 252, 260], ["asthma", "DISEASE", 264, 270], ["pulmonary", "ORGAN", 242, 251], ["RV infection", "PROBLEM", 92, 104], ["repair response", "TREATMENT", 212, 227], ["pulmonary fibrosis", "PROBLEM", 242, 260], ["asthma exacerbations", "PROBLEM", 264, 284], ["RV", "ANATOMY", 92, 94], ["infection", "OBSERVATION", 95, 104], ["pulmonary", "ANATOMY", 242, 251], ["fibrosis", "OBSERVATION", 252, 260], ["asthma", "OBSERVATION", 264, 270]]], ["We argue that an active repair process, which includes the cooperative action of innate immune cells and regional stem cells that maintains barrier integrity under homeostatic conditions and reestablishes it in the event of epithelial loss associated with RV infection, must be considered to be an essential part of the overall host response to both RV and other infections of the RT.", [["immune cells", "ANATOMY", 88, 100], ["stem cells", "ANATOMY", 114, 124], ["barrier", "ANATOMY", 140, 147], ["epithelial", "ANATOMY", 224, 234], ["RV", "ANATOMY", 256, 258], ["epithelial loss", "DISEASE", 224, 239], ["RV infection", "DISEASE", 256, 268], ["infections", "DISEASE", 363, 373], ["innate immune cells", "CELL", 81, 100], ["regional stem cells", "CELL", 105, 124], ["barrier", "TISSUE", 140, 147], ["epithelial", "TISSUE", 224, 234], ["innate immune cells", "CELL_TYPE", 81, 100], ["regional stem cells", "CELL_TYPE", 105, 124], ["an active repair process", "TREATMENT", 14, 38], ["innate immune cells", "TREATMENT", 81, 100], ["regional stem cells", "PROBLEM", 105, 124], ["homeostatic conditions", "TREATMENT", 164, 186], ["epithelial loss", "PROBLEM", 224, 239], ["RV infection", "PROBLEM", 256, 268], ["other infections of the RT", "PROBLEM", 357, 383], ["active", "OBSERVATION_MODIFIER", 17, 23], ["repair", "OBSERVATION", 24, 30], ["regional stem cells", "OBSERVATION", 105, 124], ["barrier integrity", "OBSERVATION_MODIFIER", 140, 157], ["epithelial loss", "OBSERVATION", 224, 239], ["RV", "ANATOMY", 256, 258], ["infection", "OBSERVATION", 259, 268], ["host response", "OBSERVATION", 328, 341], ["RV", "ANATOMY", 350, 352], ["infections", "OBSERVATION", 363, 373]]]], "PMC3940032": [["ObservationThe 2\u2032,5\u2032-oligoadenylate (2-5A) synthetase (OAS)/RNase L system is a uniquely regulated innate immune pathway that restricts viral infections (reviewed in reference 1).", [["2\u2032,5\u2032-oligoadenylate (2-5A", "CHEMICAL", 15, 41], ["viral infections", "DISEASE", 136, 152], ["2\u2032,5\u2032-oligoadenylate", "CHEMICAL", 15, 35], ["2-5A) synthetase", "GENE_OR_GENE_PRODUCT", 37, 53], ["OAS", "GENE_OR_GENE_PRODUCT", 55, 58], ["RNase L", "GENE_OR_GENE_PRODUCT", 60, 67], ["oligoadenylate (2-5A) synthetase", "PROTEIN", 21, 53], ["OAS", "PROTEIN", 55, 58], ["RNase L", "PROTEIN", 60, 67], ["Observation", "TEST", 0, 11], ["The 2\u2032,5\u2032-oligoadenylate (2-5A) synthetase (OAS)/RNase L system", "TREATMENT", 11, 74], ["restricts viral infections", "PROBLEM", 126, 152]]], ["The interferon (IFN) inducible OAS family of proteins include pathogen recognition receptors for viral double-stranded RNA (dsRNA) that synthesize 2-5A from ATP.", [["2-5A", "CHEMICAL", 147, 151], ["ATP", "CHEMICAL", 157, 160], ["ATP", "CHEMICAL", 157, 160], ["interferon", "GENE_OR_GENE_PRODUCT", 4, 14], ["pathogen recognition receptors", "GENE_OR_GENE_PRODUCT", 62, 92], ["2-5A", "SIMPLE_CHEMICAL", 147, 151], ["ATP", "SIMPLE_CHEMICAL", 157, 160], ["interferon (IFN) inducible OAS family", "PROTEIN", 4, 41], ["pathogen recognition receptors", "PROTEIN", 62, 92], ["viral double-stranded RNA", "RNA", 97, 122], ["The interferon (IFN) inducible OAS family of proteins", "TREATMENT", 0, 53], ["pathogen recognition receptors", "TREATMENT", 62, 92], ["viral double-stranded RNA (dsRNA", "TREATMENT", 97, 129], ["stranded RNA", "OBSERVATION_MODIFIER", 110, 122]]], ["In mice, the enzymatically active species of OAS include OAS1a, OAS2, and OAS3 (reviewed in reference 2).", [["mice", "ORGANISM", 3, 7], ["OAS1a", "GENE_OR_GENE_PRODUCT", 57, 62], ["OAS1a", "PROTEIN", 57, 62], ["OAS2", "PROTEIN", 64, 68], ["OAS3", "PROTEIN", 74, 78], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["the enzymatically active species of OAS", "PROBLEM", 9, 48], ["OAS1a", "TEST", 57, 62], ["OAS2", "TEST", 64, 68], ["active", "OBSERVATION_MODIFIER", 27, 33]]], ["2-5A binds with high affinity and specificity to the latent cytoplasmic endoribonuclease, RNase L, causing its dimerization and activation (3).", [["cytoplasmic", "ANATOMY", 60, 71], ["2-5A", "CHEMICAL", 0, 4], ["2-5A", "SIMPLE_CHEMICAL", 0, 4], ["cytoplasmic", "ORGANISM_SUBSTANCE", 60, 71], ["RNase L", "GENE_OR_GENE_PRODUCT", 90, 97], ["latent cytoplasmic endoribonuclease", "PROTEIN", 53, 88], ["RNase L", "PROTEIN", 90, 97], ["high affinity", "PROBLEM", 16, 29], ["latent", "OBSERVATION_MODIFIER", 53, 59], ["cytoplasmic endoribonuclease", "OBSERVATION", 60, 88], ["RNase L", "OBSERVATION_MODIFIER", 90, 97], ["dimerization", "OBSERVATION", 111, 123]]], ["RNase L then cleaves both viral and cellular single-stranded regions of RNA, predominantly at UpU and UpA dinucleotides (4), leading to inhibition of viral replication in vivo (5).ObservationThe RNase L antiviral mechanism varies, depending on the types of RNA molecules that are cleaved (reviewed in reference 1).", [["cellular", "ANATOMY", 36, 44], ["dinucleotides", "CHEMICAL", 106, 119], ["RNase L", "GENE_OR_GENE_PRODUCT", 0, 7], ["cellular", "CELL", 36, 44], ["UpU", "GENE_OR_GENE_PRODUCT", 94, 97], ["RNase L", "GENE_OR_GENE_PRODUCT", 195, 202], ["RNase L", "PROTEIN", 0, 7], ["viral and cellular single-stranded regions", "DNA", 26, 68], ["UpU", "PROTEIN", 94, 97], ["RNase L", "PROTEIN", 195, 202], ["RNA molecules", "PROTEIN", 257, 270], ["RNase L", "TREATMENT", 0, 7], ["both viral and cellular single-stranded regions of RNA", "PROBLEM", 21, 75], ["UpA dinucleotides", "TREATMENT", 102, 119], ["viral replication", "TREATMENT", 150, 167], ["The RNase L antiviral mechanism", "TREATMENT", 191, 222], ["RNA molecules", "PROBLEM", 257, 270], ["viral", "OBSERVATION", 26, 31], ["cellular", "OBSERVATION_MODIFIER", 36, 44], ["single", "OBSERVATION_MODIFIER", 45, 51], ["stranded regions", "OBSERVATION_MODIFIER", 52, 68], ["RNA", "ANATOMY", 72, 75], ["viral replication", "OBSERVATION", 150, 167], ["RNase L", "OBSERVATION_MODIFIER", 195, 202], ["antiviral", "OBSERVATION", 203, 212]]], ["If the RNA substrate for RNase L is viral genomic single-stranded RNA, even a single cleavage event per viral genome might prevent replication.", [["RNase L", "GENE_OR_GENE_PRODUCT", 25, 32], ["RNase L", "PROTEIN", 25, 32], ["viral genomic single-stranded RNA", "RNA", 36, 69], ["viral genome", "DNA", 104, 116], ["the RNA substrate", "TEST", 3, 20], ["RNase", "PROBLEM", 25, 30], ["viral genomic single-stranded RNA", "PROBLEM", 36, 69], ["a single cleavage event", "PROBLEM", 76, 99], ["viral genome", "TREATMENT", 104, 116], ["viral genomic", "OBSERVATION", 36, 49], ["stranded RNA", "OBSERVATION_MODIFIER", 57, 69], ["viral genome", "OBSERVATION", 104, 116]]], ["Cleavage of viral mRNA is a mechanism that could potentially apply to RNA and DNA viruses with different replication strategies.", [["DNA", "CELLULAR_COMPONENT", 78, 81], ["viral mRNA", "RNA", 12, 22], ["viral mRNA", "PROBLEM", 12, 22], ["DNA viruses", "PROBLEM", 78, 89], ["different replication strategies", "TREATMENT", 95, 127], ["viral mRNA", "OBSERVATION", 12, 22]]], ["In addition, degradation of cellular RNA, including rRNA in intact ribosomes, could damage host cell machinery required for protein synthesis (6, 7).", [["cellular", "ANATOMY", 28, 36], ["ribosomes", "ANATOMY", 67, 76], ["cell", "ANATOMY", 96, 100], ["cellular", "CELL", 28, 36], ["rRNA", "CELLULAR_COMPONENT", 52, 56], ["ribosomes", "CELLULAR_COMPONENT", 67, 76], ["host cell", "CELL", 91, 100], ["cellular RNA", "RNA", 28, 40], ["rRNA", "RNA", 52, 56], ["cellular RNA", "PROBLEM", 28, 40], ["rRNA in intact ribosomes", "PROBLEM", 52, 76], ["protein synthesis", "TREATMENT", 124, 141], ["cellular RNA", "OBSERVATION", 28, 40], ["intact ribosomes", "OBSERVATION", 60, 76], ["host cell machinery", "OBSERVATION", 91, 110]]], ["Also, RNase L restricts viral infections by causing apoptosis through an unknown mechanism involving Jun N-terminal kinase (JNK) (5, 6, 8).", [["viral infections", "DISEASE", 24, 40], ["N", "CHEMICAL", 105, 106], ["RNase L", "GENE_OR_GENE_PRODUCT", 6, 13], ["Jun N-terminal kinase", "GENE_OR_GENE_PRODUCT", 101, 122], ["JNK", "GENE_OR_GENE_PRODUCT", 124, 127], ["RNase L", "PROTEIN", 6, 13], ["Jun N-terminal kinase", "PROTEIN", 101, 122], ["JNK", "PROTEIN", 124, 127], ["RNase L restricts viral infections", "PROBLEM", 6, 40], ["apoptosis", "PROBLEM", 52, 61], ["RNase L", "OBSERVATION_MODIFIER", 6, 13], ["restricts", "OBSERVATION_MODIFIER", 14, 23], ["viral infections", "OBSERVATION", 24, 40], ["terminal", "ANATOMY_MODIFIER", 107, 115], ["kinase", "ANATOMY", 116, 122]]], ["Furthermore, RNase L activation results in autophagy in a pathway involving JNK and protein kinase R (PKR) that can either enhance or decrease viral replication (9, 10).", [["RNase L", "GENE_OR_GENE_PRODUCT", 13, 20], ["JNK", "GENE_OR_GENE_PRODUCT", 76, 79], ["protein kinase R", "GENE_OR_GENE_PRODUCT", 84, 100], ["PKR", "GENE_OR_GENE_PRODUCT", 102, 105], ["RNase L", "PROTEIN", 13, 20], ["JNK", "PROTEIN", 76, 79], ["protein kinase R", "PROTEIN", 84, 100], ["PKR", "PROTEIN", 102, 105], ["RNase L activation", "TEST", 13, 31], ["JNK and protein kinase", "TEST", 76, 98], ["PKR", "TEST", 102, 105], ["decrease viral replication", "PROBLEM", 134, 160], ["decrease", "OBSERVATION_MODIFIER", 134, 142], ["viral replication", "OBSERVATION", 143, 160]]], ["Finally, RNase L indirectly controls viral infections by enhancing viral induction of IFN-\u03b2 induction in some cell types and in animals (11).ObservationRNase L amplifies IFN-\u03b2 induction by producing small RNA cleavage products from cellular or viral RNA that interact with RIG-I and MDA5 (11, 12).", [["cell", "ANATOMY", 110, 114], ["cellular", "ANATOMY", 232, 240], ["viral infections", "DISEASE", 37, 53], ["RNase L", "GENE_OR_GENE_PRODUCT", 9, 16], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 86, 91], ["cell", "CELL", 110, 114], ["ObservationRNase L", "GENE_OR_GENE_PRODUCT", 141, 159], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 170, 175], ["cellular", "CELL", 232, 240], ["RIG-I", "GENE_OR_GENE_PRODUCT", 273, 278], ["MDA5", "GENE_OR_GENE_PRODUCT", 283, 287], ["RNase L", "PROTEIN", 9, 16], ["IFN", "PROTEIN", 86, 89], ["\u03b2", "PROTEIN", 90, 91], ["IFN", "PROTEIN", 170, 173], ["\u03b2", "PROTEIN", 174, 175], ["cellular or viral RNA", "RNA", 232, 253], ["RIG-I", "PROTEIN", 273, 278], ["MDA5", "PROTEIN", 283, 287], ["RNase L indirectly controls viral infections", "PROBLEM", 9, 53], ["enhancing viral induction", "TREATMENT", 57, 82], ["IFN-\u03b2 induction", "TREATMENT", 86, 101], ["ObservationRNase L amplifies IFN", "TREATMENT", 141, 173], ["\u03b2 induction", "TREATMENT", 174, 185], ["small RNA cleavage products", "PROBLEM", 199, 226], ["viral RNA", "PROBLEM", 244, 253], ["viral infections", "OBSERVATION", 37, 53], ["enhancing", "OBSERVATION_MODIFIER", 57, 66], ["viral induction", "OBSERVATION_MODIFIER", 67, 82], ["some cell types", "OBSERVATION_MODIFIER", 105, 120], ["small", "OBSERVATION_MODIFIER", 199, 204], ["RNA cleavage", "OBSERVATION", 205, 217], ["viral RNA", "OBSERVATION", 244, 253]]], ["Accordingly, Rnasel\u2212/\u2212 mice produce less IFN-\u03b2, as measured in serum, after infection with encephalomyocarditis virus (EMCV) (intraperitoneally) or Sendai virus (intranasally) than do wild-type (WT) mice (11).", [["serum", "ANATOMY", 63, 68], ["intraperitoneally", "ANATOMY", 126, 143], ["infection", "DISEASE", 76, 85], ["Rnasel\u2212", "GENE_OR_GENE_PRODUCT", 13, 20], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 41, 46], ["serum", "ORGANISM_SUBSTANCE", 63, 68], ["encephalomyocarditis virus", "ORGANISM", 91, 117], ["EMCV", "ORGANISM", 119, 123], ["Sendai virus", "ORGANISM", 148, 160], ["wild-type (WT) mice", "ORGANISM", 184, 203], ["Rnasel\u2212", "PROTEIN", 13, 20], ["IFN-\u03b2", "PROTEIN", 41, 46], ["mice", "SPECIES", 23, 27], ["encephalomyocarditis virus", "SPECIES", 91, 117], ["Sendai virus", "SPECIES", 148, 160], ["mice", "SPECIES", 199, 203], ["mice", "SPECIES", 23, 27], ["encephalomyocarditis virus", "SPECIES", 91, 117], ["EMCV", "SPECIES", 119, 123], ["Sendai virus", "SPECIES", 148, 160], ["mice", "SPECIES", 199, 203], ["Rnasel\u2212/\u2212 mice", "TREATMENT", 13, 27], ["IFN", "TEST", 41, 44], ["infection", "PROBLEM", 76, 85], ["encephalomyocarditis virus", "PROBLEM", 91, 117], ["Sendai virus", "PROBLEM", 148, 160], ["infection", "OBSERVATION", 76, 85]]], ["The small RNA cleavage products produced by RNase L that enhance IFN-\u03b2 production can be either cellular (self) or viral (nonself) and typically have some double-strand regions, a 5\u2032-hydroxyl, and a phosphate at the 2\u2032,3\u2032-cyclic terminus (11, 12).", [["cellular", "ANATOMY", 96, 104], ["5\u2032-hydroxyl", "CHEMICAL", 180, 191], ["phosphate", "CHEMICAL", 199, 208], ["5\u2032-hydroxyl", "CHEMICAL", 180, 191], ["phosphate", "CHEMICAL", 199, 208], ["RNase L", "GENE_OR_GENE_PRODUCT", 44, 51], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 65, 70], ["cellular", "CELL", 96, 104], ["5\u2032-hydroxyl", "SIMPLE_CHEMICAL", 180, 191], ["phosphate", "SIMPLE_CHEMICAL", 199, 208], ["RNase L", "PROTEIN", 44, 51], ["IFN", "PROTEIN", 65, 68], ["\u03b2", "PROTEIN", 69, 70], ["double-strand regions", "DNA", 155, 176], ["The small RNA cleavage products", "TREATMENT", 0, 31], ["cellular (self) or viral (nonself)", "PROBLEM", 96, 130], ["some double-strand regions", "PROBLEM", 150, 176], ["a 5\u2032-hydroxyl", "TREATMENT", 178, 191], ["a phosphate", "TEST", 197, 208], ["small", "OBSERVATION_MODIFIER", 4, 9], ["RNA cleavage", "OBSERVATION", 10, 22], ["RNase L", "OBSERVATION_MODIFIER", 44, 51]]], ["Previously we showed in human hepatoma Huh7 cells that RNase L released a small RNA product from the NS5B region of hepatitis C virus (HCV) genomic RNA that bound to RIG-I, causing displacement of its repressor domain, stimulating its ATPase function, and propagating signaling through the mitochondrial antiviral signaling protein (MAVS) to the IFN-\u03b2 gene (12).", [["hepatoma Huh7 cells", "ANATOMY", 30, 49], ["mitochondrial", "ANATOMY", 290, 303], ["hepatitis C", "DISEASE", 116, 127], ["human", "ORGANISM", 24, 29], ["hepatoma Huh7 cells", "CELL", 30, 49], ["RNase L", "GENE_OR_GENE_PRODUCT", 55, 62], ["hepatitis C virus", "ORGANISM", 116, 133], ["HCV", "ORGANISM", 135, 138], ["RIG-I", "GENE_OR_GENE_PRODUCT", 166, 171], ["ATPase", "GENE_OR_GENE_PRODUCT", 235, 241], ["mitochondrial", "CELLULAR_COMPONENT", 290, 303], ["MAVS", "GENE_OR_GENE_PRODUCT", 333, 337], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 346, 351], ["human hepatoma Huh7 cells", "CELL_LINE", 24, 49], ["RNase L", "PROTEIN", 55, 62], ["NS5B region", "DNA", 101, 112], ["hepatitis C virus (HCV) genomic RNA", "RNA", 116, 151], ["RIG-I", "PROTEIN", 166, 171], ["repressor domain", "PROTEIN", 201, 217], ["ATPase", "PROTEIN", 235, 241], ["mitochondrial antiviral signaling protein", "PROTEIN", 290, 331], ["MAVS", "PROTEIN", 333, 337], ["IFN-\u03b2 gene", "DNA", 346, 356], ["human", "SPECIES", 24, 29], ["hepatitis C virus", "SPECIES", 116, 133], ["human", "SPECIES", 24, 29], ["hepatitis C virus", "SPECIES", 116, 133], ["HCV", "SPECIES", 135, 138], ["human hepatoma Huh7 cells", "PROBLEM", 24, 49], ["RNase L", "PROBLEM", 55, 62], ["a small RNA product", "PROBLEM", 72, 91], ["hepatitis C virus (HCV) genomic RNA", "PROBLEM", 116, 151], ["displacement of its repressor domain", "PROBLEM", 181, 217], ["propagating signaling", "PROBLEM", 256, 277], ["the mitochondrial antiviral signaling protein", "TREATMENT", 286, 331], ["the IFN", "TEST", 342, 349], ["hepatoma", "ANATOMY", 30, 38], ["Huh7 cells", "OBSERVATION", 39, 49], ["small RNA", "OBSERVATION_MODIFIER", 74, 83], ["NS5B", "OBSERVATION_MODIFIER", 101, 105], ["hepatitis", "OBSERVATION", 116, 125], ["displacement", "OBSERVATION_MODIFIER", 181, 193], ["mitochondrial antiviral", "OBSERVATION", 290, 313]]], ["The small RNA from HCV RNA was also shown to induce a hepatic innate immune response when injected into mice.", [["hepatic", "ANATOMY", 54, 61], ["HCV", "ORGANISM", 19, 22], ["hepatic", "ORGAN", 54, 61], ["mice", "ORGANISM", 104, 108], ["small RNA", "RNA", 4, 13], ["HCV RNA", "RNA", 19, 26], ["mice", "SPECIES", 104, 108], ["HCV", "SPECIES", 19, 22], ["mice", "SPECIES", 104, 108], ["The small RNA from HCV RNA", "PROBLEM", 0, 26], ["small", "OBSERVATION_MODIFIER", 4, 9], ["RNA", "OBSERVATION", 10, 13], ["HCV RNA", "OBSERVATION", 19, 26], ["hepatic", "ANATOMY", 54, 61]]], ["Similarly, an mRNA of parainfluenza virus 5 activated type I IFN production, independently of the encoded protein, by a pathway involving RNase L and MDA5 (13).", [["parainfluenza virus 5", "ORGANISM", 22, 43], ["type I IFN", "GENE_OR_GENE_PRODUCT", 54, 64], ["RNase L", "GENE_OR_GENE_PRODUCT", 138, 145], ["MDA5", "GENE_OR_GENE_PRODUCT", 150, 154], ["mRNA", "RNA", 14, 18], ["IFN", "PROTEIN", 61, 64], ["encoded protein", "PROTEIN", 98, 113], ["RNase L", "PROTEIN", 138, 145], ["MDA5 (13)", "PROTEIN", 150, 159], ["parainfluenza virus", "SPECIES", 22, 41], ["parainfluenza virus", "SPECIES", 22, 41], ["parainfluenza virus", "PROBLEM", 22, 41], ["parainfluenza virus", "OBSERVATION", 22, 41]]], ["Also RNase L was shown to be a factor in type I IFN induction in response to herpes simplex virus 2 infection (14).", [["herpes simplex virus 2 infection", "DISEASE", 77, 109], ["RNase L", "GENE_OR_GENE_PRODUCT", 5, 12], ["type I IFN", "GENE_OR_GENE_PRODUCT", 41, 51], ["herpes simplex virus 2", "ORGANISM", 77, 99], ["RNase L", "PROTEIN", 5, 12], ["IFN", "PROTEIN", 48, 51], ["herpes simplex virus", "SPECIES", 77, 97], ["herpes simplex virus", "SPECIES", 77, 97], ["a factor", "PROBLEM", 29, 37], ["type I IFN induction", "TREATMENT", 41, 61], ["herpes simplex virus 2 infection", "PROBLEM", 77, 109], ["herpes simplex", "OBSERVATION", 77, 91]]], ["Recently, we reported large differences (up to 100-fold) in basal expression of different OAS isoforms between different types of primary mouse cells (15).", [["cells", "ANATOMY", 144, 149], ["OAS", "GENE_OR_GENE_PRODUCT", 90, 93], ["mouse", "ORGANISM", 138, 143], ["cells", "CELL", 144, 149], ["OAS isoforms", "PROTEIN", 90, 102], ["primary mouse cells", "CELL_TYPE", 130, 149], ["mouse", "SPECIES", 138, 143], ["mouse", "SPECIES", 138, 143], ["large differences", "PROBLEM", 22, 39], ["different OAS isoforms", "PROBLEM", 80, 102], ["primary mouse cells", "PROBLEM", 130, 149], ["large", "OBSERVATION_MODIFIER", 22, 27], ["differences", "OBSERVATION_MODIFIER", 28, 39], ["basal", "ANATOMY_MODIFIER", 60, 65], ["different OAS", "OBSERVATION_MODIFIER", 80, 93], ["different types", "OBSERVATION_MODIFIER", 111, 126], ["primary mouse cells", "OBSERVATION", 130, 149]]], ["Notably, bone marrow-derived macrophages (BMMs), as well as primary microglia, brain resident macrophages, expressed the highest levels of different OAS isoforms compared with several other primary cell types.", [["bone marrow-derived macrophages", "ANATOMY", 9, 40], ["BMMs", "ANATOMY", 42, 46], ["primary microglia", "ANATOMY", 60, 77], ["brain resident macrophages", "ANATOMY", 79, 105], ["cell", "ANATOMY", 198, 202], ["bone marrow-derived macrophages", "CELL", 9, 40], ["BMMs", "CELL", 42, 46], ["microglia", "CELL", 68, 77], ["brain resident macrophages", "CELL", 79, 105], ["OAS", "GENE_OR_GENE_PRODUCT", 149, 152], ["cell", "CELL", 198, 202], ["bone marrow-derived macrophages", "CELL_TYPE", 9, 40], ["BMMs", "CELL_TYPE", 42, 46], ["primary microglia", "CELL_TYPE", 60, 77], ["brain resident macrophages", "CELL_TYPE", 79, 105], ["OAS isoforms", "PROTEIN", 149, 161], ["primary cell types", "CELL_TYPE", 190, 208], ["bone marrow-derived macrophages (BMMs)", "PROBLEM", 9, 47], ["different OAS isoforms", "PROBLEM", 139, 161], ["bone", "ANATOMY", 9, 13], ["marrow", "ANATOMY", 14, 20], ["macrophages", "OBSERVATION_MODIFIER", 29, 40], ["primary microglia", "OBSERVATION", 60, 77], ["brain", "ANATOMY", 79, 84], ["macrophages", "OBSERVATION", 94, 105], ["primary cell types", "OBSERVATION", 190, 208]]], ["In a separate study, peritoneal macrophages (p-Macs) were observed to have high basal expression of OAS (16).", [["peritoneal macrophages", "ANATOMY", 21, 43], ["peritoneal macrophages", "CELL", 21, 43], ["p-Macs", "GENE_OR_GENE_PRODUCT", 45, 51], ["peritoneal macrophages", "CELL_TYPE", 21, 43], ["a separate study", "TEST", 3, 19], ["peritoneal macrophages (p-Macs", "TREATMENT", 21, 51], ["high basal expression of OAS", "PROBLEM", 75, 103], ["peritoneal", "ANATOMY", 21, 31], ["macrophages", "OBSERVATION", 32, 43]]], ["In addition, we previously compared basal levels of RNase L in 9 rodent and 11 human cell lines (17).", [["cell lines", "ANATOMY", 85, 95], ["RNase L", "GENE_OR_GENE_PRODUCT", 52, 59], ["human", "ORGANISM", 79, 84], ["cell lines", "CELL", 85, 95], ["RNase L", "PROTEIN", 52, 59], ["human cell lines", "CELL_LINE", 79, 95], ["rodent", "SPECIES", 65, 71], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 79, 84], ["RNase L in 9 rodent", "TREATMENT", 52, 71], ["11 human cell lines", "TREATMENT", 76, 95], ["cell lines", "OBSERVATION", 85, 95]]], ["The mouse and human macrophage-like cell lines RAW264.7 and U937, respectively, were among the cell lines expressing the highest levels of RNase L protein.", [["macrophage-like cell lines RAW264.7", "ANATOMY", 20, 55], ["U937", "ANATOMY", 60, 64], ["cell lines", "ANATOMY", 95, 105], ["mouse", "ORGANISM", 4, 9], ["human", "ORGANISM", 14, 19], ["macrophage-like cell lines RAW264.7", "CELL", 20, 55], ["U937", "CELL", 60, 64], ["cell lines", "CELL", 95, 105], ["RNase L", "GENE_OR_GENE_PRODUCT", 139, 146], ["mouse and human macrophage-like cell lines", "CELL_LINE", 4, 46], ["RAW264.7", "CELL_LINE", 47, 55], ["U937", "CELL_LINE", 60, 64], ["cell lines", "CELL_LINE", 95, 105], ["RNase L protein", "PROTEIN", 139, 154], ["mouse", "SPECIES", 4, 9], ["human", "SPECIES", 14, 19], ["mouse", "SPECIES", 4, 9], ["human", "SPECIES", 14, 19], ["human macrophage", "TEST", 14, 30], ["U937", "TEST", 60, 64], ["the cell lines", "TREATMENT", 91, 105], ["RNase L protein", "TREATMENT", 139, 154], ["cell lines", "OBSERVATION", 36, 46], ["cell lines", "OBSERVATION", 95, 105]]], ["In the same study, different mouse fibroblast cell lines (NIH 3T3, SVT2, and L929) were shown to express relatively low levels of RNase L protein.", [["fibroblast cell lines", "ANATOMY", 35, 56], ["NIH 3T3", "ANATOMY", 58, 65], ["SVT2", "ANATOMY", 67, 71], ["L929", "ANATOMY", 77, 81], ["mouse", "ORGANISM", 29, 34], ["fibroblast cell lines", "CELL", 35, 56], ["NIH 3T3", "CELL", 58, 65], ["SVT2", "CELL", 67, 71], ["L929", "CELL", 77, 81], ["RNase L", "GENE_OR_GENE_PRODUCT", 130, 137], ["mouse fibroblast cell lines", "CELL_LINE", 29, 56], ["NIH 3T3", "CELL_LINE", 58, 65], ["SVT2", "CELL_LINE", 67, 71], ["L929", "CELL_LINE", 77, 81], ["RNase L protein", "PROTEIN", 130, 145], ["mouse", "SPECIES", 29, 34], ["mouse", "SPECIES", 29, 34], ["the same study", "TEST", 3, 17], ["different mouse fibroblast cell lines", "PROBLEM", 19, 56], ["NIH 3T3", "TEST", 58, 65], ["SVT2", "TEST", 67, 71], ["relatively low levels of RNase L protein", "PROBLEM", 105, 145], ["different", "OBSERVATION_MODIFIER", 19, 28], ["mouse", "OBSERVATION_MODIFIER", 29, 34], ["fibroblast cell lines", "OBSERVATION", 35, 56], ["relatively", "OBSERVATION_MODIFIER", 105, 115], ["low levels", "OBSERVATION_MODIFIER", 116, 126]]], ["However, the effect of RNase L on IFN induction might vary, depending on where the IFN is measured, the subtype of IFN being measured, the type of virus and its route of infection, and the type of cells that are infected.", [["cells", "ANATOMY", 197, 202], ["infection", "DISEASE", 170, 179], ["RNase L", "GENE_OR_GENE_PRODUCT", 23, 30], ["IFN", "GENE_OR_GENE_PRODUCT", 34, 37], ["IFN", "GENE_OR_GENE_PRODUCT", 83, 86], ["IFN", "GENE_OR_GENE_PRODUCT", 115, 118], ["cells", "CELL", 197, 202], ["RNase L", "PROTEIN", 23, 30], ["IFN", "PROTEIN", 34, 37], ["IFN", "PROTEIN", 83, 86], ["IFN", "PROTEIN", 115, 118], ["RNase L on IFN induction", "TREATMENT", 23, 47], ["IFN", "PROBLEM", 115, 118], ["the type of virus", "PROBLEM", 135, 152], ["infection", "PROBLEM", 170, 179], ["the type of cells", "PROBLEM", 185, 202], ["infected", "PROBLEM", 212, 220], ["infection", "OBSERVATION", 170, 179], ["infected", "OBSERVATION", 212, 220]]], ["Here we have investigated the last of these variables, namely cell-type-specific effects of RNase L on IFN induction.ObservationLevels of mRNAs for Rnasel and different Oas genes were monitored by quantitative reverse transcription-PCR (qRT-PCR) in MEF cell lines, BMMs, peritoneal macrophages (p-Macs), and freshly isolated splenic macrophages (Fig. 1A).", [["cell", "ANATOMY", 62, 66], ["MEF cell lines", "ANATOMY", 249, 263], ["BMMs", "ANATOMY", 265, 269], ["peritoneal macrophages", "ANATOMY", 271, 293], ["p-Macs", "ANATOMY", 295, 301], ["splenic macrophages", "ANATOMY", 325, 344], ["cell", "CELL", 62, 66], ["RNase L", "GENE_OR_GENE_PRODUCT", 92, 99], ["IFN", "GENE_OR_GENE_PRODUCT", 103, 106], ["Rnasel", "GENE_OR_GENE_PRODUCT", 148, 154], ["Oas", "GENE_OR_GENE_PRODUCT", 169, 172], ["MEF cell lines", "CELL", 249, 263], ["BMMs", "CELL", 265, 269], ["peritoneal macrophages", "CELL", 271, 293], ["p-Macs", "CELL", 295, 301], ["splenic macrophages", "CELL", 325, 344], ["Fig. 1A", "CELL", 346, 353], ["RNase L", "PROTEIN", 92, 99], ["IFN", "PROTEIN", 103, 106], ["mRNAs", "RNA", 138, 143], ["Rnasel", "PROTEIN", 148, 154], ["Oas genes", "DNA", 169, 178], ["MEF cell lines", "CELL_LINE", 249, 263], ["BMMs", "CELL_TYPE", 265, 269], ["peritoneal macrophages", "CELL_TYPE", 271, 293], ["p-Macs", "CELL_LINE", 295, 301], ["freshly isolated splenic macrophages", "CELL_TYPE", 308, 344], ["RNase L", "TREATMENT", 92, 99], ["IFN induction", "TREATMENT", 103, 116], ["mRNAs", "TREATMENT", 138, 143], ["Rnasel", "TREATMENT", 148, 154], ["quantitative reverse transcription", "TEST", 197, 231], ["PCR", "TEST", 232, 235], ["qRT", "TEST", 237, 240], ["PCR", "TEST", 241, 244], ["MEF cell lines", "TREATMENT", 249, 263], ["BMMs", "PROBLEM", 265, 269], ["peritoneal macrophages", "PROBLEM", 271, 293], ["freshly isolated splenic macrophages", "PROBLEM", 308, 344], ["cell lines", "OBSERVATION", 253, 263], ["peritoneal", "ANATOMY", 271, 281], ["macrophages", "OBSERVATION", 282, 293], ["splenic", "ANATOMY", 325, 332], ["macrophages", "OBSERVATION", 333, 344]]], ["Compared to MEFs, BMMs had elevated levels of mRNAs for Rnasel (200-fold), Oas1a (9-fold), Oas2 (34-fold), Oas3 (7-fold), and Oasl1 (32-fold) (Fig. 1A).", [["MEFs", "ANATOMY", 12, 16], ["BMMs", "ANATOMY", 18, 22], ["MEFs", "CELL", 12, 16], ["BMMs", "CELL", 18, 22], ["Rnasel", "GENE_OR_GENE_PRODUCT", 56, 62], ["Oas1a", "GENE_OR_GENE_PRODUCT", 75, 80], ["Oas2", "GENE_OR_GENE_PRODUCT", 91, 95], ["Oas3", "GENE_OR_GENE_PRODUCT", 107, 111], ["Oasl1", "GENE_OR_GENE_PRODUCT", 126, 131], ["MEFs", "CELL_TYPE", 12, 16], ["BMMs", "CELL_TYPE", 18, 22], ["mRNAs", "RNA", 46, 51], ["Rnasel", "PROTEIN", 56, 62], ["Oas1a", "PROTEIN", 75, 80], ["Oas2", "PROTEIN", 91, 95], ["Oas3", "PROTEIN", 107, 111], ["Oasl1", "PROTEIN", 126, 131], ["elevated levels of mRNAs", "PROBLEM", 27, 51], ["Rnasel", "TEST", 56, 62], ["Oas1a", "TEST", 75, 80], ["Oas2", "TEST", 91, 95], ["Oas3", "TEST", 107, 111], ["Oasl1", "TEST", 126, 131]]], ["Oas1a, Oas2, and Oas3 encode OAS isoforms that are enzymatically active, whereas Oasl1 encodes a protein that lacks the ability to synthesize 2-5A and is a negative regulator of type I IFN synthesis (18).", [["2-5A", "CHEMICAL", 142, 146], ["Oas1a", "GENE_OR_GENE_PRODUCT", 0, 5], ["Oas2", "GENE_OR_GENE_PRODUCT", 7, 11], ["Oas3", "GENE_OR_GENE_PRODUCT", 17, 21], ["OAS", "GENE_OR_GENE_PRODUCT", 29, 32], ["Oasl1", "GENE_OR_GENE_PRODUCT", 81, 86], ["2-5A", "GENE_OR_GENE_PRODUCT", 142, 146], ["type I IFN", "GENE_OR_GENE_PRODUCT", 178, 188], ["Oas1a", "PROTEIN", 0, 5], ["Oas2", "PROTEIN", 7, 11], ["Oas3", "PROTEIN", 17, 21], ["OAS isoforms", "PROTEIN", 29, 41], ["Oasl1", "PROTEIN", 81, 86], ["type I IFN", "PROTEIN", 178, 188], ["type I IFN synthesis", "PROBLEM", 178, 198], ["active", "OBSERVATION_MODIFIER", 65, 71]]], ["Similarly, compared to MEFs, p-Macs had increased levels of mRNAs for Rnasel (260-fold), Oas1a (7-fold), Oas2 (19-fold), Oas3 (3-fold), and Oasl1 (8-fold).", [["MEFs", "ANATOMY", 23, 27], ["MEFs", "CELL", 23, 27], ["p-Macs", "GENE_OR_GENE_PRODUCT", 29, 35], ["Rnasel", "GENE_OR_GENE_PRODUCT", 70, 76], ["Oas1a", "GENE_OR_GENE_PRODUCT", 89, 94], ["Oas2", "GENE_OR_GENE_PRODUCT", 105, 109], ["Oas3", "GENE_OR_GENE_PRODUCT", 121, 125], ["Oasl1", "GENE_OR_GENE_PRODUCT", 140, 145], ["MEFs", "CELL_TYPE", 23, 27], ["Macs", "DNA", 31, 35], ["mRNAs", "RNA", 60, 65], ["Rnasel", "PROTEIN", 70, 76], ["Oas1a", "PROTEIN", 89, 94], ["Oas2", "PROTEIN", 105, 109], ["Oas3", "PROTEIN", 121, 125], ["Oasl1", "PROTEIN", 140, 145], ["MEFs", "TEST", 23, 27], ["increased levels of mRNAs", "PROBLEM", 40, 65], ["Rnasel", "TEST", 70, 76], ["Oas1a", "TEST", 89, 94], ["Oas2", "TEST", 105, 109], ["Oas3", "TEST", 121, 125], ["Oasl1", "TEST", 140, 145], ["increased", "OBSERVATION_MODIFIER", 40, 49]]], ["To control for possible activation of macrophages in vitro, splenic macrophages were isolated by fluorescence-activated cell sorter (FACS) and immediately processed for RNA isolation followed by qRT-PCR.", [["macrophages", "ANATOMY", 38, 49], ["splenic macrophages", "ANATOMY", 60, 79], ["cell", "ANATOMY", 120, 124], ["macrophages", "CELL", 38, 49], ["splenic macrophages", "CELL", 60, 79], ["cell", "CELL", 120, 124], ["macrophages", "CELL_TYPE", 38, 49], ["splenic macrophages", "CELL_TYPE", 60, 79], ["FACS", "CELL_LINE", 133, 137], ["activation of macrophages", "PROBLEM", 24, 49], ["splenic macrophages", "PROBLEM", 60, 79], ["RNA isolation", "TREATMENT", 169, 182], ["macrophages", "OBSERVATION", 38, 49], ["splenic", "ANATOMY", 60, 67], ["macrophages", "OBSERVATION", 68, 79]]], ["Splenic macrophages also had increased basal levels of mRNAs for Rnasel (142-fold), Oas1a (4.6-fold), Oas2 (2.2-fold), and Oas3 (3.5-fold); however, Oasl1 mRNA levels were unchanged.", [["Splenic macrophages", "ANATOMY", 0, 19], ["Splenic macrophages", "CELL", 0, 19], ["Rnasel", "GENE_OR_GENE_PRODUCT", 65, 71], ["Oas1a", "GENE_OR_GENE_PRODUCT", 84, 89], ["Oas2", "GENE_OR_GENE_PRODUCT", 102, 106], ["Oas3", "GENE_OR_GENE_PRODUCT", 123, 127], ["Oasl1", "GENE_OR_GENE_PRODUCT", 149, 154], ["Splenic macrophages", "CELL_TYPE", 0, 19], ["mRNAs", "RNA", 55, 60], ["Rnasel", "PROTEIN", 65, 71], ["Oas1a", "PROTEIN", 84, 89], ["Oas2", "PROTEIN", 102, 106], ["Oas3", "PROTEIN", 123, 127], ["Oasl1 mRNA", "RNA", 149, 159], ["Splenic macrophages", "PROBLEM", 0, 19], ["increased basal levels of mRNAs", "PROBLEM", 29, 60], ["Rnasel", "TEST", 65, 71], ["Oas1a", "TEST", 84, 89], ["Oas2", "TEST", 102, 106], ["Oas3", "TEST", 123, 127], ["Oasl1 mRNA levels", "TEST", 149, 166], ["macrophages", "OBSERVATION", 8, 19], ["increased", "OBSERVATION_MODIFIER", 29, 38], ["basal", "OBSERVATION_MODIFIER", 39, 44], ["levels", "OBSERVATION_MODIFIER", 45, 51], ["unchanged", "OBSERVATION_MODIFIER", 172, 181]]], ["These findings show enhanced basal mRNA expression of Rnasel and most enzymatically active isoforms of OAS in macrophages compared with MEFs.", [["macrophages", "ANATOMY", 110, 121], ["MEFs", "ANATOMY", 136, 140], ["Rnasel", "GENE_OR_GENE_PRODUCT", 54, 60], ["OAS", "GENE_OR_GENE_PRODUCT", 103, 106], ["macrophages", "CELL", 110, 121], ["MEFs", "CELL", 136, 140], ["Rnasel", "PROTEIN", 54, 60], ["OAS", "PROTEIN", 103, 106], ["macrophages", "CELL_TYPE", 110, 121], ["MEFs", "CELL_TYPE", 136, 140], ["enhanced basal mRNA expression of Rnasel", "PROBLEM", 20, 60], ["OAS in macrophages", "PROBLEM", 103, 121], ["enhanced", "OBSERVATION_MODIFIER", 20, 28], ["basal", "ANATOMY_MODIFIER", 29, 34], ["mRNA expression", "OBSERVATION", 35, 50], ["most enzymatically", "OBSERVATION_MODIFIER", 65, 83], ["active", "OBSERVATION_MODIFIER", 84, 90], ["isoforms", "OBSERVATION_MODIFIER", 91, 99], ["OAS", "OBSERVATION_MODIFIER", 103, 106], ["macrophages", "OBSERVATION", 110, 121]]], ["Western blot assays were done to monitor differences in RNase L protein levels.", [["RNase L", "GENE_OR_GENE_PRODUCT", 56, 63], ["RNase L", "PROTEIN", 56, 63], ["Western blot assays", "TEST", 0, 19], ["RNase L protein levels", "TEST", 56, 78]]], ["Whereas RNase L was observed in wild-type BMMs, p-MACs, and splenic macrophages, RNase L was not observed in wild-type MEFs (Fig. 1B).", [["BMMs", "ANATOMY", 42, 46], ["splenic macrophages", "ANATOMY", 60, 79], ["MEFs", "ANATOMY", 119, 123], ["RNase L", "GENE_OR_GENE_PRODUCT", 8, 15], ["BMMs", "CELL", 42, 46], ["p-MACs", "GENE_OR_GENE_PRODUCT", 48, 54], ["splenic macrophages", "CELL", 60, 79], ["RNase L", "GENE_OR_GENE_PRODUCT", 81, 88], ["MEFs", "CELL", 119, 123], ["Fig. 1B", "CELL", 125, 132], ["RNase L", "PROTEIN", 8, 15], ["wild-type BMMs", "CELL_TYPE", 32, 46], ["MACs", "CELL_TYPE", 50, 54], ["splenic macrophages", "CELL_TYPE", 60, 79], ["RNase L", "PROTEIN", 81, 88], ["wild-type MEFs", "CELL_LINE", 109, 123], ["type BMMs", "PROBLEM", 37, 46], ["splenic macrophages", "PROBLEM", 60, 79], ["type BMMs", "OBSERVATION_MODIFIER", 37, 46], ["splenic", "ANATOMY", 60, 67], ["macrophages", "OBSERVATION", 68, 79]]], ["However, in WT MEFs, low levels of Rnasel mRNA were detected by qRT-PCR, and low levels of RNase L protein were apparent by monitoring characteristic, discrete rRNA cleavage products during poly(rI):poly(rC) (pIC) transfection or encephalomyocarditis virus (EMCV) infection (Fig. 1A and C, lanes 2 and 3, respectively).", [["MEFs", "ANATOMY", 15, 19], ["encephalomyocarditis virus (EMCV) infection", "DISEASE", 230, 273], ["poly(rI)", "CHEMICAL", 190, 198], ["poly(rC)", "CHEMICAL", 199, 207], ["MEFs", "CELL", 15, 19], ["Rnasel", "GENE_OR_GENE_PRODUCT", 35, 41], ["RNase L", "GENE_OR_GENE_PRODUCT", 91, 98], ["encephalomyocarditis virus", "ORGANISM", 230, 256], ["EMCV", "ORGANISM", 258, 262], ["Rnasel mRNA", "RNA", 35, 46], ["RNase L protein", "PROTEIN", 91, 106], ["rRNA cleavage products", "PROTEIN", 160, 182], ["encephalomyocarditis virus", "SPECIES", 230, 256], ["encephalomyocarditis virus", "SPECIES", 230, 256], ["EMCV", "SPECIES", 258, 262], ["WT MEFs", "TEST", 12, 19], ["low levels of Rnasel mRNA", "PROBLEM", 21, 46], ["qRT", "TEST", 64, 67], ["PCR", "TEST", 68, 71], ["low levels of RNase L protein", "PROBLEM", 77, 106], ["discrete rRNA cleavage products", "TREATMENT", 151, 182], ["poly(rC) (pIC) transfection", "PROBLEM", 199, 226], ["encephalomyocarditis virus (EMCV) infection", "PROBLEM", 230, 273], ["rRNA cleavage", "OBSERVATION", 160, 173], ["encephalomyocarditis virus", "OBSERVATION", 230, 256]]], ["The rRNA fragments were, however, produced at much higher levels in p-Macs and BMMs than in MEFs (Fig. 1C, lanes 5, 6, 8, and 9).", [["fragments", "ANATOMY", 9, 18], ["BMMs", "ANATOMY", 79, 83], ["MEFs", "ANATOMY", 92, 96], ["p-Macs", "GENE_OR_GENE_PRODUCT", 68, 74], ["BMMs", "CELL", 79, 83], ["MEFs", "CELL", 92, 96], ["rRNA fragments", "DNA", 4, 18], ["Macs", "CELL_TYPE", 70, 74], ["BMMs", "CELL_TYPE", 79, 83], ["MEFs", "CELL_TYPE", 92, 96], ["The rRNA fragments", "PROBLEM", 0, 18], ["MEFs", "TEST", 92, 96], ["rRNA fragments", "OBSERVATION", 4, 18]]], ["Consistent with our prior results (11), 2-5A transfection induced IFN-\u03b2 in WT MEFs but not in Rnasel\u2212/\u2212 MEFs, as determined by enzyme-linked immunosorbent assay (ELISA) (Fig. 1D).", [["MEFs", "ANATOMY", 78, 82], ["Rnasel\u2212/\u2212 MEFs", "ANATOMY", 94, 108], ["2-5A", "SIMPLE_CHEMICAL", 40, 44], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 66, 71], ["WT MEFs", "CELL", 75, 82], ["Rnasel\u2212/\u2212 MEFs", "CELL", 94, 108], ["IFN-\u03b2", "PROTEIN", 66, 71], ["Rnasel\u2212/\u2212 MEFs", "CELL_LINE", 94, 108], ["A transfection induced IFN", "TREATMENT", 43, 69], ["WT MEFs", "PROBLEM", 75, 82], ["enzyme", "TEST", 127, 133], ["immunosorbent assay", "TEST", 141, 160]]], ["In contrast, 2-5A transfection failed to induce IFN-\u03b2 in either WT or Rnasel\u2212/\u2212 BMMs (Fig. 1D).", [["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 48, 53], ["IFN", "PROTEIN", 48, 51], ["\u03b2", "PROTEIN", 52, 53], ["Rnasel\u2212/\u2212 BMMs", "CELL_LINE", 70, 84], ["A transfection", "TREATMENT", 16, 30], ["IFN", "TEST", 48, 51], ["\u03b2", "PROBLEM", 52, 53]]], ["We verified uptake of 2-5A and activation of RNase L in BMMs with rRNA cleavage assays (data not shown).ObservationTo determine effects of RNase L on IFN-\u03b2 induction by dsRNA, cells were transfected with different concentration of pIC (Fig. 1E).", [["BMMs", "ANATOMY", 56, 60], ["cells", "ANATOMY", 176, 181], ["2-5A", "CHEMICAL", 22, 26], ["2-5A", "SIMPLE_CHEMICAL", 22, 26], ["RNase L", "GENE_OR_GENE_PRODUCT", 45, 52], ["BMMs", "CELL", 56, 60], ["RNase L", "GENE_OR_GENE_PRODUCT", 139, 146], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 150, 155], ["cells", "CELL", 176, 181], ["RNase L", "PROTEIN", 45, 52], ["BMMs", "CELL_TYPE", 56, 60], ["RNase L", "PROTEIN", 139, 146], ["IFN", "PROTEIN", 150, 153], ["\u03b2", "PROTEIN", 154, 155], ["pIC", "PROTEIN", 231, 234], ["uptake", "TEST", 12, 18], ["RNase L in BMMs", "TREATMENT", 45, 60], ["rRNA cleavage assays", "TEST", 66, 86], ["RNase L", "TREATMENT", 139, 146], ["IFN", "TREATMENT", 150, 153], ["pIC (Fig. 1E", "TREATMENT", 231, 243], ["uptake", "OBSERVATION_MODIFIER", 12, 18]]], ["Similar to our prior study (11), RNase L enhanced IFN-\u03b2 induction to a much greater extent in WT MEFs than in Rnasel\u2212/\u2212 MEFs (Fig. 1E).", [["MEFs", "ANATOMY", 97, 101], ["Rnasel\u2212/\u2212 MEFs", "ANATOMY", 110, 124], ["RNase L", "GENE_OR_GENE_PRODUCT", 33, 40], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 50, 55], ["MEFs", "CELL", 97, 101], ["Rnasel\u2212/\u2212 MEFs", "CELL", 110, 124], ["RNase L", "PROTEIN", 33, 40], ["IFN", "PROTEIN", 50, 53], ["\u03b2", "PROTEIN", 54, 55], ["WT MEFs", "CELL_LINE", 94, 101], ["Rnasel\u2212/\u2212 MEFs", "CELL_LINE", 110, 124], ["our prior study", "TEST", 11, 26], ["RNase L enhanced IFN", "TREATMENT", 33, 53], ["\u03b2 induction", "TREATMENT", 54, 65]]], ["Remarkably, however, the effect of RNase L on IFN induction was reversed in both BMMs and p-MACs.", [["BMMs", "ANATOMY", 81, 85], ["RNase L", "GENE_OR_GENE_PRODUCT", 35, 42], ["IFN", "GENE_OR_GENE_PRODUCT", 46, 49], ["BMMs", "CELL", 81, 85], ["p-MACs", "SIMPLE_CHEMICAL", 90, 96], ["RNase L", "PROTEIN", 35, 42], ["IFN", "PROTEIN", 46, 49], ["BMMs", "CELL_TYPE", 81, 85], ["RNase L on IFN induction", "TREATMENT", 35, 59]]], ["IFN-\u03b2 accumulated to higher levels in Rnasel\u2212/\u2212 BMMs (6.5-fold) and p-Macs (4.5-fold) than in WT p-Macs and BMMs (in response to 2 \u00b5g per ml of pIC) (Fig. 1E).", [["Rnasel\u2212/\u2212 BMMs", "ANATOMY", 38, 52], ["BMMs", "ANATOMY", 108, 112], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 0, 5], ["p-Macs", "GENE_OR_GENE_PRODUCT", 68, 74], ["p-Macs", "GENE_OR_GENE_PRODUCT", 97, 103], ["BMMs", "CELL", 108, 112], ["IFN", "PROTEIN", 0, 3], ["\u03b2", "PROTEIN", 4, 5], ["BMMs", "CELL_TYPE", 48, 52], ["Macs", "PROTEIN", 70, 74], ["BMMs", "CELL_TYPE", 108, 112], ["IFN", "TEST", 0, 3], ["Rnasel\u2212", "TEST", 38, 45], ["BMMs", "TEST", 48, 52], ["Macs", "TEST", 70, 74], ["higher levels", "OBSERVATION_MODIFIER", 21, 34], ["BMMs", "OBSERVATION", 48, 52]]], ["Without transfection reagent, however, there was no effect of RNase L deletion on pIC induction of IFN-\u03b2 in BMMs and p-Macs, suggesting that Toll-like receptor 3 (TLR3)-mediated induction of IFN was unaffected by RNase L (19) (data not shown).ObservationTo extend these studies to viral induction of IFN-\u03b2, cells were infected with EMCV.", [["BMMs", "ANATOMY", 108, 112], ["cells", "ANATOMY", 307, 312], ["RNase L", "GENE_OR_GENE_PRODUCT", 62, 69], ["pIC", "GENE_OR_GENE_PRODUCT", 82, 85], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 99, 104], ["BMMs", "CELL", 108, 112], ["p-Macs", "GENE_OR_GENE_PRODUCT", 117, 123], ["Toll-like receptor 3", "GENE_OR_GENE_PRODUCT", 141, 161], ["TLR3", "GENE_OR_GENE_PRODUCT", 163, 167], ["IFN", "GENE_OR_GENE_PRODUCT", 191, 194], ["RNase L", "GENE_OR_GENE_PRODUCT", 213, 220], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 300, 305], ["cells", "CELL", 307, 312], ["EMCV", "ORGANISM", 332, 336], ["RNase L", "PROTEIN", 62, 69], ["IFN", "PROTEIN", 99, 102], ["\u03b2", "PROTEIN", 103, 104], ["BMMs", "CELL_TYPE", 108, 112], ["Macs", "PROTEIN", 119, 123], ["TLR3", "PROTEIN", 163, 167], ["IFN", "PROTEIN", 191, 194], ["RNase L", "PROTEIN", 213, 220], ["IFN", "PROTEIN", 300, 303], ["\u03b2", "PROTEIN", 304, 305], ["EMCV", "SPECIES", 332, 336], ["transfection reagent", "TREATMENT", 8, 28], ["RNase L deletion", "PROBLEM", 62, 78], ["pIC induction", "TREATMENT", 82, 95], ["IFN", "TREATMENT", 99, 102], ["Toll-like receptor 3 (TLR3)-mediated induction of IFN", "TREATMENT", 141, 194], ["these studies", "TEST", 264, 277], ["viral induction", "TREATMENT", 281, 296], ["IFN", "TEST", 300, 303], ["cells", "PROBLEM", 307, 312], ["EMCV", "TREATMENT", 332, 336], ["no", "UNCERTAINTY", 49, 51]]], ["Viral infection induced IFN-\u03b2 in WT MEFs but not in Rnasel\u2212/\u2212 MEFs (Fig. 1F).", [["MEFs", "ANATOMY", 36, 40], ["Rnasel\u2212/\u2212 MEFs", "ANATOMY", 52, 66], ["Viral infection", "DISEASE", 0, 15], ["Viral", "ORGANISM", 0, 5], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 24, 29], ["WT MEFs", "CELL", 33, 40], ["IFN", "PROTEIN", 24, 27], ["\u03b2", "PROTEIN", 28, 29], ["Rnasel\u2212/\u2212 MEFs", "CELL_LINE", 52, 66], ["Viral infection", "PROBLEM", 0, 15], ["IFN", "TEST", 24, 27], ["WT MEFs", "PROBLEM", 33, 40], ["infection", "OBSERVATION", 6, 15]]], ["Again, there was a reversal of the effect of RNase L on IFN-\u03b2 induction in the myeloid cell types.", [["myeloid cell", "ANATOMY", 79, 91], ["RNase L", "GENE_OR_GENE_PRODUCT", 45, 52], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 56, 61], ["myeloid cell", "CELL", 79, 91], ["RNase L", "PROTEIN", 45, 52], ["IFN", "PROTEIN", 56, 59], ["\u03b2", "PROTEIN", 60, 61], ["myeloid cell types", "CELL_TYPE", 79, 97], ["RNase L", "TREATMENT", 45, 52], ["IFN", "TREATMENT", 56, 59], ["\u03b2 induction", "TREATMENT", 60, 71], ["myeloid cell types", "OBSERVATION", 79, 97]]], ["Deletion of RNase L increased IFN-\u03b2 production in response to EMCV infection by about 2-fold in p-Macs and BMMs (Fig. 1F).", [["BMMs", "ANATOMY", 107, 111], ["infection", "DISEASE", 67, 76], ["RNase L", "GENE_OR_GENE_PRODUCT", 12, 19], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 30, 35], ["EMCV", "ORGANISM", 62, 66], ["p-Macs", "SIMPLE_CHEMICAL", 96, 102], ["BMMs", "CELL", 107, 111], ["RNase L", "PROTEIN", 12, 19], ["IFN", "PROTEIN", 30, 33], ["\u03b2", "PROTEIN", 34, 35], ["BMMs", "CELL_TYPE", 107, 111], ["EMCV", "SPECIES", 62, 66], ["Deletion of RNase L increased IFN", "PROBLEM", 0, 33], ["\u03b2 production", "PROBLEM", 34, 46], ["EMCV infection", "PROBLEM", 62, 76], ["RNase L", "OBSERVATION_MODIFIER", 12, 19], ["increased", "OBSERVATION_MODIFIER", 20, 29], ["IFN", "OBSERVATION_MODIFIER", 30, 33], ["EMCV infection", "OBSERVATION", 62, 76]]], ["To determine if the differences in viral induction of IFN-\u03b2 were related to the antiviral effect of RNase L, after one cycle of virus growth (8 h at a multiplicity of infection [MOI] of 0.1), viral yields were measured by plaque assays on type I IFN receptor (Ifnar)\u2212/\u2212 MEF indicator cells.", [["plaque", "ANATOMY", 222, 228], ["Ifnar)\u2212/\u2212 MEF indicator cells", "ANATOMY", 260, 289], ["infection", "DISEASE", 167, 176], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 54, 59], ["RNase L", "GENE_OR_GENE_PRODUCT", 100, 107], ["type I IFN receptor", "GENE_OR_GENE_PRODUCT", 239, 258], ["Ifnar", "GENE_OR_GENE_PRODUCT", 260, 265], ["cells", "CELL", 284, 289], ["IFN-\u03b2", "PROTEIN", 54, 59], ["RNase L", "PROTEIN", 100, 107], ["type I IFN receptor (Ifnar)\u2212/\u2212 MEF indicator cells", "CELL_LINE", 239, 289], ["IFN", "TEST", 54, 57], ["RNase L", "TREATMENT", 100, 107], ["virus growth", "PROBLEM", 128, 140], ["infection", "PROBLEM", 167, 176], ["viral yields", "PROBLEM", 192, 204], ["plaque assays", "TEST", 222, 235], ["type I IFN receptor", "TREATMENT", 239, 258], ["MEF indicator cells", "PROBLEM", 270, 289], ["plaque", "OBSERVATION", 222, 228]]], ["Viral yields were increased 85-, 8-, and 5-fold in Rnasel\u2212/\u2212 MEFs, p-Macs, and BMMs, respectively, compared to the corresponding WT cells (Fig. 1G).", [["Rnasel\u2212/\u2212 MEFs", "ANATOMY", 51, 65], ["p-Macs", "ANATOMY", 67, 73], ["BMMs", "ANATOMY", 79, 83], ["cells", "ANATOMY", 132, 137], ["Viral", "ORGANISM", 0, 5], ["MEFs", "CELL", 61, 65], ["p-Macs", "GENE_OR_GENE_PRODUCT", 67, 73], ["BMMs", "CELL", 79, 83], ["cells", "CELL", 132, 137], ["Fig. 1G", "CELL", 139, 146], ["Rnasel\u2212/\u2212 MEFs", "CELL_LINE", 51, 65], ["Macs", "CELL_LINE", 69, 73], ["BMMs", "CELL_TYPE", 79, 83], ["WT cells", "CELL_TYPE", 129, 137], ["Viral yields", "TEST", 0, 12], ["Rnasel\u2212", "TEST", 51, 58], ["MEFs", "TEST", 61, 65], ["increased", "OBSERVATION_MODIFIER", 18, 27]]], ["Therefore, RNase L deficiency resulted in higher viral yields in MEFs than in p-Macs and BMMs.", [["MEFs", "ANATOMY", 65, 69], ["BMMs", "ANATOMY", 89, 93], ["RNase L", "GENE_OR_GENE_PRODUCT", 11, 18], ["MEFs", "CELL", 65, 69], ["p-Macs", "GENE_OR_GENE_PRODUCT", 78, 84], ["BMMs", "CELL", 89, 93], ["RNase L", "PROTEIN", 11, 18], ["MEFs", "CELL_TYPE", 65, 69], ["Macs", "CELL_TYPE", 80, 84], ["BMMs", "CELL_TYPE", 89, 93], ["RNase L deficiency", "PROBLEM", 11, 29], ["higher viral yields in MEFs", "PROBLEM", 42, 69], ["BMMs", "PROBLEM", 89, 93], ["RNase L", "OBSERVATION_MODIFIER", 11, 18], ["deficiency", "OBSERVATION", 19, 29], ["higher", "OBSERVATION_MODIFIER", 42, 48], ["viral yields", "OBSERVATION", 49, 61], ["BMMs", "OBSERVATION", 89, 93]]], ["These results are consistent with the observation that RNase L gene knockout increased IFN-\u03b2 production in p-Macs and BMMs but decreased IFN-\u03b2 production in MEFs.", [["p-Macs", "ANATOMY", 107, 113], ["BMMs", "ANATOMY", 118, 122], ["MEFs", "ANATOMY", 157, 161], ["RNase L", "GENE_OR_GENE_PRODUCT", 55, 62], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 87, 92], ["p-Macs", "GENE_OR_GENE_PRODUCT", 107, 113], ["BMMs", "CELL", 118, 122], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 137, 142], ["MEFs", "CELL", 157, 161], ["RNase L gene", "DNA", 55, 67], ["IFN", "PROTEIN", 87, 90], ["\u03b2", "PROTEIN", 91, 92], ["BMMs", "CELL_TYPE", 118, 122], ["IFN", "PROTEIN", 137, 140], ["\u03b2", "PROTEIN", 141, 142], ["MEFs", "CELL_TYPE", 157, 161], ["the observation", "TEST", 34, 49], ["RNase L gene knockout increased IFN", "PROBLEM", 55, 90], ["BMMs", "PROBLEM", 118, 122], ["decreased IFN", "PROBLEM", 127, 140], ["production in MEFs", "PROBLEM", 143, 161], ["consistent with", "UNCERTAINTY", 18, 33], ["increased", "OBSERVATION_MODIFIER", 77, 86]]], ["In the Rnasel\u2212/\u2212 MEFs, the decrease in IFN-\u03b2 production in combination with a loss of nuclease activity likely combined to cause an increase in EMCV titers.", [["Rnasel\u2212/\u2212 MEFs", "ANATOMY", 7, 21], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 39, 44], ["EMCV", "ORGANISM", 144, 148], ["Rnasel\u2212/\u2212 MEFs", "CELL_LINE", 7, 21], ["IFN", "PROTEIN", 39, 42], ["\u03b2", "PROTEIN", 43, 44], ["nuclease", "PROTEIN", 86, 94], ["EMCV", "SPECIES", 144, 148], ["the decrease in IFN-\u03b2 production", "PROBLEM", 23, 55], ["a loss of nuclease activity", "PROBLEM", 76, 103], ["an increase in EMCV titers", "PROBLEM", 129, 155], ["decrease", "OBSERVATION_MODIFIER", 27, 35], ["increase", "OBSERVATION_MODIFIER", 132, 140], ["EMCV titers", "OBSERVATION", 144, 155]]], ["In Rnasel\u2212/\u2212 BMMs, the absence of nuclease activity normally provided by RNase L overrides the increase in IFN levels, allowing virus to replicate to higher titers in Rnasel\u2212/\u2212 than in WT macrophages.ObservationApoptosis is known to occur in cells that sustain high levels of RNA damage due to RNase L activity (5, 6, 8).", [["Rnasel\u2212/\u2212 BMMs", "ANATOMY", 3, 17], ["macrophages", "ANATOMY", 188, 199], ["cells", "ANATOMY", 242, 247], ["ObservationApoptosis", "DISEASE", 200, 220], ["RNase L", "GENE_OR_GENE_PRODUCT", 73, 80], ["IFN", "GENE_OR_GENE_PRODUCT", 107, 110], ["Rnasel\u2212", "GENE_OR_GENE_PRODUCT", 167, 174], ["\u2212", "GENE_OR_GENE_PRODUCT", 175, 176], ["WT macrophages", "CELL", 185, 199], ["cells", "CELL", 242, 247], ["RNase L", "GENE_OR_GENE_PRODUCT", 294, 301], ["Rnasel\u2212/\u2212 BMMs", "CELL_LINE", 3, 17], ["nuclease", "PROTEIN", 34, 42], ["RNase L", "PROTEIN", 73, 80], ["IFN", "PROTEIN", 107, 110], ["Rnasel\u2212", "PROTEIN", 167, 174], ["WT macrophages", "CELL_TYPE", 185, 199], ["RNase L", "PROTEIN", 294, 301], ["nuclease activity", "PROBLEM", 34, 51], ["the increase in IFN levels", "PROBLEM", 91, 117], ["virus", "PROBLEM", 128, 133], ["RNA damage", "PROBLEM", 276, 286], ["RNase L activity", "PROBLEM", 294, 310], ["BMMs", "OBSERVATION", 13, 17], ["increase", "OBSERVATION_MODIFIER", 95, 103]]], ["Therefore, cell viability and apoptosis were monitored in cell types expressing low and high basal levels of OAS and RNase L. There was no effect on cell viability of pIC transfection in WT MEFs or Rnasel\u2212/\u2212 MEFs as determined by 3-(4,5-dimethyl-2-thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) colorimetric assays (Fig. 2A).", [["cell", "ANATOMY", 11, 15], ["cell", "ANATOMY", 58, 62], ["cell", "ANATOMY", 149, 153], ["pIC", "ANATOMY", 167, 170], ["MEFs", "ANATOMY", 190, 194], ["Rnasel\u2212/\u2212 MEFs", "ANATOMY", 198, 212], ["3-(4,5-dimethyl-2-thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium", "CHEMICAL", 230, 321], ["MTS", "CHEMICAL", 323, 326], ["3-(4,5-dimethyl-2-thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium", "CHEMICAL", 230, 321], ["MTS", "CHEMICAL", 323, 326], ["cell", "CELL", 11, 15], ["cell", "CELL", 58, 62], ["RNase L.", "GENE_OR_GENE_PRODUCT", 117, 125], ["cell", "CELL", 149, 153], ["pIC", "GENE_OR_GENE_PRODUCT", 167, 170], ["MEFs", "CELL", 190, 194], ["Rnasel\u2212/\u2212 MEFs", "CELL", 198, 212], ["3-(4,5-dimethyl-2-thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium", "SIMPLE_CHEMICAL", 230, 321], ["MTS", "SIMPLE_CHEMICAL", 323, 326], ["OAS", "PROTEIN", 109, 112], ["WT MEFs", "CELL_LINE", 187, 194], ["Rnasel\u2212/\u2212 MEFs", "CELL_LINE", 198, 212], ["cell viability", "TEST", 11, 25], ["apoptosis", "TEST", 30, 39], ["low and high basal levels of OAS and RNase L.", "PROBLEM", 80, 125], ["pIC transfection", "TREATMENT", 167, 183], ["Rnasel\u2212", "TEST", 198, 205], ["carboxymethoxyphenyl)", "TREATMENT", 267, 288], ["tetrazolium (MTS", "TREATMENT", 310, 326], ["colorimetric assays", "TEST", 328, 347], ["cell viability", "OBSERVATION", 11, 25], ["no", "UNCERTAINTY", 136, 138]]], ["In contrast, pIC transfection reduced viability of WT p-Macs or BMMs by ~2-fold, whereas pIC transfection had no effect on viability of Rnasel\u2212/\u2212 p-Macs or BMMs.", [["WT p-Macs", "ANATOMY", 51, 60], ["BMMs", "ANATOMY", 64, 68], ["Rnasel\u2212/\u2212 p-Macs", "ANATOMY", 136, 152], ["BMMs", "ANATOMY", 156, 160], ["pIC", "GENE_OR_GENE_PRODUCT", 13, 16], ["p-Macs", "GENE_OR_GENE_PRODUCT", 54, 60], ["BMMs", "CELL", 64, 68], ["pIC", "GENE_OR_GENE_PRODUCT", 89, 92], ["BMMs", "CELL", 156, 160], ["pIC", "PROTEIN", 13, 16], ["WT p-Macs", "CELL_LINE", 51, 60], ["BMMs", "CELL_TYPE", 64, 68], ["pIC", "PROTEIN", 89, 92], ["Rnasel\u2212/\u2212 p-Macs", "CELL_LINE", 136, 152], ["BMMs", "CELL_TYPE", 156, 160], ["pIC transfection", "TREATMENT", 13, 29], ["pIC transfection", "TEST", 89, 105], ["Rnasel\u2212", "TEST", 136, 143], ["BMMs", "PROBLEM", 156, 160], ["reduced", "OBSERVATION_MODIFIER", 30, 37], ["viability", "OBSERVATION_MODIFIER", 38, 47], ["no", "UNCERTAINTY", 110, 112]]], ["Similarly, no apoptosis was detected in pIC-transfected WT or Rnasel\u2212/\u2212 MEFs as determined by lack of caspase 3/7 activation (Fig. 2B).", [["Rnasel\u2212/\u2212 MEFs", "ANATOMY", 62, 76], ["pIC", "GENE_OR_GENE_PRODUCT", 40, 43], ["WT", "CELL", 56, 58], ["Rnasel\u2212/\u2212 MEFs", "CELL", 62, 76], ["caspase 3/7", "GENE_OR_GENE_PRODUCT", 102, 113], ["pIC-transfected WT", "CELL_LINE", 40, 58], ["Rnasel\u2212/\u2212 MEFs", "CELL_LINE", 62, 76], ["caspase 3/7", "PROTEIN", 102, 113], ["apoptosis", "PROBLEM", 14, 23], ["Rnasel\u2212/\u2212 MEFs", "TREATMENT", 62, 76], ["no", "UNCERTAINTY", 11, 13], ["apoptosis", "OBSERVATION", 14, 23]]], ["However, caspase activation assays showed that pIC transfection induced apoptosis of WT p-Macs and BMMs, but not in Rnasel\u2212/\u2212 p-MACs and BMMs (Fig. 2B).", [["WT p-Macs", "ANATOMY", 85, 94], ["BMMs", "ANATOMY", 99, 103], ["BMMs", "ANATOMY", 137, 141], ["caspase", "GENE_OR_GENE_PRODUCT", 9, 16], ["pIC", "GENE_OR_GENE_PRODUCT", 47, 50], ["p-Macs", "GENE_OR_GENE_PRODUCT", 88, 94], ["BMMs", "CELL", 99, 103], ["BMMs", "CELL", 137, 141], ["caspase", "PROTEIN", 9, 16], ["pIC", "PROTEIN", 47, 50], ["BMMs", "CELL_TYPE", 99, 103], ["Rnasel\u2212/\u2212 p-MACs", "CELL_LINE", 116, 132], ["BMMs", "CELL_TYPE", 137, 141], ["caspase activation assays", "TEST", 9, 34], ["pIC transfection", "PROBLEM", 47, 63], ["WT", "TEST", 85, 87], ["BMMs", "PROBLEM", 99, 103], ["Rnasel\u2212", "TEST", 116, 123]]], ["These results were confirmed by monitoring poly(ADP-ribose) polymerase (PARP) cleavage in Western blots (Fig. 2C).", [["poly(ADP-ribose", "CHEMICAL", 43, 58], ["poly(ADP-ribose)", "CHEMICAL", 43, 59], ["poly(ADP-ribose) polymerase", "GENE_OR_GENE_PRODUCT", 43, 70], ["PARP", "GENE_OR_GENE_PRODUCT", 72, 76], ["poly(ADP-ribose) polymerase", "PROTEIN", 43, 70], ["PARP", "PROTEIN", 72, 76], ["monitoring poly(ADP-ribose) polymerase (PARP) cleavage", "TREATMENT", 32, 86]]], ["Cleaved PARP was observed after pIC transfection of WT BMMs and p-Macs but not in identically treated WT MEFs.", [["BMMs", "ANATOMY", 55, 59], ["MEFs", "ANATOMY", 105, 109], ["PARP", "GENE_OR_GENE_PRODUCT", 8, 12], ["BMMs", "CELL", 55, 59], ["p-Macs", "GENE_OR_GENE_PRODUCT", 64, 70], ["MEFs", "CELL", 105, 109], ["PARP", "PROTEIN", 8, 12], ["pIC", "PROTEIN", 32, 35], ["BMMs", "CELL_TYPE", 55, 59], ["p-Macs but not in identically treated WT MEFs", "CELL_LINE", 64, 109], ["Cleaved PARP", "PROBLEM", 0, 12], ["pIC transfection", "TREATMENT", 32, 48], ["WT BMMs", "PROBLEM", 52, 59]]], ["EMCV infection resulted in death of both WT and Rnasel\u2212/\u2212 MEFs (Fig. 2D).", [["Rnasel\u2212/\u2212 MEFs", "ANATOMY", 48, 62], ["EMCV infection", "DISEASE", 0, 14], ["death", "DISEASE", 27, 32], ["EMCV", "ORGANISM", 0, 4], ["Rnasel\u2212/\u2212 MEFs", "CELL_LINE", 48, 62], ["EMCV", "SPECIES", 0, 4], ["EMCV infection", "PROBLEM", 0, 14], ["death", "PROBLEM", 27, 32], ["WT", "TEST", 41, 43], ["Rnasel\u2212", "TEST", 48, 55], ["infection", "OBSERVATION", 5, 14]]], ["However, while EMCV reduced viability of WT BMMs by about 2.5-fold, a smaller (1.2-fold) reduction of viability was observed in EMCV-infected Rnasel\u2212/\u2212 BMMs (Fig. 2D).", [["BMMs", "ANATOMY", 44, 48], ["BMMs", "ANATOMY", 152, 156], ["EMCV", "ORGANISM", 15, 19], ["BMMs", "CELL", 44, 48], ["EMCV", "ORGANISM", 128, 132], ["BMMs", "CELL", 152, 156], ["WT BMMs", "CELL_TYPE", 41, 48], ["BMMs", "CELL_TYPE", 152, 156], ["EMCV", "SPECIES", 15, 19], ["EMCV", "SPECIES", 128, 132], ["WT BMMs", "PROBLEM", 41, 48], ["a smaller (1.2-fold) reduction of viability", "PROBLEM", 68, 111], ["EMCV", "TEST", 128, 132], ["reduced", "OBSERVATION_MODIFIER", 20, 27], ["viability", "OBSERVATION_MODIFIER", 28, 37], ["smaller", "OBSERVATION_MODIFIER", 70, 77], ["infected", "OBSERVATION_MODIFIER", 133, 141]]], ["EMCV appears to have caused necrotic death of MEFs, as there was no measurable apoptosis as determined by lack of caspase 3/7 activity (Fig. 2E).", [["MEFs", "ANATOMY", 46, 50], ["death", "DISEASE", 37, 42], ["EMCV", "ORGANISM", 0, 4], ["MEFs", "CELL", 46, 50], ["caspase 3/7", "GENE_OR_GENE_PRODUCT", 114, 125], ["caspase 3/7", "PROTEIN", 114, 125], ["EMCV", "SPECIES", 0, 4], ["EMCV", "PROBLEM", 0, 4], ["necrotic death of MEFs", "PROBLEM", 28, 50], ["measurable apoptosis", "PROBLEM", 68, 88], ["appears to have caused", "UNCERTAINTY", 5, 27], ["necrotic", "OBSERVATION_MODIFIER", 28, 36], ["MEFs", "OBSERVATION", 46, 50], ["no", "UNCERTAINTY", 65, 67], ["measurable", "OBSERVATION_MODIFIER", 68, 78], ["apoptosis", "OBSERVATION", 79, 88]]], ["In contrast, EMCV infection caused apoptosis of WT BMMs but not of Rnasel\u2212/\u2212 BMMs, as determined by caspase 3/7 activity assays (Fig. 2E).", [["BMMs", "ANATOMY", 51, 55], ["Rnasel\u2212/\u2212 BMMs", "ANATOMY", 67, 81], ["infection", "DISEASE", 18, 27], ["EMCV", "ORGANISM", 13, 17], ["BMMs", "CELL", 51, 55], ["caspase 3/7", "GENE_OR_GENE_PRODUCT", 100, 111], ["WT BMMs", "CELL_TYPE", 48, 55], ["Rnasel\u2212/\u2212 BMMs", "CELL_LINE", 67, 81], ["caspase 3/7", "PROTEIN", 100, 111], ["EMCV", "SPECIES", 13, 17], ["EMCV infection", "PROBLEM", 13, 27], ["WT BMMs", "PROBLEM", 48, 55], ["Rnasel\u2212/\u2212 BMMs", "PROBLEM", 67, 81], ["infection", "OBSERVATION", 18, 27], ["BMMs", "OBSERVATION", 77, 81]]], ["In addition, PARP cleavage assays showed viral induction of apoptosis in WT BMMs and WT p-Macs but not in WT MEFs (Fig. 2F).", [["BMMs", "ANATOMY", 76, 80], ["MEFs", "ANATOMY", 109, 113], ["PARP", "GENE_OR_GENE_PRODUCT", 13, 17], ["BMMs", "CELL", 76, 80], ["p-Macs", "GENE_OR_GENE_PRODUCT", 88, 94], ["MEFs", "CELL", 109, 113], ["PARP", "PROTEIN", 13, 17], ["BMMs", "CELL_TYPE", 76, 80], ["Macs", "PROTEIN", 90, 94], ["WT MEFs", "CELL_LINE", 106, 113], ["PARP cleavage assays", "TEST", 13, 33], ["apoptosis", "PROBLEM", 60, 69], ["WT BMMs", "PROBLEM", 73, 80], ["WT", "TEST", 85, 87]]], ["These findings show that RNase L contributes to apoptosis of BMMs and p-Macs in response to either pIC transfection or EMCV infection.", [["BMMs", "ANATOMY", 61, 65], ["EMCV infection", "DISEASE", 119, 133], ["RNase L", "GENE_OR_GENE_PRODUCT", 25, 32], ["BMMs", "CELL", 61, 65], ["p-Macs", "GENE_OR_GENE_PRODUCT", 70, 76], ["pIC", "GENE_OR_GENE_PRODUCT", 99, 102], ["EMCV", "ORGANISM", 119, 123], ["RNase L", "PROTEIN", 25, 32], ["BMMs", "CELL_TYPE", 61, 65], ["Macs", "PROTEIN", 72, 76], ["EMCV", "SPECIES", 119, 123], ["apoptosis of BMMs", "PROBLEM", 48, 65], ["pIC transfection", "TREATMENT", 99, 115], ["EMCV infection", "PROBLEM", 119, 133], ["apoptosis", "OBSERVATION_MODIFIER", 48, 57], ["BMMs", "OBSERVATION", 61, 65], ["EMCV", "OBSERVATION_MODIFIER", 119, 123], ["infection", "OBSERVATION", 124, 133]]], ["However, low levels of OAS isoforms and RNase L in WT MEFs are insufficient to induce apoptosis in response to either pIC transfection or EMCV infection.ObservationOur results show that, paradoxically, RNase L can either enhance or reduce IFN-\u03b2 induction by viral infection, depending on basal levels of 2-5A pathway enzymes OAS and RNase L. RNase L generates small RNA molecules from either self (cellular) or nonself (viral) RNA that activate the RIG-I or MDA5/MAVS/TBK/IRF3 axis that drives transcription of the IFN-\u03b2 gene (11, 12).", [["MEFs", "ANATOMY", 54, 58], ["cellular", "ANATOMY", 398, 406], ["EMCV infection", "DISEASE", 138, 152], ["viral infection", "DISEASE", 258, 273], ["OAS", "GENE_OR_GENE_PRODUCT", 23, 26], ["RNase L", "GENE_OR_GENE_PRODUCT", 40, 47], ["MEFs", "CELL", 54, 58], ["pIC", "GENE_OR_GENE_PRODUCT", 118, 121], ["EMCV", "ORGANISM", 138, 142], ["RNase L", "GENE_OR_GENE_PRODUCT", 202, 209], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 239, 244], ["2-5A", "SIMPLE_CHEMICAL", 304, 308], ["RNase L. RNase L", "GENE_OR_GENE_PRODUCT", 333, 349], ["cellular", "CELL", 398, 406], ["RIG-I", "GENE_OR_GENE_PRODUCT", 449, 454], ["MDA5", "GENE_OR_GENE_PRODUCT", 458, 462], ["MAVS", "GENE_OR_GENE_PRODUCT", 463, 467], ["TBK", "GENE_OR_GENE_PRODUCT", 468, 471], ["IRF3", "GENE_OR_GENE_PRODUCT", 472, 476], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 515, 520], ["OAS isoforms", "PROTEIN", 23, 35], ["RNase L", "PROTEIN", 40, 47], ["RNase L", "PROTEIN", 202, 209], ["IFN", "PROTEIN", 239, 242], ["\u03b2", "PROTEIN", 243, 244], ["2-5A pathway enzymes", "PROTEIN", 304, 324], ["OAS", "PROTEIN", 325, 328], ["RNase", "PROTEIN", 333, 338], ["RNase L", "PROTEIN", 342, 349], ["small RNA molecules", "RNA", 360, 379], ["self (cellular) or nonself (viral) RNA", "RNA", 392, 430], ["MDA5", "PROTEIN", 458, 462], ["MAVS", "PROTEIN", 463, 467], ["TBK", "PROTEIN", 468, 471], ["IRF3", "PROTEIN", 472, 476], ["IFN-\u03b2 gene", "DNA", 515, 525], ["EMCV", "SPECIES", 138, 142], ["low levels of OAS isoforms", "PROBLEM", 9, 35], ["RNase L in WT MEFs", "TEST", 40, 58], ["apoptosis", "PROBLEM", 86, 95], ["pIC transfection", "TREATMENT", 118, 134], ["EMCV infection", "PROBLEM", 138, 152], ["IFN", "TEST", 239, 242], ["viral infection", "PROBLEM", 258, 273], ["basal levels", "TEST", 288, 300], ["RNase L. RNase", "TEST", 333, 347], ["small RNA molecules", "PROBLEM", 360, 379], ["nonself (viral) RNA", "PROBLEM", 411, 430], ["MAVS", "PROBLEM", 463, 467], ["TBK", "PROBLEM", 468, 471], ["IRF3 axis", "PROBLEM", 472, 481], ["low levels", "OBSERVATION_MODIFIER", 9, 19], ["EMCV", "OBSERVATION_MODIFIER", 138, 142], ["infection", "OBSERVATION", 143, 152], ["viral", "OBSERVATION_MODIFIER", 258, 263], ["infection", "OBSERVATION", 264, 273], ["small", "OBSERVATION_MODIFIER", 360, 365], ["RNA molecules", "OBSERVATION", 366, 379], ["IRF3 axis", "OBSERVATION", 472, 481]]], ["However, this phenomenon occurs only in cell types, such as MEFs, that have relatively low basal levels of OAS isoforms and RNase L. In cell types, such as macrophages, that have high basal levels of OAS (15) and RNase L (Fig. 1A), there is a different outcome\u2014reduced rather than increased production of IFN-\u03b2 following viral infection.", [["cell", "ANATOMY", 40, 44], ["MEFs", "ANATOMY", 60, 64], ["cell", "ANATOMY", 136, 140], ["macrophages", "ANATOMY", 156, 167], ["viral infection", "DISEASE", 321, 336], ["cell", "CELL", 40, 44], ["MEFs", "CELL", 60, 64], ["OAS", "GENE_OR_GENE_PRODUCT", 107, 110], ["RNase L.", "GENE_OR_GENE_PRODUCT", 124, 132], ["cell", "CELL", 136, 140], ["macrophages", "CELL", 156, 167], ["OAS (15)", "GENE_OR_GENE_PRODUCT", 200, 208], ["RNase L", "GENE_OR_GENE_PRODUCT", 213, 220], ["Fig. 1A", "GENE_OR_GENE_PRODUCT", 222, 229], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 305, 310], ["MEFs", "CELL_TYPE", 60, 64], ["OAS isoforms", "PROTEIN", 107, 119], ["RNase", "PROTEIN", 124, 129], ["macrophages", "CELL_TYPE", 156, 167], ["RNase L", "PROTEIN", 213, 220], ["Fig. 1A", "PROTEIN", 222, 229], ["IFN", "PROTEIN", 305, 308], ["\u03b2", "PROTEIN", 309, 310], ["this phenomenon", "PROBLEM", 9, 24], ["relatively low basal levels of OAS isoforms", "PROBLEM", 76, 119], ["RNase L. In cell types", "PROBLEM", 124, 146], ["high basal levels of OAS", "PROBLEM", 179, 203], ["increased production of IFN", "PROBLEM", 281, 308], ["viral infection", "PROBLEM", 321, 336], ["cell types", "OBSERVATION", 40, 50], ["MEFs", "OBSERVATION", 60, 64], ["low basal", "OBSERVATION_MODIFIER", 87, 96], ["OAS isoforms", "OBSERVATION", 107, 119], ["cell types", "OBSERVATION", 136, 146], ["viral", "OBSERVATION_MODIFIER", 321, 326], ["infection", "OBSERVATION", 327, 336]]], ["RNase L is known to cleave both viral and cellular RNA molecules, including both mRNA and rRNA in intact ribosomes (7, 20).", [["cellular", "ANATOMY", 42, 50], ["ribosomes", "ANATOMY", 105, 114], ["RNase L", "GENE_OR_GENE_PRODUCT", 0, 7], ["cellular", "CELL", 42, 50], ["rRNA", "CELLULAR_COMPONENT", 90, 94], ["ribosomes", "CELLULAR_COMPONENT", 105, 114], ["RNase L", "PROTEIN", 0, 7], ["viral and cellular RNA molecules", "RNA", 32, 64], ["mRNA", "RNA", 81, 85], ["rRNA", "RNA", 90, 94], ["both viral and cellular RNA molecules", "PROBLEM", 27, 64], ["both mRNA and rRNA in intact ribosomes", "PROBLEM", 76, 114], ["both", "OBSERVATION_MODIFIER", 27, 31], ["viral", "OBSERVATION", 32, 37], ["cellular RNA molecules", "OBSERVATION", 42, 64], ["both", "ANATOMY_MODIFIER", 76, 80], ["mRNA", "ANATOMY", 81, 85], ["rRNA", "OBSERVATION_MODIFIER", 90, 94], ["intact", "OBSERVATION_MODIFIER", 98, 104], ["ribosomes", "OBSERVATION_MODIFIER", 105, 114]]], ["The damage to cellular RNA by RNase L, resulting in inhibition of protein synthesis (6, 21) and apoptosis (5, 6, 8), is the likely cause of reduced IFN synthesis in macrophages.", [["cellular", "ANATOMY", 14, 22], ["macrophages", "ANATOMY", 165, 176], ["cellular", "CELL", 14, 22], ["RNase L", "GENE_OR_GENE_PRODUCT", 30, 37], ["IFN", "GENE_OR_GENE_PRODUCT", 148, 151], ["macrophages", "CELL", 165, 176], ["cellular RNA", "RNA", 14, 26], ["RNase L", "PROTEIN", 30, 37], ["IFN", "PROTEIN", 148, 151], ["macrophages", "CELL_TYPE", 165, 176], ["The damage to cellular RNA", "PROBLEM", 0, 26], ["RNase L", "TEST", 30, 37], ["protein synthesis", "PROBLEM", 66, 83], ["apoptosis", "TEST", 96, 105], ["reduced IFN synthesis in macrophages", "PROBLEM", 140, 176], ["cellular RNA", "OBSERVATION", 14, 26], ["RNase L", "OBSERVATION_MODIFIER", 30, 37], ["protein synthesis", "OBSERVATION", 66, 83], ["likely cause of", "UNCERTAINTY", 124, 139], ["reduced", "OBSERVATION_MODIFIER", 140, 147], ["IFN synthesis", "OBSERVATION", 148, 161]]], ["The RNase L-mediated suppression of IFN production in macrophages occurs despite high expression of the IFN-stimulated gene products RIG-I and MDA5 (15) that function in signaling to the IFN-\u03b2 gene.", [["macrophages", "ANATOMY", 54, 65], ["RNase", "GENE_OR_GENE_PRODUCT", 4, 9], ["IFN", "GENE_OR_GENE_PRODUCT", 36, 39], ["macrophages", "CELL", 54, 65], ["RIG-I", "GENE_OR_GENE_PRODUCT", 133, 138], ["MDA5 (15)", "GENE_OR_GENE_PRODUCT", 143, 152], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 187, 192], ["RNase", "PROTEIN", 4, 9], ["IFN", "PROTEIN", 36, 39], ["macrophages", "CELL_TYPE", 54, 65], ["IFN-stimulated gene products", "PROTEIN", 104, 132], ["RIG-I", "PROTEIN", 133, 138], ["MDA5", "PROTEIN", 143, 147], ["IFN-\u03b2 gene", "DNA", 187, 197], ["The RNase L-mediated suppression", "TREATMENT", 0, 32], ["IFN production in macrophages", "PROBLEM", 36, 65], ["the IFN", "TREATMENT", 100, 107], ["stimulated gene products", "TREATMENT", 108, 132], ["the IFN", "TEST", 183, 190]]], ["Furthermore, Mda5 expression as determined by qRT-PCR was 35-fold higher in BMMs than in MEFs (data not shown).", [["BMMs", "ANATOMY", 76, 80], ["MEFs", "ANATOMY", 89, 93], ["Mda5", "GENE_OR_GENE_PRODUCT", 13, 17], ["BMMs", "CELL", 76, 80], ["MEFs", "CELL", 89, 93], ["Mda5", "PROTEIN", 13, 17], ["BMMs", "CELL_TYPE", 76, 80], ["MEFs", "CELL_TYPE", 89, 93], ["qRT", "TEST", 46, 49], ["PCR", "TEST", 50, 53], ["BMMs", "OBSERVATION", 76, 80]]], ["We previously reported that induction of IFN-\u03b2 in response to 2-5A transfection was partially reduced in Mda5\u2212/\u2212 or Rig-i\u2212/\u2212 MEFs compared with WT MEFs (11).", [["Rig-i\u2212/\u2212 MEFs", "ANATOMY", 116, 129], ["MEFs", "ANATOMY", 147, 151], ["2-5A", "CHEMICAL", 62, 66], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 41, 46], ["2-5A", "SIMPLE_CHEMICAL", 62, 66], ["Mda5\u2212", "GENE_OR_GENE_PRODUCT", 105, 110], ["\u2212", "GENE_OR_GENE_PRODUCT", 111, 112], ["Rig", "GENE_OR_GENE_PRODUCT", 116, 119], ["MEFs", "CELL", 147, 151], ["IFN", "PROTEIN", 41, 44], ["\u03b2", "PROTEIN", 45, 46], ["Mda5\u2212/\u2212 or Rig-i\u2212/\u2212 MEFs", "CELL_LINE", 105, 129], ["IFN", "TEST", 41, 44], ["Mda5\u2212", "TEST", 105, 110], ["Rig", "TEST", 116, 119], ["\u2212 MEFs", "PROBLEM", 123, 129], ["WT MEFs", "TEST", 144, 151]]], ["These findings highlight the robustness of RNase L activity in myeloid cells that results in the degradation of mRNA and rRNA, thereby reducing IFN induction despite high levels of MDA5, a protein that senses both pIC and EMCV (22).ObservationWe propose that viral infections of cell types that mediate tissue integrity (such as fibroblasts) produce higher levels of type I IFNs as a result of RNase L and the small RNAs that it generates.", [["myeloid cells", "ANATOMY", 63, 76], ["cell", "ANATOMY", 279, 283], ["tissue", "ANATOMY", 303, 309], ["fibroblasts", "ANATOMY", 329, 340], ["viral infections", "DISEASE", 259, 275], ["RNase L", "GENE_OR_GENE_PRODUCT", 43, 50], ["myeloid cells", "CELL", 63, 76], ["rRNA", "CELLULAR_COMPONENT", 121, 125], ["IFN", "GENE_OR_GENE_PRODUCT", 144, 147], ["MDA5", "GENE_OR_GENE_PRODUCT", 181, 185], ["pIC", "GENE_OR_GENE_PRODUCT", 214, 217], ["EMCV", "ORGANISM", 222, 226], ["cell", "CELL", 279, 283], ["tissue", "TISSUE", 303, 309], ["fibroblasts", "CELL", 329, 340], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 367, 378], ["RNase L", "GENE_OR_GENE_PRODUCT", 394, 401], ["RNase L", "PROTEIN", 43, 50], ["myeloid cells", "CELL_TYPE", 63, 76], ["mRNA", "RNA", 112, 116], ["IFN", "PROTEIN", 144, 147], ["MDA5", "PROTEIN", 181, 185], ["pIC", "PROTEIN", 214, 217], ["fibroblasts", "CELL_TYPE", 329, 340], ["type I IFNs", "PROTEIN", 367, 378], ["RNase L", "PROTEIN", 394, 401], ["small RNAs", "RNA", 410, 420], ["RNase L activity in myeloid cells", "PROBLEM", 43, 76], ["the degradation of mRNA and rRNA", "PROBLEM", 93, 125], ["reducing IFN induction", "TREATMENT", 135, 157], ["high levels of MDA5", "PROBLEM", 166, 185], ["viral infections of cell types", "PROBLEM", 259, 289], ["tissue integrity", "PROBLEM", 303, 319], ["type I IFNs", "PROBLEM", 367, 378], ["RNase L and the small RNAs", "PROBLEM", 394, 420], ["RNase L", "OBSERVATION_MODIFIER", 43, 50], ["activity", "OBSERVATION_MODIFIER", 51, 59], ["myeloid cells", "OBSERVATION", 63, 76], ["viral", "OBSERVATION_MODIFIER", 259, 264], ["infections", "OBSERVATION", 265, 275], ["cell types", "OBSERVATION", 279, 289], ["tissue", "OBSERVATION_MODIFIER", 303, 309], ["integrity", "OBSERVATION_MODIFIER", 310, 319], ["small RNAs", "OBSERVATION", 410, 420]]], ["The amplification of IFN production contributes to tissue protection (11).", [["tissue", "ANATOMY", 51, 57], ["IFN", "GENE_OR_GENE_PRODUCT", 21, 24], ["tissue", "TISSUE", 51, 57], ["IFN", "PROTEIN", 21, 24], ["IFN production", "PROBLEM", 21, 35]]], ["In virus-infected macrophages, high basal levels of OAS and RNase L result in lower levels of type I IFNs, at least in response to pIC transfection or EMCV infection.", [["macrophages", "ANATOMY", 18, 29], ["EMCV infection", "DISEASE", 151, 165], ["macrophages", "CELL", 18, 29], ["OAS", "GENE_OR_GENE_PRODUCT", 52, 55], ["RNase L", "GENE_OR_GENE_PRODUCT", 60, 67], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 94, 105], ["pIC", "GENE_OR_GENE_PRODUCT", 131, 134], ["EMCV", "ORGANISM", 151, 155], ["virus-infected macrophages", "CELL_TYPE", 3, 29], ["OAS", "PROTEIN", 52, 55], ["RNase L", "PROTEIN", 60, 67], ["type I IFNs", "PROTEIN", 94, 105], ["EMCV", "SPECIES", 151, 155], ["virus", "PROBLEM", 3, 8], ["infected macrophages", "PROBLEM", 9, 29], ["high basal levels of OAS", "PROBLEM", 31, 55], ["RNase L result", "PROBLEM", 60, 74], ["type I IFNs", "PROBLEM", 94, 105], ["pIC transfection", "TREATMENT", 131, 147], ["EMCV infection", "PROBLEM", 151, 165], ["virus", "OBSERVATION", 3, 8], ["infected", "OBSERVATION_MODIFIER", 9, 17], ["macrophages", "OBSERVATION", 18, 29], ["high", "OBSERVATION_MODIFIER", 31, 35], ["basal", "OBSERVATION_MODIFIER", 36, 41], ["levels", "OBSERVATION_MODIFIER", 42, 48], ["lower levels", "OBSERVATION_MODIFIER", 78, 90], ["pIC transfection", "OBSERVATION", 131, 147], ["EMCV infection", "OBSERVATION", 151, 165]]], ["However, despite different patterns of the type I IFN response, both MEFs and macrophages contribute to host survival.", [["MEFs", "ANATOMY", 69, 73], ["macrophages", "ANATOMY", 78, 89], ["type I IFN", "GENE_OR_GENE_PRODUCT", 43, 53], ["MEFs", "CELL", 69, 73], ["macrophages", "CELL", 78, 89], ["IFN", "PROTEIN", 50, 53], ["MEFs", "CELL_TYPE", 69, 73], ["macrophages", "CELL_TYPE", 78, 89], ["the type I IFN response", "PROBLEM", 39, 62]]], ["In a prior study, using the murine coronavirus mouse model, we found that RNase L activity in liver sinusoidal resident macrophages, Kupffer cells, seems to prevent spread of the virus into the liver parenchyma and the consequent development of hepatitis (23).", [["liver sinusoidal resident macrophages", "ANATOMY", 94, 131], ["Kupffer cells", "ANATOMY", 133, 146], ["liver parenchyma", "ANATOMY", 194, 210], ["hepatitis", "DISEASE", 245, 254], ["murine", "ORGANISM", 28, 34], ["coronavirus", "ORGANISM", 35, 46], ["mouse", "ORGANISM", 47, 52], ["RNase L", "GENE_OR_GENE_PRODUCT", 74, 81], ["liver sinusoidal resident macrophages", "CELL", 94, 131], ["Kupffer cells", "CELL", 133, 146], ["liver parenchyma", "MULTI-TISSUE_STRUCTURE", 194, 210], ["RNase L", "PROTEIN", 74, 81], ["liver sinusoidal resident macrophages", "CELL_TYPE", 94, 131], ["Kupffer cells", "CELL_TYPE", 133, 146], ["murine", "SPECIES", 28, 34], ["coronavirus", "SPECIES", 35, 46], ["mouse", "SPECIES", 47, 52], ["murine coronavirus mouse", "SPECIES", 28, 52], ["a prior study", "TEST", 3, 16], ["the murine coronavirus mouse model", "TEST", 24, 58], ["RNase L activity", "TEST", 74, 90], ["the virus into the liver parenchyma", "PROBLEM", 175, 210], ["hepatitis", "PROBLEM", 245, 254], ["liver", "ANATOMY", 94, 99], ["sinusoidal", "ANATOMY_MODIFIER", 100, 110], ["macrophages", "ANATOMY", 120, 131], ["Kupffer cells", "OBSERVATION", 133, 146], ["virus", "OBSERVATION", 179, 184], ["liver", "ANATOMY", 194, 199], ["parenchyma", "ANATOMY_MODIFIER", 200, 210], ["hepatitis", "OBSERVATION", 245, 254]]], ["In this manner, high levels of OAS and RNase L in macrophages also contribute to tissue protection.", [["macrophages", "ANATOMY", 50, 61], ["tissue", "ANATOMY", 81, 87], ["OAS", "GENE_OR_GENE_PRODUCT", 31, 34], ["RNase L", "GENE_OR_GENE_PRODUCT", 39, 46], ["macrophages", "CELL", 50, 61], ["tissue", "TISSUE", 81, 87], ["OAS", "PROTEIN", 31, 34], ["RNase L", "PROTEIN", 39, 46], ["macrophages", "CELL_TYPE", 50, 61], ["high levels of OAS", "PROBLEM", 16, 34], ["RNase L in macrophages", "TREATMENT", 39, 61], ["tissue protection", "TREATMENT", 81, 98], ["tissue protection", "OBSERVATION", 81, 98]]]], "PMC7107361": [["Study Population ::: METHODSThe screening was conducted on 5235 adult (>18 years of age) pilgrims performing the 2013 Hajj.", [["METHODSThe screening", "TEST", 21, 41]]], ["The sample size was calculated based on the number of pilgrims attending the 2012 Hajj season with 95% confidence level and 2% error margin.", [["The sample size", "TEST", 0, 15], ["size", "OBSERVATION_MODIFIER", 11, 15]]], ["The countries of the study population were preselected to cover a wide range of pilgrims from different continents.", [["the study population", "TEST", 17, 37], ["wide", "OBSERVATION_MODIFIER", 66, 70]]], ["The selection reflected the Hajj pilgrims' population, and included countries with MERS-CoV cases, countries with close geographic proximity to KSA, and countries with frequent and significant population movement from and to KSA.", [["MERS-CoV", "SPECIES", 83, 91]]], ["The individuals chosen for the trail from the selected flights were recruited on a voluntary and random basis (by selecting every 4th pilgrim from the queue at the airport processing area upon arrival or before boarding returning flights) regardless of their age, gender, or medical conditions (excluding children).", [["children", "ORGANISM", 305, 313], ["children", "SPECIES", 305, 313]]], ["A standardized data collection form was used to obtain information regarding the participants' age, gender, country of origin, and medical conditions.", [["participants", "SPECIES", 81, 93], ["A standardized data collection", "TEST", 0, 30]]], ["Vaccination history was determined from the participants' vaccination documents.Screaming and Processing of the Samples ::: METHODSNasopharyngeal samples were collected from all participants by trained physicians.", [["METHODSNasopharyngeal samples", "ANATOMY", 124, 153], ["METHODSNasopharyngeal samples", "CANCER", 124, 153], ["participants", "SPECIES", 44, 56], ["participants", "SPECIES", 178, 190], ["METHODSNasopharyngeal samples", "TEST", 124, 153]]], ["Collection, handling, and storage of the samples were done as per the CDC's guidelines for patients under investigation for MERS-CoV [18].", [["samples", "ANATOMY", 41, 48], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["MERS-CoV", "SPECIES", 124, 132], ["the samples", "TEST", 37, 48]]], ["A single nasopharyngeal swab was obtained from each pilgrim using a swab with synthetic fiber with a plastic shaft (Remel).", [["nasopharyngeal swab", "ANATOMY", 9, 28], ["swab", "ANATOMY", 68, 72], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 9, 28], ["A single nasopharyngeal swab", "TEST", 0, 28], ["a swab", "TREATMENT", 66, 72], ["synthetic fiber", "TREATMENT", 78, 93], ["a plastic shaft (Remel)", "TREATMENT", 99, 122], ["nasopharyngeal", "ANATOMY", 9, 23], ["swab", "OBSERVATION", 24, 28], ["plastic shaft", "OBSERVATION", 101, 114]]], ["The samples were then immediately placed in viral transport medium, transported on ice to the lab, and stored at \u221270\u00b0C. The screening process was conducted at the Hajj terminal of King Abdulaziz International Airport at 2 time periods: a pre-Hajj screening (which included 3210 pilgrims and was conducted in the period between 29th of September and 9th of October 2013 as the pilgrims were arriving to KSA for the Hajj), and a post-Hajj screening (which involved another 2025 pilgrims and was conducted at the end of the Hajj between the 14th and 26th of October 2013 as pilgrims were returning to their respective countries).Detection of MERS-CoV in Samples ::: METHODSMERS-CoV was detected in the samples using reverse transcriptase\u2013polymerase chain reaction (RT-PCR) targeting the region upstream of the E gene (upE) and the open reading frame 1a (nsp6 protein) as described previously [19, 20].", [["samples", "ANATOMY", 4, 11], ["samples", "ANATOMY", 699, 706], ["CoV", "ORGANISM", 675, 678], ["E", "GENE_OR_GENE_PRODUCT", 807, 808], ["upE", "GENE_OR_GENE_PRODUCT", 815, 818], ["open reading frame 1a", "GENE_OR_GENE_PRODUCT", 828, 849], ["nsp6", "GENE_OR_GENE_PRODUCT", 851, 855], ["MERS-CoV", "DNA", 639, 647], ["E gene", "DNA", 807, 813], ["upE", "DNA", 815, 818], ["open reading frame 1a", "DNA", 828, 849], ["nsp6 protein", "DNA", 851, 863], ["METHODSMERS-CoV", "SPECIES", 663, 678], ["The samples", "TEST", 0, 11], ["viral transport medium", "TREATMENT", 44, 66], ["a pre-Hajj screening", "TEST", 236, 256], ["a post-Hajj screening", "TEST", 425, 446], ["MERS-CoV in Samples", "TEST", 639, 658], ["METHODSMERS", "TEST", 663, 674], ["CoV", "PROBLEM", 675, 678], ["the samples", "TEST", 695, 706], ["reverse transcriptase\u2013polymerase chain reaction", "TREATMENT", 713, 760], ["RT-PCR", "TREATMENT", 762, 768], ["MERS-CoV", "OBSERVATION", 639, 647]]], ["Briefly, nucleic acid was purified from a 200 \u00b5L volume of sample using Magna Pure LC nucleic acid extraction kit (Roche).", [["sample", "ANATOMY", 59, 65], ["nucleic acid", "CHEMICAL", 9, 21], ["nucleic acid", "CHEMICAL", 86, 98], ["nucleic acid", "SIMPLE_CHEMICAL", 9, 21], ["nucleic acid", "TEST", 9, 21], ["Magna Pure LC nucleic acid extraction", "TREATMENT", 72, 109]]], ["Each sample was independently tested with the 2 RT-PCR assays in a 25 \u00b5L reaction containing 5 \u00b5L RNA, 12.5 \u00b5L of 2X buffer (SuperScript\u00ae III one-Step RT-PCR with Platinum Taq\u00ae [Invitrogen]), 0.4 \u00b5L MgCl2 (50 mM), 1 \u00b5L forward primer (10 \u00b5M), 1 \u00b5L reverse primer (10 \u00b5M), 1 \u00b5L probe (5 \u00b5M), 3.1 \u00b5L RNAse-free H2O2, and 1 \u00b5L SSIII/Platinum Taq enzyme mix (1 U).", [["sample", "ANATOMY", 5, 11], ["Platinum Taq\u00ae", "CHEMICAL", 163, 176], ["MgCl2", "CHEMICAL", 199, 204], ["H2O2", "CHEMICAL", 309, 313], ["MgCl2", "CHEMICAL", 199, 204], ["H2O2", "CHEMICAL", 309, 313], ["H2O2", "SIMPLE_CHEMICAL", 309, 313], ["the 2 RT-PCR assays", "TEST", 42, 61], ["a 25 \u00b5L reaction", "TREATMENT", 65, 81], ["Platinum Taq\u00ae", "TREATMENT", 163, 176], ["free H2O2", "TREATMENT", 304, 313], ["1 \u00b5L SSIII/Platinum Taq enzyme mix", "TREATMENT", 319, 353]]], ["The RT-PCR reactions were performed in a real-time LightCycler 480 machine (Roche) under the following cycling profile: 1 cycle of 55\u00b0C for 20 minutes followed by 1 cycle of 94\u00b0C for 3 minutes, then 45 cycles of 94\u00b0C for 15 seconds, 45 cycles of 58\u00b0C for 30, seconds and a single cycle of 40\u00b0C for 30 seconds.", [["The RT-PCR reactions", "TEST", 0, 20]]], ["A sample was confirmed MERS-CoV positive if both RT-PCR assays were positive as per current recommendations [20].Ethics ::: METHODSThe study was approved by the King Fahad Medical City Institutional Review Board.", [["sample", "ANATOMY", 2, 8], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 23, 31], ["MERS-CoV", "SPECIES", 23, 31], ["A sample", "TEST", 0, 8], ["MERS", "TEST", 23, 27], ["both RT-PCR assays", "TEST", 44, 62], ["METHODSThe study", "TEST", 124, 140]]], ["All participants were recruited on a voluntary basis and gave verbal consent before being included in the study.RESULTSSamples were obtained from 5235 pilgrims (3210 pre-Hajj, 2025 post-Hajj) representing 22 countries (Figure 1) from Asia, Africa, Australia, North America, and Europe.", [["participants", "ORGANISM", 4, 16], ["participants", "SPECIES", 4, 16], ["the study", "TEST", 102, 111], ["RESULTSSamples", "TEST", 112, 126]]], ["Most participants were from Asia (78%), followed by Africa (18.7%), then Europe (2.1%).", [["participants", "SPECIES", 5, 17]]], ["India was the most represented country with 17.1% of the screened population, followed by Indonesia (12.9%), Pakistan (11.9%), and Turkey (10.7%).", [["Indonesia", "TEST", 90, 99], ["Pakistan", "TEST", 109, 117]]], ["Pilgrims from Yemen, Afghanistan, China, Ethiopia, Sudan, Djibouti, and Canada were represented in the post-Hajj screening only.", [["Hajj screening", "TEST", 108, 122]]], ["The screened population included 410 pilgrims from 3 out of the 9 countries with MERS-CoV cases notified to the WHO (Jordan, Tunisia, and UK).", [["MERS-CoV", "SPECIES", 81, 89]]]], "PMC4363316": [["IntroductionTransmissible gastroenteritis virus (TGEV), belonging to the Coronaviridae family, is the pathogen of transmissible gastroenteritis of swine (TGE).", [["Transmissible gastroenteritis", "DISEASE", 12, 41], ["gastroenteritis", "DISEASE", 128, 143], ["Transmissible gastroenteritis virus", "ORGANISM", 12, 47], ["TGEV", "ORGANISM", 49, 53], ["swine", "ORGANISM", 147, 152], ["Transmissible gastroenteritis virus", "SPECIES", 12, 47], ["swine", "SPECIES", 147, 152], ["Transmissible gastroenteritis virus", "SPECIES", 12, 47], ["TGEV", "SPECIES", 49, 53], ["swine", "SPECIES", 147, 152], ["Transmissible gastroenteritis virus", "PROBLEM", 12, 47], ["transmissible gastroenteritis", "PROBLEM", 114, 143]]], ["All ages and strains of pigs are susceptible to the virus.", [["pigs", "ORGANISM", 24, 28], ["pigs", "SPECIES", 24, 28], ["pigs", "SPECIES", 24, 28], ["the virus", "PROBLEM", 48, 57], ["virus", "OBSERVATION", 52, 57]]], ["Mortality is more than 10% in 2\u20133-week-old infected pigs, but it is 100% for pigs less than 2 weeks old.", [["pigs", "ORGANISM", 52, 56], ["pigs", "ORGANISM", 77, 81], ["pigs", "SPECIES", 52, 56], ["pigs", "SPECIES", 77, 81], ["pigs", "SPECIES", 52, 56], ["pigs", "SPECIES", 77, 81], ["old infected pigs", "PROBLEM", 39, 56], ["infected", "OBSERVATION", 43, 51]]], ["Infected animals show clinical symptoms of watery diarrhea, dehydration and vomiting [1].IntroductionTGEV is highly contagious and can spread through various channels; however, the main infection route this virus is fecal-oral.", [["oral", "ANATOMY", 222, 226], ["watery diarrhea", "DISEASE", 43, 58], ["dehydration", "DISEASE", 60, 71], ["vomiting", "DISEASE", 76, 84], ["IntroductionTGEV", "CHEMICAL", 89, 105], ["infection", "DISEASE", 186, 195], ["fecal", "ORGANISM_SUBDIVISION", 216, 221], ["oral", "ORGANISM_SUBDIVISION", 222, 226], ["clinical symptoms", "PROBLEM", 22, 39], ["watery diarrhea", "PROBLEM", 43, 58], ["dehydration", "PROBLEM", 60, 71], ["vomiting", "PROBLEM", 76, 84], ["the main infection", "PROBLEM", 177, 195], ["contagious", "OBSERVATION_MODIFIER", 116, 126], ["main", "OBSERVATION_MODIFIER", 181, 185], ["infection", "OBSERVATION", 186, 195]]], ["At present, the virus is distributed worldwide; the prevalence of TGEV in different regions of China has long been reported, and TGEV infection has caused huge economic losses to the swine industry.IntroductionThe TGEV nucleic acid is single-stranded RNA with a virus particle diameter of 90\u2013200 nm.", [["TGEV", "DISEASE", 66, 70], ["TGEV infection", "DISEASE", 129, 143], ["TGEV", "CHEMICAL", 214, 218], ["nucleic acid", "CHEMICAL", 219, 231], ["TGEV", "ORGANISM", 66, 70], ["TGEV", "ORGANISM", 129, 133], ["TGEV", "ORGANISM", 214, 218], ["single-stranded RNA", "RNA", 235, 254], ["swine", "SPECIES", 183, 188], ["TGEV", "SPECIES", 66, 70], ["TGEV", "SPECIES", 129, 133], ["swine", "SPECIES", 183, 188], ["TGEV", "SPECIES", 214, 218], ["the virus", "PROBLEM", 12, 21], ["TGEV", "PROBLEM", 66, 70], ["TGEV infection", "PROBLEM", 129, 143], ["huge economic losses", "PROBLEM", 155, 175], ["The TGEV nucleic acid", "TEST", 210, 231], ["a virus particle diameter", "TREATMENT", 260, 285], ["virus", "OBSERVATION", 16, 21], ["distributed", "OBSERVATION_MODIFIER", 25, 36], ["worldwide", "OBSERVATION_MODIFIER", 37, 46], ["TGEV", "OBSERVATION", 66, 70], ["TGEV", "OBSERVATION_MODIFIER", 129, 133], ["infection", "OBSERVATION", 134, 143], ["huge", "OBSERVATION_MODIFIER", 155, 159], ["economic losses", "OBSERVATION", 160, 175], ["stranded RNA", "OBSERVATION_MODIFIER", 242, 254]]], ["The virus particles comprise three major structural proteins: the phosphoprotein (N protein or nucleoprotein) that wraps the virus genome RNA; the membrane-bound protein (M protein or E1 protein), which is embedded in the lipid membrane; and the spike glycoprotein (S protein), which forms the spike on the surface of the virus.", [["membrane", "ANATOMY", 147, 155], ["lipid membrane", "ANATOMY", 222, 236], ["surface", "ANATOMY", 307, 314], ["N protein", "GENE_OR_GENE_PRODUCT", 82, 91], ["membrane", "CELLULAR_COMPONENT", 147, 155], ["M protein", "GENE_OR_GENE_PRODUCT", 171, 180], ["E1", "GENE_OR_GENE_PRODUCT", 184, 186], ["lipid membrane", "CELLULAR_COMPONENT", 222, 236], ["spike glycoprotein (S protein", "GENE_OR_GENE_PRODUCT", 246, 275], ["surface", "CELLULAR_COMPONENT", 307, 314], ["structural proteins", "PROTEIN", 41, 60], ["phosphoprotein", "PROTEIN", 66, 80], ["N protein", "PROTEIN", 82, 91], ["nucleoprotein", "PROTEIN", 95, 108], ["virus genome RNA", "RNA", 125, 141], ["membrane-bound protein", "PROTEIN", 147, 169], ["M protein", "PROTEIN", 171, 180], ["E1 protein", "PROTEIN", 184, 194], ["spike glycoprotein", "PROTEIN", 246, 264], ["S protein", "PROTEIN", 266, 275], ["The virus particles", "PROBLEM", 0, 19], ["the phosphoprotein (N protein", "TREATMENT", 62, 91], ["nucleoprotein)", "TREATMENT", 95, 109], ["the virus genome RNA", "PROBLEM", 121, 141], ["the membrane-bound protein", "TEST", 143, 169], ["M protein", "TEST", 171, 180], ["E1 protein", "TEST", 184, 194], ["the spike glycoprotein (S protein", "TEST", 242, 275], ["the spike", "PROBLEM", 290, 299], ["the virus", "PROBLEM", 318, 327], ["virus", "OBSERVATION", 4, 9], ["lipid membrane", "OBSERVATION", 222, 236], ["spike", "OBSERVATION_MODIFIER", 294, 299]]], ["The spike glycoprotein may determine the cell tropism and the membrane fusion function of the virus, and it enables the transfer of the virus nucleoprotein into the cytoplasm.", [["cell", "ANATOMY", 41, 45], ["membrane", "ANATOMY", 62, 70], ["cytoplasm", "ANATOMY", 165, 174], ["cell", "CELL", 41, 45], ["membrane", "CELLULAR_COMPONENT", 62, 70], ["cytoplasm", "ORGANISM_SUBSTANCE", 165, 174], ["spike glycoprotein", "PROTEIN", 4, 22], ["The spike glycoprotein", "PROBLEM", 0, 22], ["the cell tropism", "PROBLEM", 37, 53], ["the membrane fusion function", "TEST", 58, 86], ["the virus", "PROBLEM", 90, 99], ["cell tropism", "OBSERVATION", 41, 53]]], ["The spike glycoprotein also carries major B lymphocyte epitopes, and plays a key role in improving immunity [2, 3].IntroductionMicroRNAs (miRNAs) are endogenous, non-coding RNAs, first found in eukaryotes with a length of 20\u201325 bp.", [["B lymphocyte", "ANATOMY", 42, 54], ["B lymphocyte", "CELL", 42, 54], ["spike glycoprotein", "PROTEIN", 4, 22], ["major B lymphocyte epitopes", "PROTEIN", 36, 63], ["miRNAs", "DNA", 138, 144], ["endogenous, non-coding RNAs", "RNA", 150, 177], ["The spike glycoprotein", "TREATMENT", 0, 22], ["major B lymphocyte epitopes", "PROBLEM", 36, 63], ["non-coding RNAs", "PROBLEM", 162, 177], ["bp", "TEST", 228, 230], ["lymphocyte epitopes", "OBSERVATION", 44, 63], ["non-coding RNAs", "OBSERVATION", 162, 177]]], ["MiRNAs are initially transcribed by RNA polymerase II in the nucleus into large transcripts called primary miRNAs (pri-miRNAs).", [["nucleus", "ANATOMY", 61, 68], ["RNA polymerase II", "GENE_OR_GENE_PRODUCT", 36, 53], ["nucleus", "CELLULAR_COMPONENT", 61, 68], ["pri-miRNAs", "GENE_OR_GENE_PRODUCT", 115, 125], ["MiRNAs", "RNA", 0, 6], ["RNA polymerase II", "PROTEIN", 36, 53], ["primary miRNAs", "RNA", 99, 113], ["pri-miRNAs", "RNA", 115, 125], ["nucleus", "ANATOMY", 61, 68], ["large", "OBSERVATION_MODIFIER", 74, 79], ["transcripts", "OBSERVATION", 80, 91], ["primary miRNAs", "OBSERVATION", 99, 113]]], ["Primary miRNAs are processed by RNase III enzyme Drosha and the cofactor Pasha into 60 nt\u201380 nt hairpin structures called precursor miRNAs (pre-miRNAs).", [["RNase III", "GENE_OR_GENE_PRODUCT", 32, 41], ["Drosha", "GENE_OR_GENE_PRODUCT", 49, 55], ["Pasha", "GENE_OR_GENE_PRODUCT", 73, 78], ["RNase III enzyme", "PROTEIN", 32, 48], ["Drosha", "PROTEIN", 49, 55], ["cofactor Pasha", "PROTEIN", 64, 78], ["60 nt\u201380 nt hairpin structures", "RNA", 84, 114], ["precursor miRNAs", "RNA", 122, 138], ["pre-miRNAs", "RNA", 140, 150], ["RNase III enzyme Drosha", "PROBLEM", 32, 55], ["RNase III", "OBSERVATION_MODIFIER", 32, 41], ["enzyme Drosha", "OBSERVATION", 42, 55]]], ["Subsequently, precursor miRNAs are transported to the cytoplasm and further cleaved by RNase III enzyme Dicer into 20\u201325 nt miRNA:miRNA* double strands.", [["cytoplasm", "ANATOMY", 54, 63], ["cytoplasm", "ORGANISM_SUBSTANCE", 54, 63], ["RNase III", "GENE_OR_GENE_PRODUCT", 87, 96], ["Dicer", "GENE_OR_GENE_PRODUCT", 104, 109], ["precursor miRNAs", "RNA", 14, 30], ["RNase III enzyme", "PROTEIN", 87, 103], ["Dicer", "PROTEIN", 104, 109], ["20\u201325 nt miRNA", "RNA", 115, 129], ["double strands", "PROBLEM", 137, 151]]], ["One strand of the miRNA duplex is incorporated into the RNA-induced silencing complex (RISC), where the mature single-stranded miRNA plays a regulatory role to target mRNAs [4\u20138].IntroductionMiRNAs play a key role in the regulation of the eukaryotic metabolic processes, including body development, hematopoiesis, organogenesis, cell differentiation, proliferation, apoptosis, fat metabolism, the occurrence of cancer and many other cellular processes [9\u201311].", [["body", "ANATOMY", 281, 285], ["cell", "ANATOMY", 329, 333], ["fat", "ANATOMY", 377, 380], ["cancer", "ANATOMY", 411, 417], ["cellular", "ANATOMY", 433, 441], ["cancer", "DISEASE", 411, 417], ["RNA-induced silencing complex", "GENE_OR_GENE_PRODUCT", 56, 85], ["RISC", "GENE_OR_GENE_PRODUCT", 87, 91], ["body", "ORGANISM_SUBDIVISION", 281, 285], ["cell", "CELL", 329, 333], ["fat", "TISSUE", 377, 380], ["cancer", "CANCER", 411, 417], ["cellular", "CELL", 433, 441], ["miRNA duplex", "DNA", 18, 30], ["RNA-induced silencing complex", "PROTEIN", 56, 85], ["RISC", "PROTEIN", 87, 91], ["mature single-stranded miRNA", "DNA", 104, 132], ["mRNAs", "RNA", 167, 172], ["IntroductionMiRNAs", "PROTEIN", 179, 197], ["the miRNA duplex", "TEST", 14, 30], ["body development", "PROBLEM", 281, 297], ["hematopoiesis", "PROBLEM", 299, 312], ["organogenesis", "PROBLEM", 314, 327], ["cell differentiation", "PROBLEM", 329, 349], ["proliferation", "PROBLEM", 351, 364], ["apoptosis", "PROBLEM", 366, 375], ["fat metabolism", "PROBLEM", 377, 391], ["cancer", "PROBLEM", 411, 417], ["many other cellular processes", "PROBLEM", 422, 451], ["strand", "OBSERVATION_MODIFIER", 4, 10], ["miRNA duplex", "OBSERVATION", 18, 30], ["silencing", "OBSERVATION_MODIFIER", 68, 77], ["complex", "OBSERVATION_MODIFIER", 78, 85], ["mature", "OBSERVATION_MODIFIER", 104, 110], ["metabolic processes", "OBSERVATION", 250, 269], ["hematopoiesis", "OBSERVATION", 299, 312], ["cell differentiation", "OBSERVATION", 329, 349], ["proliferation", "OBSERVATION_MODIFIER", 351, 364], ["cancer", "OBSERVATION", 411, 417], ["cellular processes", "OBSERVATION", 433, 451]]], ["MiRNAs can also regulate plant hormone levels and signal transduction.", [["MiRNAs", "PROTEIN", 0, 6], ["plant hormone levels", "TEST", 25, 45], ["signal transduction", "TEST", 50, 69]]], ["Recent studies indicate that numerous cellular miRNAs play a regulatory role in the interaction network between the host and viruses.", [["cellular", "ANATOMY", 38, 46], ["cellular", "CELL", 38, 46], ["Recent studies", "TEST", 0, 14], ["numerous cellular miRNAs", "PROBLEM", 29, 53], ["numerous", "OBSERVATION_MODIFIER", 29, 37], ["cellular miRNAs", "OBSERVATION", 38, 53], ["viruses", "OBSERVATION", 125, 132]]], ["The host-encoded miRNAs can regulate the process of viral infection by targeting the viral genome or host genome; e.g., host-encoded miRNAs can promote or inhibit DNA replication of the virus [12].", [["viral infection", "DISEASE", 52, 67], ["DNA", "CELLULAR_COMPONENT", 163, 166], ["viral genome", "DNA", 85, 97], ["host genome", "DNA", 101, 112], ["viral infection", "PROBLEM", 52, 67], ["the viral genome", "PROBLEM", 81, 97], ["host genome", "PROBLEM", 101, 112], ["the virus", "PROBLEM", 182, 191], ["viral", "OBSERVATION_MODIFIER", 52, 57], ["infection", "OBSERVATION", 58, 67], ["viral genome", "OBSERVATION", 85, 97], ["host genome", "OBSERVATION", 101, 112]]], ["Recently, the miRNAs regulation in of the immune response by miRNAs has been observed.", [["immune response", "OBSERVATION", 42, 57]]], ["Evidence suggested that miRNAs are also involved in the mammalian immune response, and play an important role in antiviral processes.IntroductionIn addition to the cellular miRNAs from eukaryotes, recent research also confirmed the existence of viral-encoded miRNAs, which mediated the silencing of host genes by targeting the host mRNAs.", [["cellular", "ANATOMY", 164, 172], ["cellular", "CELL", 164, 172], ["cellular miRNAs", "DNA", 164, 179], ["viral-encoded miRNAs", "DNA", 245, 265], ["host genes", "DNA", 299, 309], ["host mRNAs", "RNA", 327, 337], ["IntroductionIn", "TREATMENT", 133, 147], ["viral-encoded miRNAs", "PROBLEM", 245, 265], ["miRNAs", "OBSERVATION", 24, 30], ["antiviral processes", "OBSERVATION", 113, 132], ["cellular miRNAs", "OBSERVATION", 164, 179], ["viral", "OBSERVATION", 245, 250], ["host genes", "OBSERVATION", 299, 309], ["host mRNAs", "OBSERVATION", 327, 337]]], ["Viruses could evade recognition and destruction by the host immune system through this approach, such that the host acquires a long-term latent infection with the virus [13].", [["immune system", "ANATOMY", 60, 73], ["infection", "DISEASE", 144, 153], ["immune system", "ANATOMICAL_SYSTEM", 60, 73], ["Viruses", "PROBLEM", 0, 7], ["destruction", "PROBLEM", 36, 47], ["this approach", "TREATMENT", 82, 95], ["a long-term latent infection", "PROBLEM", 125, 153], ["the virus", "PROBLEM", 159, 168], ["long-term latent", "OBSERVATION_MODIFIER", 127, 143], ["infection", "OBSERVATION", 144, 153]]], ["In addition, the virus-encoded miRNAs could also change the infection status of the virus by regulating viral gene expression [14, 15].IntroductionMiRNA sequencing techniques based on the Illumina/Solexa high-throughput sequencing platform have overcome the limitations on miRNA research techniques, helping researchers to sequence the specific sized miRNAs from samples directly, to determine miRNA expression profiles and to discover or identify novel miRNAs in organisms without any sequence information.", [["samples", "ANATOMY", 363, 370], ["infection", "DISEASE", 60, 69], ["samples", "CANCER", 363, 370], ["the virus", "PROBLEM", 13, 22], ["the infection", "PROBLEM", 56, 69], ["the virus", "PROBLEM", 80, 89], ["IntroductionMiRNA sequencing techniques", "TEST", 135, 174], ["the Illumina", "TEST", 184, 196], ["Solexa", "TEST", 197, 203], ["miRNA research techniques", "TREATMENT", 273, 298], ["novel miRNAs in organisms", "PROBLEM", 448, 473], ["virus", "OBSERVATION", 17, 22], ["infection", "OBSERVATION", 60, 69]]], ["Northern-blotting is the most common method for confirming the expression of miRNAs, but it suffers from low sensitivity and low throughput.", [["miRNAs", "DNA", 77, 83], ["the expression of miRNAs", "PROBLEM", 59, 83], ["low sensitivity", "PROBLEM", 105, 120], ["miRNAs", "OBSERVATION", 77, 83], ["low sensitivity", "OBSERVATION_MODIFIER", 105, 120]]], ["By contrast, stem-loop RT-PCR is a sensitive and efficient method for the detection of miRNA that has been widely used in miRNA research [16\u201318].IntroductionTo determine the miRNA expression profile of the swine testis (ST) cell line after infection with TGEV, and to screen for miRNAs that play regulatory roles in the process of viral infection, small RNAs from infected and uninfected ST cells (control) were sequenced by a high-throughput sequencing system, and the transcriptome and miRNA expression profiles of both cell types were comprehensively analyzed.", [["testis", "ANATOMY", 212, 218], ["ST) cell line", "ANATOMY", 220, 233], ["ST cells", "ANATOMY", 388, 396], ["cell", "ANATOMY", 522, 526], ["infection", "DISEASE", 240, 249], ["viral infection", "DISEASE", 331, 346], ["swine", "ORGANISM", 206, 211], ["testis (ST) cell line", "CELL", 212, 233], ["TGEV", "ORGANISM", 255, 259], ["ST cells", "CELL", 388, 396], ["cell", "CELL", 522, 526], ["swine testis (ST) cell line", "CELL_LINE", 206, 233], ["small RNAs", "RNA", 348, 358], ["uninfected ST cells", "CELL_TYPE", 377, 396], ["swine", "SPECIES", 206, 211], ["swine", "SPECIES", 206, 211], ["TGEV", "SPECIES", 255, 259], ["stem-loop RT-PCR", "TEST", 13, 29], ["miRNA", "PROBLEM", 87, 92], ["the swine testis", "PROBLEM", 202, 218], ["infection", "PROBLEM", 240, 249], ["TGEV", "PROBLEM", 255, 259], ["miRNAs", "TREATMENT", 279, 285], ["viral infection", "PROBLEM", 331, 346], ["small RNAs", "PROBLEM", 348, 358], ["infected and uninfected ST cells", "PROBLEM", 364, 396], ["infection", "OBSERVATION", 240, 249], ["viral", "OBSERVATION_MODIFIER", 331, 336], ["infection", "OBSERVATION", 337, 346], ["small RNAs", "OBSERVATION", 348, 358], ["infected", "OBSERVATION_MODIFIER", 364, 372], ["both cell types", "OBSERVATION", 517, 532]]], ["This study carried out an in-depth data analysis to identify known and novel miRNAs and other small RNAs based on an miRNA database.", [["novel miRNAs", "RNA", 71, 83], ["small RNAs", "RNA", 94, 104], ["This study", "TEST", 0, 10], ["an in-depth data analysis", "TEST", 23, 48], ["novel miRNAs and other small RNAs", "PROBLEM", 71, 104], ["an miRNA database", "TEST", 114, 131]]], ["We also analyzed the viral and host target genes of the miRNAs with the aim of identifying the functions of these miRNAs.IntroductionThe results of this research should help in the development of new control strategies to treat or prevent TGEV infection.Overview of the Solexa high-throughput sequencing data ::: ResultsTo investigate the miRNA expression profiles of infected ST cells, ST cells were infected with TGEV SC strain and the normal ST cell line was used as a control.", [["ST cells", "ANATOMY", 377, 385], ["ST cells", "ANATOMY", 387, 395], ["ST cell line", "ANATOMY", 445, 457], ["TGEV infection", "DISEASE", 239, 253], ["TGEV", "ORGANISM", 239, 243], ["ST cells", "CELL", 377, 385], ["ST cells", "CELL", 387, 395], ["TGEV SC strain", "ORGANISM", 415, 429], ["ST cell line", "CELL", 445, 457], ["viral and host target genes", "DNA", 21, 48], ["miRNAs", "DNA", 56, 62], ["miRNAs", "DNA", 114, 120], ["infected ST cells", "CELL_TYPE", 368, 385], ["ST cells", "CELL_TYPE", 387, 395], ["normal ST cell line", "CELL_LINE", 438, 457], ["TGEV", "SPECIES", 239, 243], ["TGEV", "SPECIES", 415, 419], ["new control strategies", "TREATMENT", 196, 218], ["TGEV infection", "PROBLEM", 239, 253], ["infected ST cells", "PROBLEM", 368, 385], ["ST cells", "PROBLEM", 387, 395], ["TGEV SC strain", "PROBLEM", 415, 429], ["the normal ST cell line", "TREATMENT", 434, 457], ["viral", "OBSERVATION", 21, 26], ["infection", "OBSERVATION", 244, 253], ["infected", "OBSERVATION_MODIFIER", 368, 376], ["ST cells", "OBSERVATION", 377, 385], ["ST cell line", "OBSERVATION", 445, 457]]], ["15\u201325 nt sRNAs were isolated and analyzed by deep sequencing.", [["15\u201325 nt sRNAs", "DNA", 0, 14], ["nt sRNAs", "PROBLEM", 6, 14]]], ["The normal ST cell sample generated 6,150,141 clean reads (reads that pass quality filtering) and 5,877,912 adapter-trimmed reads (reads that have passed quality filtering, adapter filtering and length filtering, length \u226515 nt).", [["ST cell sample", "ANATOMY", 11, 25], ["ST cell", "CELL", 11, 18], ["6,150,141 clean reads", "DNA", 36, 57], ["5,877,912 adapter-trimmed reads", "DNA", 98, 129], ["adapter filtering and length filtering", "TREATMENT", 173, 211], ["length", "TEST", 213, 219], ["normal", "OBSERVATION", 4, 10], ["ST cell", "OBSERVATION_MODIFIER", 11, 18]]], ["The infected ST cell sample generated 7,385,050 clean reads and 6,974,168 adapter-trimmed reads.", [["ST cell sample", "ANATOMY", 13, 27], ["ST cell", "CELL", 13, 20], ["6,974,168 adapter-trimmed reads", "DNA", 64, 95], ["The infected ST cell sample", "TEST", 0, 27], ["infected", "OBSERVATION_MODIFIER", 4, 12], ["ST cell", "OBSERVATION", 13, 20]]], ["3,704,353 and 2,763,665 reads from the ST cell sample and the infected ST cell sample could be aligned to known Sus scrofa pre-miRNAs in miRBase 19, respectively (Table 1) (NCBI GEO Accession number: GSE64737).", [["ST cell sample", "ANATOMY", 39, 53], ["ST cell sample", "ANATOMY", 71, 85], ["ST cell", "CELL", 39, 46], ["ST cell", "CELL", 71, 78], ["Sus scrofa", "ORGANISM", 112, 122], ["miRBase 19", "DNA", 137, 147], ["Sus scrofa", "SPECIES", 112, 122], ["Sus scrofa", "SPECIES", 112, 122], ["the ST cell sample", "TEST", 35, 53], ["the infected ST cell sample", "PROBLEM", 58, 85], ["scrofa pre-miRNAs", "OBSERVATION", 116, 133]]], ["The length distribution of the adapter-trimmed reads was similar in infected ST and normal ST sample libraries (Fig. 1), and most of the adapter-trimmed reads were 22 nt in length.", [["ST sample", "ANATOMY", 91, 100], ["adapter-trimmed reads", "DNA", 31, 52], ["adapter-trimmed reads", "DNA", 137, 158], ["infected ST", "PROBLEM", 68, 79], ["length", "OBSERVATION_MODIFIER", 4, 10], ["infected", "OBSERVATION_MODIFIER", 68, 76]]], ["Pie charts summarizing the different classes of sRNAs in the samples are shown in Fig. 2.Analysis of host-encoded miRNA expression profile ::: ResultsIn our study, the sequencing data were processed through Illumina\u2019s Genome Analyzer Pipeline, and alignment to the reference genome of Sus scrofa identified 525 miRNAs from 477 pre-miRNAs, of which 284 mature miRNAs were annotated in miRBase 19 (S1 Table) and 241 were novel host-encoded miRNAs (S2 Table).Differential expressed miRNAs between infected ST cells and uninfected ST cells ::: ResultsThe high-throughput sequencing not only identified a series of novel miRNAs, but also provided data about their expression levels.", [["samples", "ANATOMY", 61, 68], ["ST cells", "ANATOMY", 503, 511], ["ST cells", "ANATOMY", 527, 535], ["samples", "CANCER", 61, 68], ["Sus scrofa", "ORGANISM", 285, 295], ["ST cells", "CELL", 503, 511], ["uninfected ST cells", "CELL", 516, 535], ["sRNAs", "DNA", 48, 53], ["reference genome", "DNA", 265, 281], ["miRBase 19", "DNA", 384, 394], ["novel host-encoded miRNAs", "DNA", 419, 444], ["ST cells", "CELL_TYPE", 503, 511], ["uninfected ST cells", "CELL_TYPE", 516, 535], ["Sus scrofa", "SPECIES", 285, 295], ["Sus scrofa", "SPECIES", 285, 295], ["Pie charts", "TEST", 0, 10], ["sRNAs in the samples", "PROBLEM", 48, 68], ["our study", "TEST", 153, 162], ["the sequencing data", "TEST", 164, 183], ["pre-miRNAs", "TEST", 327, 337], ["miRBase", "TEST", 384, 391], ["infected ST cells", "PROBLEM", 494, 511], ["uninfected ST cells", "PROBLEM", 516, 535], ["sRNAs", "OBSERVATION", 48, 53], ["infected", "OBSERVATION_MODIFIER", 494, 502], ["ST cells", "OBSERVATION", 503, 511], ["ST cells", "OBSERVATION", 527, 535], ["high", "OBSERVATION_MODIFIER", 551, 555]]], ["The miRNA expression profile database showed that most miRNAs were expressed by a small portion of miRNA genes.", [["miRNA genes", "DNA", 99, 110], ["The miRNA expression profile database", "TEST", 0, 37], ["a small portion of miRNA genes", "PROBLEM", 80, 110], ["small", "OBSERVATION_MODIFIER", 82, 87], ["miRNA genes", "OBSERVATION", 99, 110]]], ["In the miRNA expression profile of the infected ST cell line sample, the expression of 4% (20/491) of the miRNAs accounted for 68.6% of the total expression; and in the miRNA expression profile of the normal ST cell line sample, the expression of 4% (20/500) miRNAs accounted for 73.6% of the total expression.", [["ST cell line sample", "ANATOMY", 48, 67], ["ST cell line sample", "ANATOMY", 208, 227], ["ST cell line sample", "CELL", 48, 67], ["ST cell line sample", "CELL", 208, 227], ["4% (20/500) miRNAs", "RNA", 247, 265], ["the infected ST cell line sample", "PROBLEM", 35, 67], ["the miRNAs", "TEST", 102, 112], ["the total expression", "TEST", 136, 156], ["miRNAs", "TEST", 259, 265], ["infected", "OBSERVATION_MODIFIER", 39, 47], ["ST cell line", "OBSERVATION", 48, 60], ["miRNAs", "ANATOMY", 106, 112], ["normal ST cell line", "OBSERVATION", 201, 220]]], ["Interestingly, although there were some changes in their ranking, the miRNAs with the highest expression levels were consistent in both samples.", [["samples", "ANATOMY", 136, 143], ["some", "OBSERVATION_MODIFIER", 35, 39], ["changes", "OBSERVATION", 40, 47], ["miRNAs", "ANATOMY", 70, 76]]], ["Among them, ssc-let-7f, which is derived from the let-7-family, and the ssc-miR-21 had the highest expression level, and this result is consistent with previous studies [19].Differential expressed miRNAs between infected ST cells and uninfected ST cells ::: ResultsAmong the 525 sequenced mature miRNAs, 466 (88.8%) unique miRNAs were co-expressed in normal ST cell sample and infected ST cell sample; however, 34 (6.5%) and 25 (4.8%) were preferentially expressed in the ST cell sample and infected ST cell sample, respectively.", [["ST cells", "ANATOMY", 221, 229], ["ST cells", "ANATOMY", 245, 253], ["ST cell sample", "ANATOMY", 358, 372], ["ST cell sample", "ANATOMY", 386, 400], ["ST cell sample", "ANATOMY", 472, 486], ["ST cell sample", "ANATOMY", 500, 514], ["ssc-let-7f", "GENE_OR_GENE_PRODUCT", 12, 22], ["let-7", "GENE_OR_GENE_PRODUCT", 50, 55], ["ssc-miR-21", "GENE_OR_GENE_PRODUCT", 72, 82], ["ST cells", "CELL", 221, 229], ["uninfected ST cells", "CELL", 234, 253], ["ST cell", "CELL", 358, 365], ["ST cell", "CELL", 386, 393], ["ST cell", "CELL", 472, 479], ["ST cell", "CELL", 500, 507], ["ssc-let-7f", "DNA", 12, 22], ["let-7-family", "DNA", 50, 62], ["ssc", "DNA", 72, 75], ["miR-21", "DNA", 76, 82], ["ST cells", "CELL_TYPE", 221, 229], ["uninfected ST cells", "CELL_TYPE", 234, 253], ["525 sequenced mature miRNAs", "RNA", 275, 302], ["previous studies", "TEST", 152, 168], ["infected ST cells", "PROBLEM", 212, 229], ["uninfected ST cells", "PROBLEM", 234, 253], ["unique miRNAs", "TEST", 316, 329], ["infected ST cell sample", "TEST", 377, 400], ["the ST cell sample", "TEST", 468, 486], ["infected ST cell sample", "PROBLEM", 491, 514], ["infected", "OBSERVATION_MODIFIER", 212, 220], ["ST cells", "OBSERVATION", 221, 229], ["ST cells", "OBSERVATION", 245, 253], ["ST cell", "OBSERVATION_MODIFIER", 358, 365], ["infected", "OBSERVATION_MODIFIER", 377, 385], ["ST cell", "OBSERVATION_MODIFIER", 386, 393], ["ST cell", "ANATOMY", 472, 479], ["infected", "OBSERVATION_MODIFIER", 491, 499], ["ST cell sample", "OBSERVATION", 500, 514]]], ["Among the 241 novel miRNAs, 18 miRNAs were preferentially expressed in the TGEV-infected ST sample, and chr3\u201310158, chr5\u201312080, chr5\u201312157 and chr8\u201314894 had the maximum expression levels.Differential expressed miRNAs between infected ST cells and uninfected ST cells ::: ResultsAnalysis of library sequencing data resulted in the identification of the 59 unique miRNAs that displayed significant differential expression between the infected ST cell and normal ST cell samples.", [["ST sample", "ANATOMY", 89, 98], ["ST cells", "ANATOMY", 235, 243], ["ST cells", "ANATOMY", 259, 267], ["ST cell", "ANATOMY", 442, 449], ["ST cell samples", "ANATOMY", 461, 476], ["TGEV", "ORGANISM", 75, 79], ["ST sample", "CANCER", 89, 98], ["chr3\u201310158", "GENE_OR_GENE_PRODUCT", 104, 114], ["chr5\u201312080", "GENE_OR_GENE_PRODUCT", 116, 126], ["chr5\u201312157", "GENE_OR_GENE_PRODUCT", 128, 138], ["chr8\u201314894", "GENE_OR_GENE_PRODUCT", 143, 153], ["ST cells", "CELL", 235, 243], ["uninfected ST cells", "CELL", 248, 267], ["ST cell", "CELL", 442, 449], ["ST cell samples", "CELL", 461, 476], ["chr8\u201314894", "DNA", 143, 153], ["ST cells", "CELL_TYPE", 235, 243], ["uninfected ST cells", "CELL_TYPE", 248, 267], ["TGEV", "SPECIES", 75, 79], ["miRNAs", "TEST", 31, 37], ["the TGEV", "TEST", 71, 79], ["chr3", "TEST", 104, 108], ["chr5", "TEST", 116, 120], ["the maximum expression levels", "PROBLEM", 158, 187], ["infected ST cells", "PROBLEM", 226, 243], ["uninfected ST cells", "PROBLEM", 248, 267], ["library sequencing data", "TEST", 291, 314], ["the infected ST cell", "PROBLEM", 429, 449], ["maximum expression", "OBSERVATION", 162, 180], ["infected", "OBSERVATION_MODIFIER", 226, 234], ["ST cells", "OBSERVATION", 235, 243], ["ST cells", "OBSERVATION", 259, 267], ["significant", "OBSERVATION_MODIFIER", 385, 396], ["differential expression", "OBSERVATION", 397, 420], ["infected", "OBSERVATION_MODIFIER", 433, 441], ["ST cell", "OBSERVATION", 442, 449], ["normal ST cell samples", "OBSERVATION", 454, 476]]], ["Among these 59 miRNAs, 15 were significantly upregulated, while 44 were significantly downregulated upon TGEV infection (Fig. 3).", [["TGEV infection", "DISEASE", 105, 119], ["TGEV", "ORGANISM", 105, 109], ["TGEV", "SPECIES", 105, 109], ["miRNAs", "TEST", 15, 21], ["TGEV infection", "PROBLEM", 105, 119], ["TGEV", "OBSERVATION_MODIFIER", 105, 109], ["infection", "OBSERVATION", 110, 119]]], ["The differentially expressed miRNAs data are graphed on the scatter plot (Fig. 4).Confirmation of differential expression of miRNAs ::: ResultsStem-loop RT-qPCR detection assays were used to confirm the expression of certain novel miRNAs and differentially expressed miRNAs in normal ST cell and the infected ST cell samples.", [["ST cell", "ANATOMY", 284, 291], ["ST cell samples", "ANATOMY", 309, 324], ["ST cell", "CELL", 284, 291], ["ST cell samples", "CELL", 309, 324], ["novel miRNAs", "RNA", 225, 237], ["normal ST cell", "CELL_TYPE", 277, 291], ["miRNAs data", "TEST", 29, 40], ["the scatter plot", "TEST", 56, 72], ["ResultsStem", "TEST", 136, 147], ["loop RT-qPCR detection assays", "TEST", 148, 177], ["certain novel miRNAs", "PROBLEM", 217, 237], ["the infected ST cell samples", "PROBLEM", 296, 324], ["ST cell", "OBSERVATION_MODIFIER", 284, 291], ["infected", "OBSERVATION_MODIFIER", 300, 308], ["ST cell samples", "OBSERVATION", 309, 324]]], ["The selected miRNAs comprised four differentially expressed miRNAs (ssc-miR-19a, ssc-miR-28\u20133p, ssc-miR-92a and ssc-miR195) and four novel miRNAs (chr13\u20134473, chr6\u201312459, GL892871\u20132\u201316764 and chr9\u201315250).", [["ssc-miR-19a", "GENE_OR_GENE_PRODUCT", 68, 79], ["ssc-miR-28\u20133p", "GENE_OR_GENE_PRODUCT", 81, 94], ["ssc-miR-92a", "GENE_OR_GENE_PRODUCT", 96, 107], ["ssc-miR195", "GENE_OR_GENE_PRODUCT", 112, 122], ["chr13\u20134473", "GENE_OR_GENE_PRODUCT", 147, 157], ["chr6\u201312459", "GENE_OR_GENE_PRODUCT", 159, 169], ["chr9\u201315250", "GENE_OR_GENE_PRODUCT", 192, 202], ["miRNAs", "DNA", 60, 66], ["ssc", "DNA", 68, 71], ["miR", "DNA", 72, 75], ["19a", "DNA", 76, 79], ["ssc", "DNA", 81, 84], ["miR", "DNA", 85, 88], ["28\u20133p", "DNA", 89, 94], ["ssc", "DNA", 96, 99], ["miR", "DNA", 100, 103], ["92a", "DNA", 104, 107], ["ssc", "DNA", 112, 115], ["miR195", "DNA", 116, 122], ["miRNAs", "DNA", 139, 145], ["chr13", "DNA", 147, 152], ["GL892871\u20132\u201316764", "DNA", 171, 187], ["chr9", "DNA", 192, 196], ["ssc", "TEST", 68, 71], ["ssc", "TEST", 81, 84], ["ssc", "TEST", 96, 99], ["ssc", "TEST", 112, 115]]], ["There were some differences in the results, because of the use of different technologies, but the results showed a general consistency between stem-loop RT-qPCR and high-throughput sequencing (Table 2).Target prediction and gene functional annotation of the targets of differentially expressed miRNAs ::: ResultsThe putative target genes of the 59 differentially expressed miRNAs (miRBase annotated) and 241 novel miRNAs were predicted using on-line miRNA target prediction tools to probe the biological roles of the miRNAs (S3 Table).", [["putative target genes", "DNA", 316, 337], ["59 differentially expressed miRNAs", "RNA", 345, 379], ["miRBase annotated", "RNA", 381, 398], ["miRNAs", "DNA", 517, 523], ["qPCR", "TEST", 156, 160], ["novel miRNAs", "TEST", 408, 420], ["miRNAs", "ANATOMY", 517, 523]]], ["To predict the putative TGEV targets for the differentially expressed miRNAs, the miRNA target gene database miRGen 3.0 was used with stringent criteria.", [["TGEV", "ORGANISM", 24, 28], ["TGEV targets", "DNA", 24, 36], ["miRNA target gene", "DNA", 82, 99], ["miRGen 3.0", "DNA", 109, 119], ["TGEV", "SPECIES", 24, 28]]], ["The results showed that some of the differentially expressed miRNAs directly targeted the 3' UTR or 5' UTR of the TGEV genome: ssc-miR-28\u20133p, ssc-miR-126\u20135p and ssc-miR-30b-5p target the 3' UTR (28297 bp\u201328571 bp) and ssc-miR-2411 and chrX-16275 target the 5' UTR (1 bp\u2013303 bp) (Fig. 5).", [["3' UTR", "CELLULAR_COMPONENT", 90, 96], ["5' UTR", "CELLULAR_COMPONENT", 100, 106], ["ssc-miR-28\u20133p", "GENE_OR_GENE_PRODUCT", 127, 140], ["ssc-miR-126\u20135p", "GENE_OR_GENE_PRODUCT", 142, 156], ["ssc-miR-30b-5p", "GENE_OR_GENE_PRODUCT", 161, 175], ["ssc-miR-2411", "GENE_OR_GENE_PRODUCT", 218, 230], ["chrX-16275", "GENE_OR_GENE_PRODUCT", 235, 245], ["3' UTR", "DNA", 90, 96], ["5' UTR", "DNA", 100, 106], ["TGEV genome", "DNA", 114, 125], ["ssc", "DNA", 127, 130], ["miR", "DNA", 131, 134], ["28\u20133p", "DNA", 135, 140], ["ssc", "DNA", 142, 145], ["miR", "DNA", 146, 149], ["126\u20135p", "DNA", 150, 156], ["ssc", "DNA", 161, 164], ["miR", "DNA", 165, 168], ["30b", "DNA", 169, 172], ["5p", "DNA", 173, 175], ["3' UTR", "DNA", 187, 193], ["28297 bp", "DNA", 195, 203], ["ssc", "DNA", 218, 221], ["miR-2411", "DNA", 222, 230], ["chrX-16275", "DNA", 235, 245], ["5' UTR", "DNA", 257, 263], ["TGEV", "SPECIES", 114, 118], ["ssc", "TEST", 127, 130], ["ssc", "TEST", 142, 145], ["ssc", "TEST", 161, 164], ["bp", "TEST", 201, 203], ["bp", "TEST", 210, 212], ["ssc", "TEST", 218, 221], ["miR", "TEST", 222, 225], ["chrX", "TEST", 235, 239], ["UTR", "TEST", 260, 263], ["bp", "TEST", 267, 269], ["bp", "TEST", 274, 276], ["ssc", "ANATOMY", 127, 130]]], ["This study also found a series of miRNAs that target host-encoded pre-miRNAs; for example, ssc-miR-9, ssc-miR-19a, ssc-miR-142\u20135p, ssc-miR-134 and ssc-miR-20c-5p all target ssc-mir-21.", [["ssc-miR-9", "GENE_OR_GENE_PRODUCT", 91, 100], ["ssc-miR-19a", "GENE_OR_GENE_PRODUCT", 102, 113], ["ssc-miR-142\u20135p", "GENE_OR_GENE_PRODUCT", 115, 129], ["ssc-miR-134", "GENE_OR_GENE_PRODUCT", 131, 142], ["ssc-miR-20c", "GENE_OR_GENE_PRODUCT", 147, 158], ["ssc-mir-21", "GENE_OR_GENE_PRODUCT", 173, 183], ["ssc-miR-9", "DNA", 91, 100], ["ssc", "DNA", 102, 105], ["miR", "DNA", 106, 109], ["19a", "DNA", 110, 113], ["ssc", "DNA", 115, 118], ["miR", "DNA", 119, 122], ["142\u20135p", "DNA", 123, 129], ["ssc", "DNA", 131, 134], ["miR-134", "DNA", 135, 142], ["ssc", "DNA", 147, 150], ["miR", "DNA", 151, 154], ["20c", "DNA", 155, 158], ["ssc", "DNA", 173, 176], ["mir-21", "DNA", 177, 183], ["This study", "TEST", 0, 10], ["example", "TEST", 82, 89], ["ssc", "TEST", 91, 94], ["miR", "TEST", 95, 98], ["ssc", "TEST", 102, 105], ["ssc", "TEST", 115, 118], ["ssc", "TEST", 131, 134], ["ssc", "TEST", 147, 150]]], ["GO annotation was performed for the target genes of five designated differentially expressed miRNAs (miR-146b, miR-155\u20135p, miR-195, miR-124a and miR-1306\u20135p).", [["miR-146b", "GENE_OR_GENE_PRODUCT", 101, 109], ["miR-155\u20135p", "GENE_OR_GENE_PRODUCT", 111, 121], ["miR-195", "GENE_OR_GENE_PRODUCT", 123, 130], ["miR-124a", "GENE_OR_GENE_PRODUCT", 132, 140], ["miR-1306\u20135p", "GENE_OR_GENE_PRODUCT", 145, 156], ["target genes", "DNA", 36, 48], ["miR-146b", "DNA", 101, 109], ["miR-155\u20135p", "DNA", 111, 121], ["miR-195", "DNA", 123, 130], ["miR", "DNA", 132, 135], ["124a", "DNA", 136, 140], ["miR", "DNA", 145, 148], ["1306\u20135p", "DNA", 149, 156], ["miR", "TEST", 123, 126]]], ["The results showed that the differential expressed miRNAs and their target genes constituted a complex regulatory network: multiple miRNAs were linked through their common target genes.", [["target genes", "DNA", 68, 80], ["common target genes", "DNA", 165, 184], ["multiple miRNAs", "PROBLEM", 123, 138]]], ["This complex regulatory network could regulate the expression of multiple genes through one miRNA, but could also regulate the expression of certain genes through several miRNAs in combination (S1 Fig. and S2 Fig.).", [["miRNAs", "DNA", 171, 177]]], ["For example, the significantly differentially expressed miRNAs, miR-9, miR-9\u20131 and miR-9\u20132 all target IL12A, but the immune-related gene IL7R was individually regulated by miR-140\u20133p.", [["miR-9", "GENE_OR_GENE_PRODUCT", 64, 69], ["miR-9\u20131", "GENE_OR_GENE_PRODUCT", 71, 78], ["miR-9\u20132", "GENE_OR_GENE_PRODUCT", 83, 90], ["IL12A", "GENE_OR_GENE_PRODUCT", 102, 107], ["IL7R", "GENE_OR_GENE_PRODUCT", 137, 141], ["miR-140\u20133p", "GENE_OR_GENE_PRODUCT", 172, 182], ["miR-9", "DNA", 64, 69], ["miR-9\u20131", "DNA", 71, 78], ["miR-9\u20132", "DNA", 83, 90], ["IL12A", "DNA", 102, 107], ["IL7R", "DNA", 137, 141], ["miR-140\u20133p", "DNA", 172, 182], ["miRNAs", "TEST", 56, 62], ["miR", "TEST", 64, 67], ["miR", "TEST", 71, 74], ["miR", "TEST", 83, 86]]], ["The in-depth analysis of the miRNA regulatory mechanism in gene expression will contribute to our understanding of the complexity of eukaryote genomes and gene regulatory networks.Target prediction and gene functional annotation of the targets of differentially expressed miRNAs ::: ResultsThe target genes were associated with cellular components, molecular functions and biological processes; the GO enrichment analysis revealed that the target genes were functionally enriched in immune system process, cellular process, metabolic process and others (Fig. 6; S4 Table).Target prediction and gene functional annotation of the targets of differentially expressed miRNAs ::: ResultsKEGG analysis identified 143 overrepresented pathways, suggesting that these signaling pathways are regulated by the differentially expressed miRNAs during virus infection (S5 Table).Target prediction and gene functional annotation of the targets of differentially expressed miRNAs ::: ResultsThe analysis showed the target genes of the differential expressed miRNAs belong to the T cell receptor signaling pathway, which is involved in the regulation of T cell development, cytokine production and the activation of induced cell death, which is crucial for anti-virus activity.", [["cellular", "ANATOMY", 328, 336], ["immune system", "ANATOMY", 483, 496], ["cellular", "ANATOMY", 506, 514], ["T cell", "ANATOMY", 1063, 1069], ["T cell", "ANATOMY", 1137, 1143], ["cell", "ANATOMY", 1207, 1211], ["infection", "DISEASE", 844, 853], ["death", "DISEASE", 1212, 1217], ["cellular", "CELL", 328, 336], ["cellular", "CELL", 506, 514], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 1063, 1078], ["T cell", "CELL", 1137, 1143], ["cell", "CELL", 1207, 1211], ["eukaryote genomes", "DNA", 133, 150], ["gene regulatory networks", "DNA", 155, 179], ["target genes", "DNA", 294, 306], ["target genes", "DNA", 440, 452], ["T cell receptor", "PROTEIN", 1063, 1078], ["cytokine", "PROTEIN", 1157, 1165], ["eukaryote genomes", "TREATMENT", 133, 150], ["cellular components", "PROBLEM", 328, 347], ["molecular functions and biological processes", "PROBLEM", 349, 393], ["the GO enrichment analysis", "TEST", 395, 421], ["cellular process", "PROBLEM", 506, 522], ["ResultsKEGG analysis", "TEST", 675, 695], ["these signaling pathways", "PROBLEM", 753, 777], ["the differentially expressed miRNAs during virus infection", "PROBLEM", 795, 853], ["The analysis", "TEST", 975, 987], ["T cell development", "TREATMENT", 1137, 1155], ["cytokine production", "PROBLEM", 1157, 1176], ["induced cell death", "PROBLEM", 1199, 1217], ["anti-virus activity", "PROBLEM", 1240, 1259], ["metabolic process", "OBSERVATION", 524, 541], ["T cell", "OBSERVATION", 1137, 1143], ["cell death", "OBSERVATION", 1207, 1217]]], ["Pathways involved in cancer suggested that the differential expressed miRNAs play a regulatory role in cell proliferation and cell cycle progression.DiscussionTGEV is highly contagious.", [["cancer", "ANATOMY", 21, 27], ["cell", "ANATOMY", 103, 107], ["cell", "ANATOMY", 126, 130], ["cancer", "DISEASE", 21, 27], ["cancer", "CANCER", 21, 27], ["cell", "CELL", 103, 107], ["cell", "CELL", 126, 130], ["cancer", "PROBLEM", 21, 27], ["cell proliferation", "PROBLEM", 103, 121], ["cell cycle progression", "PROBLEM", 126, 148], ["cancer", "OBSERVATION", 21, 27], ["cell proliferation", "OBSERVATION", 103, 121], ["highly", "OBSERVATION_MODIFIER", 167, 173], ["contagious", "OBSERVATION", 174, 184]]], ["Once pigs are infected with the virus, it can spread to the entire breeding farm in 2 or 3 days.", [["pigs", "ORGANISM", 5, 9], ["pigs", "SPECIES", 5, 9], ["pigs", "SPECIES", 5, 9], ["the virus", "PROBLEM", 28, 37], ["infected", "OBSERVATION", 14, 22]]], ["Dogs, cats and foxes can carry TGEV, but TGEV is not pathogenic for these animals.", [["Dogs", "ORGANISM", 0, 4], ["cats", "ORGANISM", 6, 10], ["foxes", "ORGANISM", 15, 20], ["TGEV", "ORGANISM", 31, 35], ["TGEV", "ORGANISM", 41, 45], ["Dogs", "SPECIES", 0, 4], ["cats", "SPECIES", 6, 10], ["TGEV", "SPECIES", 31, 35], ["TGEV", "SPECIES", 41, 45], ["TGEV", "PROBLEM", 31, 35], ["TGEV", "PROBLEM", 41, 45]]], ["In addition, birds can spread TGEV, especially starlings.", [["TGEV", "DISEASE", 30, 34], ["birds", "ORGANISM", 13, 18], ["TGEV", "ORGANISM", 30, 34], ["TGEV", "SPECIES", 30, 34]]], ["Similar to porcine epidemic diarrhea virus (PEDV), transmissible gastroenteritis virus of swine (TGEV) also belongs to the genus Coronavirus, family Coronavirus, Nidovirales.", [["porcine epidemic diarrhea virus", "DISEASE", 11, 42], ["transmissible gastroenteritis", "DISEASE", 51, 80], ["porcine epidemic diarrhea virus", "ORGANISM", 11, 42], ["transmissible gastroenteritis virus", "ORGANISM", 51, 86], ["swine", "ORGANISM", 90, 95], ["TGEV", "ORGANISM", 97, 101], ["Coronavirus", "GENE_OR_GENE_PRODUCT", 129, 140], ["porcine epidemic diarrhea virus", "SPECIES", 11, 42], ["transmissible gastroenteritis virus", "SPECIES", 51, 86], ["swine", "SPECIES", 90, 95], ["TGEV", "SPECIES", 97, 101], ["porcine epidemic diarrhea virus", "SPECIES", 11, 42], ["PEDV", "SPECIES", 44, 48], ["transmissible gastroenteritis virus", "SPECIES", 51, 86], ["swine", "SPECIES", 90, 95], ["TGEV", "SPECIES", 97, 101], ["porcine epidemic diarrhea virus", "PROBLEM", 11, 42], ["PEDV", "PROBLEM", 44, 48], ["transmissible gastroenteritis virus of swine (TGEV", "PROBLEM", 51, 101], ["Nidovirales", "TREATMENT", 162, 173], ["porcine", "OBSERVATION_MODIFIER", 11, 18], ["epidemic", "OBSERVATION_MODIFIER", 19, 27], ["diarrhea virus", "OBSERVATION", 28, 42], ["gastroenteritis virus", "OBSERVATION", 65, 86], ["genus Coronavirus", "ANATOMY", 123, 140]]], ["The clinical symptoms caused by the infection of these two viruses are quite similar, TGEV and PEDV infection have caused serious damage to the farming industry [20, 21]; however, compared with other Coronavirus, research on TGEV still lags behind.", [["infection", "DISEASE", 36, 45], ["PEDV", "CHEMICAL", 95, 99], ["infection", "DISEASE", 100, 109], ["TGEV", "ORGANISM", 86, 90], ["TGEV", "ORGANISM", 225, 229], ["TGEV", "SPECIES", 86, 90], ["PEDV", "SPECIES", 95, 99], ["TGEV", "SPECIES", 225, 229], ["The clinical symptoms", "PROBLEM", 0, 21], ["the infection of these two viruses", "PROBLEM", 32, 66], ["TGEV", "PROBLEM", 86, 90], ["PEDV infection", "PROBLEM", 95, 109], ["serious damage", "PROBLEM", 122, 136]]], ["Currently, there are no commercial biological products for TGEV infection, and there is also no effective treatment for porcine transmissible gastroenteritis.", [["TGEV infection", "DISEASE", 59, 73], ["transmissible gastroenteritis", "DISEASE", 128, 157], ["TGEV", "ORGANISM", 59, 63], ["porcine", "ORGANISM", 120, 127], ["porcine", "SPECIES", 120, 127], ["TGEV", "SPECIES", 59, 63], ["commercial biological products", "TREATMENT", 24, 54], ["TGEV infection", "PROBLEM", 59, 73], ["effective treatment", "TREATMENT", 96, 115], ["porcine transmissible gastroenteritis", "PROBLEM", 120, 157], ["no", "UNCERTAINTY", 21, 23], ["infection", "OBSERVATION", 64, 73], ["gastroenteritis", "OBSERVATION", 142, 157]]], ["Research on the molecular regulatory mechanisms acting during TGEV infection would have great significance for the prevention of infection by other Coronaviruses, including Human Coronavirus (HCoV) and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV).DiscussionContinuing miRNA research has indicated that miRNAs are involved in the interaction between a variety of viruses and their hosts.", [["infection", "DISEASE", 67, 76], ["infection", "DISEASE", 129, 138], ["Acute Respiratory Syndrome Coronavirus", "DISEASE", 209, 247], ["SARS", "DISEASE", 249, 253], ["TGEV", "ORGANISM", 62, 66], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 148, 161], ["Human Coronavirus (HCoV)", "ORGANISM", 173, 197], ["Severe Acute Respiratory Syndrome Coronavirus", "ORGANISM", 202, 247], ["SARS-CoV", "ORGANISM", 249, 257], ["miRNAs", "DNA", 314, 320], ["Human", "SPECIES", 173, 178], ["TGEV", "SPECIES", 62, 66], ["Human Coronavirus", "SPECIES", 173, 190], ["HCoV", "SPECIES", 192, 196], ["Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV", "SPECIES", 202, 257], ["TGEV infection", "PROBLEM", 62, 76], ["infection", "PROBLEM", 129, 138], ["other Coronaviruses", "PROBLEM", 142, 161], ["Human Coronavirus (HCoV)", "PROBLEM", 173, 197], ["Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 202, 247], ["infection", "OBSERVATION", 129, 138], ["Severe", "OBSERVATION_MODIFIER", 202, 208], ["Acute", "OBSERVATION_MODIFIER", 209, 214], ["Respiratory Syndrome Coronavirus", "OBSERVATION", 215, 247]]], ["This phenomenon provided a paradigm shift in our understanding of latent infection and reactivation mechanisms of the virus.", [["infection", "DISEASE", 73, 82], ["a paradigm shift", "TREATMENT", 25, 41], ["latent infection", "PROBLEM", 66, 82], ["the virus", "PROBLEM", 114, 123], ["latent", "OBSERVATION_MODIFIER", 66, 72], ["infection", "OBSERVATION", 73, 82]]], ["MiRNAs and their targets may represent new antiviral targets for therapy.DiscussionRecent studies indicate that host-encoded miRNAs play an important regulatory role in the virus life cycle.", [["MiRNAs", "DNA", 0, 6], ["miRNAs", "DNA", 125, 131], ["new antiviral targets", "TREATMENT", 39, 60], ["therapy", "TREATMENT", 65, 72], ["DiscussionRecent studies", "TEST", 73, 97], ["the virus life cycle", "TREATMENT", 169, 189], ["may represent", "UNCERTAINTY", 25, 38], ["new", "OBSERVATION_MODIFIER", 39, 42], ["antiviral targets", "OBSERVATION", 43, 60]]], ["However, the host-encoded miRNAs do not always play an inhibitory role during viral infection.", [["viral infection", "DISEASE", 78, 93], ["viral infection", "PROBLEM", 78, 93], ["viral", "OBSERVATION_MODIFIER", 78, 83], ["infection", "OBSERVATION", 84, 93]]], ["Host-encoded miRNA expression profiles can be changed by virus infection and virus-encoded miRNAs can also regulate the viral infection status and the expression of viral proteins through complementarity with the 3' UTR of the target gene.", [["infection", "DISEASE", 63, 72], ["infection", "DISEASE", 126, 135], ["3' UTR", "CELLULAR_COMPONENT", 213, 219], ["viral proteins", "PROTEIN", 165, 179], ["3' UTR", "DNA", 213, 219], ["target gene", "DNA", 227, 238], ["virus infection", "PROBLEM", 57, 72], ["virus", "PROBLEM", 77, 82], ["the viral infection status", "PROBLEM", 116, 142], ["viral proteins through complementarity", "PROBLEM", 165, 203], ["the 3' UTR", "TREATMENT", 209, 219], ["viral", "OBSERVATION_MODIFIER", 120, 125], ["infection", "OBSERVATION", 126, 135]]], ["[28\u201332]DiscussionPrevious studies showed that TGEV could effectively proliferate in ST cells; therefore, the ST cell line is an important culture system for TGEV research.", [["ST cells", "ANATOMY", 84, 92], ["ST cell line", "ANATOMY", 109, 121], ["TGEV", "ORGANISM", 46, 50], ["ST cells", "CELL", 84, 92], ["ST cell line", "CELL", 109, 121], ["TGEV", "ORGANISM", 157, 161], ["ST cells", "CELL_TYPE", 84, 92], ["ST cell line", "CELL_LINE", 109, 121], ["TGEV", "SPECIES", 46, 50], ["TGEV", "SPECIES", 157, 161], ["DiscussionPrevious studies", "TEST", 7, 33], ["TGEV", "PROBLEM", 46, 50], ["the ST cell line", "TREATMENT", 105, 121]]], ["The ST cell culture system can improve the immunogenicity of the vaccine relative to other cell lines; therefore, the ST cell line is also the ideal cell line for the preparation of a TGEV vaccine.DiscussionCurrently, there are a very limited number of publications on miRNA expression profiles in porcine cells, and none that compare the differential expression profiles between passaged porcine testicular cells and primary porcine testicular cells.", [["ST cell", "ANATOMY", 4, 11], ["cell lines", "ANATOMY", 91, 101], ["ST cell line", "ANATOMY", 118, 130], ["cell line", "ANATOMY", 149, 158], ["cells", "ANATOMY", 306, 311], ["testicular cells", "ANATOMY", 397, 413], ["testicular cells", "ANATOMY", 434, 450], ["ST cell", "CELL", 4, 11], ["cell lines", "CELL", 91, 101], ["ST cell line", "CELL", 118, 130], ["cell line", "CELL", 149, 158], ["TGEV", "ORGANISM", 184, 188], ["porcine", "ORGANISM", 298, 305], ["cells", "CELL", 306, 311], ["porcine", "ORGANISM", 389, 396], ["testicular cells", "CELL", 397, 413], ["porcine", "ORGANISM", 426, 433], ["testicular cells", "CELL", 434, 450], ["ST cell culture", "CELL_LINE", 4, 19], ["cell lines", "CELL_LINE", 91, 101], ["ST cell line", "CELL_LINE", 118, 130], ["porcine cells", "CELL_TYPE", 298, 311], ["porcine testicular cells", "CELL_TYPE", 389, 413], ["primary porcine testicular cells", "CELL_TYPE", 418, 450], ["porcine", "SPECIES", 389, 396], ["porcine", "SPECIES", 426, 433], ["TGEV", "SPECIES", 184, 188], ["porcine", "SPECIES", 389, 396], ["porcine", "SPECIES", 426, 433], ["The ST cell culture system", "TEST", 0, 26], ["the vaccine", "TREATMENT", 61, 72], ["other cell lines", "TREATMENT", 85, 101], ["the ST cell line", "TREATMENT", 114, 130], ["the ideal cell line", "TREATMENT", 139, 158], ["a TGEV vaccine", "TREATMENT", 182, 196], ["miRNA expression profiles in porcine cells", "PROBLEM", 269, 311], ["passaged porcine testicular cells", "TREATMENT", 380, 413], ["primary porcine testicular cells", "TREATMENT", 418, 450], ["cell lines", "OBSERVATION", 91, 101], ["cell line", "OBSERVATION", 121, 130], ["ideal cell line", "OBSERVATION", 143, 158], ["porcine cells", "OBSERVATION", 298, 311], ["testicular cells", "OBSERVATION", 397, 413], ["porcine testicular cells", "OBSERVATION", 426, 450]]], ["Studies on miRNA expression profiles after viral infection and the regulation mechanisms of miRNAs during viral infection are also in their initial stages.DiscussionIn this study, TGEV-infected ST cells were chosen as the research subjects, and we preliminarily explored the miRNA molecular regulatory pathways during infection with the virus.", [["ST cells", "ANATOMY", 194, 202], ["viral infection", "DISEASE", 43, 58], ["viral infection", "DISEASE", 106, 121], ["infection", "DISEASE", 318, 327], ["TGEV", "ORGANISM", 180, 184], ["ST cells", "CELL", 194, 202], ["TGEV-infected ST cells", "CELL_LINE", 180, 202], ["TGEV", "SPECIES", 180, 184], ["miRNA expression profiles", "TEST", 11, 36], ["viral infection", "PROBLEM", 43, 58], ["miRNAs during viral infection", "PROBLEM", 92, 121], ["this study", "TEST", 168, 178], ["TGEV", "PROBLEM", 180, 184], ["infected ST cells", "PROBLEM", 185, 202], ["the virus", "PROBLEM", 333, 342], ["viral", "OBSERVATION_MODIFIER", 43, 48], ["infection", "OBSERVATION", 49, 58], ["viral infection", "OBSERVATION", 106, 121]]], ["We believe that the results of this study will assist with the prevention and treatment of the viral disease.DiscussionIn a previous study of miRNA expression profile of the porcine reproductive system, 732 mature miRNAs were detected, but the study did not involve the miRNA expression profiles of a testicular cell line [33\u201334].", [["testicular cell line", "ANATOMY", 301, 321], ["viral disease", "DISEASE", 95, 108], ["porcine", "ORGANISM", 174, 181], ["reproductive system", "ANATOMICAL_SYSTEM", 182, 201], ["testicular cell line", "CELL", 301, 321], ["testicular cell line", "CELL_LINE", 301, 321], ["this study", "TEST", 31, 41], ["the prevention", "TREATMENT", 59, 73], ["treatment", "TREATMENT", 78, 87], ["the viral disease", "PROBLEM", 91, 108], ["a previous study", "TEST", 122, 138], ["the study", "TEST", 240, 249], ["viral disease", "OBSERVATION", 95, 108], ["testicular", "ANATOMY", 301, 311], ["cell line", "OBSERVATION", 312, 321]]], ["In this study, ST cell samples were collected after infection with TGEV, 241 novel host-encoded miRNAs were identified.", [["ST cell samples", "ANATOMY", 15, 30], ["infection", "DISEASE", 52, 61], ["ST cell samples", "CELL", 15, 30], ["TGEV", "ORGANISM", 67, 71], ["TGEV", "SPECIES", 67, 71], ["this study", "TEST", 3, 13], ["ST cell samples", "TEST", 15, 30], ["infection", "PROBLEM", 52, 61], ["TGEV", "PROBLEM", 67, 71]]], ["MiRNAs frequently vary compared with their miRBase reference sequences.", [["miRBase reference sequences", "DNA", 43, 70], ["their miRBase reference sequences", "TEST", 37, 70]]], ["In this study, precursor miRNAs produced multiple mature variants (isomiRs).", [["isomiRs", "GENE_OR_GENE_PRODUCT", 67, 74], ["precursor miRNAs", "RNA", 15, 31], ["this study", "TEST", 3, 13], ["multiple mature variants", "PROBLEM", 41, 65], ["multiple", "OBSERVATION_MODIFIER", 41, 49], ["mature variants", "OBSERVATION", 50, 65]]], ["It appeared that much of the isomiR variability could be explained by variability in either Dicer or Drosha cleavage positions within the pre-miRNA hairpin.DiscussionMiRNAs have a regulatory impact on virus transcripts to support the viral replication cycle and allow the virus to escape the host immune system [35, 36].", [["isomiR", "GENE_OR_GENE_PRODUCT", 29, 35], ["Dicer", "GENE_OR_GENE_PRODUCT", 92, 97], ["Drosha", "GENE_OR_GENE_PRODUCT", 101, 107], ["Dicer", "PROTEIN", 92, 97], ["Drosha", "PROTEIN", 101, 107], ["pre-miRNA hairpin", "RNA", 138, 155], ["DiscussionMiRNAs", "PROTEIN", 156, 172], ["virus transcripts", "RNA", 201, 218], ["the isomiR variability", "PROBLEM", 25, 47], ["Drosha cleavage positions", "PROBLEM", 101, 126], ["the pre-miRNA hairpin", "TREATMENT", 134, 155], ["virus transcripts", "TREATMENT", 201, 218], ["the viral replication cycle", "TREATMENT", 230, 257], ["the virus", "PROBLEM", 268, 277], ["could be explained", "UNCERTAINTY", 48, 66], ["variability", "OBSERVATION_MODIFIER", 70, 81], ["Dicer", "OBSERVATION", 92, 97], ["Drosha cleavage", "OBSERVATION", 101, 116], ["pre-miRNA hairpin", "OBSERVATION", 138, 155]]], ["We concluded that there is a very important relationship between these miRNAs and the replication or translation of TGEV.", [["TGEV", "ORGANISM", 116, 120], ["TGEV", "SPECIES", 116, 120], ["the replication", "TREATMENT", 82, 97], ["translation of TGEV", "TREATMENT", 101, 120]]], ["Further study of the mechanism is essential for virus prevention or treatment.DiscussionThe immune system is the crucial barrier for resisting viral infection.", [["immune system", "ANATOMY", 92, 105], ["viral infection", "DISEASE", 143, 158], ["Further study", "TEST", 0, 13], ["virus prevention", "TREATMENT", 48, 64], ["treatment", "TREATMENT", 68, 77], ["the crucial barrier", "TREATMENT", 109, 128], ["resisting viral infection", "PROBLEM", 133, 158], ["viral", "OBSERVATION_MODIFIER", 143, 148], ["infection", "OBSERVATION", 149, 158]]], ["In recent years, research on molecular regulation mechanism of mammalian immune-related genes has made tremendous progress, but the details of the molecular regulation mechanism of immune-related genes that are mediated by miRNA remain unknown.DiscussionIn recent years, the role of miRNAs in the immune response has been revealed.", [["mammalian immune-related genes", "DNA", 63, 93], ["miRNAs", "DNA", 283, 289], ["immune-related genes", "PROBLEM", 181, 201], ["mammalian immune", "OBSERVATION", 63, 79]]], ["Evidence shows that the mammalian immune response is associated with the regulation of miRNA.", [["mammalian immune response", "OBSERVATION", 24, 49], ["miRNA", "ANATOMY", 87, 92]]], ["Recent research showed that the pathogen-associated molecular pattern (PAMP), pattern receptors (PRR) induced miRNA expression via a series of signaling pathways, thereby regulating innate immunity.", [["pathogen-associated molecular pattern", "GENE_OR_GENE_PRODUCT", 32, 69], ["PAMP", "GENE_OR_GENE_PRODUCT", 71, 75], ["PRR", "GENE_OR_GENE_PRODUCT", 97, 100], ["PAMP", "PROTEIN", 71, 75], ["pattern receptors", "PROTEIN", 78, 95], ["PRR", "PROTEIN", 97, 100], ["Recent research", "TEST", 0, 15], ["the pathogen", "PROBLEM", 28, 40], ["miRNA expression", "PROBLEM", 110, 126], ["signaling pathways", "PROBLEM", 143, 161]]], ["Therefore, the identification and characterization of the regulatory miRNAs involved in the innate immune response is essential for the in-depth study of animal immune regulatory mechanisms and the treatment of the viral diseases [37].DiscussionIn this study, a large number of immune-related miRNAs were significantly differentially expressed upon infection by TGEV.", [["viral diseases", "DISEASE", 215, 229], ["infection", "DISEASE", 349, 358], ["TGEV", "ORGANISM", 362, 366], ["regulatory miRNAs", "DNA", 58, 75], ["TGEV", "SPECIES", 362, 366], ["the identification", "TEST", 11, 29], ["the in-depth study", "TEST", 132, 150], ["animal immune regulatory mechanisms", "TREATMENT", 154, 189], ["the viral diseases", "PROBLEM", 211, 229], ["this study", "TEST", 248, 258], ["immune-related miRNAs", "PROBLEM", 278, 299], ["infection", "PROBLEM", 349, 358], ["regulatory miRNAs", "OBSERVATION", 58, 75], ["viral diseases", "OBSERVATION", 215, 229], ["large", "OBSERVATION_MODIFIER", 262, 267], ["infection", "OBSERVATION", 349, 358]]], ["In particular, mature miR-146 and miR-155 were significantly upregulated in infected ST cells compared with the control group; the fold changes of miR-146 and miR-155 between the infected ST cells and the control group were 3.30 and 1.74, respectively.", [["ST cells", "ANATOMY", 85, 93], ["ST cells", "ANATOMY", 188, 196], ["miR-155", "CHEMICAL", 159, 166], ["miR-146", "GENE_OR_GENE_PRODUCT", 22, 29], ["miR-155", "GENE_OR_GENE_PRODUCT", 34, 41], ["ST cells", "CELL", 85, 93], ["miR-146", "GENE_OR_GENE_PRODUCT", 147, 154], ["miR-155", "GENE_OR_GENE_PRODUCT", 159, 166], ["ST cells", "CELL", 188, 196], ["miR-155", "DNA", 34, 41], ["infected ST cells", "CELL_TYPE", 76, 93], ["miR-155", "DNA", 159, 166], ["infected ST cells", "CELL_TYPE", 179, 196], ["mature miR", "TEST", 15, 25], ["miR", "TEST", 34, 37], ["infected ST cells", "PROBLEM", 76, 93], ["miR", "TEST", 147, 150], ["miR", "TEST", 159, 162], ["the infected ST cells", "PROBLEM", 175, 196], ["infected", "OBSERVATION", 76, 84], ["infected", "OBSERVATION", 179, 187]]], ["Previous research showed that miR-146 and miR-155 play a key regulatory role on host immune function.[38\u201340].", [["miR-155", "CHEMICAL", 42, 49], ["miR-146", "GENE_OR_GENE_PRODUCT", 30, 37], ["miR-155", "GENE_OR_GENE_PRODUCT", 42, 49], ["miR-146", "DNA", 30, 37], ["miR-155", "DNA", 42, 49], ["Previous research", "TEST", 0, 17], ["miR", "TEST", 30, 33]]], ["In this study, the sequencing data confirmed the results of previous studies, and proved that in addition to immune cells, normal cells also abundantly expressed miR-146 and miR-155 when stimulated by viral antigens and are involved in the regulation of immunity.Virus and cells ::: Materials and MethodsTGEV Sichuan strain and the ST cell line (Provided by Animal Biotechnology Center of Sichuan Agricultural University) were used in this study.", [["immune cells", "ANATOMY", 109, 121], ["cells", "ANATOMY", 130, 135], ["cells", "ANATOMY", 273, 278], ["ST cell line", "ANATOMY", 332, 344], ["immune cells", "CELL", 109, 121], ["normal cells", "CELL", 123, 135], ["miR-146", "GENE_OR_GENE_PRODUCT", 162, 169], ["miR-155", "GENE_OR_GENE_PRODUCT", 174, 181], ["Virus", "ORGANISM", 263, 268], ["cells", "CELL", 273, 278], ["ST cell line", "CELL", 332, 344], ["immune cells", "CELL_TYPE", 109, 121], ["miR-146", "DNA", 162, 169], ["miR-155", "DNA", 174, 181], ["viral antigens", "PROTEIN", 201, 215], ["ST cell line", "CELL_LINE", 332, 344], ["this study", "TEST", 3, 13], ["the sequencing data", "TEST", 15, 34], ["previous studies", "TEST", 60, 76], ["immune cells", "PROBLEM", 109, 121], ["miR", "TEST", 174, 177], ["Materials", "TREATMENT", 283, 292], ["MethodsTGEV Sichuan strain", "TREATMENT", 297, 323], ["the ST cell line", "TREATMENT", 328, 344], ["this study", "TEST", 435, 445], ["cell line", "OBSERVATION", 335, 344]]], ["Cell cultures were performed at 106 cells/175 cm2 dishes and were maintained under standard conditions of 37\u00b0C and 5% CO2 in modified RPMI-1640 nutrient solution (Thermo Fisher Scientific, Waltham, UK), supplemented with 10% heat-inactivated fetal bovine serum and 50 mg/ml penicillin/streptomycin antibiotic solution (GIBCO, Beijing, China).Virus and cells ::: Materials and MethodsThe experiment consisted of pooled samples, samples were performed in triplicates.", [["Cell cultures", "ANATOMY", 0, 13], ["cells", "ANATOMY", 36, 41], ["serum", "ANATOMY", 255, 260], ["cells", "ANATOMY", 352, 357], ["samples", "ANATOMY", 418, 425], ["samples", "ANATOMY", 427, 434], ["CO2", "CHEMICAL", 118, 121], ["RPMI-1640", "CHEMICAL", 134, 143], ["penicillin", "CHEMICAL", 274, 284], ["streptomycin", "CHEMICAL", 285, 297], ["CO2", "CHEMICAL", 118, 121], ["penicillin", "CHEMICAL", 274, 284], ["streptomycin", "CHEMICAL", 285, 297], ["Cell cultures", "CELL", 0, 13], ["cells", "CELL", 36, 41], ["CO2", "SIMPLE_CHEMICAL", 118, 121], ["bovine", "ORGANISM", 248, 254], ["serum", "ORGANISM_SUBSTANCE", 255, 260], ["penicillin", "SIMPLE_CHEMICAL", 274, 284], ["streptomycin", "SIMPLE_CHEMICAL", 285, 297], ["Virus", "ORGANISM", 342, 347], ["cells", "CELL", 352, 357], ["bovine", "SPECIES", 248, 254], ["bovine", "SPECIES", 248, 254], ["Cell cultures", "TEST", 0, 13], ["inactivated fetal bovine serum", "TREATMENT", 230, 260], ["penicillin", "TREATMENT", 274, 284], ["streptomycin antibiotic solution", "TREATMENT", 285, 317], ["Methods", "TREATMENT", 376, 383], ["pooled samples", "TEST", 411, 425], ["samples", "TEST", 427, 434]]], ["When the cells were 70% confluent in the culture dishes, they were infected with TGEV at 10 PFU per cell.", [["cells", "ANATOMY", 9, 14], ["cell", "ANATOMY", 100, 104], ["cells", "CELL", 9, 14], ["TGEV", "ORGANISM", 81, 85], ["cell", "CELL", 100, 104], ["TGEV", "SPECIES", 81, 85], ["the culture dishes", "TEST", 37, 55], ["TGEV", "TREATMENT", 81, 85], ["confluent", "OBSERVATION_MODIFIER", 24, 33]]], ["The infected and control cells groups were harvested at 72 post infection (hpi), and resuspended in Trizol (Invitrogen, Shanghai, China) and stored at-70\u00b0C. All infected and control samples were combined into a single control group and a single infected group, respectively.Data sources ::: Materials and MethodsThe full genomic sequence of TGEV has been determined and is available in the GenBank Genome database (ftp://ftp.ncbi.nih.gov/refseq/release/viral/) (accession no.: DQ811788).", [["cells", "ANATOMY", 25, 30], ["samples", "ANATOMY", 182, 189], ["infection", "DISEASE", 64, 73], ["cells", "CELL", 25, 30], ["TGEV", "ORGANISM", 341, 345], ["TGEV", "SPECIES", 341, 345], ["The infected and control cells groups", "TREATMENT", 0, 37], ["infection", "PROBLEM", 64, 73], ["Trizol", "TREATMENT", 100, 106], ["All infected and control samples", "PROBLEM", 157, 189], ["a single control group", "TREATMENT", 209, 231], ["Methods", "TREATMENT", 305, 312], ["TGEV", "PROBLEM", 341, 345], ["infected", "OBSERVATION_MODIFIER", 4, 12], ["infection", "OBSERVATION", 64, 73], ["infected", "OBSERVATION", 161, 169], ["infected", "OBSERVATION", 245, 253]]], ["The Sus scrofa genomic sequence and gene annotation information are available at the University of California Santa Cruz (UCSC) Genome browser (http://genome.ucsc.edu/index.html).", [["Sus scrofa", "ORGANISM", 4, 14], ["Sus scrofa genomic sequence", "DNA", 4, 31], ["University of California Santa Cruz (UCSC) Genome browser", "DNA", 85, 142], ["Sus scrofa", "SPECIES", 4, 14], ["Sus scrofa", "SPECIES", 4, 14]]], ["Novel annotated pig-encoded miRNAs are available in miRBase (http://www.mirbase.org/).RNA isolation ::: Materials and MethodsThe total RNA was extracted from the TGEV-infected ST cells and control ST cells using the Trizol reagent (Invitrogen), according to the manufacturer\u2019s instruction.", [["ST cells", "ANATOMY", 176, 184], ["ST cells", "ANATOMY", 197, 205], ["pig", "ORGANISM", 16, 19], ["TGEV", "ORGANISM", 162, 166], ["ST cells", "CELL", 176, 184], ["control ST cells", "CELL", 189, 205], ["pig-encoded miRNAs", "DNA", 16, 34], ["TGEV-infected ST cells", "CELL_LINE", 162, 184], ["ST cells", "CELL_TYPE", 197, 205], ["pig", "SPECIES", 16, 19], ["TGEV", "SPECIES", 162, 166], ["Methods", "TREATMENT", 118, 125], ["The total RNA", "TEST", 125, 138], ["the TGEV", "TEST", 158, 166], ["infected ST cells", "PROBLEM", 167, 184], ["the Trizol reagent", "TREATMENT", 212, 230], ["total", "OBSERVATION_MODIFIER", 129, 134]]], ["The NanoDrop ND-1000 spectrophotometer (Nano Drop Inc., Wilmington, DE, USA) was used to accurately measure the concentration (OD 260) and protein contamination (Ratio OD260/OD280) of the total RNA samples.", [["samples", "ANATOMY", 198, 205], ["The NanoDrop ND-1000 spectrophotometer (Nano Drop Inc.", "TREATMENT", 0, 54], ["Wilmington, DE, USA)", "TREATMENT", 56, 76], ["protein contamination", "TEST", 139, 160], ["the total RNA samples", "TREATMENT", 184, 205]]], ["The Agilent 2100 Bioanalyzer (Agilent, Beijing, China) was used to accurately assess the quality and concentration of the sequencing library.", [["The Agilent 2100 Bioanalyzer (Agilent, Beijing, China)", "TREATMENT", 0, 54], ["the sequencing library", "TREATMENT", 118, 140]]], ["Denaturing agarose gel electrophoresis was used to assess the RNA integrity and gDNA contamination.", [["agarose", "SIMPLE_CHEMICAL", 11, 18], ["Denaturing agarose gel electrophoresis", "TREATMENT", 0, 38], ["gDNA contamination", "PROBLEM", 80, 98]]], ["The same RNA samples were used in the stem-loop RT-PCR experiments to verify the expression of specific miRNAs.", [["samples", "ANATOMY", 13, 20], ["The same RNA samples", "TEST", 0, 20], ["PCR experiments", "TEST", 51, 66], ["stem", "ANATOMY", 38, 42], ["specific miRNAs", "OBSERVATION", 95, 110]]], ["Total RNA of infected and control samples were mixed during high-throughput sequencing, respectively.Small RNA library construction and sequencing ::: Materials and MethodsTotal RNA of each sample was used to prepare the miRNA sequencing library, which included the following steps: 1) 3'-adapter ligation with T4 RNA ligase 2 (truncated); 2) 5'-adapter ligation with T4 RNA ligase; 3) cDNA synthesis with an RT primer; 4) PCR amplification; and 5) extraction and purification of 120\u2013140 bp PCR amplified fragments (corresponding to ~15\u201325 nt small RNAs) from polyacrylamide gels.", [["samples", "ANATOMY", 34, 41], ["fragments", "ANATOMY", 505, 514], ["polyacrylamide", "CHEMICAL", 560, 574], ["samples", "CANCER", 34, 41], ["T4 RNA ligase 2", "GENE_OR_GENE_PRODUCT", 311, 326], ["MethodsTotal RNA", "RNA", 165, 181], ["miRNA sequencing library", "DNA", 221, 245], ["T4 RNA ligase 2", "PROTEIN", 311, 326], ["T4 RNA ligase", "PROTEIN", 368, 381], ["RT primer", "DNA", 409, 418], ["120\u2013140 bp PCR amplified fragments", "DNA", 480, 514], ["~15\u201325 nt small RNAs", "RNA", 533, 553], ["Total RNA of infected and control samples", "PROBLEM", 0, 41], ["MethodsTotal RNA of each sample", "TREATMENT", 165, 196], ["'-adapter ligation", "TREATMENT", 287, 305], ["T4 RNA ligase", "TREATMENT", 311, 324], ["adapter ligation", "TREATMENT", 346, 362], ["T4 RNA ligase", "TREATMENT", 368, 381], ["cDNA synthesis", "TREATMENT", 386, 400], ["an RT primer", "TREATMENT", 406, 418], ["PCR amplification", "TEST", 423, 440], ["extraction", "TREATMENT", 449, 459], ["purification", "TEST", 464, 476], ["bp PCR", "TEST", 488, 494], ["amplified fragments", "PROBLEM", 495, 514], ["nt small RNAs", "PROBLEM", 540, 553], ["polyacrylamide gels", "TREATMENT", 560, 579], ["infected", "OBSERVATION", 13, 21], ["RNA library construction", "OBSERVATION", 107, 131]]], ["An Agilent 2100 Bioanalyzer quantified the libraries, after which the samples were diluted to a final concentration of 8 pM and cluster generation was performed on the Illumina cBot using TruSeq Rapid SR cluster kit (#GD-402\u20134001, Illumina), following the manufacturer\u2019s instructions.", [["samples", "ANATOMY", 70, 77], ["Illumina cBot", "DNA", 168, 181]]], ["The DNA fragments in the libraries were denatured with 0.1M NaOH to generate single-stranded DNA molecules, captured on Illumina flow cells, amplified in situ and finally sequenced for 36 cycles on Illumina HiSeq 2000 (Illumina, San Diego, CA, USA), according to the manufacturer\u2019s instructions [41].miRNA-seq data analysis ::: Materials and MethodsAfter the sequencing images were generated, image analysis and base calling were performed using Off-Line Basecaller software (OLB V1.8.0) (http://support.illumina.com/sequencing/sequencing_software/offline_basecaller_olb.ilmn).", [["cells", "ANATOMY", 134, 139], ["NaOH", "CHEMICAL", 60, 64], ["NaOH", "CHEMICAL", 60, 64], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["DNA", "CELLULAR_COMPONENT", 93, 96], ["cells", "CELL", 134, 139], ["DNA fragments", "DNA", 4, 17], ["single-stranded DNA molecules", "PROTEIN", 77, 106], ["Illumina flow cells", "CELL_LINE", 120, 139], ["OLB V1", "DNA", 476, 482], ["The DNA fragments in the libraries", "PROBLEM", 0, 34], ["0.1M NaOH", "TREATMENT", 55, 64], ["single-stranded DNA molecules", "TREATMENT", 77, 106], ["Illumina flow cells", "TREATMENT", 120, 139], ["Illumina HiSeq", "TEST", 198, 212], ["the sequencing images", "TEST", 355, 376], ["image analysis", "TEST", 393, 407], ["DNA", "OBSERVATION_MODIFIER", 4, 7], ["fragments", "OBSERVATION_MODIFIER", 8, 17], ["libraries", "ANATOMY", 25, 34], ["flow cells", "OBSERVATION", 129, 139]]], ["Subsequently, 3' adapter sequences were trimmed from clean reads (reads that passed Solexa CHASTITY quality filter) and the reads shorter than 15 nt were discarded.", [["3' adapter sequences", "DNA", 14, 34], ["3' adapter sequences", "TREATMENT", 14, 34], ["Solexa CHASTITY quality filter", "TREATMENT", 84, 114]]], ["Known sequences of mRNA, rRNA, tRNA, snRNA, and snoRNA were also excluded.", [["rRNA", "CELLULAR_COMPONENT", 25, 29], ["snoRNA", "CELLULAR_COMPONENT", 48, 54], ["mRNA", "RNA", 19, 23], ["rRNA", "RNA", 25, 29], ["tRNA", "RNA", 31, 35], ["snRNA", "RNA", 37, 42], ["snoRNA", "RNA", 48, 54], ["mRNA", "TEST", 19, 23], ["rRNA", "TEST", 25, 29], ["tRNA, snRNA, and snoRNA", "PROBLEM", 31, 54], ["snoRNA", "OBSERVATION", 48, 54], ["were also excluded", "UNCERTAINTY", 55, 73]]], ["The 3'-adapter-trimmed-reads (\u2265 15 nt) were aligned to the latest known Sus scrofa reference miRNA precursor set in the Sanger miRBase 19 (http://www.mirbase.org/), using Novoalign (v2.07.11).", [["Sus scrofa", "ORGANISM", 72, 82], ["3'-adapter-trimmed-reads", "DNA", 4, 28], ["Sanger miRBase 19", "DNA", 120, 137], ["Sus scrofa", "SPECIES", 72, 82], ["Sus scrofa", "SPECIES", 72, 82]]], ["Reads with counts < 2 were discarded when calculating the miRNA expression.", [["miRNA expression", "OBSERVATION", 58, 74]]], ["To characterize the isomiR variability, any sequence that matched the miRNA precursors in the mature miRNA region \u00b14nt (no more than one mismatch) were accepted as mature miRNA isomiRs, which were then grouped according to the 5-prime (5p) or 3-prime (3p) arm of the precursor hairpin. miRDeep2 (http://www.mdc-berlin.de/en/research/research_teams/systems_biology_of_gene_regulatory_elements/projects/miRDeep/) was used to predict novel pig-encoded miRNAs.", [["isomiR", "GENE_OR_GENE_PRODUCT", 20, 26], ["miRDeep2", "GENE_OR_GENE_PRODUCT", 286, 294], ["pig", "ORGANISM", 437, 440], ["isomiR", "DNA", 20, 26], ["miRNA precursors", "RNA", 70, 86], ["mature miRNA region", "DNA", 94, 113], ["mature miRNA isomiRs", "DNA", 164, 184], ["5-prime (5p) or 3-prime (3p) arm", "DNA", 227, 259], ["precursor hairpin", "DNA", 267, 284], ["miRDeep2", "PROTEIN", 286, 294], ["pig-encoded miRNAs", "DNA", 437, 455], ["pig", "SPECIES", 437, 440], ["pig", "SPECIES", 437, 440], ["the isomiR variability", "PROBLEM", 16, 38], ["any sequence", "TEST", 40, 52], ["the precursor hairpin", "TREATMENT", 263, 284], ["miRDeep2 (http://www.mdc-berlin.de/en/research/research_teams/systems_biology_of_gene_regulatory_elements/projects/miRDeep/)", "TREATMENT", 286, 410], ["miRNA precursors", "OBSERVATION", 70, 86], ["precursor hairpin", "OBSERVATION", 267, 284]]], ["For novel miRNA prediction, we pooled all sequence data from the 3' adapter-trimmed files and all adapter-trimmed sequences of length <17 bp and with >1 mismatch were excluded from prediction pipeline.", [["3' adapter-trimmed files", "DNA", 65, 89], ["adapter-trimmed sequences", "DNA", 98, 123], ["all sequence data", "TEST", 38, 55], ["length", "TEST", 127, 133], ["bp", "TEST", 138, 140]]], ["Mfold software (http://mfold.rna.albany.edu/) and the Vienna RNAfold web server (http://rna.tbi.univie.at/cgi-bin/RNAfold.cgi) predicted the fold-back secondary structures of the novel miRNAs, under default folding conditions.", [["the novel miRNAs", "PROBLEM", 175, 191], ["back", "ANATOMY", 146, 150], ["novel miRNAs", "OBSERVATION", 179, 191]]], ["The ratio of the normalized read counts between two samples based on the most abundant isomiR read counts.miRNA-seq data analysis ::: Materials and MethodsThe IDEG6 web tool (http://telethon.bio.unipd.it/bioinfo/IDEG6/) was used to determine the significance of the observed differences in miRNA counts between the two samples.", [["samples", "ANATOMY", 52, 59], ["samples", "ANATOMY", 319, 326], ["isomiR", "PROTEIN", 87, 93], ["IDEG6", "DNA", 159, 164], ["The ratio", "TEST", 0, 9], ["two samples", "TEST", 48, 59], ["Methods", "TREATMENT", 148, 155], ["miRNA counts", "TEST", 290, 302], ["miRNA counts", "OBSERVATION", 290, 302]]], ["When comparing differential miRNA expression between two samples (TGEV infected ST cells/ Control ST cells), differentially expressed miRNAs may be determined by fold change filtering, normalized most abundant tag counts were used for fold-change calculation.", [["samples", "ANATOMY", 57, 64], ["ST cells", "ANATOMY", 80, 88], ["ST cells", "ANATOMY", 98, 106], ["TGEV", "ORGANISM", 66, 70], ["ST cells", "CELL", 80, 88], ["Control ST cells", "CELL", 90, 106], ["TGEV infected ST cells", "CELL_LINE", 66, 88], ["Control ST cells", "CELL_LINE", 90, 106], ["TGEV", "SPECIES", 66, 70], ["two samples", "TEST", 53, 64], ["TGEV infected ST cells/ Control ST cells", "TREATMENT", 66, 106], ["fold change filtering", "PROBLEM", 162, 183]]], ["In the present study, the fold change \u2265 1.5 indicates that the miRNA in the TGEV-infected sample is up-regulated, while a fold change \u2264 0.67 indicates that the miRNA in a PCMV-infected sample is down-regulated (We identified differentially expressed miRNAs based on the normalized most abundant tag counts).Target prediction and functional enrichment of differentially expressed miRNAs ::: Materials and MethodsThe miRNA target gene database miRGen 3.0 (http://www.diana.pcbi.upenn.edu/miRGen.html) was used to predict miRNA target genes and for bioinformatic analysis of gene function.", [["sample", "ANATOMY", 90, 96], ["sample", "ANATOMY", 185, 191], ["TGEV", "ORGANISM", 76, 80], ["PCMV", "GENE_OR_GENE_PRODUCT", 171, 175], ["miRNA target gene", "DNA", 415, 432], ["miRGen 3.0", "DNA", 442, 452], ["miRNA target genes", "DNA", 519, 537], ["TGEV", "SPECIES", 76, 80], ["the present study", "TEST", 3, 20], ["the fold change", "TEST", 22, 37], ["the miRNA in the TGEV", "PROBLEM", 59, 80], ["infected sample", "TEST", 81, 96], ["a fold change", "TEST", 120, 133], ["the miRNA", "PROBLEM", 156, 165], ["a PCMV", "TEST", 169, 175], ["infected sample", "PROBLEM", 176, 191], ["Methods", "TREATMENT", 404, 411], ["database miRGen", "TEST", 433, 448], ["bioinformatic analysis", "TEST", 546, 568], ["miRNA", "OBSERVATION", 63, 68], ["infected", "OBSERVATION_MODIFIER", 81, 89], ["miRNA", "OBSERVATION", 160, 165], ["infected", "OBSERVATION", 176, 184], ["functional enrichment", "OBSERVATION", 329, 350]]], ["This database integrates four major miRNA target prediction tools: PicTar (http://pictar.mdc-berlin.de/), miRnada (http://www.microrna.org/microrna/home.do), DIANA-microT (http://diana.cslab.ece.ntua.gr/microT/) and TargetScanS (http://genes.mit.edu/tscan/targetscanS2005.html) [42\u201346].Target prediction and functional enrichment of differentially expressed miRNAs ::: Materials and MethodsThe Gene Ontology (GO) project provides a controlled vocabulary to describe gene and gene product attributes in any organism (http://www.geneontology.org).", [["a controlled vocabulary", "PROBLEM", 430, 453]]], ["The ontology covers three domains: Biological Process, Cellular Component and Molecular Function.", [["Cellular", "OBSERVATION_MODIFIER", 55, 63], ["Component", "OBSERVATION_MODIFIER", 64, 73], ["Molecular Function", "OBSERVATION", 78, 96]]], ["The target genes of differentially expressed miRNAs were subjected to GO analysis on the web-based tool Database for Annotation, Visualization, and Integrated Discovery (DAVID, http://david.abcc.ncifcrf.gov/).", [["target genes", "DNA", 4, 16], ["Visualization", "TEST", 129, 142]]], ["The significance of the gene function screening of the corresponding target genes was performed at a P-value \u22640.05.Target prediction and functional enrichment of differentially expressed miRNAs ::: Materials and MethodsPathway analysis is a functional analysis that maps genes to the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways.", [["target genes", "DNA", 69, 81], ["the gene function screening", "TEST", 20, 47], ["MethodsPathway analysis", "TEST", 212, 235], ["a functional analysis", "TEST", 239, 260], ["functional enrichment", "OBSERVATION", 137, 158]]], ["The P-value (EASE-score, Fisher-Pvalue or Hypergeometric-Pvalue) denotes the significance of the pathway correlated to the conditions.", [["P-value", "DNA", 4, 11], ["The P-value", "TEST", 0, 11], ["Fisher", "TEST", 25, 31]]], ["The lower the P-value, the more significant the pathway (the recommended P-value cut-off is 0.05).Stem-loop RT-PCR analysis ::: Materials and MethodsStem-loop RT-PCR was carried out using the SYBR Green PCR Core Reagents Kit (Applied Biosystems, Foster City, CA, USA), according to the manufacturer\u2019s instructions.", [["P-value cut-", "TEST", 73, 85], ["Stem-loop RT-PCR analysis", "TEST", 98, 123], ["Materials", "TEST", 128, 137], ["MethodsStem-loop RT-PCR", "TREATMENT", 142, 165], ["lower", "ANATOMY_MODIFIER", 4, 9]]], ["The transcription product, miRNA-specific forward primer and universal reverse primer were used in the stem-loop RT-PCR test to confirm the expressions of miRNAs (S6 Table).", [["transcription product", "PROTEIN", 4, 25], ["forward primer", "DNA", 42, 56], ["universal reverse primer", "DNA", 61, 85], ["miRNAs", "DNA", 155, 161], ["S6 Table", "PROTEIN", 163, 171], ["universal reverse primer", "TREATMENT", 61, 85], ["the stem-loop RT-PCR test", "TEST", 99, 124]]], ["The amplification conditions were: 94\u00b0C 3 min; 40 cycles of 95\u00b0C 20 s, 60\u00b0C 40 s and 72\u00b0C 20 s; and elongation at 72\u00b0C for 5 min.", [["elongation", "TEST", 100, 110]]], ["Stem-loop RT-PCR reactions were performed using the ABI Prism 7900 Sequence Detection System (Applied Biosystems), according to the manufacturer\u2019s instructions [47, 48].Conclusions ::: Materials and MethodsThis is the first comprehensive study of the miRNA expression profile of ST cells after infection with TGEV using a deep sequencing approach.", [["ST cells", "ANATOMY", 279, 287], ["infection", "DISEASE", 294, 303], ["ST cells", "CELL", 279, 287], ["TGEV", "ORGANISM", 309, 313], ["ST cells", "CELL_TYPE", 279, 287], ["TGEV", "SPECIES", 309, 313], ["Stem-loop RT-PCR reactions", "TEST", 0, 26], ["the ABI Prism", "TEST", 48, 61], ["the first comprehensive study", "TEST", 214, 243], ["ST cells", "PROBLEM", 279, 287], ["infection", "PROBLEM", 294, 303], ["TGEV", "PROBLEM", 309, 313], ["a deep sequencing approach", "TREATMENT", 320, 346]]], ["241 pig-encoded novel miRNAs were identified.", [["pig", "ORGANISM", 4, 7], ["pig", "SPECIES", 4, 7], ["pig", "SPECIES", 4, 7], ["miRNAs", "ANATOMY", 22, 28]]], ["We also analyzed the miRNA regulatory network, identified differential expressed miRNAs between the ST cell line and TEGV-infected ST cells, and performed GO analysis for target genes of the differentially expressed miRNAs.", [["ST cell line", "ANATOMY", 100, 112], ["ST cells", "ANATOMY", 131, 139], ["ST cell line", "CELL", 100, 112], ["TEGV", "CELL", 117, 121], ["ST cells", "CELL", 131, 139], ["ST cell line", "CELL_LINE", 100, 112], ["TEGV-infected ST cells", "CELL_LINE", 117, 139], ["target genes", "DNA", 171, 183], ["differentially expressed miRNAs", "DNA", 191, 222], ["TEGV", "SPECIES", 117, 121], ["the ST cell line", "TEST", 96, 112], ["infected ST cells", "PROBLEM", 122, 139], ["GO analysis", "TEST", 155, 166], ["ST", "ANATOMY", 100, 102], ["cell line", "OBSERVATION", 103, 112], ["expressed miRNAs", "OBSERVATION", 206, 222]]], ["We believe that the data and the analysis will contribute to the understanding of miRNA regulation mechanisms during viral infection, and will lead to new approaches for the treatment or prevention of viral diseases.", [["viral infection", "DISEASE", 117, 132], ["viral diseases", "DISEASE", 201, 215], ["the data", "TEST", 16, 24], ["the analysis", "TEST", 29, 41], ["miRNA regulation mechanisms", "PROBLEM", 82, 109], ["viral infection", "PROBLEM", 117, 132], ["the treatment", "TREATMENT", 170, 183], ["viral diseases", "PROBLEM", 201, 215], ["viral diseases", "OBSERVATION", 201, 215]]]], "8edbdef3df17aa5323a6cccd5a686b3356dffa00": [["Adapting interventions for telepsychology is a promising strategy to support families in this time of substantial need (Stiles-Shields et al., 2020; Wosik et al., 2020) .", [["telepsychology", "DISEASE", 27, 41], ["Adapting interventions", "TREATMENT", 0, 22], ["telepsychology", "TREATMENT", 27, 41]]], ["As pediatric psychologists and co-investigators in a multisite pilot study evaluating a brief group behavioral intervention for caregivers of children with newly diagnosed Attention-Deficit/Hyperactivity Disorder (ADHD), we encountered the dilemma of offering the intervention under these unusual circumstances.", [["Attention-Deficit/Hyperactivity Disorder", "DISEASE", 172, 212], ["ADHD", "DISEASE", 214, 218], ["children", "ORGANISM", 142, 150], ["children", "SPECIES", 142, 150], ["a multisite pilot study", "TEST", 51, 74], ["a brief group behavioral intervention", "TREATMENT", 86, 123], ["Hyperactivity Disorder", "PROBLEM", 190, 212], ["the intervention", "TREATMENT", 260, 276]]], ["Given physical distancing requirements and guidance that telepsychology approaches might enhance access to care (DuPaul et al., 2020) , we transitioned from inperson delivery to telepsychology following a rapidcycle quality improvement (RCQI) approach (Schurman et al., 2015) .", [["telepsychology", "TREATMENT", 178, 192]]], ["In this topical review, we describe how we used treatment fidelity to guide adaptations, as well as our preliminary findings and lessons learned.IntroductionBehavioral parent training (BPT), provided individually or in groups (Daley et al., 2018) , is an evidence-based intervention for children with ADHD (Evans et al., 2018) .", [["ADHD", "DISEASE", 301, 305], ["children", "ORGANISM", 287, 295], ["children", "SPECIES", 287, 295], ["treatment fidelity", "TREATMENT", 48, 66]]], ["Preliminary evidence supports the efficacy of telepsychology delivery of individualized BPT.", [["telepsychology delivery", "TREATMENT", 46, 69], ["individualized BPT", "PROBLEM", 73, 91]]], ["Promising approaches have included (a) the use of webinars and other parentpaced learning tools (DuPaul et al., 2018) and (b) individualized therapy using telepsychology (Gurwitch et al., 2020; Sibley et al., 2017) .", [["webinars", "TREATMENT", 50, 58]]], ["Emerging evidence also supports implementation of group parenting interventions using telepsychology (Reese et al., 2015; Xie et al., 2013) .", [["group parenting interventions", "TREATMENT", 50, 79]]], ["However, these studies have not formally measured or used content and process fidelity to guide the telepsychology adaptations.", [["these studies", "TEST", 9, 22]]], ["By using treatment fidelity as a guiding principle to preserve the intervention's essential components, our approach may offer useful directions for research and practice in pediatric psychology.Using Treatment Fidelity to Guide Adaptations for TelepsychologyBootcamp for ADHD (BC-ADHD), a brief (four-session) in-person group intervention for caregivers of children ages 5-11 newly diagnosed with ADHD, includes components of BPT, motivational interviewing, and supportive therapy to promote family engagement in follow-up treatment (Nissley-Tsiopinis, Mautone, & Power, 2012) .", [["ADHD", "DISEASE", 272, 276], ["BC-ADHD", "DISEASE", 278, 285], ["ADHD", "DISEASE", 398, 402], ["children", "ORGANISM", 358, 366], ["person", "SPECIES", 314, 320], ["children", "SPECIES", 358, 366], ["treatment fidelity", "TREATMENT", 9, 27], ["the intervention", "TREATMENT", 63, 79], ["Telepsychology", "TEST", 245, 259], ["ADHD", "PROBLEM", 272, 276], ["ADHD", "PROBLEM", 398, 402], ["motivational interviewing", "TREATMENT", 432, 457], ["supportive therapy", "TREATMENT", 463, 481], ["treatment", "TREATMENT", 524, 533]]], ["In March 2020, we were in year 2 of a multisite pilot study of BC-ADHD when physical distancing orders led us to transition to telepsychology.", [["ADHD", "DISEASE", 66, 70], ["telepsychology", "DISEASE", 127, 141], ["a multisite pilot study", "TEST", 36, 59], ["BC", "TEST", 63, 65], ["ADHD", "PROBLEM", 66, 70]]], ["We employed RCQI methods to deliver BC-ADHD using telepsychology and electronic methods to evaluate the program.", [["ADHD", "DISEASE", 39, 43], ["BC", "TEST", 36, 38]]], ["Our transition raised important questions: Can telepsychology parent training groups be delivered with high quality (i.e., fidelity); and how acceptable and feasible are these for caregivers and clinicians?Using Treatment Fidelity to Guide Adaptations for TelepsychologyWhen transitioning to telepsychology, we sought to maintain a balance between content and process fidelity.", [["Telepsychology", "TEST", 256, 270]]], ["Treatment fidelity provides a foundation from which clinicians can monitor and enhance the implementation of interventions.", [["interventions", "TREATMENT", 109, 122]]], ["Power et al. (2005) defined fidelity as a multidimensional construct that subsumes the content (how much of the treatment is delivered) and process (how well the treatment is delivered) of an intervention.", [["the treatment", "TREATMENT", 108, 121], ["an intervention", "TREATMENT", 189, 204]]], ["Overemphasizing content would result in didactic lectures, minimizing opportunities for participant self-discovery and selfempowerment; whereas overemphasizing process would deprive caregivers of knowledge they need to advocate for their children and navigate complex healthcare and educational systems.", [["selfempowerment", "DISEASE", 119, 134], ["children", "ORGANISM", 238, 246], ["children", "SPECIES", 238, 246], ["Overemphasizing content", "PROBLEM", 0, 23]]], ["In planning for telepsychology groups, we endeavored to promote fidelity to the five core therapeutic processes that we consider key to BC-ADHD: (a) keeping caregivers focused on foundational principles and evidence-based practices, (b) encouraging active caregiver engagement, (c) providing emotional validation, (d) eliciting and strengthening change talk, and (e) building connections among caregivers.Using Treatment Fidelity to Guide Adaptations for TelepsychologyIn addition to the fidelity with which an intervention is delivered, family engagement or responsiveness (Carroll et al., 2007) and treatment satisfaction are important considerations.", [["ADHD", "DISEASE", 139, 143], ["emotional validation", "TREATMENT", 292, 312], ["Telepsychology", "TEST", 455, 469], ["an intervention", "TREATMENT", 508, 523], ["treatment satisfaction", "TREATMENT", 601, 623]]], ["Table I provides definitions, implementation challenges, and recommended adaptations for group telepsychology to maximize fidelity, engagement, and satisfaction.", [["group telepsychology", "TREATMENT", 89, 109]]], ["Additional adaptations included shortening sessions from 90 to 60 min in some groups due to caregiver feedback; highlighting key points and referring families to handouts for further details; and informing families that we would be available after session if they wanted additional time to speak with us or each other (two families utilized this option).Preliminary Findings and Lessons LearnedOur team implemented BC-ADHD in a telepsychology format to three groups of caregivers of a total of 20 Hispanic, and 2 Black; age 5-11) who were recently diagnosed with ADHD at two tertiary care children's hospitals in large Northeastern U.S. cities.", [["ADHD", "DISEASE", 418, 422], ["ADHD", "DISEASE", 563, 567], ["children", "SPECIES", 589, 597], ["shortening sessions", "TREATMENT", 32, 51], ["this option", "TREATMENT", 341, 352], ["BC", "TEST", 415, 417], ["ADHD", "PROBLEM", 418, 422], ["ADHD", "PROBLEM", 563, 567]]], ["At the start of the program, five children were taking medication to treat ADHD.", [["ADHD", "DISEASE", 75, 79], ["children", "ORGANISM", 34, 42], ["children", "SPECIES", 34, 42], ["medication", "TREATMENT", 55, 65], ["ADHD", "PROBLEM", 75, 79]]], ["These families were referred to inperson groups after initial evaluations in ADHD clinics using established mechanisms for follow-up care.", [["ADHD", "DISEASE", 77, 81], ["initial evaluations", "TEST", 54, 73]]], ["All participating caregivers chose to follow through with the program upon transitioning to telepsychology.", [["telepsychology", "DISEASE", 92, 106]]], ["The groups were comprised of 5, 7, and 8 families, and the families of racial/ethnic minority background were distributed among the groups.", [["racial/ethnic minority background", "PROBLEM", 71, 104]]], ["Caregivers who completed assessments were 17 biological mothers, 2 adoptive mothers, and 1 biological father.", [["mothers", "ORGANISM", 56, 63], ["mothers", "ORGANISM", 76, 83]]], ["Overall, 19 mothers and 15 fathers participated in the program by attending at least one session.", [["mothers", "ORGANISM", 12, 19]]], ["Study procedures were approved by each institution's Institutional Review Board, and caregivers and clinicians provided informed consent.", [["Study procedures", "TEST", 0, 16]]], ["Observers completed the same content and process fidelity measures that were used in our previous research with in-person groups (Normand et al., 2019) .", [["process fidelity measures", "TREATMENT", 41, 66]]], ["The content fidelity checklist included 13-14 items (0-1 scale, 0 \u00bc not implemented, 1 \u00bc implemented), and the process fidelity checklist included 5 items (1-4 scale, 1 \u00bc low process fidelity, 4 \u00bc high process fidelity).", [["The content fidelity checklist", "TEST", 0, 30]]], ["Post-treatment satisfaction questionnaires were administered at the end of the group using the same treatment evaluation form that was used for in-person groups (Nissley-Tsiopinis et al., 2012) .", [["the same treatment evaluation", "TEST", 91, 120]]], ["To accommodate caregivers' needs and schedules, the data collection process was changed from real-time, paperbased survey completion to surveys administered electronically; 13 families completed post-treatment satisfaction questionnaires.", [["the data collection process", "TEST", 48, 75]]], ["Preliminary results indicated that caregivers were highly satisfied with all aspects of the program (overall M \u00bc 5.7, SD \u00bc 1.2, range \u00bc 5.4-6.0 across items).Preliminary Findings and Lessons LearnedIn addition, caregivers were asked to share qualitative feedback about their telepsychology experience after each of the four sessions (see Table II ).", [["overall M", "TEST", 101, 110], ["SD", "TEST", 118, 120], ["\u00bc", "TEST", 134, 135]]], ["Our data collection methods varied across sites using RCQI methods to quickly adapt from in-person to telepsychology and to maximize the amount of meaningful feedback received from caregivers while reducing time burden (e.g., focus groups at the end of the session by videoconference, emailed questions, REDCap survey).", [["Our data collection methods", "TEST", 0, 27], ["RCQI methods", "TREATMENT", 54, 66]]], ["Overall, clinicians highlighted the additional effort required to monitor, engage, and connect all families in the group when attempting to achieve fidelity to group processes.DiscussionBy accelerating the removal of barriers to telepsychology, the emergency response to COVID-19 has raised hopes that virtual methods of service delivery may improve access to behavioral health services, including evidence-based group BPT, for many families.", [["telepsychology", "DISEASE", 229, 243], ["service delivery", "TREATMENT", 321, 337]]], ["The proliferation of telepsychology (more specifically group telepsychology) has also generated questions about quality of care-treatment fidelity-that need to be addressed.", [["treatment fidelity", "TREATMENT", 128, 146], ["proliferation", "OBSERVATION_MODIFIER", 4, 17]]], ["A comparison of clinician fidelity and caregiver satisfaction among groups delivered in person (Nissley-Tsiopinis et al., in preparation; Normand et al., 2019) with these three groups delivered via telepsychology suggests that content (96% for telepsychology vs. 97% for in-person) and process fidelity (M \u00bc 3.7, SD \u00bc 0.5 for telepsychology vs. M \u00bc 3.7, SD \u00bc 0.5 for in-person) and parent satisfaction (M \u00bc 5.7 for telepsychology vs. M \u00bc 5.6 for in-person) are comparable across delivery formats.", [["person", "SPECIES", 88, 94], ["person", "SPECIES", 274, 280], ["person", "SPECIES", 370, 376], ["person", "SPECIES", 449, 455], ["telepsychology", "TEST", 244, 258]]], ["First, our sample was very small and limited to primarily White, college-educated caregivers from two-parent households.", [["small", "OBSERVATION_MODIFIER", 27, 32]]], ["Given that disadvantaged populations are less likely to have technology resources needed to participate in telepsychology (Swenson & Ghertner, 2020) , the promise of telepsychology may be considerably more modest in this population.", [["telepsychology", "DISEASE", 107, 121], ["telepsychology", "DISEASE", 166, 180]]], ["Also, due to our data collection methods, it was not possible to determine the number of caregivers who identified each theme related to telepsychology service delivery.", [["our data collection methods", "TEST", 13, 40], ["telepsychology service delivery", "TREATMENT", 137, 168]]], ["Fourth, the status of future reimbursement for telepsychology service delivery is uncertain, but given its potential to reduce barriers to care, advocacy efforts are needed to ensure financial sustainability.", [["telepsychology service delivery", "TREATMENT", 47, 78], ["barriers to care", "TREATMENT", 127, 143], ["advocacy efforts", "TREATMENT", 145, 161]]], ["BC-ADHD \u00bc Bootcamp for Attention-Deficit/Hyperactivity Disorder.", [["ADHD", "DISEASE", 3, 7], ["Attention-Deficit/Hyperactivity Disorder", "DISEASE", 23, 63], ["BC", "TEST", 0, 2], ["ADHD", "PROBLEM", 3, 7], ["Hyperactivity Disorder", "PROBLEM", 41, 63], ["Hyperactivity Disorder", "OBSERVATION", 41, 63]]], ["The above feedback was given in response to four questions: (1) What was it like participating in a group session using video technology? (2) Were there any things about using video that you liked or thought were helpful? (3) Were there any things about using video that you thought made it difficult to participate or learn? (4) What suggestions do you have to improve these video sessions (or the program when delivered by video)?", [["video technology", "TEST", 120, 136]]], ["Many of the families who completed surveys after participating in BC-ADHD also participated in the focus groups that were conducted after each of the four sessions of BC-ADHD.", [["ADHD", "DISEASE", 69, 73], ["ADHD", "DISEASE", 170, 174], ["ADHD", "PROBLEM", 69, 73], ["BC", "TEST", 167, 169], ["ADHD", "PROBLEM", 170, 174]]], ["Given the strategies used to collect these data, it is possible that a family identified a specific theme more than one time. more diverse samples, multimethod and multiinformant measurement approaches, and controlled designs is needed to assess the efficacy and generalizability of telepsychology parent training groups (see Stiles-Shields et al, 2020 , for additional pediatric psychology research considerations during COVID-19).DiscussionIn conclusion, our experience suggests that telepsychology parent training groups can be delivered with high quality (i.e., fidelity) and are acceptable and feasible for caregivers and clinicians, although findings may not generalize to other caregiver populations.", [["samples", "ANATOMY", 139, 146], ["multimethod and multiinformant measurement approaches", "TEST", 148, 201], ["telepsychology parent training groups", "TREATMENT", 283, 320], ["telepsychology parent training groups", "TREATMENT", 486, 523]]], ["This approach has promise for increasing access to services for families of children with ADHD, disruptive behavior, and executive functioning difficulties.AcknowledgmentsWe would like to thank the families who participated in this study, without whom we could not have done this work.", [["ADHD", "DISEASE", 90, 94], ["disruptive behavior", "DISEASE", 96, 115], ["children", "ORGANISM", 76, 84], ["children", "SPECIES", 76, 84], ["ADHD", "PROBLEM", 90, 94], ["disruptive behavior", "PROBLEM", 96, 115], ["executive functioning difficulties", "PROBLEM", 121, 155], ["this study", "TEST", 227, 237]]], ["We express our appreciation to the many staff and students who assisted with intervention delivery and data collection.", [["intervention delivery", "TREATMENT", 77, 98], ["data collection", "TEST", 103, 118]]], ["Finally, we want to thank the Writers' Group at Boston Children's Hospital's Division of Developmental Medicine for their helpful review.FundingThis work was supported by a seed grant through Division of Developmental Medicine at Boston Children's Hospital, an internal department fellowship from the Division of Developmental and Behavioral Pediatrics at Children's Hospital of Philadelphia (CHOP), and a pilot grant from the Institut du Savoir Montfort (ISM) at H\u00f4 pital Montfort.", [["Children", "SPECIES", 237, 245], ["Children", "SPECIES", 356, 364]]]], "7096311f6e64d50eafe1114727198bda4514f643": [["range of tropical and subtropical regions, with wetlands, grassy plains (known as savannahs), and low mountainous landscapes.", [["low mountainous landscapes", "PROBLEM", 98, 124], ["tropical", "OBSERVATION_MODIFIER", 9, 17], ["subtropical", "ANATOMY_MODIFIER", 22, 33], ["regions", "ANATOMY_MODIFIER", 34, 41], ["low", "OBSERVATION_MODIFIER", 98, 101], ["mountainous landscapes", "OBSERVATION", 102, 124]]], ["That diversity also extends to the presence of many regional and social inequalities, including severe income inequality.", [["severe income inequality", "PROBLEM", 96, 120], ["many", "OBSERVATION_MODIFIER", 47, 51], ["regional", "OBSERVATION_MODIFIER", 52, 60], ["social inequalities", "OBSERVATION", 65, 84], ["severe", "OBSERVATION_MODIFIER", 96, 102]]], ["In 1988, the Brazilian Constitution defined health as a universal right, and in 1990, a Unified Health System (Sistema \u00danico de Sa\u00fade) was created to deliver access to health care for a substantial proportion of the population (1, 2) .", [["right", "ANATOMY_MODIFIER", 66, 71]]]], "31f2b0f55f9b8bfb75904c0eca57dbb6f79bbf94": [["IntroductionThe relationships between pathogens and their hosts are highly variable, ranging from newly emergent zoonotic infections such as SARS coronavirus (Peiris et al. 2004 ) to codivergent associations that span millions of years, like those seen in the papillomaviruses (Bernard et al. 2006) .", [["zoonotic infections", "DISEASE", 113, 132], ["SARS coronavirus", "DISEASE", 141, 157], ["papillomaviruses", "ORGANISM", 260, 276], ["SARS coronavirus", "SPECIES", 141, 157], ["SARS coronavirus", "SPECIES", 141, 157], ["pathogens", "PROBLEM", 38, 47], ["newly emergent zoonotic infections", "PROBLEM", 98, 132], ["SARS coronavirus", "PROBLEM", 141, 157], ["zoonotic", "OBSERVATION_MODIFIER", 113, 121], ["infections", "OBSERVATION", 122, 132]]], ["In particular, methodological advances have enabled the incorporation of temporal information from time-structured sequence data into strict or relaxed molecular clock models (Drummond et al. , 2006 Drummond and Rambaut 2007) , which can then be used to estimate the timing of epidemiologically important events (cross-species transmissions, epidemic outbreaks), as well as historically important ones (the origin of multiple viral subtypes, host-pathogen codivergence).", [["multiple viral subtypes", "PROBLEM", 417, 440]]], ["RNA viruses are particularly well suited to analyses of this type as their rapid replication rate, large population sizes, and error-prone polymerase result in large amounts of genetic diversity being generated in measurable amounts of evolutionary time.", [["error-prone polymerase", "PROTEIN", 127, 149], ["RNA viruses", "PROBLEM", 0, 11], ["large population sizes", "PROBLEM", 99, 121], ["error-prone polymerase", "TEST", 127, 149], ["genetic diversity", "PROBLEM", 177, 194], ["viruses", "OBSERVATION", 4, 11], ["large", "OBSERVATION_MODIFIER", 99, 104], ["population", "OBSERVATION_MODIFIER", 105, 115], ["sizes", "OBSERVATION_MODIFIER", 116, 121], ["large", "OBSERVATION_MODIFIER", 160, 165], ["amounts", "OBSERVATION_MODIFIER", 166, 173], ["genetic diversity", "OBSERVATION", 177, 194]]], ["Sequence analysis programs such as Bayesian Evolutionary Analysis By Sampling Trees (BEAST) are of particular importance in this regard as they utilize the genetic variation present in a sample to simultaneously estimate both demographic and evolutionary parameters in the context of time and space (Drummond et al. , 2006 Drummond and Rambaut 2007; Lemey et al. 2009 ).IntroductionCodivergence with host species over thousands or millions of years has often been invoked as the primary evolutionary mechanism shaping the diversity of many DNA (and some RNA) viruses (Beer et al. 1999; Charrel et al. 1999; Sugimoto et al. 2002; Nemirov et al. 2004 ).", [["DNA", "CELLULAR_COMPONENT", 540, 543], ["Sequence analysis programs", "TEST", 0, 26], ["Bayesian Evolutionary Analysis", "TEST", 35, 65], ["evolutionary parameters", "TEST", 242, 265], ["space (Drummond et al", "TREATMENT", 293, 314], ["many DNA", "PROBLEM", 535, 543]]], ["Importantly, inferences about key aspects of viral biology including the rate of evolutionary change in the viral genome and the timescale of speciation events, have often been made based on the assumption of host-virus codivergence, which automatically places the evolution of these viruses on the same scale as their hosts (Nakao et al. 1997; Hughes and Friedman 2000; Sugimoto et al. 2002; Nishimoto et al. 2006; Krumbholz et al. 2008) .", [["viral genome", "DNA", 108, 120], ["evolutionary change", "PROBLEM", 81, 100], ["the viral genome", "PROBLEM", 104, 120], ["host-virus codivergence", "PROBLEM", 209, 232], ["these viruses", "PROBLEM", 278, 291], ["viral genome", "OBSERVATION", 108, 120], ["viruses", "OBSERVATION", 284, 291]]], ["However, by incorporating timing information from time-sampled (heterochronous) sequences into inferences about the history of viral populations, it is possible to generate independent estimates of the rate and timescale of virus evolution, without requiring the strong assumption of codivergence.", [["viral populations", "PROBLEM", 127, 144], ["virus evolution", "PROBLEM", 224, 239], ["codivergence", "TREATMENT", 284, 296], ["viral populations", "OBSERVATION", 127, 144], ["virus", "OBSERVATION", 224, 229]]], ["Critically, analyses of this type have demonstrated that some host-virus systems that were once thought to be examples of codivergence may in fact be the result of much more recent evolutionary associations (Shackelton et al. 2006; Romano et al. 2008; Harkins et al. 2009; Lewis-Rogers and Crandall 2009; Ramsden et al. 2009 ).IntroductionDespite widespread interest in using novel statistical models that incorporate heterochronous data to answer a wide range of biological questions, concerns have been raised surrounding biases in evolutionary rate estimates that may be inherent to these methods (Ho et al. 2005; Penny 2005; Ho and Larson 2006; Emerson 2007; Ho, Kolokotronis, and Allaby 2007; Navascues and Emerson 2009 ).", [["some host-virus systems", "PROBLEM", 57, 80], ["codivergence", "PROBLEM", 122, 134]]], ["For example, a time-dependent relationship has been demonstrated to exist for the molecular clock, such that molecular evolution is accelerated on short timescales (Ho et al. 2005; Ho and Larson 2006; Ho, Kolokotronis, and Allaby 2007; Ho, Shapiro, et al. 2007) .", [["the molecular clock", "PROBLEM", 78, 97]]], ["Concerns have also been raised regarding the tendency of inference tools to recover substitution rates that are too rapid when population structure in the data is unaccounted for or when inappropriate calibration points are used (Ho et al. 2008; Navascues and Emerson 2009) .", [["inference tools", "PROBLEM", 57, 72], ["substitution rates", "TREATMENT", 84, 102]]], ["Ascribing times to samples and accommodating these in analyses are effectively an assertion that these times span a consequential proportion of the total evolutionary history of the taxa in question and conditions the analysis on rates that are sufficiently high that this is true.", [["the taxa", "TREATMENT", 178, 186], ["the analysis", "TEST", 214, 226]]], ["Such analyses have been used extensively to estimate the evolutionary and epidemiological characteristics of a wide range of rapidly evolving RNA and single-stranded DNA viruses and appear to return estimates that accord well with the known epidemiology of these pathogens (Shackelton et al. 2005; de Oliveira et al. 2006; Bryant et al. 2007; Rambaut et al. 2008; Firth et al. 2009 ).", [["DNA", "CELLULAR_COMPONENT", 166, 169], ["Such analyses", "TEST", 0, 13], ["rapidly evolving RNA", "PROBLEM", 125, 145], ["single-stranded DNA viruses", "PROBLEM", 150, 177]]], ["However, the utility of these methods in estimating the evolutionary dynamics of double-stranded (ds) DNA viruses, which may evolve far more slowly than RNA viruses, has not yet been investigated.", [["DNA", "CELLULAR_COMPONENT", 102, 105], ["these methods", "TEST", 24, 37], ["double-stranded (ds) DNA viruses", "PROBLEM", 81, 113], ["RNA viruses", "PROBLEM", 153, 164]]], ["Indeed, the use of heterochronous phylogenetic modeling has resulted in surprisingly high evolutionary rate estimates for JC virus (Shackelton et al. 2006) , variola virus (VARV) (Li et al. 2007) , and the bacterium Neisseria gonorrhoeae (P\u00e9rez-Losada et al. 2007) .IntroductionIn this study, we examine the ability of current inference tools to estimate relatively low evolutionary rates such as those thought to commonly characterize dsDNA viruses.", [["variola virus", "DISEASE", 158, 171], ["Neisseria gonorrhoeae", "DISEASE", 216, 237], ["JC virus", "ORGANISM", 122, 130], ["variola virus", "ORGANISM", 158, 171], ["Neisseria gonorrhoeae", "ORGANISM", 216, 237], ["variola virus", "SPECIES", 158, 171], ["Neisseria gonorrhoeae", "SPECIES", 216, 237], ["JC virus", "SPECIES", 122, 130], ["variola virus", "SPECIES", 158, 171], ["VARV", "SPECIES", 173, 177], ["Neisseria gonorrhoeae", "SPECIES", 216, 237], ["heterochronous phylogenetic modeling", "PROBLEM", 19, 55], ["JC virus", "PROBLEM", 122, 130], ["variola virus (VARV)", "PROBLEM", 158, 178], ["the bacterium Neisseria gonorrhoeae", "PROBLEM", 202, 237], ["this study", "TEST", 281, 291], ["relatively low evolutionary rates", "PROBLEM", 355, 388], ["dsDNA viruses", "PROBLEM", 436, 449], ["variola virus", "OBSERVATION", 158, 171]]], ["Indeed, Rector et al. (2007) suggest that dsDNA viruses are inappropriate for time-structured analyses because their low mutation rates (;0.003 mutations/genome/replication, Drake 1991; Drake and Hwang 2005; Duffy et al. 2008 ) will lead to immeasurable levels of genetic change over a given sampling interval.", [["dsDNA viruses", "PROBLEM", 42, 55], ["their low mutation rates", "PROBLEM", 111, 135], ["genetic change", "PROBLEM", 264, 278]]], ["This raises the possibility that the high rates of evolutionary change previously reported for dsDNA viruses arise spuriously, and possibly inevitably, from the models employed.", [["evolutionary change", "PROBLEM", 51, 70], ["dsDNA viruses", "PROBLEM", 95, 108], ["raises the possibility", "UNCERTAINTY", 5, 27], ["high", "OBSERVATION_MODIFIER", 37, 41]]], ["However, if no measurable evolutionary change has occurred within a given sampling period, we would expect any analytical outcomes to exhibit behavior consistent with a lack of temporal structure in the data.", [["measurable evolutionary change", "PROBLEM", 15, 45]]], ["Here, we use a variety of human dsDNA virus systems to investigate the ability of heterochronous phylogenetic modeling to 1) accurately estimate the fit of a molecular clock to dsDNA virus data sets with varying sample sizes and distributions, 2) recover the correct nucleotide substitution rate or reveal that there is a lack of temporal structure in the data, and 3) place the time to the most recent common ancestor (TMRCA) of these viruses within the correct time frame (when known).", [["nucleotide", "CHEMICAL", 267, 277], ["nucleotide", "CHEMICAL", 267, 277], ["human", "ORGANISM", 26, 31], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 26, 31], ["human dsDNA virus systems", "TREATMENT", 26, 51], ["the correct nucleotide substitution rate", "TEST", 255, 295], ["these viruses", "PROBLEM", 430, 443], ["viruses", "OBSERVATION", 436, 443]]], ["To further assess the behavior of these analytical tools, we created synthetic data sets under a variety of sampling schemes and substitution rates, from an ''RNA viruslike'' rate of 1 \u00c2 10 \u00c04 substitutions per site per year (subs/ site/year) to a ''dsDNA virus-like'' rate of 1 \u00c2 10 \u00c08 subs/ site/year.", [["sampling schemes", "TREATMENT", 108, 124], ["substitution rates", "TREATMENT", 129, 147]]], ["Using these data, we examined the ability of standard modeling tools to recover the nucleotide substitution rate and TMRCA from a population when the true evolutionary history of a sample is known.IntroductionWe considered seven dsDNA viruses in our analysis.", [["nucleotide", "CHEMICAL", 84, 94], ["nucleotide", "CHEMICAL", 84, 94], ["these data", "TEST", 6, 16], ["the nucleotide substitution rate", "TREATMENT", 80, 112], ["TMRCA", "TREATMENT", 117, 122], ["IntroductionWe", "TREATMENT", 197, 211], ["seven dsDNA viruses", "PROBLEM", 223, 242], ["our analysis", "TEST", 246, 258]]], ["Human papillomavirus type-16 (HPV-16) is one of more than 100 human viruses within the large Papillomaviridae family of dsDNA viruses with small genomes ranging from ;6 to 8 kbp.", [["Human papillomavirus type", "DISEASE", 0, 25], ["Human papillomavirus type-16", "ORGANISM", 0, 28], ["HPV-16", "ORGANISM", 30, 36], ["human", "ORGANISM", 62, 67], ["Papillomaviridae", "GENE_OR_GENE_PRODUCT", 93, 109], ["dsDNA", "GENE_OR_GENE_PRODUCT", 120, 125], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 62, 67], ["Human papillomavirus type-16 (HPV-16", "SPECIES", 0, 36], ["human", "SPECIES", 62, 67], ["Human papillomavirus type", "TEST", 0, 25], ["HPV", "TEST", 30, 33], ["dsDNA viruses", "PROBLEM", 120, 133], ["small genomes", "PROBLEM", 139, 152]]], ["Many types of HPV (including HPV-16) apparently exhibit strong patterns of codivergence with human populations, mirroring the global movement of humans out of Africa and clustering phylogenetically by ethnicity rather than by current geographic distribution (Ong et al. 1993; Bernard et al. 2006; Chen et al. 2009 ).", [["HPV", "ORGANISM", 14, 17], ["HPV-16", "ORGANISM", 29, 35], ["human", "ORGANISM", 93, 98], ["humans", "ORGANISM", 145, 151], ["human", "SPECIES", 93, 98], ["humans", "SPECIES", 145, 151], ["HPV", "SPECIES", 14, 17], ["human", "SPECIES", 93, 98], ["humans", "SPECIES", 145, 151], ["HPV", "PROBLEM", 14, 17], ["HPV", "TEST", 29, 32], ["human populations", "PROBLEM", 93, 110], ["HPV", "OBSERVATION", 14, 17], ["global", "OBSERVATION_MODIFIER", 126, 132], ["movement", "OBSERVATION_MODIFIER", 133, 141]]], ["The rate of nucleotide substitution for HPV-18 has been estimated at ;4.5 \u00c2 10 \u00c0 7 subs/site/year based on codivergence with human populations, similar to estimates obtained for the feline papillomaviruses (1.95 \u00c2 10 \u00c08 subs/site/year), again assuming codivergence (Ong et al. 1993; Rector et al. 2007) .IntroductionTwo members of the Alphaherpesvirinae were also included in this analysis: herpes simplex virus-1 (HSV-1) and varicella-zoster (VZ) virus.", [["nucleotide", "CHEMICAL", 12, 22], ["feline papillomaviruses", "DISEASE", 182, 205], ["herpes simplex virus", "DISEASE", 391, 411], ["varicella-zoster (VZ) virus", "DISEASE", 426, 453], ["nucleotide", "CHEMICAL", 12, 22], ["HPV-18", "ORGANISM", 40, 46], ["human", "ORGANISM", 125, 130], ["feline", "ORGANISM", 182, 188], ["papillomaviruses", "ORGANISM", 189, 205], ["Alphaherpesvirinae", "GENE_OR_GENE_PRODUCT", 335, 353], ["herpes simplex virus-1", "ORGANISM", 391, 413], ["HSV-1", "ORGANISM", 415, 420], ["varicella-zoster (VZ) virus", "ORGANISM", 426, 453], ["human", "SPECIES", 125, 130], ["feline", "SPECIES", 182, 188], ["herpes simplex virus-1", "SPECIES", 391, 413], ["HSV-1", "SPECIES", 415, 420], ["varicella-zoster", "SPECIES", 426, 442], ["human", "SPECIES", 125, 130], ["feline papillomaviruses", "SPECIES", 182, 205], ["herpes simplex virus-1", "SPECIES", 391, 413], ["HSV-1", "SPECIES", 415, 420], ["varicella-zoster (VZ) virus", "SPECIES", 426, 453], ["nucleotide substitution", "TREATMENT", 12, 35], ["HPV", "TEST", 40, 43], ["human populations", "PROBLEM", 125, 142], ["the feline papillomaviruses", "PROBLEM", 178, 205], ["this analysis", "TEST", 376, 389], ["herpes simplex virus", "TEST", 391, 411], ["HSV", "TEST", 415, 418], ["varicella-zoster (VZ) virus", "PROBLEM", 426, 453]]], ["Herpesviruses are large dsDNA viruses (genomes range from 125 to 240 kbp) that infect both vertebrates and invertebrates.", [["Herpesviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["Herpesviruses", "PROBLEM", 0, 13], ["large dsDNA viruses", "PROBLEM", 18, 37], ["large", "OBSERVATION_MODIFIER", 18, 23], ["dsDNA viruses", "OBSERVATION", 24, 37]]], ["Phylogenies of the alphaherpesviruses show topologies highly congruent with those of their diverse tetrapod hosts, and evolutionary rates for HSV-1 have been estimated at 3.5 \u00c2 10 \u00c08 to 3.0 \u00c2 10 \u00c09 subs/site/year based on the assumption of a codivergent history with their hosts (Sakaoka et al. 1994; McGeoch et al. 2000) .", [["HSV-1", "ORGANISM", 142, 147], ["HSV-1", "SPECIES", 142, 147], ["HSV-1", "SPECIES", 142, 147], ["evolutionary rates", "TEST", 119, 137], ["HSV", "TEST", 142, 145], ["tetrapod hosts", "OBSERVATION", 99, 113]]], ["In contrast, the evolutionary history of VZ is less conclusive, with evidence of both a codivergence relationship with humans (Wagenaar et al. 2003 ) and a more recent origin suggested by phylogenetic analyses (Muir et al. 2002) .IntroductionBK virus is a human polyomavirus with a ;5 kbp genome that is closely related to JC virus.", [["VZ", "CELL", 41, 43], ["humans", "ORGANISM", 119, 125], ["IntroductionBK virus", "ORGANISM", 230, 250], ["human", "ORGANISM", 256, 261], ["JC virus", "ORGANISM", 323, 331], ["5 kbp genome", "DNA", 283, 295], ["humans", "SPECIES", 119, 125], ["human", "SPECIES", 256, 261], ["humans", "SPECIES", 119, 125], ["IntroductionBK virus", "SPECIES", 230, 250], ["human polyomavirus", "SPECIES", 256, 274], ["JC virus", "SPECIES", 323, 331], ["VZ", "PROBLEM", 41, 43], ["IntroductionBK virus", "PROBLEM", 230, 250], ["a human polyomavirus", "PROBLEM", 254, 274], ["5 kbp genome", "PROBLEM", 283, 295], ["JC virus", "PROBLEM", 323, 331], ["closely related to", "UNCERTAINTY", 304, 322], ["JC virus", "OBSERVATION", 323, 331]]], ["Polyomaviruses were historically considered examples of human-virus codivergence, and both BK and JC viruses have been Evolutionary Rates of dsDNA Viruses \u00b7 doi:10.1093/molbev/msq088 used as markers for patterns of human evolution and migration.", [["human", "ORGANISM", 56, 61], ["BK", "ORGANISM", 91, 93], ["JC viruses", "ORGANISM", 98, 108], ["human", "ORGANISM", 215, 220], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 215, 220], ["human-virus", "SPECIES", 56, 67], ["JC viruses", "SPECIES", 98, 108], ["human", "SPECIES", 215, 220], ["Polyomaviruses", "PROBLEM", 0, 14], ["human-virus codivergence", "PROBLEM", 56, 80], ["JC viruses", "PROBLEM", 98, 108], ["JC viruses", "OBSERVATION", 98, 108], ["migration", "OBSERVATION_MODIFIER", 235, 244]]], ["However, more rigorous phylogenetic analyses of the relationship between a variety of polyomaviruses and their primate hosts have suggested that no significant similarities in tree topology or evolutionary timescale exist between these groups (P\u00e9rez-Losada et al. 2006; Shackelton et al. 2006; Zheng et al. 2007; Krumbholz et al. 2008) .", [["polyomaviruses", "ORGANISM", 86, 100], ["polyomaviruses", "TREATMENT", 86, 100], ["significant similarities in tree topology", "PROBLEM", 148, 189], ["polyomaviruses", "OBSERVATION", 86, 100]]], ["Estimates of the rate of evolution of BK virus are greatly affected by the use of different calibration assumptions, ranging from an intrahost rate estimate of 2-5 \u00c2 10 \u00c05 subs/site/year (Chen et al. 2004) to rates of 1.41 \u00c2 10 \u00c07 to 4 \u00c2 10 \u00c08 subs/site/year based on the assumption of codivergence between viral and human populations (Yasunaga and Miyata 1982; Krumbholz et al. 2008) .IntroductionVARV is the etiological agent of the human-specific pathogen smallpox, from the Poxviridae family (genome size 5 ;190 kbp).", [["smallpox", "DISEASE", 459, 467], ["BK virus", "ORGANISM", 38, 46], ["human", "ORGANISM", 317, 322], ["human", "ORGANISM", 435, 440], ["pathogen smallpox", "ORGANISM", 450, 467], ["genome size 5", "DNA", 497, 510], ["human", "SPECIES", 317, 322], ["human", "SPECIES", 435, 440], ["BK virus", "SPECIES", 38, 46], ["human", "SPECIES", 317, 322], ["human", "SPECIES", 435, 440], ["BK virus", "PROBLEM", 38, 46], ["different calibration assumptions", "TREATMENT", 82, 115], ["an intrahost rate", "TEST", 130, 147], ["rates", "TEST", 209, 214], ["codivergence", "PROBLEM", 286, 298], ["viral and human populations", "PROBLEM", 307, 334], ["the Poxviridae family (genome size", "TREATMENT", 474, 508], ["BK virus", "OBSERVATION", 38, 46]]], ["The first unequivocal description of smallpox in human populations occurred in 4th century AD in China, although cases have been suspected as far back as 1,122 BC (Li et al. 2007 ).", [["smallpox", "DISEASE", 37, 45], ["AD", "DISEASE", 91, 93], ["human", "ORGANISM", 49, 54], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54], ["smallpox in human populations", "PROBLEM", 37, 66], ["smallpox", "OBSERVATION", 37, 45]]], ["Previous estimates based on time-structured sequence data have placed the origin of smallpox at 207-231 ybp using strict and relaxed clocks, respectively (Li et al. 2007 ).", [["smallpox", "DISEASE", 84, 92], ["structured sequence data", "TEST", 33, 57], ["smallpox", "PROBLEM", 84, 92], ["smallpox", "OBSERVATION", 84, 92]]], ["However, this extremely recent estimate has been disregarded as being at odds with both historical/epidemiological data and with the low genetic diversity identified in serially sampled sequences (Esposito et al. 2006; Li et al. 2007) .", [["the low genetic diversity", "PROBLEM", 129, 154], ["serially sampled sequences", "TEST", 169, 195]]], ["In contrast, calibration with historical records of smallpox infection (all of which are debatable) placed the TMRCA for VARV at 1,400-6,300 ybp, depending on the choice of calibration point, with correspondingly lower substitution rates (Li et al. 2007; Babkin and Shchelkunov 2008; Hughes et al. 2009; Shchelkunov 2009 ).", [["smallpox infection", "DISEASE", 52, 70], ["smallpox infection", "PROBLEM", 52, 70], ["VARV", "TREATMENT", 121, 125], ["smallpox", "OBSERVATION_MODIFIER", 52, 60], ["infection", "OBSERVATION", 61, 70]]], ["Importantly, any calibration of contemporary strains using historical records is potentially problematic as selective sweeps and population bottlenecks can purge genetic diversity from the population, resulting in a TMRCA that is far more recent than the historical association of the virus with its host.IntroductionThe origins and emergence patterns of human adenoviruses (HAdV, genome sizes range from ;26 to 45 kbp) are considerably more vague.", [["human", "ORGANISM", 355, 360], ["adenoviruses", "ORGANISM", 361, 373], ["HAdV", "ORGANISM", 375, 379], ["human", "SPECIES", 355, 360], ["human adenoviruses", "SPECIES", 355, 373], ["contemporary strains", "PROBLEM", 32, 52], ["selective sweeps and population bottlenecks", "PROBLEM", 108, 151], ["a TMRCA", "PROBLEM", 214, 221], ["the virus", "PROBLEM", 281, 290], ["human adenoviruses", "PROBLEM", 355, 373], ["HAdV", "PROBLEM", 375, 379], ["sizes", "OBSERVATION_MODIFIER", 388, 393], ["more vague", "OBSERVATION_MODIFIER", 437, 447]]], ["The Adenoviridae form five distinct clades, corresponding to their mammal, reptile, bird, amphibian, and fish hosts.", [["bird", "ORGANISM_SUBDIVISION", 84, 88], ["fish", "ORGANISM", 105, 109], ["The Adenoviridae", "TREATMENT", 0, 16], ["five distinct", "OBSERVATION_MODIFIER", 22, 35], ["clades", "OBSERVATION", 36, 42]]], ["This phylogenetic structure has led to the hypothesis that the five lineages codiverged along with the host classes, with an estimated date for the split between human and chimpanzee adenoviruses at ;5 mya (Benk\u00f6 and Harrach 2003) .", [["human", "ORGANISM", 162, 167], ["chimpanzee", "ORGANISM", 172, 182], ["adenoviruses", "ORGANISM", 183, 195], ["human", "SPECIES", 162, 167], ["chimpanzee", "SPECIES", 172, 182], ["human", "SPECIES", 162, 167], ["the split between human and chimpanzee adenoviruses", "TREATMENT", 144, 195]]], ["Subsequent work has demonstrated that although some HAdV groups may show cursory support for a codivergent history with primates (subtype C), other groups do not (subtypes B and E).", [["HAdV", "ORGANISM", 52, 56]]], ["In addition, examination of the primate adenoviruses shows that the majority of human and non-human adenoviruses are mixed throughout the tree (Madisch et al. 2005; Roy et al. 2009 ).Virus Data SetsData sets for each of the seven dsDNA viruses were compiled based on availability in GenBank.", [["primate", "ORGANISM", 32, 39], ["adenoviruses", "ORGANISM", 40, 52], ["human", "ORGANISM", 80, 85], ["non-human adenoviruses", "ORGANISM", 90, 112], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 80, 85], ["examination of the primate adenoviruses", "TEST", 13, 52], ["human and non-human adenoviruses", "TREATMENT", 80, 112], ["the seven dsDNA viruses", "PROBLEM", 220, 243], ["tree", "ANATOMY_MODIFIER", 138, 142]]], ["Full genome sequences were used when available; otherwise, appropriate smaller gene segments were used to maximize the size of the data sets.", [["Full genome sequences", "TEST", 0, 21]]], ["In all cases, the sampling year was also collected for each sequence, and only samples that had not been exposed to extensive laboratory manipulation were included.", [["samples", "ANATOMY", 79, 86], ["extensive laboratory manipulation", "TEST", 116, 149]]], ["Each data set was aligned manually using Se-Al (v2.0a11 Carbon, http://tree.bio.ed.ac.uk/software/seal) and examined for evidence of recombination using the Bootscan, Chimaera, GENECONV, MaxChi, RDP, and SisScan methods with default parameters, implemented in the RDP3 software package (Martin et al. 2005) .", [["Se", "CHEMICAL", 41, 43], ["Se", "CHEMICAL", 41, 43], ["Al", "CHEMICAL", 44, 46], ["Carbon", "CHEMICAL", 56, 62], ["the Bootscan", "TEST", 153, 165], ["default parameters", "TEST", 225, 243]]], ["Potential recombinant sequences were identified when three or more methods within RDP3 were in agreement with P , 0.001.", [["RDP3", "GENE_OR_GENE_PRODUCT", 82, 86], ["RDP3", "DNA", 82, 86], ["Potential recombinant sequences", "TEST", 0, 31]]], ["All potential recombinants were removed from further analysis.Phylogenetic AnalysisMaximum likelihood (ML) phylogenies were estimated using PAUP* (4.0b, Swofford 2003) for each alignment using the Tree Bisection-Reconnection method of branch swapping and the best nucleotide substitution model as determined by Modeltest (v3.7, Posada and Crandall 1998) .", [["nucleotide", "CHEMICAL", 264, 274], ["nucleotide", "CHEMICAL", 264, 274], ["All potential recombinants", "TREATMENT", 0, 26], ["further analysis", "TEST", 45, 61], ["the Tree Bisection", "TREATMENT", 193, 211], ["branch swapping", "TREATMENT", 235, 250], ["the best nucleotide substitution model", "TREATMENT", 255, 293], ["Modeltest", "TEST", 311, 320], ["Tree Bisection", "OBSERVATION", 197, 211], ["branch", "ANATOMY_MODIFIER", 235, 241]]], ["The clock-like behavior of each data set was then assessed using a regression of root-to-tip genetic distances inferred from the ML trees against sampling time in the program Path-O-Gen (v1.1, http://tree.bio.ed.ac.uk/software/pathogen/; Drummond et al. 2003) .", [["root", "ANATOMY", 81, 85], ["a regression of root", "TREATMENT", 65, 85]]], ["Under this analysis, the correlation coefficient indicates the amount of variation in genetic distance that is explained by sampling time.", [["this analysis", "TEST", 6, 19], ["variation in genetic distance", "PROBLEM", 73, 102], ["amount", "OBSERVATION_MODIFIER", 63, 69], ["variation", "OBSERVATION_MODIFIER", 73, 82], ["genetic distance", "OBSERVATION", 86, 102]]], ["This provides a correlative measure of the goodness-of-fit of the data to a strict molecular clock and designates a root for the phylogeny that is most consistent with a molecular clock.Phylogenetic AnalysisPhylogenies incorporating sampling time were then estimated for each data set using the Bayesian Markov chain Monte Carlo (MCMC) inference methods made available in BEAST (v.1.4.8, Drummond and Rambaut 2007) .", [["root", "ANATOMY", 116, 120], ["root", "ORGAN", 116, 120], ["Phylogenetic AnalysisPhylogenies", "PROBLEM", 186, 218], ["the Bayesian Markov chain Monte Carlo (MCMC)", "TREATMENT", 291, 335], ["most consistent with", "UNCERTAINTY", 147, 167], ["molecular clock", "OBSERVATION", 170, 185]]], ["These analyses were run using either the Hasegawa-Kishino-Yano (HKY) or general time-reversible (GTR) model of nucleotide substitution and with or without an among-site rate heterogeneity parameter (gamma) depending on the model that best fit the data.", [["nucleotide", "CHEMICAL", 111, 121], ["nucleotide", "CHEMICAL", 111, 121], ["These analyses", "TEST", 0, 14], ["the Hasegawa", "TEST", 37, 49], ["nucleotide substitution", "TREATMENT", 111, 134]]], ["For protein-coding genes, the alignment was also partitioned into codon positions, whereas the full-genome alignments also included a parameter for invariant sites.", [["protein-coding genes", "DNA", 4, 24], ["codon positions", "DNA", 66, 81], ["full-genome alignments", "DNA", 95, 117], ["protein-coding genes", "PROBLEM", 4, 24], ["invariant sites", "PROBLEM", 148, 163]]], ["Genealogies were estimated under 1) a strict molecular clock, 2) a relaxed molecular clock with an uncorrelated lognormal (UCLN) distribution of rates, and 3) a relaxed molecular clock with an uncorrelated exponential distribution of rates.", [["a relaxed molecular clock", "PROBLEM", 159, 184], ["molecular clock", "OBSERVATION", 169, 184], ["exponential", "OBSERVATION_MODIFIER", 206, 217], ["distribution", "OBSERVATION_MODIFIER", 218, 230]]], ["A variety of prior probability distributions on the parameter characterizing the rate of evolutionary change under a molecular clock were explored.", [["prior probability distributions", "PROBLEM", 13, 44], ["evolutionary change", "PROBLEM", 89, 108], ["variety", "OBSERVATION_MODIFIER", 2, 9], ["probability distributions", "OBSERVATION", 19, 44], ["molecular clock", "OBSERVATION", 117, 132]]], ["These included both a uniform distribution with boundaries at 0 and 100 and an exponential distribution with mean expectations that ranged from 1.0 \u00c2 10 \u00c06 to Firth et al. \u00b7 doi:10 .1093/molbev/msq088 MBE 1.0.", [["uniform", "OBSERVATION_MODIFIER", 22, 29], ["distribution", "OBSERVATION_MODIFIER", 30, 42]]], ["The evolutionary and coalescent parameters were estimated under both the hypothesis of a constant population size and using the less constrained Bayesian skyline coalescent model (Pybus et al. 2000; Strimmer and Pybus 2001; Drummond et al. 2005) .", [["coalescent parameters", "TEST", 21, 42], ["a constant population size", "PROBLEM", 87, 113], ["coalescent", "OBSERVATION_MODIFIER", 21, 31], ["size", "OBSERVATION_MODIFIER", 109, 113]]], ["A minimum of two independent MCMC simulations for each model-clock combination were performed for no less than 100 million generations, subsampling every 10,000 generations to decrease autocorrelation between model parameter samples.", [["each model-clock combination", "TREATMENT", 50, 78], ["model parameter samples", "TEST", 209, 232]]], ["The two runs were combined for inspection after removing a 10% burn-in from each, and statistical confidence in the parameter estimates was assessed by reporting marginal posterior parameter means and their associated 95% highest probability density (95% HPD) intervals.Phylogenetic AnalysisTo test the temporal signature present in these data sets, we used a tip-date randomization technique Ramsden et al. 2009 ).", [["inspection", "TEST", 31, 41], ["a 10% burn", "TREATMENT", 57, 67], ["the parameter estimates", "TEST", 112, 135], ["Phylogenetic Analysis", "TEST", 270, 291], ["a tip-date randomization technique", "TREATMENT", 358, 392]]], ["Here, a null distribution of mean substitution rates was generated by randomizing the sampling date associated with each sequence, 20 times per alignment.", [["mean substitution rates", "PROBLEM", 29, 52], ["mean substitution", "OBSERVATION", 29, 46]]], ["The substitution rate was then reestimated in BEAST for each randomized data set under the bestfitting model for the true data, as above.", [["The substitution rate", "TREATMENT", 0, 21], ["the true data", "TEST", 113, 126]]], ["To assess the significance of the temporal structure present in the data, the mean evolutionary rate estimate from the observed data was compared with the 95% HPDs estimated from the randomized data sets.", [["temporal", "OBSERVATION_MODIFIER", 34, 42]]], ["We also expect the lower tail of the 95% HPD of the evolutionary rates from the randomized data to be large and tend strongly toward zero.Synthetic Data SetsSynthetic data sets were used to test the ability of heterochronous phylogenetic modeling to correctly recover the true nucleotide substitution rates from a range of values that may exist in DNA viruses (1 \u00c2 10 \u00c04 to 1 \u00c2 10 \u00c08 subs/site/year), given the type of data used in the first part of this study.", [["nucleotide", "CHEMICAL", 277, 287], ["nucleotide", "CHEMICAL", 277, 287], ["DNA", "CELLULAR_COMPONENT", 348, 351], ["the randomized data", "TEST", 76, 95], ["heterochronous phylogenetic modeling", "PROBLEM", 210, 246], ["the true nucleotide substitution rates", "PROBLEM", 268, 306], ["DNA viruses", "PROBLEM", 348, 359], ["this study", "TEST", 450, 460], ["lower", "ANATOMY_MODIFIER", 19, 24], ["tail", "ANATOMY_MODIFIER", 25, 29], ["large", "OBSERVATION", 102, 107], ["nucleotide substitution", "OBSERVATION", 277, 300]]], ["Synthetic data sets were generated to reflect the evolutionary processes in two of the seven dsDNA data sets analyzed, VARV and HSV-1, which represent the typical range one might encounter in an analysis of temporally sampled data (table 1).", [["HSV-1", "ORGANISM", 128, 133], ["HSV-1", "SPECIES", 128, 133], ["Synthetic data sets", "TEST", 0, 19], ["the evolutionary processes", "PROBLEM", 46, 72], ["VARV", "TEST", 119, 123], ["HSV", "TEST", 128, 131], ["an analysis", "TEST", 192, 203]]], ["The VARV-like synthetic data consisted of 50 sequences of 100,000 bp sampled from 1946 to 1982 (similar to a full-genome alignment), whereas the HSV-1-like synthetic data consisted of 84 sequences that were 1,200 bp in length, sampled from 1981 to 2008 (a typical single-gene alignment).", [["HSV-1", "ORGANISM", 145, 150], ["VARV", "DNA", 4, 8], ["HSV-1", "DNA", 145, 150], ["HSV-1", "SPECIES", 145, 150], ["bp", "TEST", 66, 68], ["the HSV", "TEST", 141, 148], ["bp", "TEST", 213, 215], ["length", "TEST", 219, 225]]], ["Sequences for each data set were generated in the following manner.", [["each data set", "TEST", 14, 27]]], ["The yearof-sampling distribution associated with the sequences was fixed to those values from the VARV and HSV-1 data sets, and random phylogenies were drawn from a coalescent process based on each group of taxa (N 5 50 or 84) using an MCMC algorithm and assuming a constant population size.", [["HSV", "ORGANISM", 107, 110], ["VARV and HSV-1 data sets", "DNA", 98, 122], ["HSV-1", "SPECIES", 107, 112], ["the VARV", "TEST", 94, 102], ["HSV", "TEST", 107, 110], ["random phylogenies", "TEST", 128, 146], ["a coalescent process", "PROBLEM", 163, 183], ["taxa", "TEST", 207, 211], ["an MCMC algorithm", "TEST", 233, 250], ["a constant population size", "PROBLEM", 264, 290], ["size", "OBSERVATION_MODIFIER", 286, 290]]], ["The root height for each phylogeny was fixed at one of the following intervals: 100, 1,000, 10,000, 100,000, and 1,000,000 ybp.", [["root", "ANATOMY", 4, 8], ["root", "ORGAN", 4, 8], ["root", "OBSERVATION_MODIFIER", 4, 8], ["height", "OBSERVATION_MODIFIER", 9, 15]]], ["Sequences of the appropriate length were simulated along each random tree following the HKY model of sequence evolution with data set-specific base frequencies and transition/transversion ratios based on the ML estimate of these values from the actual virus data sets.", [["the appropriate length", "TEST", 13, 35], ["data set", "TEST", 125, 133], ["transition/transversion ratios", "TEST", 164, 194]]], ["Gamma-distributed rate variation was also initially added to the HSV-1-like simulations, but as the inclusion of this parameter did not impact the results of the simulations, it was removed from additional replications (data not shown).", [["HSV", "ORGANISM", 65, 68], ["HSV-1", "SPECIES", 65, 70], ["Gamma-distributed rate variation", "PROBLEM", 0, 32], ["the HSV", "TEST", 61, 68], ["distributed", "OBSERVATION_MODIFIER", 6, 17], ["rate variation", "OBSERVATION", 18, 32]]], ["For the first set of synthetic data, the rate of evolution followed a strict molecular clock (standard deviation [SD] around the mean rate of 0.0) set at one of the following values corresponding to each specified value of the root height: 1 \u00c2 10 \u00c04 subs/site/year (when the root height was 100 ybp), 1 \u00c2 10 \u00c05 subs/site/year, 1 \u00c2 10 \u00c06 subs/site/year, 1 \u00c2 10 \u00c07 subs/site/year, and 1 \u00c2 10 \u00c08 subs/ site/year (when the root height was one million ybp).", [["root", "ANATOMY", 227, 231], ["root", "ANATOMY", 275, 279], ["root", "ANATOMY", 419, 423], ["root", "TISSUE", 227, 231], ["root", "ORGAN", 275, 279], ["root", "TISSUE", 419, 423], ["the mean rate", "TEST", 125, 138], ["the root height", "TEST", 271, 286], ["root", "ANATOMY", 227, 231]]], ["Twenty independent replicate data sets were created for each root height/clock rate and each virus type.", [["root", "ANATOMY", 61, 65], ["root", "TISSUE", 61, 65], ["each root height/clock rate", "TEST", 56, 83], ["each virus type", "PROBLEM", 88, 103]]], ["By covarying the tree height and substitution rate in this manner, the observed genetic diversity of each synthetic data set was held constant and similar to that observed in the VARV and HSV-1 data sets.", [["VARV and HSV-1 data sets", "DNA", 179, 203], ["HSV-1", "SPECIES", 188, 193], ["substitution rate", "TEST", 33, 50], ["the VARV and HSV", "TEST", 175, 191], ["tree", "OBSERVATION_MODIFIER", 17, 21], ["height", "OBSERVATION_MODIFIER", 22, 28]]], ["This allowed for a direct assessment of the power of this method to estimate substitution rates under successive conditions in which smaller proportions of overall genetic diversity can be attributed to the sampling interval.", [["a direct assessment", "TEST", 17, 36], ["this method", "TREATMENT", 53, 64], ["substitution rates", "TREATMENT", 77, 95], ["smaller", "OBSERVATION_MODIFIER", 133, 140], ["overall", "OBSERVATION_MODIFIER", 156, 163], ["genetic diversity", "OBSERVATION", 164, 181]]], ["Posterior inference was performed on each data set assuming a strict molecular clock, the HKY model of nucleotide substitution and constant population size.", [["nucleotide", "CHEMICAL", 103, 113], ["nucleotide", "CHEMICAL", 103, 113], ["nucleotide substitution", "PROBLEM", 103, 126], ["constant population size", "PROBLEM", 131, 155], ["nucleotide substitution", "OBSERVATION", 103, 126], ["constant", "OBSERVATION_MODIFIER", 131, 139], ["population", "OBSERVATION_MODIFIER", 140, 150], ["size", "OBSERVATION_MODIFIER", 151, 155]]], ["Convergence of all parameters was verified visually using the program Tracer (http://tree.bio.ed.ac.uk/software/ tracer/).Synthetic Data SetsAn additional set of simulations was performed using both the HSV-1 and VARV-like data, but incorporating branch-rate heterogeneity into the sequence simulation process.", [["HSV", "ORGANISM", 203, 206], ["HSV-1", "SPECIES", 203, 208], ["the HSV", "TEST", 199, 206]]], ["In this case, sequences were evolved assuming a UCLN-relaxed molecular clock with mean rates of 1 \u00c2 10 \u00c06 , 1 \u00c2 10 \u00c07 , and 1 \u00c2 10 \u00c08 subs/site/year and a SD of 2.0 around the mean, with corresponding root heights as above.", [["root", "ANATOMY", 201, 205], ["root", "ORGAN", 201, 205], ["a UCLN", "TEST", 46, 52], ["mean rates", "TEST", 82, 92], ["a SD", "TEST", 153, 157], ["root heights", "OBSERVATION", 201, 213]]], ["Twenty replicate data sets were created with each substitution rate for each virus type, and the posterior inferences were performed assuming a strict clock, as above.Synthetic Data SetsThe recovered estimates of the nucleotide substitution rates and TMRCA (posterior mean and 95% HPD) from each group of simulations were then compared with the known values of the simulated data.", [["nucleotide", "CHEMICAL", 217, 227], ["nucleotide", "CHEMICAL", 217, 227], ["each substitution rate", "TEST", 45, 67], ["each virus type", "PROBLEM", 72, 87], ["the nucleotide substitution rates", "TEST", 213, 246], ["TMRCA", "TEST", 251, 256], ["posterior", "ANATOMY_MODIFIER", 97, 106], ["strict clock", "OBSERVATION", 144, 156]]], ["The number of simulations that included the true rate and TMRCA estimates within the 95% HPDs was recorded for each clock rate/root height.", [["root", "ANATOMY", 127, 131], ["root", "TISSUE", 127, 131], ["the true rate", "TEST", 40, 53], ["root height", "OBSERVATION", 127, 138]]], ["In total, 320 MCMC analyses of simulated data were performed, 160 each for VARV-and HSV-1-like data.Synthetic Data SetsA sample xml file for use in BEAST is included as Supplementary Information (Supplementary Material online).Inference of Substitution RatesThe Bayesian MCMC inference of each dsDNA virus data set converged efficiently on a posterior mean value for all parameters with correspondingly narrow posterior distributions around the mean rate and TMRCA.", [["HSV-1", "ORGANISM", 84, 89], ["HSV-1", "SPECIES", 84, 89], ["simulated data", "TEST", 31, 45], ["VARV", "TEST", 75, 79], ["HSV", "TEST", 84, 87], ["Synthetic Data", "TEST", 100, 114], ["Substitution Rates", "TREATMENT", 240, 258], ["each dsDNA virus data", "TEST", 289, 310], ["a posterior mean value", "TEST", 340, 362], ["correspondingly narrow posterior distributions", "PROBLEM", 387, 433], ["narrow", "OBSERVATION_MODIFIER", 403, 409], ["posterior", "OBSERVATION_MODIFIER", 410, 419], ["distributions", "OBSERVATION_MODIFIER", 420, 433], ["mean rate", "OBSERVATION", 445, 454]]], ["No substantial differences in the posterior estimates of the mean evolutionary rates were observed when the initial values or prior distribution of the rate parameter were varied.", [["the rate parameter", "TEST", 148, 166], ["substantial", "OBSERVATION_MODIFIER", 3, 14], ["differences", "OBSERVATION_MODIFIER", 15, 26], ["posterior", "ANATOMY_MODIFIER", 34, 43]]], ["The mean evolutionary rates estimated for the seven dsDNA virus data sets ranged from 10 \u00c06 to 10 \u00c03 subs/site/year (VARV/VZ and HPV-16, respectively) (table 2).", [["The mean evolutionary rates", "PROBLEM", 0, 27], ["the seven dsDNA virus data sets", "PROBLEM", 42, 73], ["VARV", "TEST", 117, 121], ["HPV", "TEST", 129, 132], ["VZ", "ANATOMY", 122, 124]]], ["The 95% HPDs ranged from 10 \u00c07 (human adenovirus subtype-C [HAdV-C]) to 10 \u00c02 subs/site/year (HPV-16) and varied by no more than an order of magnitude from their corresponding posterior mean in either direction (table 2) .", [["HPDs", "CANCER", 8, 12], ["human", "ORGANISM", 32, 37], ["adenovirus subtype-C", "ORGANISM", 38, 58], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["The", "TEST", 0, 3], ["HPDs", "TEST", 8, 12], ["human adenovirus subtype", "TEST", 32, 56], ["HAdV", "TEST", 60, 64], ["HPV", "TEST", 94, 97], ["posterior", "ANATOMY_MODIFIER", 176, 185]]], ["Interestingly, with the exception of HPV-16, the mean evolutionary rates estimated were also highly consistent across data sets, ranging from 6 \u00c2 10 \u00c06 to 8 \u00c2 10 \u00c05 subs/site/year.", [["HPV-16", "ORGANISM", 37, 43], ["HPV-16", "SPECIES", 37, 43], ["HPV", "TEST", 37, 40], ["the mean evolutionary rates", "TEST", 45, 72]]], ["These estimates were highly robust to choice of clock, rate distribution, or demographic model parameters but were much higher than expected based on previous estimates of the substitution rate of dsDNA viruses (table 2) (Bernard 1994; Duffy et al. 2008) .", [["demographic model parameters", "TEST", 77, 105], ["dsDNA viruses", "PROBLEM", 197, 210]]], ["In fact, the evolutionary rates estimated for HPV-16, HSV-1, BK virus, human adenovirus subtype-B (HAdV-B), and HAdV-C all approached those measured in RNA viruses (Jenkins et al. 2002; Duffy et al. 2008 ).", [["HPV-16", "ORGANISM", 46, 52], ["HSV-1", "ORGANISM", 54, 59], ["BK virus", "ORGANISM", 61, 69], ["human adenovirus subtype-B (HAdV-B)", "ORGANISM", 71, 106], ["HAdV-C", "ORGANISM", 112, 118], ["HSV-1", "SPECIES", 54, 59], ["BK virus", "SPECIES", 61, 69], ["human", "SPECIES", 71, 76], ["HPV-16", "SPECIES", 46, 52], ["HSV-1", "SPECIES", 54, 59], ["BK virus", "SPECIES", 61, 69], ["human", "SPECIES", 71, 76], ["HAdV-C", "SPECIES", 112, 118], ["the evolutionary rates", "TEST", 9, 31], ["HPV", "TEST", 46, 49], ["HSV", "TEST", 54, 57], ["BK virus", "PROBLEM", 61, 69], ["human adenovirus subtype", "TEST", 71, 95], ["HAdV", "PROBLEM", 112, 116]]], ["In addition, these high rates were associated with extremely recent TMRCA estimates in all cases, ranging from ;10 (HPV-16) to ;800 ybp (BK) (table 2) .", [["extremely recent TMRCA estimates", "PROBLEM", 51, 83], ["HPV", "TEST", 116, 119]]], ["Most dsDNA viruses are thought to evolve primarily through codivergence with their hosts, and this process should be reflected in low rates of evolutionary change (Villarreal et al. 2000; Holmes 2004; Holmes and Drummond 2007) .", [["Most dsDNA viruses", "PROBLEM", 0, 18], ["viruses", "OBSERVATION", 11, 18], ["low rates", "OBSERVATION_MODIFIER", 130, 139]]], ["If we allow that the seven dsDNA viruses used in this study do indeed evolve at a low rate consistent with a codivergent history (an assumption that is not contentious in many cases), the possibility must be considered that the high substitution rates estimated here are the result of estimation error and do not reflect the true evolutionary history of the data.", [["the seven dsDNA viruses", "PROBLEM", 17, 40], ["this study", "TEST", 49, 59], ["the high substitution rates", "PROBLEM", 224, 251]]], ["As it is possible that such erroneous results are due to a shallow sampling interval relative to the actual timescale of evolution ( fig. 1) , we assessed the strength of the temporal structure in our data sets by utilizing a randomization procedure.Randomization TestThe sequence-sampling time associations in each data set were randomized 20 times per virus, and the evolutionary rates were reestimated from each of these data sets.", [["a shallow sampling interval", "PROBLEM", 57, 84], ["a randomization procedure", "TREATMENT", 224, 249], ["Randomization Test", "TEST", 250, 268], ["The sequence", "TEST", 268, 280], ["the evolutionary rates", "TEST", 365, 387], ["shallow", "OBSERVATION_MODIFIER", 59, 66], ["temporal", "ANATOMY_MODIFIER", 175, 183]]], ["The hypothesis of significant temporal structure was rejected when the value of the mean evolutionary rate estimated from the real data fell within the 95% HPDs of those estimated from the randomized data.", [["significant temporal structure", "PROBLEM", 18, 48], ["the mean evolutionary rate", "TEST", 80, 106], ["significant", "OBSERVATION_MODIFIER", 18, 29], ["temporal", "OBSERVATION_MODIFIER", 30, 38], ["structure", "OBSERVATION", 39, 48]]], ["Comparisons between the actual and randomized estimates for each virus revealed significant support for the presence of temporal structure in the data in all but two cases (HAdV-C and VZ) ( fig. 2) .", [["VZ", "TISSUE", 184, 186], ["each virus", "PROBLEM", 60, 70], ["temporal", "OBSERVATION_MODIFIER", 120, 128], ["structure", "OBSERVATION", 129, 138]]], ["Indeed, the 95% HPDs of the actual rate estimates fell outside the entire distribution of the randomized data sets for HSV-1, BK, VARV, and HAdV-B ( fig. 2) .Randomization TestBased on this analysis, it is clear that there is no support for a high substitution rate in either HAdV-C or VZ.", [["HSV-1", "ORGANISM", 119, 124], ["BK", "ORGANISM", 126, 128], ["VARV", "GENE_OR_GENE_PRODUCT", 130, 134], ["HAdV-B", "ORGANISM", 140, 146], ["HAdV-C", "GENE_OR_GENE_PRODUCT", 276, 282], ["VZ", "CELL", 286, 288], ["HSV-1", "SPECIES", 119, 124], ["VARV", "SPECIES", 130, 134], ["HAdV-B", "SPECIES", 140, 146], ["the actual rate estimates", "TEST", 24, 49], ["HSV", "TEST", 119, 122], ["BK", "TEST", 126, 128], ["VARV", "TEST", 130, 134], ["HAdV", "TEST", 140, 144], ["this analysis", "TEST", 185, 198], ["a high substitution rate", "PROBLEM", 241, 265], ["VZ", "PROBLEM", 286, 288], ["HAdV", "OBSERVATION", 276, 280]]], ["If these sequences were sampled over a time interval that was too narrow relative to the rate of viral evolution (i.e., recent samples of slowly evolving/codiverging viruses), the dates at which the samples were taken should confer little information about the evolutionary dynamics of the virus ( fig. 1) .", [["samples", "ANATOMY", 199, 206], ["viral evolution", "PROBLEM", 97, 112], ["slowly evolving/codiverging viruses", "PROBLEM", 138, 173], ["the virus", "PROBLEM", 286, 295], ["viral", "OBSERVATION", 97, 102]]], ["Estimates of evolutionary rates from the actual and randomized data sets should then recover comparable values, producing a pattern similar to that seen in HAdV-C and VZ ( fig. 2 ).", [["HAdV-C", "ORGANISM", 156, 162], ["VZ", "CELL", 167, 169], ["evolutionary rates", "PROBLEM", 13, 31], ["evolutionary", "OBSERVATION_MODIFIER", 13, 25], ["rates", "OBSERVATION_MODIFIER", 26, 31]]], ["One caveat of this approach stems from the ability of the randomizations to breakup both temporal and geographic structure in the data.", [["this approach stems", "TREATMENT", 14, 33], ["the randomizations", "TREATMENT", 54, 72], ["temporal", "OBSERVATION_MODIFIER", 89, 97]]], ["Therefore, if hidden population substructure is contributing to erroneous rate estimates (Navascues and Emerson 2009) , it would be broken-up by the temporal randomization process.Root-to-Tip RegressionsA conservative assessment of the degree of clock-like evolution present in a data set is achieved by fitting a regression of the year-of-sampling against the root-to-tip genetic distance of each sample, measured from an ML tree.", [["root", "ANATOMY", 361, 365], ["sample", "ANATOMY", 398, 404], ["hidden population substructure", "PROBLEM", 14, 44], ["erroneous rate estimates", "PROBLEM", 64, 88], ["conservative assessment", "TEST", 205, 228], ["temporal", "ANATOMY_MODIFIER", 149, 157], ["ML tree", "OBSERVATION", 423, 430]]], ["When this regression was calculated for the seven dsDNA virus data sets studied here, the resultant correlation strongly supported the presence of molecular clock-like structure in VARV, weakly suggested the presence of clock-like evolution in HAdV-B, HSV-1, and VZ and revealed no support at all for this hypothesis in the HPV-16, BK, and HAdV-C data sets (fig. 3) .", [["VARV", "GENE_OR_GENE_PRODUCT", 181, 185], ["HAdV-B", "ORGANISM", 244, 250], ["HSV-1", "ORGANISM", 252, 257], ["VZ", "CELL", 263, 265], ["HPV-16", "ORGANISM", 324, 330], ["BK", "CELL", 332, 334], ["HAdV-B", "SPECIES", 244, 250], ["HSV-1", "SPECIES", 252, 257], ["HPV-16", "SPECIES", 324, 330], ["molecular clock-like structure in VARV", "PROBLEM", 147, 185], ["HAdV", "PROBLEM", 244, 248], ["HSV", "TEST", 252, 255], ["VZ", "PROBLEM", 263, 265], ["support", "TREATMENT", 282, 289], ["this hypothesis", "PROBLEM", 301, 316], ["the HPV", "TEST", 320, 327], ["BK", "TEST", 332, 334], ["HAdV", "TEST", 340, 344], ["molecular clock", "OBSERVATION", 147, 162], ["no", "UNCERTAINTY", 279, 281]]], ["These results were not surprising for the HPV-16 data set considering that the sequences were sampled over only a 4-year interval (table 1) and are consistent with the lack of temporal structure in the HAdV-C data identified by the randomization analysis ( fig. 2) .", [["the HPV", "TEST", 38, 45], ["the sequences", "TEST", 75, 88], ["the randomization analysis", "TEST", 228, 254], ["consistent with", "UNCERTAINTY", 148, 163], ["temporal", "OBSERVATION_MODIFIER", 176, 184], ["structure", "OBSERVATION", 185, 194]]], ["Firth et al. \u00b7 doi:10.1093/molbev/msq088 MBE Taken together, the heterochronous phylogenetic modeling analyses, randomization procedure, and regression analyses suggest the presence of high evolutionary rates in the HSV-1, BK, VARV, and HAdV-B data sets, with varying levels of consistency.", [["HSV-1", "ORGANISM", 216, 221], ["BK", "CELL", 223, 225], ["HAdV-B", "CELL", 237, 243], ["\u00b7 doi:10.1093/molbev/msq088 MBE", "SPECIES", 13, 44], ["HSV-1", "SPECIES", 216, 221], ["VARV", "SPECIES", 227, 231], ["the heterochronous phylogenetic modeling analyses", "TEST", 61, 110], ["randomization procedure", "TREATMENT", 112, 135], ["regression analyses", "TEST", 141, 160], ["high evolutionary rates", "PROBLEM", 185, 208], ["the HSV", "TEST", 212, 219], ["BK", "TEST", 223, 225], ["VARV", "TEST", 227, 231], ["HAdV", "PROBLEM", 237, 241]]], ["The VARV data set was unique in that the relatively high rates of nucleotide substitution estimated by BEAST (;9.32 \u00c2 10 \u00c06 subs/site/ year, table 2) for this virus were strongly supported by both the randomization and regression analyses (figs.", [["nucleotide", "CHEMICAL", 66, 76], ["nucleotide", "CHEMICAL", 66, 76], ["VARV", "DNA", 4, 8], ["nucleotide substitution", "PROBLEM", 66, 89], ["this virus", "PROBLEM", 154, 164], ["regression analyses", "TEST", 219, 238], ["nucleotide substitution", "OBSERVATION", 66, 89]]], ["In contrast, high substitution rates for the HSV-1, BK, and HAdV-B data sets were supported by the randomization procedure but showed a weaker correlation between root-to-tip genetic distance and sampling time (R 2 5 0.141, 0.004, and 0.327, respectively) than that found in VARV (R 2 5 0.679).Synthetic DataWhen sequences were generated under a model approximating a strict molecular clock (i.e., all branches of the tree evolve at the same rate), posterior inference was able to recover the correct substitution rate with narrow 95% HPDs for all 20 replicates of both the VARV-and HSV-1-like data sets when the rate was 10 \u00c04 subs/site/year ( fig. 4) .", [["root", "ANATOMY", 163, 167], ["HSV-1", "ORGANISM", 45, 50], ["BK", "CELL", 52, 54], ["HSV-1", "ORGANISM", 583, 588], ["DataWhen sequences", "DNA", 304, 322], ["HSV-1", "SPECIES", 45, 50], ["HSV-1", "SPECIES", 583, 588], ["high substitution rates", "TREATMENT", 13, 36], ["the HSV", "TEST", 41, 48], ["BK", "TEST", 52, 54], ["HAdV", "TEST", 60, 64], ["the randomization procedure", "TREATMENT", 95, 122], ["Synthetic DataWhen sequences", "TEST", 294, 322], ["the VARV", "TEST", 570, 578], ["HSV", "TEST", 583, 586], ["the rate", "TEST", 609, 617], ["branches", "ANATOMY_MODIFIER", 402, 410], ["tree", "ANATOMY_MODIFIER", 418, 422], ["posterior", "ANATOMY_MODIFIER", 449, 458]]], ["The true substitution rates were returned with similar accuracy and precision for the VARV-like data sets when the rate was 10 \u00c05 or 10 \u00c06 subs/site/year ( fig. 4) .", [["The true substitution rates", "TEST", 0, 27], ["the VARV", "TEST", 82, 90], ["the rate", "TEST", 111, 119]]], ["However, at 10 \u00c07 and 10 \u00c08 subs/site/year, the mean substitution rates were consistently higher than the true values but characterized by long-tail posterior distributions tending toward zero ( fig. 4) .", [["the mean substitution rates", "TEST", 44, 71], ["long-tail posterior distributions", "PROBLEM", 139, 172], ["higher", "OBSERVATION_MODIFIER", 90, 96], ["long", "OBSERVATION_MODIFIER", 139, 143], ["tail", "ANATOMY_MODIFIER", 144, 148], ["posterior", "ANATOMY_MODIFIER", 149, 158]]], ["For all VARV-like simulations, the true NOTE.-Estimates were made under a variety of molecular clock models (strict, relaxed with a lognormal distribution of rates, and relaxed with an exponential distribution of rates), as well as under two demographic models (constant population size and Bayesian skyline [BS] ).", [["size", "OBSERVATION_MODIFIER", 282, 286]]], ["UCED, uncorrelated exponential distribution.Synthetic DataEvolutionary Rates of dsDNA Viruses \u00b7 doi:10.1093/molbev/msq088 substitution rate was contained within the 95% HPDs of the estimated rate, as were the estimated TMRCAs (data not shown).", [["molbev", "GENE_OR_GENE_PRODUCT", 108, 114], ["substitution rate", "TEST", 122, 139], ["the estimated TMRCAs", "TEST", 205, 225], ["uncorrelated", "OBSERVATION_MODIFIER", 6, 18], ["exponential", "OBSERVATION_MODIFIER", 19, 30], ["distribution", "OBSERVATION_MODIFIER", 31, 43], ["dsDNA Viruses", "OBSERVATION", 80, 93]]], ["We were considerably less successful at recovering the true substitution rates for the HSV-1-like syn-thetic data sets.", [["HSV-1", "ORGANISM", 87, 92], ["HSV-1", "SPECIES", 87, 92], ["the HSV", "TEST", 83, 90]]], ["When the true substitution rate was 10 \u00c05 subs/site/year, the posterior mean estimates were close to the true value; however, some of the individual posterior distributions of the rate were highly skewed .", [["the true substitution rate", "TEST", 5, 31], ["the posterior mean estimates", "TEST", 58, 86], ["posterior", "ANATOMY_MODIFIER", 62, 71], ["individual", "OBSERVATION_MODIFIER", 138, 148], ["posterior", "OBSERVATION_MODIFIER", 149, 158], ["distributions", "OBSERVATION_MODIFIER", 159, 172]]], ["Similarly, when the set rate was 10 \u00c06 subs/site/year or lower, our tools were unable to recover a mean rate that was close to the true value, and the 95% HPDs ranged from the highest possible rate supported by the data to a value approaching zero ( fig. 4 ).", [["the set rate", "TEST", 16, 28], ["a mean rate", "TEST", 97, 108], ["HPDs", "TEST", 155, 159]]], ["We consider these widely skewed posterior distributions of the rate to signify a lack of significant temporal structure in the data, an effect not seen in estimates based on our real data where values close to zero were not observed.Synthetic DataTo determine if the high substitution rates recovered for the dsDNA viruses analyzed in the first part of this study could be a result of deviations from the molecular clock model coupled with low temporal signal in the data, we added branch-rate heterogeneity (i.e., relaxed clock behavior) to the synthetic data sets when the mean rate was set to 10 \u00c06 , 10 \u00c07 , and 10 \u00c08 subs/site/year and reestimated the rate of substitution.", [["significant temporal structure in the data", "PROBLEM", 89, 131], ["our real data", "TEST", 174, 187], ["the high substitution rates", "PROBLEM", 263, 290], ["the dsDNA viruses", "PROBLEM", 305, 322], ["this study", "TEST", 353, 363], ["the molecular clock model", "TEST", 401, 426], ["low temporal signal", "PROBLEM", 440, 459], ["branch-rate heterogeneity", "PROBLEM", 482, 507], ["the mean rate", "TEST", 571, 584], ["widely", "OBSERVATION_MODIFIER", 18, 24], ["skewed", "OBSERVATION_MODIFIER", 25, 31], ["posterior", "OBSERVATION_MODIFIER", 32, 41], ["significant", "OBSERVATION_MODIFIER", 89, 100], ["temporal", "OBSERVATION_MODIFIER", 101, 109], ["structure", "OBSERVATION", 110, 119]]], ["The posterior mean and 95% HPDs estimated from these synthetic data sets were similar to those returned from the data simulated under a strict clock ( fig. 5) .", [["The posterior mean", "TEST", 0, 18], ["HPDs", "TEST", 27, 31], ["these synthetic data sets", "TEST", 47, 72], ["posterior", "ANATOMY_MODIFIER", 4, 13]]], ["When the true rate of the VARV-like data was set at 10 \u00c06 subs/site/year, the resultant estimates were close to the true values; however, substantial deviations from the known values occurred when the rates were set to 10 \u00c07 or 10 \u00c08 subs/site/year, with correspondingly larger 95% HPDs (fig. 5) .", [["VARV", "DNA", 26, 30], ["substantial deviations", "PROBLEM", 138, 160], ["the known values", "PROBLEM", 166, 182], ["the rates", "TEST", 197, 206], ["substantial", "OBSERVATION_MODIFIER", 138, 149], ["deviations", "OBSERVATION", 150, 160], ["larger", "OBSERVATION_MODIFIER", 271, 277]]], ["The rates estimated from the HSV-1-like data simulated with branch-rate heterogeneity also closely mirrored those from the data simulated under a strict clock.", [["HSV-1", "ORGANISM", 29, 34], ["HSV-1", "SPECIES", 29, 34], ["The rates", "TEST", 0, 9], ["the HSV", "TEST", 25, 32], ["branch-rate heterogeneity", "PROBLEM", 60, 85]]], ["The mean substitution rates estimated from all HSV-1-like data were higher than the true values and again associated with wide, long-tail posterior distributions that tended toward zero (fig. 5 ).", [["HSV-1", "ORGANISM", 47, 52], ["HSV-1", "SPECIES", 47, 52], ["The mean substitution rates", "TEST", 0, 27], ["all HSV", "TEST", 43, 50], ["wide, long-tail posterior distributions", "PROBLEM", 122, 161], ["mean substitution", "OBSERVATION", 4, 21], ["wide", "OBSERVATION_MODIFIER", 122, 126], ["tail", "ANATOMY_MODIFIER", 133, 137], ["posterior", "ANATOMY_MODIFIER", 138, 147]]], ["As before, we consider these distributions to indicate a lack of temporal structure in the data at these low evolutionary rates.DiscussionBased on the distribution of rates from our synthetic data sets, we are able to make a number of general conclusions about the use of heterochronous data to estimate the substitution rates and divergence times of potentially slowly evolving dsDNA viruses.", [["heterochronous data", "TREATMENT", 272, 291], ["the substitution rates", "PROBLEM", 304, 326], ["slowly evolving dsDNA viruses", "PROBLEM", 363, 392], ["temporal", "OBSERVATION_MODIFIER", 65, 73], ["structure", "OBSERVATION", 74, 83], ["dsDNA viruses", "OBSERVATION", 379, 392]]], ["In particular, given a data set containing a large enough number of variable sites (such as the .", [["variable sites", "PROBLEM", 68, 82], ["large", "OBSERVATION_MODIFIER", 45, 50], ["enough number", "OBSERVATION_MODIFIER", 51, 64], ["variable sites", "OBSERVATION_MODIFIER", 68, 82]]], ["This analysis supports the presence of temporal structure in the data for VARV and HAdV-B, while suggesting the presence of temporal structure for HSV-1 and VZ.", [["HAdV-B", "CELL", 83, 89], ["HSV-1", "ORGANISM", 147, 152], ["VZ", "CELL", 157, 159], ["HAdV-B", "SPECIES", 83, 89], ["HSV-1", "SPECIES", 147, 152], ["This analysis", "TEST", 0, 13], ["VARV", "PROBLEM", 74, 78], ["HAdV", "PROBLEM", 83, 87], ["HSV", "PROBLEM", 147, 150], ["VZ", "PROBLEM", 157, 159], ["temporal", "OBSERVATION_MODIFIER", 39, 47], ["structure", "OBSERVATION", 48, 57], ["temporal", "ANATOMY_MODIFIER", 124, 132], ["HSV", "OBSERVATION", 147, 150]]], ["No evidence for temporal structure within the sampled period was found for the HPV-16, BK, and HAdV-C data sets using this method.DiscussionEvolutionary Rates of dsDNA Viruses \u00b7 doi:10.1093/molbev/msq088 VARV data set), it is possible to accurately estimate substitution rates that range from 10 \u00c04 to approximately 10 \u00c07 subs/site/year using temporally sampled viruses, even if the data do not conform to a strict molecular clock (figs.", [["HPV-16", "ORGANISM", 79, 85], ["BK", "CELL", 87, 89], ["HPV-16", "SPECIES", 79, 85], ["temporal structure", "PROBLEM", 16, 34], ["the HPV", "TEST", 75, 82], ["BK", "TEST", 87, 89], ["HAdV", "TEST", 95, 99], ["this method", "TREATMENT", 118, 129], ["dsDNA Viruses", "PROBLEM", 162, 175], ["temporally sampled viruses", "PROBLEM", 343, 369], ["evidence for", "UNCERTAINTY", 3, 15], ["temporal", "OBSERVATION_MODIFIER", 16, 24], ["structure", "OBSERVATION", 25, 34]]], ["This is dependent on the length of sequence, and for a data set containing only a small number of informative nucleotide sites (as in the case of HSV-1), the temporal signal in the data begins to break down at evolutionary rates below 1 \u00c2 10 \u00c05 subs/site/year (figs.", [["nucleotide", "CHEMICAL", 110, 120], ["nucleotide", "CHEMICAL", 110, 120], ["HSV-1", "ORGANISM", 146, 151], ["HSV-1", "SPECIES", 146, 151], ["a data", "TEST", 53, 59], ["informative nucleotide sites", "PROBLEM", 98, 126], ["HSV", "TEST", 146, 149], ["dependent", "OBSERVATION_MODIFIER", 8, 17], ["small", "OBSERVATION_MODIFIER", 82, 87]]], ["In these cases, the sampling interval is probably too small relative to the rate of evolution of the virus.", [["the sampling interval", "TEST", 16, 37], ["the virus", "PROBLEM", 97, 106], ["probably", "UNCERTAINTY", 41, 49], ["too small", "OBSERVATION_MODIFIER", 50, 59], ["virus", "OBSERVATION", 101, 106]]], ["Therefore, any substitution rate estimated using these types of data will likely not converge on the true rate but will instead return a wide posterior distribution of the rate that tends toward zero ( fig. 5 ).", [["any substitution rate", "TEST", 11, 32], ["wide", "OBSERVATION_MODIFIER", 137, 141], ["posterior", "OBSERVATION_MODIFIER", 142, 151]]], ["This behavior is also likely to be robust to a poor fit to the molecular clock (e.g., the use of a strict clock with highly rate-variable data) and can be interpreted as an indication that the data are not appropriate for a temporal analysis by a program such as BEAST.DiscussionInterestingly, the shape and lower tails of the posterior distributions estimated from our synthetic data at low rates were similar to those returned from analyzing the HPV-16, HAdV-C, and VZ data sets (table 2) .", [["HPV-16", "ORGANISM", 448, 454], ["HAdV-C", "CELL", 456, 462], ["a poor fit", "PROBLEM", 45, 55], ["a strict clock", "TREATMENT", 97, 111], ["a temporal analysis", "TEST", 222, 241], ["our synthetic data", "TEST", 366, 384], ["the HPV", "TEST", 444, 451], ["HAdV", "TEST", 456, 460], ["lower", "ANATOMY_MODIFIER", 308, 313], ["tails", "ANATOMY_MODIFIER", 314, 319], ["posterior", "ANATOMY_MODIFIER", 327, 336]]], ["This strongly suggests that there is insufficient temporal structure in these data to undertake an analysis of the nucleotide substitution rate in the absence of external calibration points.", [["nucleotide", "CHEMICAL", 115, 125], ["nucleotide", "CHEMICAL", 115, 125], ["insufficient temporal structure", "PROBLEM", 37, 68], ["an analysis", "TEST", 96, 107], ["the nucleotide substitution rate", "TEST", 111, 143], ["insufficient", "OBSERVATION_MODIFIER", 37, 49], ["temporal", "OBSERVATION_MODIFIER", 50, 58], ["structure", "OBSERVATION", 59, 68], ["external calibration", "OBSERVATION", 162, 182]]], ["However, a very different pattern was seen in the HSV-1, BK, VARV, and HAdV-B data sets ( fig. 4) .", [["HSV-1", "ORGANISM", 50, 55], ["BK", "CELL", 57, 59], ["VARV", "CELL", 61, 65], ["HSV-1", "SPECIES", 50, 55], ["VARV", "SPECIES", 61, 65], ["a very different pattern", "PROBLEM", 9, 33], ["the HSV", "TEST", 46, 53], ["BK", "TEST", 57, 59], ["VARV", "TEST", 61, 65], ["HAdV", "PROBLEM", 71, 75]]], ["Here, analysis of the observed data sets resulted in high substitution rate estimates associated with tight 95% HPDs, a pattern that we were unable to reproduce using the synthetic data even with the inclusion of large amounts of branch-rate heterogeneity (i.e., when applying a SD of 2.0 log 10 to the mean clock rate).", [["high substitution rate estimates", "PROBLEM", 53, 85], ["the synthetic data", "TEST", 167, 185], ["high substitution", "OBSERVATION", 53, 70], ["large", "OBSERVATION_MODIFIER", 213, 218], ["amounts", "OBSERVATION_MODIFIER", 219, 226], ["branch", "OBSERVATION_MODIFIER", 230, 236], ["rate heterogeneity", "OBSERVATION", 237, 255]]], ["As such, extensive rate heterogeneity across the phylogeny is unlikely to explain the high substitution rates observed in these viruses, and we are therefore unable to justify the high rates of evolution measured for some of these dsDNA viruses by simply invoking estimation error.", [["extensive rate heterogeneity", "PROBLEM", 9, 37], ["the high substitution rates", "PROBLEM", 82, 109], ["these viruses", "PROBLEM", 122, 135], ["these dsDNA viruses", "PROBLEM", 225, 244], ["extensive", "OBSERVATION_MODIFIER", 9, 18], ["rate heterogeneity", "OBSERVATION", 19, 37], ["unlikely to explain", "UNCERTAINTY", 62, 81], ["high substitution", "OBSERVATION", 86, 103], ["viruses", "OBSERVATION", 128, 135]]], ["The analysis of contemporaneously sampled, slowly evolving viruses results in a posterior distribution that reveals the lack of structure in the data, a phenomenon unlike the posterior distributions recovered from the analysis of these viruses.", [["The analysis", "TEST", 0, 12], ["slowly evolving viruses", "PROBLEM", 43, 66], ["a phenomenon", "PROBLEM", 151, 163], ["the analysis", "TEST", 214, 226], ["these viruses", "PROBLEM", 230, 243], ["viruses", "OBSERVATION", 59, 66], ["posterior", "ANATOMY_MODIFIER", 80, 89], ["posterior", "ANATOMY_MODIFIER", 175, 184], ["viruses", "OBSERVATION", 236, 243]]], ["Hence, our simulations support the conclusion that VARV is evolving at a rate close to 1 \u00c2 10 \u00c05 subs/site/year and indicates that there is no obvious flaw in the analysis of the HSV-1, BK, and HAdV-B data sets that could result in erroneous substitution rate estimates.", [["VARV", "GENE_OR_GENE_PRODUCT", 51, 55], ["HSV-1", "ORGANISM", 179, 184], ["BK", "CELL", 186, 188], ["HSV-1", "SPECIES", 179, 184], ["obvious flaw", "PROBLEM", 143, 155], ["the analysis", "TEST", 159, 171], ["the HSV", "TEST", 175, 182], ["BK", "TEST", 186, 188], ["HAdV", "PROBLEM", 194, 198], ["erroneous substitution rate estimates", "PROBLEM", 232, 269], ["no obvious", "UNCERTAINTY", 140, 150], ["flaw", "OBSERVATION", 151, 155], ["erroneous substitution", "OBSERVATION", 232, 254]]], ["Therefore, we accept high rates of evolution in VARV and tentatively suggest FIG.", [["VARV", "CANCER", 48, 52], ["FIG", "PROTEIN", 77, 80], ["VARV", "SPECIES", 48, 52], ["high", "OBSERVATION_MODIFIER", 21, 25], ["FIG", "OBSERVATION", 77, 80]]], ["Substitution rates (posterior mean and 95% HPD) estimated from synthetic data sets based on the VARV and HSV-1 data sets from the first part of this study.", [["HSV-1", "SPECIES", 105, 110], ["Substitution rates", "TEST", 0, 18], ["posterior mean", "TEST", 20, 34], ["synthetic data sets", "TEST", 63, 82], ["the VARV", "TEST", 92, 100], ["HSV", "TEST", 105, 108], ["this study", "TEST", 144, 154]]], ["Twenty replicates of both the VARV-and HSV-1-like data sets were generated under strict molecular clocks evolving at each of 10 \u00c04 , 10 \u00c05 , 10 \u00c06 , 10 \u00c07 , and 10 \u00c08 subs/site/year.", [["VARV", "GENE_OR_GENE_PRODUCT", 30, 34], ["HSV-1", "ORGANISM", 39, 44], ["VARV-and HSV-1-like data sets", "DNA", 30, 59], ["\u00c04 , 10 \u00c05 , 10 \u00c06 , 10 \u00c07 , and 10 \u00c08 subs/site", "DNA", 128, 176], ["HSV-1", "SPECIES", 39, 44], ["the VARV", "TEST", 26, 34], ["HSV", "TEST", 39, 42], ["molecular clocks", "OBSERVATION", 88, 104]]], ["The dashed lines show the true mean evolutionary rate for each group of simulations of the corresponding color.", [["dashed lines", "CELL", 4, 16], ["dashed lines", "CELL_LINE", 4, 16], ["The dashed lines", "TREATMENT", 0, 16]]], ["The mean and 95% HPDs of the substitution rates for VARV and HSV-1 under the best evolutionary model are shown for comparison.", [["HSV-1", "ORGANISM", 61, 66], ["VARV", "SPECIES", 52, 56], ["HSV-1", "SPECIES", 61, 66], ["The mean", "TEST", 0, 8], ["the substitution rates", "TEST", 25, 47], ["VARV", "TEST", 52, 56], ["HSV", "TEST", 61, 64], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["Firth et al. \u00b7 doi:10.1093/molbev/msq088 MBE that high substitution rates may also occur in the thymidine kinase gene of HSV-1, the HAdV-B hexon (capsid) gene, and potentially in BK virus, although further work is clearly needed.", [["thymidine", "CHEMICAL", 96, 105], ["thymidine", "CHEMICAL", 96, 105], ["thymidine kinase", "GENE_OR_GENE_PRODUCT", 96, 112], ["HSV-1", "ORGANISM", 121, 126], ["HAdV-B hexon", "GENE_OR_GENE_PRODUCT", 132, 144], ["capsid", "GENE_OR_GENE_PRODUCT", 146, 152], ["BK virus", "ORGANISM", 179, 187], ["thymidine kinase gene", "DNA", 96, 117], ["HSV-1", "DNA", 121, 126], ["HAdV-B hexon (capsid) gene", "DNA", 132, 158], ["HSV-1", "SPECIES", 121, 126], ["BK virus", "SPECIES", 179, 187], ["doi:", "TEST", 15, 19], ["high substitution rates", "PROBLEM", 50, 73], ["HSV", "TEST", 121, 124], ["the HAdV", "PROBLEM", 128, 136], ["B hexon (capsid) gene", "TREATMENT", 137, 158], ["BK virus", "PROBLEM", 179, 187]]], ["It is also possible that these high rates are the result of model misspecifications that have not yet been identified.", [["these high rates", "PROBLEM", 25, 41], ["model misspecifications", "PROBLEM", 60, 83], ["is also possible", "UNCERTAINTY", 3, 19], ["high", "OBSERVATION", 31, 35]]], ["We now consider the case of some of these viruses in more detail.VARVThe rate of nucleotide substitution in VARV obtained from our analysis (;1 \u00c2 10 \u00c05 subs/site/year) accords well with rates previously estimated (and discarded) using a variety of methods.", [["nucleotide", "CHEMICAL", 81, 91], ["nucleotide", "CHEMICAL", 81, 91], ["VARV", "CANCER", 108, 112], ["VARV", "DNA", 108, 112], ["nucleotide substitution", "TREATMENT", 81, 104], ["our analysis", "TEST", 127, 139], ["a variety of methods", "TREATMENT", 235, 255], ["viruses", "OBSERVATION", 42, 49], ["nucleotide substitution", "OBSERVATION", 81, 104]]], ["Multiple attempts have been made to use historical documentation of the (potentially) first smallpox outbreaks in endemically infected regions as calibration points to estimate the divergence dates and substitution rate of VARV (Li et al. 2007; Babkin and Shchelkunov 2008; Shchelkunov 2009 ).", [["VARV", "SPECIES", 223, 227], ["substitution rate of VARV", "TREATMENT", 202, 227]]], ["Accordingly, the choice of calibration points has dramatically influenced many of these estimates, resulting in an approximate TMRCA for VARV ranging from 200 to 6,000 ybp, with correspondingly variable substitution rates (Li et al. 2007; Babkin and Shchelkunov 2008; Shchelkunov 2009 ).", [["VARV", "TEST", 137, 141]]], ["In most cases, these externally calibrated estimates are orders of magnitude lower from those achieved using temporally sampled sequences (Li et al. 2007, this study) .VARVIn an attempt to clarify the timescale of VARV evolution, Hughes et al. (2009) estimated the substitution rate using the synonymous sites of 132 protein-coding genes distributed throughout the genome and scaled the rate around the two dates previously suggested for the introduction of the P-II clade into South America (the 16th century African slave trade or the 18th century West African slave trade).", [["132 protein-coding genes", "DNA", 313, 337], ["P-II clade", "DNA", 462, 472], ["this study", "TEST", 155, 165], ["the substitution rate", "TREATMENT", 261, 282], ["the P-II clade", "TREATMENT", 458, 472]]], ["The use of either of these calibration points had little impact on the overall rate estimate, which ranged from 4 to 6 \u00c2 10 \u00c06 subs/site/year and was similar to both our rate estimate and that of Babkin and Shchelkunov (2008) (2-3 \u00c2 10 \u00c06 subs/site/year).VARVTwo primary pieces of information have been used to support the idea that VARV is a slowly evolving virus with a long history of association with human populations.", [["VARV", "CHEMICAL", 333, 337], ["VARV", "GENE_OR_GENE_PRODUCT", 333, 337], ["human", "ORGANISM", 405, 410], ["human", "SPECIES", 405, 410], ["VARV", "SPECIES", 333, 337], ["human", "SPECIES", 405, 410], ["a slowly evolving virus", "PROBLEM", 341, 364], ["human populations", "PROBLEM", 405, 422]]], ["The first is that epidemiologically linked isolates appear to accumulate no mutational changes over the period of 1 year (Li et al. 2007 ).", [["mutational changes", "PROBLEM", 76, 94], ["mutational", "OBSERVATION", 76, 86]]], ["However, it is also theoretically possible to explain this observation by invoking selective sweeps or severe population bottlenecks during transmission, which act to reduce the variability accrued during replication in a single individual.", [["severe population bottlenecks", "PROBLEM", 103, 132], ["the variability", "PROBLEM", 174, 189], ["severe", "OBSERVATION_MODIFIER", 103, 109], ["population", "OBSERVATION", 110, 120]]], ["The second factor opposing high evolutionary rates for VARV is the suggestion of congruence between historical records of the introduction and spread of the virus in various locations, and the TMRCAs estimated for the major VARV clades.", [["the introduction", "TREATMENT", 122, 138], ["the virus", "PROBLEM", 153, 162], ["the TMRCAs", "TEST", 189, 199], ["high", "OBSERVATION_MODIFIER", 27, 31], ["virus", "OBSERVATION", 157, 162], ["VARV clades", "OBSERVATION", 224, 235]]], ["However, as noted above, the use of FIG.", [["FIG", "CHEMICAL", 36, 39], ["FIG", "SIMPLE_CHEMICAL", 36, 39], ["FIG", "PROTEIN", 36, 39], ["FIG", "TREATMENT", 36, 39]]], ["Substitution rates (posterior mean and 95% HPD) estimated from simulated data sets based on the VARV and HSV-1 data sets from the first part of this study.", [["HSV-1", "SPECIES", 105, 110], ["Substitution rates", "TEST", 0, 18], ["posterior mean", "TEST", 20, 34], ["simulated data sets", "TEST", 63, 82], ["the VARV", "TEST", 92, 100], ["HSV", "TEST", 105, 108], ["this study", "TEST", 144, 154]]], ["Twenty replicates of both the VARV-and HSV-1-like data sets were generated under relaxed molecular clocks evolving at each of 10 \u00c06 , 10 \u00c07 , and 10 \u00c08 subs/site/year.", [["VARV", "GENE_OR_GENE_PRODUCT", 30, 34], ["HSV-1", "ORGANISM", 39, 44], ["VARV-and HSV-1-like data sets", "DNA", 30, 59], ["\u00c06 , 10 \u00c07 , and 10 \u00c08 subs/site", "DNA", 129, 161], ["HSV-1", "SPECIES", 39, 44], ["the VARV", "TEST", 26, 34], ["HSV", "TEST", 39, 42], ["molecular clocks", "OBSERVATION", 89, 105]]], ["The dashed lines show the true mean evolutionary rate for each group of simulations of the corresponding color.", [["dashed lines", "CELL", 4, 16], ["dashed lines", "CELL_LINE", 4, 16], ["The dashed lines", "TREATMENT", 0, 16]]], ["The mean and 95% HPDs of the substitution rates for VARV and HSV-1 under the best evolutionary model are shown for comparison.VARVEvolutionary Rates of dsDNA Viruses \u00b7 doi:10.1093/molbev/msq088 historical records as calibration points from which the rate and divergence times of viruses are estimated is problematic.", [["HSV-1", "ORGANISM", 61, 66], ["VARV", "SPECIES", 52, 56], ["HSV-1", "SPECIES", 61, 66], ["The mean", "TEST", 0, 8], ["the substitution rates", "TEST", 25, 47], ["VARV", "TEST", 52, 56], ["HSV", "TEST", 61, 64], ["dsDNA Viruses", "TEST", 152, 165], ["the rate", "TEST", 246, 254], ["viruses", "PROBLEM", 279, 286], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["dsDNA Viruses", "OBSERVATION", 152, 165]]], ["In particular, these epidemiological records do not necessarily correlate with the true origin or introduction of a pathogen, as revealed by the different dates used for the same introductions of VARV in multiple locations, and the last common ancestor of any contemporaneously sampled set of viruses may be of more recent origin than the common ancestor of the entire species (Hughes et al. 2009; Shchelkunov 2009 ).", [["VARV", "CHEMICAL", 196, 200], ["a pathogen", "PROBLEM", 114, 124], ["VARV", "TREATMENT", 196, 200], ["viruses", "PROBLEM", 293, 300], ["viruses", "OBSERVATION", 293, 300]]], ["In contrast, the current analysis only estimates the TMRCA of the sample, not of VARV itself, and may therefore return TMRCA estimates more recent than the known age of this human pathogen, particularly if there has been a large-scale reduction in diversity (i.e., selective sweep or population bottleneck) in the recent history of VARV.", [["sample", "ANATOMY", 66, 72], ["VARV", "CANCER", 81, 85], ["human", "ORGANISM", 174, 179], ["VARV", "CANCER", 332, 336], ["human", "SPECIES", 174, 179], ["human", "SPECIES", 174, 179], ["VARV", "SPECIES", 332, 336], ["the current analysis", "TEST", 13, 33], ["this human pathogen", "PROBLEM", 169, 188], ["a large-scale reduction in diversity", "PROBLEM", 221, 257], ["large", "OBSERVATION_MODIFIER", 223, 228], ["-scale", "OBSERVATION_MODIFIER", 228, 234], ["reduction", "OBSERVATION_MODIFIER", 235, 244]]], ["Although we cannot exclude all estimation errors in the case of VARV, the high level of genetic variation in our data explained by temporal sampling (R 2 5 0.68) lends support to the existence of rapid evolutionary rates in VARV (Hughes et al. 2009 , this study).HSV-1The cases of HSV-1 and HAdV-B are considerably more perplexing than that of VARV.", [["HSV-1", "ORGANISM", 263, 268], ["HSV-1", "ORGANISM", 281, 286], ["HAdV-B", "ORGANISM", 291, 297], ["VARV", "CANCER", 344, 348], ["HSV-1", "SPECIES", 281, 286], ["VARV", "SPECIES", 224, 228], ["HSV-1", "SPECIES", 263, 268], ["HSV-1", "SPECIES", 281, 286], ["HAdV-B", "SPECIES", 291, 297], ["VARV", "SPECIES", 344, 348], ["our data", "TEST", 109, 117], ["temporal sampling", "TEST", 131, 148], ["this study", "TEST", 251, 261], ["HSV", "TEST", 263, 266], ["HSV", "TEST", 281, 284], ["HAdV", "PROBLEM", 291, 295], ["cannot exclude", "UNCERTAINTY", 12, 26], ["rapid", "OBSERVATION_MODIFIER", 196, 201]]], ["The estimated substitution rates for these viruses were highly consistent between models (table 2) and were supported by the randomization test of temporal structure in the data ( fig. 2 ).", [["The estimated substitution rates", "TREATMENT", 0, 32], ["these viruses", "PROBLEM", 37, 50], ["the randomization test", "TEST", 121, 143], ["substitution rates", "OBSERVATION", 14, 32]]], ["In addition, we were unable to reproduce similarly high estimates of the substitution rate from viral data sets known to be slowly evolving through the analysis of synthetic data.", [["the substitution rate", "PROBLEM", 69, 90], ["viral data sets", "TEST", 96, 111], ["the analysis", "TEST", 148, 160], ["synthetic data", "TEST", 164, 178]]], ["In particular, the possibility that genes within herpesviruses such as HSV-1 could be evolving at a rate of 10 \u00c05 subs/site/year is perhaps one of the most difficult results of this study to reconcile with the biology of the virus as it is presently understood.HSV-1Herpesviruses are prototypic examples of host-pathogen codivergence and comparing the phylogeny of their vertebrate hosts with that of the virus indeed reveals strong topological congruence (McGeoch and Cook 1994; McGeoch et al. 1995 McGeoch et al. , 2000 Jackson 2005 ).", [["herpesviruses", "ORGANISM", 49, 62], ["HSV-1", "ORGANISM", 71, 76], ["HSV-1Herpesviruses", "ORGANISM", 261, 279], ["HSV-1", "SPECIES", 71, 76], ["HSV-1Herpesviruses", "SPECIES", 261, 279], ["genes within herpesviruses", "PROBLEM", 36, 62], ["HSV", "PROBLEM", 71, 74], ["this study", "TEST", 177, 187], ["the virus", "PROBLEM", 221, 230], ["HSV", "TEST", 261, 264], ["the virus", "PROBLEM", 401, 410]]], ["However, the substitution rate for herpesviruses such as HSV-1 has not previously been measured independently from the hypothesis of codivergence.", [["HSV-1", "ORGANISM", 57, 62], ["HSV-1", "SPECIES", 57, 62], ["HSV-1", "SPECIES", 57, 62], ["the substitution rate", "TEST", 9, 30], ["herpesviruses", "PROBLEM", 35, 48], ["HSV", "TEST", 57, 60]]], ["A key measure of the evolutionary rate of herpesviruses originated from the analysis of 63 variable restriction endonuclease sites in 242 HSV-1 samples from three human populations represented by six countries: Asian (Korea, Japan, and China), African (Kenya), and European (Sweden and the United States) (Sakaoka et al. 1994) .", [["samples", "ANATOMY", 144, 151], ["herpesviruses", "ORGANISM", 42, 55], ["HSV-1", "ORGANISM", 138, 143], ["human", "ORGANISM", 163, 168], ["63 variable restriction endonuclease sites", "DNA", 88, 130], ["HSV-1", "SPECIES", 138, 143], ["human", "SPECIES", 163, 168], ["HSV-1", "SPECIES", 138, 143], ["human", "SPECIES", 163, 168], ["herpesviruses", "PROBLEM", 42, 55], ["the analysis", "TEST", 72, 84], ["variable restriction endonuclease sites", "PROBLEM", 91, 130], ["HSV", "TEST", 138, 141]]], ["Based on rough estimates of the divergence times between these ethnic groups (110,000 years for the split between African and European/Asian populations and 50,000 years for the split of Asian from European groups) and the nucleotide differences between them, a substitution rate of 3.5 \u00c2 10 \u00c08 subs/site/year was estimated (Sakaoka et al. 1994 ).", [["nucleotide", "CHEMICAL", 223, 233], ["African and European/Asian populations", "TREATMENT", 114, 152], ["the nucleotide differences", "PROBLEM", 219, 245], ["a substitution rate", "TEST", 260, 279]]], ["This rate is two-to-three orders of magnitude lower than any of the substitution rates we estimate here, including that of HSV-1 and VARV (table 2) .", [["HSV-1", "GENE_OR_GENE_PRODUCT", 123, 128], ["HSV-1", "SPECIES", 123, 128], ["This rate", "TEST", 0, 9], ["the substitution rates", "TEST", 64, 86], ["HSV", "TEST", 123, 126]]], ["Hughes et al. (2009) suggested previously that the HSV-1 rate of Sakaoka et al. (1994) might be too low given the substitution rates estimated for VARV.", [["HSV-1", "ORGANISM", 51, 56], ["VARV", "PROTEIN", 147, 151], ["HSV-1", "SPECIES", 51, 56], ["VARV", "SPECIES", 147, 151], ["the HSV", "TEST", 47, 54], ["the substitution rates", "TREATMENT", 110, 132], ["VARV", "PROBLEM", 147, 151]]], ["However, a genespecific mutation rate of approximately 2 \u00c2 10 \u00c08 mutations/site/replication has been experimentally derived for the thymidine kinase gene of HSV-1 (the same gene analyzed here), an estimate congruent with both the substitution rate estimated by Sakaoka et al. (1994) and for dsDNA viruses generally (Drake 1991; Lu et al. 2002; Drake and Hwang 2005) .HSV-1If the mutation rate of HSV-1 is 2 \u00c2 10 \u00c08 mutations/ site/replication, we must then ask if it is possible for this rate to be translated into the substitution rate of 10 \u00c05 subs/site/year we estimated?", [["thymidine", "CHEMICAL", 132, 141], ["thymidine", "CHEMICAL", 132, 141], ["thymidine kinase", "GENE_OR_GENE_PRODUCT", 132, 148], ["HSV-1", "ORGANISM", 157, 162], ["HSV-1If", "ORGANISM", 367, 374], ["HSV-1", "ORGANISM", 396, 401], ["thymidine kinase gene", "DNA", 132, 153], ["HSV-1", "DNA", 157, 162], ["HSV-1", "SPECIES", 157, 162], ["HSV-1If", "SPECIES", 367, 374], ["HSV-1", "SPECIES", 396, 401], ["a genespecific mutation rate", "TEST", 9, 37], ["the thymidine kinase", "TEST", 128, 148], ["HSV", "TEST", 157, 160], ["the substitution rate", "TEST", 226, 247], ["dsDNA viruses", "PROBLEM", 291, 304], ["HSV", "TEST", 367, 370], ["the mutation rate", "TEST", 375, 392], ["HSV", "TEST", 396, 399]]], ["The most likely mechanism through which such an inflated substitution rate could occur is through strong and continuous positive selection.", [["an inflated substitution rate", "PROBLEM", 45, 74], ["most likely", "UNCERTAINTY", 4, 15], ["inflated", "OBSERVATION", 48, 56]]], ["To test for the presence of positive selection within our HSV-1 thymidine kinase gene alignment, the overall ratio of nonsynonymous to synonymous substitutions per site (d N /d S ) was estimated using the program HyPhy (Kosakovsky Pond et al. 2005) .", [["thymidine", "CHEMICAL", 64, 73], ["thymidine", "CHEMICAL", 64, 73], ["HSV-1 thymidine kinase", "GENE_OR_GENE_PRODUCT", 58, 80], ["HSV-1 thymidine kinase gene alignment", "DNA", 58, 95], ["HSV-1", "SPECIES", 58, 63], ["positive selection", "PROBLEM", 28, 46], ["our HSV", "TEST", 54, 61], ["nonsynonymous to synonymous substitutions", "PROBLEM", 118, 159], ["positive", "OBSERVATION", 28, 36], ["synonymous substitutions", "OBSERVATION", 135, 159]]], ["The d N /d S ratio for this data set was 0.700, consistent with either localized positive selection on some codons or perhaps a substantial relaxation of purifying selection on this gene, as has been previously suggested (Drake and Hwang 2005) .", [["The d N /d S ratio", "TEST", 0, 18], ["this data", "TEST", 23, 32], ["localized positive selection on some codons", "PROBLEM", 71, 114], ["consistent with", "UNCERTAINTY", 48, 63], ["positive selection", "OBSERVATION", 81, 99], ["substantial", "OBSERVATION_MODIFIER", 128, 139], ["relaxation", "OBSERVATION", 140, 150]]], ["Hence, although positive selection may be contributing to the high substitution rates estimated for this gene, it seems highly unlikely that such adaptive evolution could result in a substitution rate that is three orders of magnitude higher than expected.", [["the high substitution rates", "PROBLEM", 58, 85], ["a substitution rate", "TEST", 181, 200], ["high substitution", "OBSERVATION", 62, 79], ["seems highly unlikely", "UNCERTAINTY", 114, 135]]], ["We are therefore unable to conclusively reconcile the high substitution rates estimated here for HSV-1 (and potentially the related VZ virus), with what is known about the background mutation rate and biology of herpesviruses.", [["HSV-1", "ORGANISM", 97, 102], ["VZ virus", "ORGANISM", 132, 140], ["herpesviruses", "ORGANISM", 212, 225], ["HSV-1", "SPECIES", 97, 102], ["the high substitution rates", "PROBLEM", 50, 77], ["HSV", "PROBLEM", 97, 100], ["the related VZ virus", "PROBLEM", 120, 140], ["herpesviruses", "PROBLEM", 212, 225]]], ["At the very least, our HSV-1 analysis strongly suggests that future research should focus on acquiring sufficient herpesvirus data to allow for a rigorous estimate of the substitution and replication rates of these viruses, independent from any assumption of codivergence.High Rates of Evolution in dsDNA Viruses?Clearly, the high rates of molecular evolution we have measured here for all seven dsDNA viruses are not easily explained by the understood biology of these (and other) dsDNA viruses.", [["HSV-1", "ORGANISM", 23, 28], ["herpesvirus", "ORGANISM", 114, 125], ["dsDNA viruses", "ORGANISM", 482, 495], ["HSV-1", "SPECIES", 23, 28], ["our HSV-1 analysis", "TEST", 19, 37], ["the substitution", "TREATMENT", 167, 183], ["these viruses", "PROBLEM", 209, 222], ["codivergence", "PROBLEM", 259, 271], ["dsDNA Viruses", "PROBLEM", 299, 312], ["all seven dsDNA viruses", "PROBLEM", 386, 409], ["dsDNA viruses", "PROBLEM", 482, 495], ["dsDNA Viruses", "OBSERVATION", 299, 312], ["high", "OBSERVATION_MODIFIER", 326, 330]]], ["However, we cannot simply attribute the remarkably similar rate estimates across the seven viruses to an error in the method of estimation, as we were unable to recover comparably high estimates from the analysis of our synthetic data sets.", [["the analysis", "TEST", 200, 212]]], ["Although we have little confidence in the rates estimated for some of our data sets (HAdV-C, VZ, HPV-16), others are suggestive of high substitution rates in dsDNA viruses (VARV, HAdV-B, and perhaps HSV-1 and BK) and clearly merit further investigation.", [["HAdV-C", "ORGANISM", 85, 91], ["HPV-16", "ORGANISM", 97, 103], ["dsDNA viruses", "ORGANISM", 158, 171], ["HAdV-B", "ORGANISM", 179, 185], ["HSV-1", "ORGANISM", 199, 204], ["BK", "CELL", 209, 211], ["VARV", "SPECIES", 173, 177], ["HAdV-B", "SPECIES", 179, 185], ["HSV-1", "SPECIES", 199, 204], ["the rates", "TEST", 38, 47], ["HAdV", "TEST", 85, 89], ["VZ", "TEST", 93, 95], ["HPV", "TEST", 97, 100], ["high substitution rates in dsDNA viruses", "PROBLEM", 131, 171], ["VARV", "TEST", 173, 177], ["HAdV", "TEST", 179, 183], ["HSV", "TEST", 199, 202], ["further investigation", "TEST", 231, 252], ["suggestive of", "UNCERTAINTY", 117, 130], ["high substitution", "OBSERVATION", 131, 148]]], ["It is possible to identify two general mechanisms that may Firth et al. \u00b7 doi:10.1093/molbev/msq088 MBE be driving the substitution rate of these viruses above the background mutation rate (;2 \u00c2 10 \u00c08 to 7 \u00c2 10 \u00c07 mutations/site/replication, Drake et al. 1998) .", [["these viruses", "PROBLEM", 140, 153], ["viruses", "OBSERVATION", 146, 153]]], ["First, as the rate of viral replication directly impacts the long-term substitution rate (this parameter is analogous to generation time), very high replication rates have the potential to inflate the substitution rates of dsDNA viruses (McLysaght et al. 2003; Gubser et al. 2004; Esposito et al. 2006; Hughes et al. 2009 ).", [["viral replication", "TREATMENT", 22, 39], ["the long-term substitution rate", "TREATMENT", 57, 88], ["dsDNA viruses", "PROBLEM", 223, 236], ["viral replication", "OBSERVATION", 22, 39]]], ["The impact of high replication rates may be particularly important for those viruses that are highly transmissible and/or result in acute infections in humans (VARV, HAdV-B) but are unlikely to have a similar effect in those viruses causing asymptomatic, latent, and/or chronic infections (BK, HSV-1) in the host.", [["infections", "DISEASE", 138, 148], ["infections", "DISEASE", 278, 288], ["humans", "ORGANISM", 152, 158], ["VARV, HAdV-B", "ORGANISM", 160, 172], ["HSV-1", "ORGANISM", 294, 299], ["humans", "SPECIES", 152, 158], ["humans", "SPECIES", 152, 158], ["VARV", "SPECIES", 160, 164], ["HAdV-B", "SPECIES", 166, 172], ["HSV-1", "SPECIES", 294, 299], ["high replication rates", "TREATMENT", 14, 36], ["those viruses", "PROBLEM", 71, 84], ["acute infections in humans", "PROBLEM", 132, 158], ["HAdV", "PROBLEM", 166, 170], ["those viruses", "PROBLEM", 219, 232], ["chronic infections", "PROBLEM", 270, 288], ["BK", "TEST", 290, 292], ["HSV", "TEST", 294, 297], ["high replication", "OBSERVATION", 14, 30], ["acute", "OBSERVATION_MODIFIER", 132, 137], ["infections", "OBSERVATION", 138, 148], ["latent", "OBSERVATION_MODIFIER", 255, 261], ["chronic", "OBSERVATION_MODIFIER", 270, 277], ["infections", "OBSERVATION", 278, 288]]], ["Unfortunately, the replication rates of these viruses during natural infections in the host are unknown.", [["infections", "DISEASE", 69, 79], ["these viruses", "PROBLEM", 40, 53], ["natural infections in the host", "PROBLEM", 61, 91], ["viruses", "OBSERVATION", 46, 53], ["infections", "OBSERVATION", 69, 79]]], ["Second, as discussed in the context of HSV-1, strong (diversifying) positive selection could also act to increase the substitution rate above the (neutral) mutation rate.", [["HSV-1", "ORGANISM", 39, 44], ["HSV-1", "SPECIES", 39, 44], ["HSV", "TEST", 39, 42], ["the substitution rate", "TEST", 114, 135]]], ["Positive selection is most likely to be observed in viruses that cause a strong immune response in the host or are the target of intense vaccination or intervention campaigns.", [["viruses", "PROBLEM", 52, 59], ["intense vaccination", "TREATMENT", 129, 148], ["intervention campaigns", "TREATMENT", 152, 174], ["selection", "OBSERVATION", 9, 18], ["most likely to be", "UNCERTAINTY", 22, 39], ["viruses", "OBSERVATION", 52, 59]]], ["However, as with replication rates, relatively little is known about the extent and nature of adaptive evolution in dsDNA viruses, although to date positive selection has not been identified in the protein-coding genes of VARV (Hughes et al. 2009 ).High Rates of Evolution in dsDNA Viruses?More generally, understanding the mechanisms of dsDNA virus evolution is central to the accurate assessment of these infectious agents as potentially emerging diseases of both humans and animals, particularly as the focus thus far has been primarily directed toward RNA viruses.", [["dsDNA virus", "ORGANISM", 338, 349], ["humans", "ORGANISM", 466, 472], ["protein-coding genes", "DNA", 198, 218], ["humans", "SPECIES", 466, 472], ["humans", "SPECIES", 466, 472], ["adaptive evolution in dsDNA viruses", "PROBLEM", 94, 129], ["dsDNA Viruses", "PROBLEM", 276, 289], ["dsDNA virus evolution", "PROBLEM", 338, 359], ["the accurate assessment", "TEST", 374, 397], ["these infectious agents", "TREATMENT", 401, 424], ["dsDNA viruses", "OBSERVATION", 116, 129], ["dsDNA Viruses", "OBSERVATION", 276, 289], ["infectious", "OBSERVATION", 407, 417]]], ["Investigating the rates and processes of dsDNA virus evolution independent of the hypothesis of codivergence therefore constitutes an important avenue for future research.Supplementary MaterialSupplementary information is available at Molecular Biology and Evolution online (http://www.mbe.oxfordjournals .org/).", [["dsDNA virus", "ORGANISM", 41, 52], ["dsDNA virus evolution", "PROBLEM", 41, 62], ["dsDNA virus", "OBSERVATION", 41, 52]]]], "bd0427d3165442d8f45e07e5d16addd38a96b161": [["The question of differences in mental health between Latino subgroups has been of interest to researchers stretching back to the early 1980s; however, previously published data on mental disorders and psychiatric symptoms between Latino subgroups remain sparse.", [["psychiatric", "DISEASE", 201, 212], ["mental disorders", "PROBLEM", 180, 196], ["psychiatric symptoms", "PROBLEM", 201, 221]]], ["With few exceptions, national surveys have combined Latinos into a homogeneous, monolithic group.", [["few", "OBSERVATION_MODIFIER", 5, 8], ["homogeneous", "OBSERVATION_MODIFIER", 67, 78], ["monolithic group", "OBSERVATION", 80, 96]]], ["When doing so, these show that Latinos, in aggregate, are at lower risk of all lifetime psychiatric disorders compared to non-Latino whites (Alegr\u00eda et al., 2008; Breslau et al., 2006; Kessler et al., 2003) .", [["psychiatric disorders", "DISEASE", 88, 109], ["all lifetime psychiatric disorders", "PROBLEM", 75, 109]]], ["We discuss some of the landmark studies that have provided insight into intraethnic differences in the prevalence of depression and anxiety as well as the immigration histories, and sociopolitical difficulties that differentially affect mental health.", [["depression", "DISEASE", 117, 127], ["anxiety", "DISEASE", 132, 139], ["the landmark studies", "TEST", 19, 39], ["depression", "PROBLEM", 117, 127], ["anxiety", "PROBLEM", 132, 139], ["depression", "OBSERVATION", 117, 127]]], ["In addition, we address social support and discrimination as important risk and protective factors in older Latino mental health.", [["social support", "TREATMENT", 24, 38]]], ["We conclude with a discussion on meeting the mental health needs of older Latinos with a focus on prevention, a promising approach to addressing mental illness in older Latinos, and future directions for mental health research in this population.", [["illness", "DISEASE", 152, 159], ["mental illness", "PROBLEM", 145, 159]]], ["Throughout the review, we make clear when the research is based on Latinos as a whole or on specific Latino groups (e.g., Mexican Americans, Cuban Americans, and Puerto Ricans).Differences in the Prevalence of Depression and AnxietyInconsistent with previous data on younger adults, Jimenez et al. (2010) found that the prevalence of depression and anxiety in older Latinos (aged older than 60 years) was equal to, and in some cases greater, compared to older non-Latino whites.", [["Depression", "DISEASE", 210, 220], ["Anxiety", "DISEASE", 225, 232], ["depression", "DISEASE", 334, 344], ["anxiety", "DISEASE", 349, 356], ["Depression", "PROBLEM", 210, 220], ["Anxiety", "PROBLEM", 225, 232], ["depression", "PROBLEM", 334, 344], ["anxiety", "PROBLEM", 349, 356], ["Depression", "OBSERVATION", 210, 220], ["depression", "OBSERVATION", 334, 344]]], ["In a study comparing lifetime and 12-month prevalence of the fourth edition of the Diagnostic and Statistical Manual (DSM-IV) psychiatric disorders, Latinos and non-Latino whites had similar lifetime prevalence rates of any depressive disorder (16.4% vs. 12.2%) and of any anxiety disorder (15.3% vs. 13.5%; Jimenez et al., 2010) .", [["psychiatric disorders", "DISEASE", 126, 147], ["depressive disorder", "DISEASE", 224, 243], ["anxiety disorder", "DISEASE", 273, 289], ["a study", "TEST", 3, 10], ["psychiatric disorders", "PROBLEM", 126, 147], ["any depressive disorder", "PROBLEM", 220, 243], ["any anxiety disorder", "PROBLEM", 269, 289]]], ["Significantly higher 12-month prevalence rates of any depressive disorder (8.0% vs. 3.2%) and major depressive episodes (7.3% vs. 2.9%) were found in Latinos than in non-Latino whites (Jimenez et al., 2010) .", [["depressive disorder", "DISEASE", 54, 73], ["depressive episodes", "DISEASE", 100, 119], ["any depressive disorder", "PROBLEM", 50, 73], ["major depressive episodes", "PROBLEM", 94, 119]]], ["The Latino sample was divided into four subethnic groups-Mexican, Puerto Rican, Cuban, and other Latinos (mainly from the Dominican Republic, Colombia, El Salvador, Ecuador, Guatemala, Honduras, Peru, and Nicaragua).", [["The Latino sample", "TEST", 0, 17]]], ["However, this study aggregated older Latinos into one large group and did not examine whether results varied across Latino subgroups due to limited sample sizes.", [["this study", "TEST", 9, 19], ["sizes", "OBSERVATION_MODIFIER", 155, 160]]], ["These studies shared a primary objective: to collect data on the prevalence of psychiatric illness, impairments associated with these disorders, and treatment seeking for these disorders among a representative sample of adults in the United States (Pennell et al., 2004) .", [["psychiatric illness", "DISEASE", 79, 98], ["These studies", "TEST", 0, 13], ["psychiatric illness", "PROBLEM", 79, 98], ["impairments", "PROBLEM", 100, 111], ["these disorders", "PROBLEM", 128, 143], ["these disorders", "PROBLEM", 171, 186]]], ["The CPES used a modified version of the World Mental Health Composite International Diagnostic Interview (Kessler & Ustun, 2004) to identify the presence of lifetime and 12-month psychiatric disorders according to the DSM-IV (American Psychiatric Association, 2000) and International Classification of Diseases-10.Differences in the Prevalence of Depression and AnxietyUsing a slightly younger subsample of the CPES data set (aged older than 55 years), Woodward et al. (2012) estimated lifetime prevalence of mood and anxiety disorders for older non-Latino whites, Latinos, Asian Americans, African Americans, and Caribbean blacks and examined demographic, socioeconomic, and immigration correlates of those disorders.", [["psychiatric disorders", "DISEASE", 179, 200], ["Depression", "DISEASE", 347, 357], ["anxiety disorders", "DISEASE", 518, 535], ["psychiatric disorders", "PROBLEM", 179, 200], ["Depression", "PROBLEM", 347, 357], ["mood and anxiety disorders", "PROBLEM", 509, 535], ["those disorders", "PROBLEM", 702, 717], ["Depression", "OBSERVATION", 347, 357]]], ["They found that older non-Latino whites and Latinos consistently had a higher prevalence of mood (13.8% and 13.9%, respectively) and anxiety disorders (16.8% and 15.2%, respectively).", [["anxiety disorders", "DISEASE", 133, 150], ["mood", "TEST", 92, 96], ["anxiety disorders", "PROBLEM", 133, 150]]], ["Furthermore, they concluded that lower risk for disorders among Latinos is more pervasive in younger cohorts and within lower education groups (Woodward et al., 2012) .", [["disorders", "PROBLEM", 48, 57]]], ["Despite this limitation, these studies-with their use of a comprehensive, fully structured diagnostic interview and a nationally representative sample-enhanced our understanding of mood and anxiety disorders across older minority groups and provided evidence of a complicated picture of mental health in older Latinos.", [["anxiety disorders", "DISEASE", 190, 207], ["these studies", "TEST", 25, 38], ["mood and anxiety disorders", "PROBLEM", 181, 207]]], ["Important differences in the prevalence of depression and anxiety may be overlooked when older and younger Latinos are lumped together.Differences in the Prevalence of Depression and AnxietyThe Hispanic Health and Nutrition Examination Survey (HHANES) conducted from July 1982 to December 1984 by the National Center for Health Statistics (NCHS) was the first nationwide population-based survey of the physical and mental health and nutrition status of the three largest Latino groups in the United States: Mexican Americans, Cuban Americans, and Puerto Ricans.", [["depression", "DISEASE", 43, 53], ["anxiety", "DISEASE", 58, 65], ["Depression", "DISEASE", 168, 178], ["Anxiety", "DISEASE", 183, 190], ["depression", "PROBLEM", 43, 53], ["anxiety", "PROBLEM", 58, 65], ["Depression", "PROBLEM", 168, 178], ["Anxiety", "PROBLEM", 183, 190], ["Nutrition Examination", "TEST", 214, 235], ["depression", "OBSERVATION", 43, 53]]], ["Results from the HHANES showed that older Latinos aged 65-74 years reported high levels of depressive symptomatology as defined by a score of 16 or higher on the Center for Epidemiologic Studies Depression scale (CES-D; Radloff & Wales 1977) in all three Latino groups.", [["depressive symptomatology", "DISEASE", 91, 116], ["Depression", "DISEASE", 195, 205], ["the HHANES", "TEST", 13, 23], ["depressive symptomatology", "PROBLEM", 91, 116], ["Epidemiologic Studies", "TEST", 173, 194], ["Depression scale (CES", "PROBLEM", 195, 216]]], ["However, there was variation between the three groups.", [["variation", "OBSERVATION_MODIFIER", 19, 28]]], ["Puerto Ricans reported the greatest prevalence of high depressive symptomatology (27.9%), Cuban Americans had the lowest prevalence (11.3%), while Mexican Americans were in between those two groups (13.2%; Moscicki et al., 1987 Moscicki et al., , 1989 Narrow et al., 1990; Potter et al., 1995) .", [["depressive symptomatology", "DISEASE", 55, 80], ["high depressive symptomatology", "PROBLEM", 50, 80]]], ["The HHANES was not specifically focused on older Latinos; therefore, the sample sizes in all three groups were low.", [["the sample sizes", "TEST", 69, 85], ["sizes", "OBSERVATION_MODIFIER", 80, 85], ["low", "OBSERVATION_MODIFIER", 111, 114]]], ["However, it was an early indication that the burden of mental illness was quite high among older Latinos as a whole, that this burden was not equally shared among various Latino subgroups, and laid the foundation for the subsequent epidemiological studies.Differences in the Prevalence of Depression and AnxietyFollowing up on the results of the HHANES, the Hispanic Established Populations for Epidemiologic Studies of the Elderly (H-EPESE) was developed to specifically focus on older Mexican Americans.", [["illness", "DISEASE", 62, 69], ["Depression", "DISEASE", 289, 299], ["Anxiety", "DISEASE", 304, 311], ["mental illness", "PROBLEM", 55, 69], ["the subsequent epidemiological studies", "TEST", 217, 255], ["Depression", "PROBLEM", 289, 299], ["Anxiety", "PROBLEM", 304, 311], ["Epidemiologic Studies", "TEST", 395, 416], ["Depression", "OBSERVATION", 289, 299]]], ["The H-EPESE assessed the physical health, mental health, and functional status of older Mexican Americans and was the first large-scale population-based study that employed a representative sample of older, community-dwelling Mexican Americans from five states in the Southwestern United States (Markides et al., 1996) .", [["based study", "TEST", 147, 158]]], ["Using the same definition of high depressive symptomatology, Black et al. (1998) found a prevalence of 25.6%, which was substantially higher than the rate reported for older Mexican Americans in the HHANES.", [["depressive symptomatology", "DISEASE", 34, 59], ["high depressive symptomatology", "PROBLEM", 29, 59], ["higher", "OBSERVATION_MODIFIER", 134, 140]]], ["The prevalence of depression was also considerably higher than rates reported in studies of older non-Latinos which had used similar methodologies (Berkman et al., 1986; Blazer et al., 1991; O'Hara et al., 1985) .Differences in the Prevalence of Depression and AnxietySimilarly, the Sacramento Area Latino Study on Aging (SALSA) was a longitudinal cohort study of older, community-dwelling Mexican Americans residing in California's Sacramento Valley who were aged 60-101 years at baseline in 1998-1999.", [["depression", "DISEASE", 18, 28], ["Depression", "DISEASE", 246, 256], ["Americans", "ORGANISM", 398, 407], ["depression", "PROBLEM", 18, 28], ["Depression", "PROBLEM", 246, 256], ["depression", "OBSERVATION", 18, 28], ["considerably", "OBSERVATION_MODIFIER", 38, 50], ["higher", "OBSERVATION_MODIFIER", 51, 57], ["Depression", "OBSERVATION", 246, 256]]], ["SALSA aimed to assess cognitive, physical, and social functioning in older Latinos in Sacramento, CA.", [["cognitive, physical, and social functioning", "DISEASE", 22, 65]]], ["Eighty-five percent of the sample was of Mexican origin with the remainder of the participants coming from Central and South America and the Caribbean.", [["participants", "SPECIES", 82, 94], ["Central", "ANATOMY_MODIFIER", 107, 114]]], ["Using the same definition of high depressive symptomatology as in HHANES and H-EPESE (i.e., CES-D \u2265 16), Gonz\u00e1lez et al. (2001) found a prevalence of depression of 25.4% among this predominately older Mexican American sample, which was nearly identical to what was reported from H-EPESE (25.6%; Black et al., 1998) .", [["depressive symptomatology", "DISEASE", 34, 59], ["depression", "DISEASE", 150, 160], ["high depressive symptomatology", "PROBLEM", 29, 59], ["H-EPESE", "TEST", 77, 84], ["CES", "TEST", 92, 95], ["depression", "PROBLEM", 150, 160], ["H-EPESE", "TEST", 279, 286]]], ["For the first time, there was convergence from two large population-based studies indicating that more than a quarter of older Mexican Americans were experiencing major psychological distress, which was higher than what was being reported for non-Latino whites (Blazer et al., 1998) .", [["psychological distress", "DISEASE", 169, 191], ["Americans", "ORGANISM", 135, 144], ["based studies", "TEST", 68, 81], ["major psychological distress", "PROBLEM", 163, 191], ["large", "OBSERVATION_MODIFIER", 51, 56], ["population", "OBSERVATION", 57, 67]]], ["However, questions still remained surrounding the prevalence of depression as well as anxiety using diagnostic measures among older Latinos at a national level.Differences in the Prevalence of Depression and AnxietyThe Health and Retirement Study (HRS; http://hrsonline. isr.umich.edu) is a longitudinal study of a population-based sample of more than 20,000 Americans older than the age of 50.", [["depression", "DISEASE", 64, 74], ["anxiety", "DISEASE", 86, 93], ["Depression", "DISEASE", 193, 203], ["Anxiety", "DISEASE", 208, 215], ["depression", "PROBLEM", 64, 74], ["anxiety", "PROBLEM", 86, 93], ["Depression", "PROBLEM", 193, 203], ["Anxiety", "PROBLEM", 208, 215], ["Retirement Study", "TEST", 230, 246], ["http://hrsonline", "TREATMENT", 253, 269], ["a longitudinal study", "TEST", 289, 309]]], ["The HRS is a representative sample of U.S. adults who reside in the community and were approaching retirement, with a 2:1 oversample of African American and Latino populations.", [["adults", "ORGANISM", 43, 49]]], ["Details of the design and historical context of the HRS have been reported previously (Juster & Suzman, 1995) .", [["HRS", "DISEASE", 52, 55], ["HRS", "CANCER", 52, 55], ["the HRS", "TEST", 48, 55]]], ["Using the HRS, Yang et al. (2008) examined the prevalence of major depression in different groups of Latino older adults.", [["major depression", "DISEASE", 61, 77], ["major depression", "PROBLEM", 61, 77], ["major", "OBSERVATION_MODIFIER", 61, 66], ["depression", "OBSERVATION", 67, 77]]], ["The majority of the sample (56%) was Mexican American followed by Cuban Americans (13%), Puerto Ricans (8%), other (8%), or not specified (15%).", [["the sample", "TEST", 16, 26], ["Puerto Ricans", "TREATMENT", 89, 102], ["majority", "OBSERVATION_MODIFIER", 4, 12]]], ["They used the Composite International Diagnostic Interview-Short Form (CIDI-SF) to estimate the prevalence of major depression over the year preceding the interview (Steffick, 2000) .", [["major depression", "DISEASE", 110, 126], ["major depression", "PROBLEM", 110, 126]]], ["The CIDI-SF major depression module is a structured lay interview keyed to criteria in the third edition of the Diagnostic and Statistical Manual (American Psychiatric Association, 1980).", [["depression", "DISEASE", 18, 28], ["The CIDI", "TEST", 0, 8], ["SF major depression module", "PROBLEM", 9, 35], ["depression", "OBSERVATION", 18, 28]]], ["Yang et al. (2008) found that Puerto Ricans had the highest prevalence of major depression (19.3%), Mexican Americans had the lowest (8.2%), and Cuban Americans were in the middle (11.7%).", [["major depression", "DISEASE", 74, 90], ["major depression", "PROBLEM", 74, 90], ["middle", "ANATOMY_MODIFIER", 173, 179]]], ["It should be noted that the sample sizes were small (Mexican Americans = 427, Cuban Americans = 101, and Puerto Ricans = 56).Differences in the Prevalence of Depression and AnxietyRecognizing that combining Latinos may be masking important intraethnic differences in major depression, Gonz\u00e1lez et al. (2010) compared the epidemiology of major depression within Latino subgroups across adulthood using the CPES data set.", [["Depression", "DISEASE", 158, 168], ["major depression", "DISEASE", 267, 283], ["major depression", "DISEASE", 337, 353], ["the sample sizes", "TEST", 24, 40], ["Cuban Americans", "TEST", 78, 93], ["Puerto Ricans", "TEST", 105, 118], ["Depression", "PROBLEM", 158, 168], ["AnxietyRecognizing", "PROBLEM", 173, 191], ["major depression", "PROBLEM", 267, 283], ["major depression", "PROBLEM", 337, 353], ["the CPES data", "TEST", 401, 414], ["sizes", "OBSERVATION_MODIFIER", 35, 40], ["small", "OBSERVATION_MODIFIER", 46, 51], ["major", "OBSERVATION_MODIFIER", 337, 342], ["depression", "OBSERVATION", 343, 353]]], ["They found that Puerto Ricans had the highest 12-month and lifetime prevalence of major depression (10.2%, 18.4%), Mexican Americans had the lowest (4.6%, 9.0%), and Cuban Americans were in the middle (5.5%, 14.8%).", [["major depression", "DISEASE", 82, 98], ["major depression", "PROBLEM", 82, 98], ["Cuban Americans", "TEST", 166, 181], ["middle", "ANATOMY_MODIFIER", 194, 200]]], ["Gonz\u00e1lez et al. (2010) did not solely focus on older adults, and when doing so, the sample sizes were small (Mexican Americans = 1,442, Cuban Americans = 577, and Puerto Ricans = 495).", [["small", "OBSERVATION_MODIFIER", 102, 107]]], ["However, these results indicate that the homogeneity of the Latino population cannot be assumed, and when taken in conjunction with the HHANES and HRS results, they provide further evidence of differences in the expression and occurrence of depression among various Latino subgroups and provide support for presenting disaggregated data from Latino subgroups.", [["depression", "DISEASE", 241, 251], ["depression", "PROBLEM", 241, 251]]], ["Table 1 summarizes findings from studies on depression and anxiety among older Latinos.Immigration Histories and Sociopolitical Difficulties That Differentially Affect Mental HealthThe U.S. Census Bureau (2011) defines Hispanic or Latino as an ethnicity that comprises individuals of Cuban, Dominican, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin regardless of race.", [["depression", "DISEASE", 44, 54], ["anxiety", "DISEASE", 59, 66], ["depression", "PROBLEM", 44, 54], ["anxiety", "PROBLEM", 59, 66], ["Sociopolitical Difficulties", "PROBLEM", 113, 140], ["Spanish culture", "TEST", 361, 376]]], ["Therefore, this is not a homogeneous, monolithic group, even though the U.S. Census definition classifies them into one uniform ethnicity.", [["homogeneous", "OBSERVATION_MODIFIER", 25, 36], ["uniform", "OBSERVATION_MODIFIER", 120, 127], ["ethnicity", "OBSERVATION", 128, 137]]], ["Although the majority of U.S. Latinos are of Mexican origin (33.7 million or 64% of the total U.S. Latino population in 2012), Latinos from Puerto Rico, Cuba, the Dominican Republic, and Central and South America account for a substantial proportion of Latinos living in the Eastern and Southern regions of the United States (Brown & Lopez, 2013) .", [["majority", "OBSERVATION_MODIFIER", 13, 21], ["Central", "ANATOMY_MODIFIER", 187, 194]]], ["Despite this heterogeneity, national studies focusing on older Latino mental health often combine Latino subgroups into one, uniform group.", [["this heterogeneity", "PROBLEM", 8, 26], ["national studies", "TEST", 28, 44]]], ["Approximately a third are foreign-born, and of these immigrants, it is estimated that 51% are undocumented (Gonzalez- Barrera & Lopez, 2013) .", [["foreign", "OBSERVATION", 26, 33]]], ["Undocumented immigrants face numerous barriers such as lack of access to mental health care, insufficient financial resources, limited knowledge of the U.S. mental health care system, limited English proficiency, and increased stigmatization, all of which increase health risks (Derose et al., 2007) .", [["increased stigmatization", "PROBLEM", 217, 241], ["increased", "OBSERVATION_MODIFIER", 217, 226], ["stigmatization", "OBSERVATION", 227, 241]]], ["Also, the adverse circumstances under which many undocumented immigrants enter the United States, the substandard conditions in which many of them live and work, and the distress associated with living life without proper documentation are additional risk factors likely to diminish well-being among this immigrant subgroup (Cavazos-Rehg et al., 2007; Garcini et al., 2016) .", [["the distress", "PROBLEM", 166, 178]]], ["These immigrant-related factors and fear of deportation are unique to Mexican Americans compared to Puerto Ricans who are American citizens and Cuban Americans who receive political and legislative protection from the Cuban Readjustment Act (G\u00fazman & Carrasco, 2011) .Immigration Histories and Sociopolitical Difficulties That Differentially Affect Mental HealthCompared to all the Latino subgroups, Puerto Ricans are unique in that they are born U.S. citizens.", [["legislative protection", "TREATMENT", 186, 208], ["Sociopolitical Difficulties", "PROBLEM", 294, 321]]], ["This dual identity may contribute to a unique sense of dissonance and is an added stressor, which over time might explain the higher likelihood of psychological distress among Puerto Ricans (Alegria, Shrout, Woo, Guarnaccia, Sribney, Vila, Polo, Cao, Mulvaney-Day, Torres, & Canino, 2007; Guarnaccia et al., 2005) .", [["psychological distress", "DISEASE", 147, 169], ["psychological distress", "PROBLEM", 147, 169], ["dissonance", "OBSERVATION", 55, 65]]], ["Against this backdrop, perhaps routine experiences of unfair treatment and inequality may heighten their attention to negative social information and experiences, which could potentially influence their mental health.", [["unfair treatment", "TREATMENT", 54, 70]]], ["The juxtaposition of Puerto Rican's privileged status as American citizens while being economically and socially marginalized in U.S. society could potentially reverberate across generations (Guarnaccia et al., 2005) .Immigration Histories and Sociopolitical Difficulties That Differentially Affect Mental HealthCuban Americans are the oldest of the Latino subgroups: 20.9% are younger than the age 18 while 16.1% are 65 or older (U.S. Census Bureau, 2011).", [["Sociopolitical Difficulties", "PROBLEM", 244, 271]]], ["Cuban immigrants were the only Latino immigrant group in the United States to receive political and legislative protection in the form of the Cuban Readjustment Act (G\u00fazman & Carrasco, 2011) .", [["legislative protection", "TREATMENT", 100, 122]]], ["Lower levels of discrimination are perhaps a function of the large numbers of Latinos living in Miami-Dade County which is 65% Latino, and Cubans comprise 54% of the Latino population (U.S. Census Bureau, 2012).", [["large", "OBSERVATION_MODIFIER", 61, 66], ["numbers", "OBSERVATION_MODIFIER", 67, 74]]], ["Fewer opportunities for intergroup interaction in the community at large may reduce exposure to ethnicity-related discrimination (Molina et al., 2013) .", [["intergroup interaction", "PROBLEM", 24, 46]]], ["However, even this picture of Cuban Americans is complicated upon further inspection.Immigration Histories and Sociopolitical Difficulties That Differentially Affect Mental HealthThe 1980 Mariel event is seen as a line of demarcation in Cuban migration to the United States (Aguirre et al., 1997) .", [["further inspection", "TEST", 66, 84], ["Sociopolitical Difficulties", "PROBLEM", 111, 138]]], ["U.S. migration policy toward Cuba was relatively unfavorable for the later arriving group, and they experienced increased discrimination and a greater likelihood of experiencing stressful life events in the United States, which are associated with declines in mental health (Ackerman et al., 2005; Cislo et al., 2010; Gonz\u00e1lez et al., 2005) .", [["increased discrimination", "PROBLEM", 112, 136]]], ["Moreover, the conditions of migration between the two groups varied drastically.", [["migration", "OBSERVATION_MODIFIER", 28, 37]]], ["Thus, early and later arriving Cubans may have unequal levels of social support from family and friends, which can serve as coping resources to offset the deleterious effects of adversity and may translate into relatively poor health and adjustment outcomes for later arrivals (Cislo et al., 2010) .Immigration Histories and Sociopolitical Difficulties That Differentially Affect Mental HealthThe healthy immigrant hypothesis, sometimes referred to as the immigrant paradox, posits that foreign nativity is protective against psychiatric disorders (Alegria, Shrout, Woo, Guarnaccia, Sribney, Vila, Polo, Cao, Mulvaney-Day, Torres, & Canino, 2007; Alegria et al., 2008) .", [["psychiatric disorders", "DISEASE", 526, 547], ["Sociopolitical Difficulties", "PROBLEM", 325, 352], ["psychiatric disorders", "PROBLEM", 526, 547]]], ["Epidemiologic studies have found that despite the stressful experiences and poverty often associated with immigration, Latino immigrants report lower rates of depressive, anxiety, and substance use disorders than U.S.-born Latinos and non-Latino whites (Alegria, Shrout, Woo, Guarnaccia, Sribney, Vila, Polo, Cao, Mulvaney-Day, Torres, & Canino, 2007; Alegria et al., 2008) .", [["depressive", "DISEASE", 159, 169], ["anxiety", "DISEASE", 171, 178], ["substance use disorders", "DISEASE", 184, 207], ["Epidemiologic studies", "TEST", 0, 21], ["depressive", "PROBLEM", 159, 169], ["anxiety", "PROBLEM", 171, 178]]], ["However, when Latinos are disaggregated by age, subethnic group, and age of migration, a more complicated picture of Latino mental health emerges.Immigration Histories and Sociopolitical Difficulties That Differentially Affect Mental HealthFindings from two studies using the CPES data set described above suggest that the healthy immigrant effects do not hold up in older age (Gonz\u00e1lez et al., 2010; Jimenez et al., 2010) .", [["Sociopolitical Difficulties", "PROBLEM", 172, 199], ["two studies", "TEST", 254, 265], ["the CPES data", "TEST", 272, 285]]], ["Jimenez et al. (2010) found that older, immigrant Latinos (aged older than 60 years) had a higher lifetime prevalence of dysthymia and generalized anxiety disorder than U.S.-born Latinos.", [["dysthymia", "DISEASE", 121, 130], ["anxiety disorder", "DISEASE", 147, 163], ["dysthymia", "PROBLEM", 121, 130], ["generalized anxiety disorder", "PROBLEM", 135, 163], ["dysthymia", "OBSERVATION", 121, 130]]], ["Similarly, results from Gonz\u00e1lez et al.'s study (2010) indicated that the prevalence of major depression was significantly higher for immigrant Latinos older than age 65 years compared to their U.S.born counterparts.", [["major depression", "DISEASE", 88, 104], ["Gonz\u00e1lez et al.'s study", "TEST", 24, 47], ["major depression", "PROBLEM", 88, 104], ["major", "OBSERVATION_MODIFIER", 88, 93], ["depression", "OBSERVATION", 94, 104]]], ["The results of these two studies suggest that immigrant health advantages earlier in life yield to the cumulative adversity of homeland estrangement, social isolation, and the overwhelming effects of socioeconomic disadvantages in later years when health needs and costs rise sharply (Gonz\u00e1lez et al., 2009 (Gonz\u00e1lez et al., , 2010 .", [["these two studies", "TEST", 15, 32], ["social isolation", "TREATMENT", 150, 166]]], ["Moreover, older immigrant Latinos may lack the language and cultural fluency necessary to overcome social isolation and access barriers to quality mental health care that could relieve anxiety and depression (Alegria, Shrout, Woo, Guarnaccia, Sribney, Vila, Polo, Cao, Mulvaney-Day, Torres, & Canino, 2007).", [["anxiety", "DISEASE", 185, 192], ["depression", "DISEASE", 197, 207], ["Latinos", "ORGANISM", 26, 33], ["cultural fluency", "PROBLEM", 60, 76], ["social isolation", "TREATMENT", 99, 115], ["access barriers", "TREATMENT", 120, 135], ["mental health care", "TREATMENT", 147, 165], ["anxiety", "PROBLEM", 185, 192], ["depression", "PROBLEM", 197, 207]]], ["Age is not the only factor where there is inconsistency in the application of the healthy immigrant hypothesis.", [["inconsistency", "OBSERVATION_MODIFIER", 42, 55]]], ["Further complicating the relationship between nativity and the risk for psychiatric illness is how the observed patterns may vary by age at arrival.Immigration Histories and Sociopolitical Difficulties That Differentially Affect Mental HealthLatino immigrants who emigrate later in life (after age 35 years) experience high levels of psychosocial distress and are at high risk for developing a depressive disorder (Alegria, Shrout, Woo, Guarnaccia, Sribney, Vila, Polo, Cao, Mulvaney-Day, Torres, & Canino, 2007; Mills & Henretta, 2001) .", [["psychiatric illness", "DISEASE", 72, 91], ["psychosocial distress", "DISEASE", 334, 355], ["depressive disorder", "DISEASE", 394, 413], ["psychiatric illness", "PROBLEM", 72, 91], ["Sociopolitical Difficulties", "PROBLEM", 174, 201], ["psychosocial distress", "PROBLEM", 334, 355], ["a depressive disorder", "PROBLEM", 392, 413], ["depressive", "OBSERVATION", 394, 404]]], ["Migration negatively affects traditional Latino cultural values (e.g., familism, respeto) that might otherwise serve to buffer stressful life circumstances linked to an increased risk of psychiatric disorders (Almeida et al., 2009; Campos et al., 2008; Jimenez, Bartels, Cardenas, Dhaliwal, & Alegria, 2012) .", [["psychiatric disorders", "DISEASE", 187, 208], ["psychiatric disorders", "PROBLEM", 187, 208], ["increased", "OBSERVATION_MODIFIER", 169, 178]]], ["For later arrival immigrants, the disruption of these cultural values might result in isolation and decreased family and social support, which are exacerbated by low English proficiency.", [["these cultural values", "TEST", 48, 69], ["social support", "TREATMENT", 121, 135], ["decreased", "OBSERVATION_MODIFIER", 100, 109]]], ["Older Latino immigrants who have not yet mastered the English language come to rely on their children who have gained greater English language proficiency through schooling and interactions with the mainstream culture.", [["children", "ORGANISM", 93, 101], ["children", "SPECIES", 93, 101], ["the mainstream culture", "TEST", 195, 217]]], ["This may lead to role reversals, where their children take a more authoritative role, which may lead to regret and disappointment in later arrival immigrants and erode the affiliative obedience and respect for older adults (Elder et al., 2005) .Immigration Histories and Sociopolitical Difficulties That Differentially Affect Mental HealthAdditional difficulties such as educational or professional qualifications not translating to the host society and being a minority in the United States can help to explain further the increased risk of depressive disorders in later arrival immigrants.", [["depressive disorders", "DISEASE", 542, 562], ["children", "ORGANISM", 45, 53], ["children", "SPECIES", 45, 53], ["Sociopolitical Difficulties", "PROBLEM", 271, 298], ["Mental HealthAdditional difficulties", "PROBLEM", 326, 362], ["depressive disorders", "PROBLEM", 542, 562]]], ["Also, later arrival immigrants may become increasingly aware of ethnic and racial categories used by the U.S. society which seem unfair and pejorative, particularly when they have an already ingrained identity coming from the majority culture.", [["ethnic and racial categories", "PROBLEM", 64, 92], ["the majority culture", "TEST", 222, 242]]], ["This may increase the risk of psychopathology, as they may experience many years of living in the United States while not fully integrated into U.S. society (Alegria, Shrout, Woo, Guarnaccia, Sribney, Vila, Polo, Cao, Mulvaney-Day, Torres, & Canino, 2007) .Risk and Protective FactorsOlder Latinos, in general, have identified a social support network as an essential component to mental health (Jimenez, Bartels, Cardenas, Dhaliwal, & Alegria, 2012) .", [["psychopathology", "DISEASE", 30, 45], ["psychopathology", "PROBLEM", 30, 45]]], ["The effect of the scattering of family members and close friends on family structure and relationships is believed to be traumatic and can lead to poor mental health (Jimenez, Bartels, Cardenas, Dhaliwal, & Alegria, 2012) .", [["traumatic", "DISEASE", 121, 130], ["traumatic", "PROBLEM", 121, 130], ["poor mental health", "PROBLEM", 147, 165], ["scattering", "OBSERVATION_MODIFIER", 18, 28]]], ["This tearing of the social fabric brings and can lead to a detrimental loss of belonging, social isolation, and increased intergenerational conflict (Almeida et al., 2009; Campos et al., 2008; Elder et al., 2005) .Risk and Protective FactorsDiscrimination is often seen as a pathogen that generates depression among people of color (Fernando, 1984) .", [["loss of belonging, social isolation", "DISEASE", 71, 106], ["depression", "DISEASE", 299, 309], ["people", "ORGANISM", 316, 322], ["people", "SPECIES", 316, 322], ["social isolation", "TREATMENT", 90, 106], ["Protective FactorsDiscrimination", "TREATMENT", 223, 255], ["a pathogen", "PROBLEM", 273, 283], ["depression", "PROBLEM", 299, 309]]], ["Specifically, it has been found that the relation between discrimination and health among Latinos is mediated by psychological distress, and that this effect is stronger for Latinos than for other racial/ethnic groups (Brondolo et al., 2011) .", [["psychological distress", "PROBLEM", 113, 135]]], ["Finch et al. (2000) found that in a sample of Mexican Americans, perceived discrimination was associated with increased levels of psychological distress.", [["psychological distress", "DISEASE", 130, 152], ["psychological distress", "PROBLEM", 130, 152]]], ["Furthermore, the closer the perceived discrimination is to one's self, the psychological distress increases (Jackson et al., 2006) .", [["the psychological distress", "PROBLEM", 71, 97]]], ["Jointly, this suggests that the effect of discrimination on psychological distress may be augmented for Puerto Ricans, who by account of their multiple stigmatized social identities-American citizens who are economically and socially marginalized in U.S. society-evidence higher levels of unfair treatment and other social stressors compared to their Latino counterparts (Molina et al., 2013) .Meeting the Mental Health Needs of Older LatinosIn order to address the mental health needs of older Latinos, it is important to keep in mind the considerable variability between Latino subgroups, which highlights the need for cultural case conceptualizations of individual patients and to tailor interventions to the unique circumstances and backgrounds of the patient.", [["psychological distress", "DISEASE", 60, 82], ["patients", "ORGANISM", 668, 676], ["patient", "ORGANISM", 756, 763], ["patients", "SPECIES", 668, 676], ["patient", "SPECIES", 756, 763], ["psychological distress", "PROBLEM", 60, 82], ["unfair treatment", "TREATMENT", 289, 305], ["tailor interventions", "TREATMENT", 684, 704]]], ["For example, in the original cognitive behavioral therapy (CBT) model, patients were taught techniques to \"control\" their depression by changing behaviors and thoughts (Lewinsohn et al., 1978) .", [["depression", "DISEASE", 122, 132], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["their depression", "PROBLEM", 116, 132]]], ["Mu\u00f1oz (1996) realized that this technique had limited contextual relevance for the predominately Mexican patients he was treating in San Francisco because there are particular realities that low-income, uninsured Mexican individuals do not have control over (e.g., the type of neighborhood they live in, and experiences of discrimination, racism, and poverty).", [["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113]]], ["This led him to adapt the CBT approach to focus on the healthy management of reality (Mu\u00f1oz, 1996) .", [["the CBT approach", "TREATMENT", 22, 38]]], ["At the same time, it is necessary to consider the extent to which common elements and interventions can generalize across Latino cultures.", [["Latino cultures", "CELL_LINE", 122, 137], ["interventions", "TREATMENT", 86, 99], ["Latino cultures", "TEST", 122, 137]]], ["The realities of clinical practice or clinical research in a public sector setting often mandate the inclusion of members from varied cultural backgrounds within a single intervention group.", [["a single intervention group", "TREATMENT", 162, 189]]], ["Further tailoring is done in order to ensure the treatment is compatible with the individual's background, age, migration history, and cultural meanings and values (Bernal et al., 2009 ).", [["cultural meanings", "TEST", 135, 152]]], ["One of the most studied evidence-based treatments that has been adapted for older Latinos is CBT.", [["based treatments", "TREATMENT", 33, 49], ["most studied", "OBSERVATION_MODIFIER", 11, 23]]], ["Although no empirical evidence suggests that Latinos respond more favorably to CBT than other forms of psychotherapy, certain dimensions of CBT are consistent with the traditional cultural characteristics and social experiences of older Latinos (Organista, 2006) .", [["CBT", "TEST", 79, 82], ["psychotherapy", "TREATMENT", 103, 116], ["CBT", "TEST", 140, 143], ["no empirical evidence suggests", "UNCERTAINTY", 9, 39], ["consistent with", "UNCERTAINTY", 148, 163]]], ["Cultural attitudes about mental illness and therapy confer blame and stigma within Latino communities (McCabe et al., 2005) .", [["illness", "DISEASE", 32, 39], ["mental illness", "PROBLEM", 25, 39], ["therapy confer blame", "TREATMENT", 44, 64]]], ["An educational and didactic approach along with the use of patient manuals and in-home assignments helps older Latinos view therapy as more of a classroom experience, thus decreasing the stigma so often attached to therapy (McCabe et al., 2005; Organista, 2006) .", [["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["didactic approach", "TREATMENT", 19, 36], ["Latinos view therapy", "TREATMENT", 111, 131], ["the stigma", "PROBLEM", 183, 193], ["therapy", "TREATMENT", 215, 222]]], ["Second, CBT is present focused and emphasizes problem solving, thus providing concrete solutions and techniques used to solve such problems.", [["concrete solutions and techniques", "TREATMENT", 78, 111], ["such problems", "PROBLEM", 126, 139]]], ["For example, the CBT technique of challenging and changing negative thoughts is potentially congruent with Latino cultural resilience (Comas-D\u00edaz, 2006) .Meeting the Mental Health Needs of Older LatinosDespite the cultural adaptations and the effectiveness of CBT and other evidence-based treatments, older Latinos, as a whole, have limited access to these treatments and, for reasons of stigma, are often reluctant to engage in help seeking (Jimenez, Bartels, Cardenas, & Alegria, 2012; Jimenez et al., 2013) .", [["the CBT technique", "TEST", 13, 30], ["CBT", "TREATMENT", 260, 263], ["these treatments", "TREATMENT", 351, 367], ["stigma", "PROBLEM", 388, 394]]], ["Furthermore, available mental health treatments may not match the preferences and beliefs of older Latinos, which can lead to the decision to not access mental health treatment (Jimenez, Bartels, Cardenas, Dhaliwal, & Alegria, 2012) .", [["mental health treatments", "TREATMENT", 23, 47], ["mental health treatment", "TREATMENT", 153, 176]]], ["Therefore, mental health treatments do not sufficiently reduce the prevalence of depression or anxiety in older Latinos, thus underscoring the importance of prevention and addressing an urgent and rapidly growing medical and public health issue.Meeting the Mental Health Needs of Older LatinosOver the last 25 years, the number of randomized controlled trials testing preventive interventions has greatly increased (Mu\u00f1oz, 2019) .", [["depression", "DISEASE", 81, 91], ["anxiety", "DISEASE", 95, 102], ["mental health treatments", "TREATMENT", 11, 35], ["depression", "PROBLEM", 81, 91], ["anxiety", "PROBLEM", 95, 102], ["randomized controlled trials", "TREATMENT", 331, 359], ["preventive interventions", "TREATMENT", 368, 392], ["increased", "OBSERVATION_MODIFIER", 405, 414]]], ["A meta-analysis of 32 studies in 2014 showed that in all sorts of groups that are at riskfrom expectant and new mothers to individuals who had experienced a stroke-such preventive interventions reduce the onset of major depressive episodes by 21%, on average (van Zoonen et al., 2014) .", [["stroke", "DISEASE", 157, 163], ["depressive episodes", "DISEASE", 220, 239], ["A meta-analysis", "TEST", 0, 15], ["32 studies", "TEST", 19, 29], ["a stroke", "PROBLEM", 155, 163], ["preventive interventions", "TREATMENT", 169, 193], ["major depressive episodes", "PROBLEM", 214, 239], ["stroke", "OBSERVATION", 157, 163]]], ["In the same year, Mu\u00f1oz et al. (2014) found that 15 of 42 randomized trials reported reductions of 50% or more in the incidence of depression.", [["depression", "DISEASE", 131, 141], ["depression", "PROBLEM", 131, 141], ["depression", "OBSERVATION", 131, 141]]], ["Moreover, depression prevention interventions consistently report effect sizes similar to those for the use of statins to prevent acute myocardial infarction during a 5-year period (van Zoonen et al., 2014) .", [["myocardial", "ANATOMY", 136, 146], ["depression", "DISEASE", 10, 20], ["statins", "CHEMICAL", 111, 118], ["acute myocardial infarction", "DISEASE", 130, 157], ["statins", "CHEMICAL", 111, 118], ["myocardial", "MULTI-TISSUE_STRUCTURE", 136, 146], ["depression prevention interventions", "TREATMENT", 10, 45], ["effect sizes", "PROBLEM", 66, 78], ["statins", "TREATMENT", 111, 118], ["acute myocardial infarction", "PROBLEM", 130, 157], ["acute", "OBSERVATION_MODIFIER", 130, 135], ["myocardial", "ANATOMY", 136, 146], ["infarction", "OBSERVATION", 147, 157]]], ["In short, the data suggest that if we implement effective interventions early on, then we could reduce new cases of depression in half (Mu\u00f1oz, 2019) .", [["depression", "DISEASE", 116, 126], ["depression", "PROBLEM", 116, 126]]], ["While these metaanalyses show robust evidence of the effectiveness of prevention interventions as a whole, they do not tell us the effect of these interventions on Latinos, specifically older Latinos.Meeting the Mental Health Needs of Older LatinosOne of the earliest prevention interventions to target depression prevention in the Latino community was the Depression Prevention Course (DPC) developed by Mu\u00f1oz (1984) .", [["depression", "DISEASE", 303, 313], ["Depression", "DISEASE", 357, 367], ["these metaanalyses", "TEST", 6, 24], ["prevention interventions", "TREATMENT", 70, 94], ["these interventions", "TREATMENT", 141, 160], ["the earliest prevention interventions", "TREATMENT", 255, 292], ["target depression prevention", "TREATMENT", 296, 324]]], ["Social learning theory (SLT; Bandura, 1977) was the basis for the DPC because the theory embodies principles of behavior change that are universally relevant and potentially applicable across cultures (Mu\u00f1oz & Mendelsson, 2005) .", [["the DPC", "TREATMENT", 62, 69], ["behavior change", "PROBLEM", 112, 127], ["cultures", "TEST", 192, 200]]], ["The DPC was designed to teach mood management skills to primary care patients in order to prevent major depressive episodes and was evaluated in a randomized controlled trial at San Francisco General Hospital with 150 primary care patients.", [["depressive episodes", "DISEASE", 104, 123], ["patients", "ORGANISM", 69, 77], ["patients", "ORGANISM", 231, 239], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 231, 239], ["mood management", "TREATMENT", 30, 45], ["major depressive episodes", "PROBLEM", 98, 123]]], ["The DPC was translated into Spanish and underwent a lengthy cultural adaptation process in order to account for the particular realities that low-income, ethnic minority, uninsured individuals do not have control over (e.g., the type of neighborhood they live in, and experiences of discrimination, racism, and poverty).", [["a lengthy cultural adaptation process", "TREATMENT", 50, 87]]], ["The DPC proved to be effective in significantly reducing depressive symptoms and the number of new episodes of major depression was lower in the experimental condition at 1-year follow-up compared to the control condition (Mu\u00f1oz & Ying, 1993; Mu\u00f1oz et al., 1995) .Meeting the Mental Health Needs of Older LatinosAlthough the DPC did not specifically target Latinos, the overall positive impact in reducing depression in this population has encouraged researchers to replicate and evaluate the intervention in various ways.", [["DPC", "CHEMICAL", 4, 7], ["depressive", "DISEASE", 57, 67], ["major depression", "DISEASE", 111, 127], ["depression", "DISEASE", 406, 416], ["DPC", "SIMPLE_CHEMICAL", 4, 7], ["The DPC", "TREATMENT", 0, 7], ["significantly reducing depressive symptoms", "PROBLEM", 34, 76], ["major depression", "PROBLEM", 111, 127], ["reducing depression", "PROBLEM", 397, 416], ["the intervention", "TREATMENT", 489, 505], ["new", "OBSERVATION_MODIFIER", 95, 98], ["major", "OBSERVATION_MODIFIER", 111, 116], ["depression", "OBSERVATION", 117, 127], ["positive", "OBSERVATION_MODIFIER", 378, 386], ["impact", "OBSERVATION_MODIFIER", 387, 393], ["reducing", "OBSERVATION_MODIFIER", 397, 405], ["depression", "OBSERVATION", 406, 416]]], ["It has been adapted for pregnant Latinas at high risk for postpartum depression in San Francisco (predominately Mexican descent) and Washington, DC (predominately Central American descent), adolescent depression in Puerto Rico, and lowincome Latinas (subgroup diverse; Le et al., 2004 Le et al., , 2011 Miranda et al., 2003; Rossell\u00f3 et al., 2008) .", [["DC", "ANATOMY", 145, 147], ["postpartum depression", "DISEASE", 58, 79], ["depression", "DISEASE", 201, 211], ["Latinas", "ORGANISM", 33, 40], ["postpartum depression", "PROBLEM", 58, 79], ["adolescent depression", "PROBLEM", 190, 211]]], ["Despite the increased focus on prevention and the success of the DPC in the Latino community, few prevention interventions have focused on older Latinos.", [["DPC", "CHEMICAL", 65, 68], ["prevention", "TREATMENT", 31, 41], ["the DPC", "TREATMENT", 61, 68], ["few prevention interventions", "TREATMENT", 94, 122], ["increased", "OBSERVATION_MODIFIER", 12, 21], ["focus", "OBSERVATION_MODIFIER", 22, 27]]], ["Given the prevalence and morbidity of depression and anxiety in later life, the inadequacies of current treatment approaches for averting years living with a disability, the disparities in access to the mental health care delivery system, and the workforce shortages to meet the mental health needs of older Latinos, development and testing of innovative strategies are needed to stop depression and anxiety from taking hold in the first place.Meeting the Mental Health Needs of Older LatinosIn an attempt to address the dearth of prevention research in older Latinos, the Happy Older Latinos are Active (HOLA; Jimenez, Reynolds et al., 2015) intervention was created.", [["depression", "DISEASE", 38, 48], ["anxiety", "DISEASE", 53, 60], ["disability", "DISEASE", 158, 168], ["depression", "DISEASE", 385, 395], ["anxiety", "DISEASE", 400, 407], ["depression", "PROBLEM", 38, 48], ["anxiety", "PROBLEM", 53, 60], ["current treatment approaches", "TREATMENT", 96, 124], ["innovative strategies", "TREATMENT", 344, 365], ["depression", "PROBLEM", 385, 395], ["anxiety", "PROBLEM", 400, 407], ["intervention", "TREATMENT", 643, 655]]], ["HOLA is a community health worker (CHW)-led, multicomponent, health promotion intervention consisting of (a) two manualized social and physical activation sessions; (b) a moderately intense group walk led by a CHW for 45 min, 3\u00d7/week for 16 weeks; (c) pleasant events scheduling; and (d) a maintenance phase consisting of one \"booster\" walking session twice a month for 6 months postintervention, then once a month for 18 months after that in order to reinforce the behavior change and maintain the effects of the intervention.", [["HOLA", "CHEMICAL", 0, 4], ["the intervention", "TREATMENT", 510, 526]]], ["Similar to the DPC, HOLA is based on SLT, but diverges from the DPC in that it incorporates the principles of Behavioral Activation to engage older Latinos in a physical activity routine as well as pleasant events scheduling to reduce the risk for major depression and generalized anxiety disorder, prevent incidence and recurrence of these disorders, and improve health-related outcomes.", [["depression", "DISEASE", 254, 264], ["anxiety disorder", "DISEASE", 281, 297], ["the DPC", "TEST", 11, 18], ["SLT", "TEST", 37, 40], ["the DPC", "PROBLEM", 60, 67], ["major depression", "PROBLEM", 248, 264], ["generalized anxiety disorder", "PROBLEM", 269, 297], ["these disorders", "PROBLEM", 335, 350]]], ["The intervention was culturally tailored based on participant feedback that directly contributed to the features, components, and delivery of the intervention.", [["The intervention", "TREATMENT", 0, 16], ["the intervention", "TREATMENT", 142, 158]]], ["Therefore, it is believed that it will appeal to all Latino subgroups.Meeting the Mental Health Needs of Older LatinosPreliminary results from the pilot study indicate that HOLA is feasible and acceptable and highlights the significant impact the intervention can have in lowering depression and anxiety vulnerability when it is relevant, respectful, and specific to the needs of the older Latino population (Jimenez et al., 2018) .", [["depression", "DISEASE", 281, 291], ["anxiety", "DISEASE", 296, 303], ["the pilot study", "TEST", 143, 158], ["lowering depression", "PROBLEM", 272, 291], ["anxiety vulnerability", "PROBLEM", 296, 317]]], ["A randomized prevention trial to examine the effectiveness of HOLA in reducing the risk for and incidence/recurrence of major depression and generalized anxiety disorder in a diverse sample of older Latinos is currently under way (NCT03870360).", [["HOLA", "CHEMICAL", 62, 66], ["depression", "DISEASE", 126, 136], ["anxiety disorder", "DISEASE", 153, 169], ["HOLA", "SIMPLE_CHEMICAL", 62, 66], ["A randomized prevention trial", "TREATMENT", 0, 29], ["HOLA", "TREATMENT", 62, 66], ["major depression", "PROBLEM", 120, 136], ["generalized anxiety disorder", "PROBLEM", 141, 169], ["major", "OBSERVATION_MODIFIER", 120, 125], ["depression", "OBSERVATION", 126, 136], ["generalized", "OBSERVATION_MODIFIER", 141, 152], ["anxiety", "OBSERVATION", 153, 160]]], ["If effective, HOLA can be explicitly linked to preventing depression and anxiety in older Latinos and rapidly disseminated as a prevention intervention throughout the country at a low cost.", [["depression", "DISEASE", 58, 68], ["anxiety", "DISEASE", 73, 80], ["HOLA", "SIMPLE_CHEMICAL", 14, 18], ["depression", "PROBLEM", 58, 68], ["anxiety", "PROBLEM", 73, 80], ["a prevention intervention", "TREATMENT", 126, 151]]], ["In the context of reductions in funding available for preventive health services, particularly within mental health, this study may exemplify the use of health promotion with minimal use of resources.Future Directions for Mental Health Research Among Older LatinosConsideration of the heterogeneity of the older Latino population is critical for the advancement of mental health research in this segment of the population.", [["this study", "TEST", 117, 127], ["reductions", "OBSERVATION_MODIFIER", 18, 28]]], ["While the present review has focused on differences among Latinos subgroups based on country of origin/descent and age, other factors such as sex/gender, acculturation/language use, and geographical region of residence in the United States should also be considered in understanding mental health determinants among older Latinos, and in the development and implementation of mental health prevention and intervention approaches for this diverse group.", [["mental health prevention", "TREATMENT", 376, 400], ["intervention approaches", "TREATMENT", 405, 428]]], ["Furthermore, the current COVID-19 pandemic is disproportionally affecting Latinos and other under-represented groups in the United States (Centers for Disease Control and Prevention [CDC], 2020a [CDC], , 2020b .", [["the current COVID", "TEST", 13, 30], ["Disease Control", "TREATMENT", 151, 166]]], ["Longitudinal studies of mental health among diverse Latinos subgroups will be better equipped to understand mental health and its determinants among older Latinos.ConclusionsThe aggregation of Latino subgroups in national studies creates an overly simplistic narrative that Latinos are at lower risk of mental illness and that foreign nativity seems protective against mental illness (i.e., immigrant paradox).", [["illness", "DISEASE", 310, 317], ["nativity", "CHEMICAL", 335, 343], ["Longitudinal studies", "TEST", 0, 20], ["national studies", "TEST", 213, 229], ["mental illness", "PROBLEM", 303, 317], ["foreign nativity", "PROBLEM", 327, 343], ["mental illness", "PROBLEM", 369, 383]]], ["This broad generalization masks key differences in the prevalence of depression and anxiety, immigration histories, and sociopolitical difficulties that differentially affect their mental health.", [["depression", "DISEASE", 69, 79], ["anxiety", "DISEASE", 84, 91], ["depression", "PROBLEM", 69, 79], ["anxiety", "PROBLEM", 84, 91], ["sociopolitical difficulties", "PROBLEM", 120, 147], ["depression", "OBSERVATION", 69, 79]]], ["Other factors such as sex/gender, acculturation/language use, and geographical region of residence in the United States should also be considered in understanding mental health determinants among older Latinos and in the development and implementation of intervention approaches.ConclusionsNativity alone does not protect from psychiatric illness once immigrants arrive as originally thought.", [["psychiatric illness", "DISEASE", 327, 346], ["intervention approaches", "TREATMENT", 255, 278]]], ["These factors signal critical windows of opportunity for addressing differential risks for older Latinos and pathways to intervene in order to prevent negative outcomes.ConclusionsAlthough numerous treatments for depression and anxiety are effective and available, many older Latinos are not accessing these services due to structural (e.g., language, income, insurance, and provider shortage) and psychological (e.g., stigma) barriers.", [["depression", "DISEASE", 213, 223], ["anxiety", "DISEASE", 228, 235], ["numerous treatments", "TREATMENT", 189, 208], ["depression", "PROBLEM", 213, 223], ["anxiety", "PROBLEM", 228, 235]]], ["These challenges combined with the scale of the problem require strategies to stop depression and anxiety from taking hold in the first place.", [["depression", "DISEASE", 83, 93], ["anxiety", "DISEASE", 98, 105], ["depression", "PROBLEM", 83, 93], ["anxiety", "PROBLEM", 98, 105]]], ["The development of depression and anxiety prevention strategies would be a means of addressing multiple inequalities in older Latino mental health.", [["depression", "DISEASE", 19, 29], ["anxiety", "DISEASE", 34, 41], ["depression", "PROBLEM", 19, 29], ["anxiety prevention strategies", "TREATMENT", 34, 63], ["depression", "OBSERVATION", 19, 29]]], ["Culturally tailored depression prevention tools have been developed and implemented successfully for younger Latinos across the United States.", [["depression", "DISEASE", 20, 30], ["Culturally tailored depression prevention tools", "PROBLEM", 0, 47]]], ["However, work remains to be done to demonstrate the longer-term sustainability of such prevention strategies in older Latinos.", [["such prevention strategies", "TREATMENT", 82, 108]]], ["Success in this endeavor would yield a substantial reduction in the burden of late-life depression and anxiety and has the potential to change practice.", [["depression", "DISEASE", 88, 98], ["anxiety", "DISEASE", 103, 110], ["a substantial reduction", "TREATMENT", 37, 60], ["late-life depression", "PROBLEM", 78, 98], ["anxiety", "PROBLEM", 103, 110], ["substantial", "OBSERVATION_MODIFIER", 39, 50], ["reduction", "OBSERVATION_MODIFIER", 51, 60], ["burden", "OBSERVATION_MODIFIER", 68, 74]]]]}